

**PT JAYAMAS MEDICA INDUSTRI Tbk  
DAN ENTITAS ANAK/*AND SUBSIDIARIES***

**LAPORAN KEUANGAN KONSOLIDASIAN/  
*CONSOLIDATED FINANCIAL STATEMENTS***

**UNTUK PERIODE YANG BERAKHIR PADA 30 JUNI 2025/  
*FOR THE PERIOD ENDED JUNE 30, 2025***

*The original consolidated financial statements  
included herein are in the Indonesian language*

**PT JAYAMAS MEDICA INDUSTRI Tbk DAN ENTITAS ANAK  
LAPORAN KEUANGAN KONSOLIDASIAN  
UNTUK PERIODE YANG BERAKHIR PADA  
30 JUNI 2025  
(Disajikan dalam Rupiah, kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI Tbk AND SUBSIDIARIES  
CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE PERIOD ENDED  
JUNE 30, 2025  
(Expressed in Rupiah, unless otherwise stated)**

**DAFTAR ISI**

**CONTENTS**

**Pernyataan Direksi**

***Director's Statement***

**Ekshibit/  
Exhibit**

**Laporan Posisi Keuangan Konsolidasian**

**A**

***Consolidated Statements of Financial Position***

**Laporan Laba Rugi dan Penghasilan  
Komprehensif Lain Konsolidasian**

**B**

***Consolidated Statements of Profit or Loss  
and Other Comprehensive Income***

**Laporan Perubahan Ekuitas Konsolidasian**

**C**

***Consolidated Statements of Changes in Equity***

**Laporan Arus Kas Konsolidasian**

**D**

***Consolidated Statements of Cash Flows***

**Catatan atas Laporan Keuangan Konsolidasian**

**E**

***Notes to the Consolidated Financial Statements***



**SURAT PERNYATAAN DIREKSI  
TENTANG TANGGUNGJAWAB ATAS  
LAPORAN KEUANGAN KONSOLIDASIAN  
UNTUK TAHUN YANG BERAKHIR PADA TANGGAL  
30 JUNI 2025  
PT JAYAMAS MEDICA INDUSTRI TBK DAN ENTITAS ANAK**

**BOARD OF DIRECTORS STATEMENT OF  
RELATING TO THE RESPONSIBILITY ON THE  
CONSOLIDATED FINANCIAL STATEMENTS FOR  
THE YEAR ENDED  
JUNE 30, 2025  
PT JAYAMAS MEDICA INDUSTRI TBK AND SUBSIDIARIES**

Kami yang bertanda tangan di bawah ini

*We the undersigned:*

1. Nama Herlien Sri Ariani  
Alamat Kantor Sebelah Selatan Jalan By Pass  
RT 005 / RW 001 Sidomojo, Krian  
Sidoarjo, Jawa Timur, Indonesia  
Alamat Domisili Jalan Ketintang Selatan XII/17  
Nomor Telepon (081)217956069  
Jabatan Direktur Utama / *President Director*

1. Name  
Office Address  
  
  
  
Domicile Address  
Phone Number  
Position

2. Nama Eka Suwignyoo  
Alamat Kantor Sebelah Selatan Jalan By Pass  
RT 005 / RW 001 Sidomojo, Krian  
Sidoarjo, Jawa Timur, Indonesia  
Alamat Domisili Woodland WL 2/11  
Nomor Telepon (081) 13009905  
Jabatan Direktur / *Director*

2. Name  
Office Address  
  
  
  
Domicile Address  
Phone Number  
Position

**Menyatakan Bahwa**

1. Kami bertanggungjawab atas penyusunan dan penyajian laporan keuangan konsolidasian PT Jayamas Medica Industri Tbk dan Entitas Anak;
2. Laporan Keuangan Konsolidasian PT Jayamas Medica Industri Tbk dan Entitas Anak telah disusun dan disajikan sesuai dengan Standar Akuntansi Keuangan di Indonesia;

**Declared that**

1. We are responsible for the preparation and presentation of the consolidated financial statement of PT Jayamas Medica Industri Tbk and subsidiaries
2. The consolidated financial statements of PT Jayamas Medica Industri Tbk and Subsidiaries have been prepared and presented in accordance with Indonesian Financial Accounting Standards;



• Tel. +62.31.8982349 / 8985269  
• Tel. +62.321 4890907



• Sebelah Selatan Jalan By Pass RT.005/RW.001, Sidomojo, Krian, Sidoarjo, Jawa Timur, Indonesia  
• Dusun Karangmenjangan RT.001/RW.001, Karangwinongan, Mojoagung, Jombang, Jawa Timur, Indonesia



for DISPOSABLE SYRINGE



PM 030674

**ISO 13485 : 2016**  
Cert No : 01 05 B 24000134



• email: [onemed@onemed.co.id](mailto:onemed@onemed.co.id)  
• website: [www.onemed.co.id](http://www.onemed.co.id)

3. a. Semua informasi dalam laporan keuangan konsolidasian PT Jayamas Medica Industri Tbk dan Entitas Anak telah dimuat secara lengkap dan benar; dan
- b. Laporan keuangan konsolidasian PT Jayamas Medica Industri Tbk dan Entitas Anak tidak mengandung informasi atau fakta material yang tidak benar, dan tidak menghilangkan informasi atau fakta material;
4. Kami bertanggungjawab atas sistem pengendalian internal dalam PT Jayamas Medica Industri Tbk dan Entitas Anak

Demikian pernyataan ini dibuat dengan sebenarnya

3. a. All information contained in the consolidated financial statements of PT Jayamas Medica Industri Tbk and Subsidiaries has been disclosed in a completed and truthful manner; and
- b. The consolidated financial statements of PT Jayamas Medica Industri Tbk and Subsidiaries do not contain any incorrect material information or fact, nor omit material information or fact;
4. We Are responsible for the internal control system of PT Jayamas Medica Industri Tbk and Subsidiaries

Thus this statement is made truthfully

Sidoarjo, 29 Juli 2025/July 29, 2025



Herlien Sri Ariani

Direktur Utama / President Director

Eka Suwignyo

Direktur / Director



• Tel. +62 31 8982349 / 8985269

• Tel. +62 321 4890907



• Sebelah Selatan Jalan By Pass RT.005/RW.001, Sidoarjo, Krajan, Sidoarjo, Jawa Timur, Indonesia

• Dusun Karangmenjangan RT.001/RW.001, Karangwinongan, Mojoagung, Jombang, Jawa Timur, Indonesia



• email: [onemed@onemed.co.id](mailto:onemed@onemed.co.id)

• website: [www.onemed.co.id](http://www.onemed.co.id)



for DISPOSABLE SYRINGE



ISO 13485 : 2016  
Cert No : 01 05 B 24000134

Ekshibit A

Exhibit A

**PT JAYAMAS MEDICA INDUSTRI Tbk DAN ENTITAS ANAK**  
**LAPORAN POSISI KEUANGAN KONSOLIDASIAN**  
**PER 30 JUNI 2025**  
**(Disajikan dalam Rupiah, kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI Tbk AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**  
**AS OF JUNE 30, 2025**  
**(Expressed in Rupiah, unless otherwise stated)**

|                                | Catatan/<br>Notes | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                                       |
|--------------------------------|-------------------|--------------------------|----------------------------------|---------------------------------------|
| <b>A S E T</b>                 |                   |                          |                                  | <b>A S S E T S</b>                    |
| <b>ASET LANCAR</b>             |                   |                          |                                  | <b>CURRENT ASSETS</b>                 |
| Kas dan setara kas             | 5                 | 1.130.358.960.131        | 1.224.705.775.933                | Cash and cash equivalents             |
| Investasi jangka pendek        | 6                 | 34.458.799.858           | 89.496.731.646                   | Short-term investments                |
| Piutang usaha                  |                   |                          |                                  | Trade receivables                     |
| Pihak berelasi                 | 7                 | 937.751.050              | 1.218.630.201                    | Related parties                       |
| Pihak ketiga - Neto            | 7                 | 301.363.460.617          | 263.973.367.250                  | Third parties – Net                   |
| Piutang non-usaha              |                   |                          |                                  | Non-trade receivables                 |
| Pihak berelasi                 | 8                 | 239.000                  | -                                | Related parties                       |
| Pihak ketiga                   | 8                 | 5.537.611.068            | 3.372.465.398                    | Third parties                         |
| Persediaan - Neto              | 9                 | 640.792.291.097          | 639.979.122.881                  | Inventories - Net                     |
| Beban dibayar di muka          | 10                | 1.808.481.466            | 2.056.347.505                    | Prepaid expenses                      |
| Uang muka pembelian            | 11                | 27.866.291.381           | 31.552.739.102                   | Advance for purchases                 |
| Pajak dibayar di muka          | 27                | 1.510.900.161            | 4.693.952.655                    | Prepaid tax                           |
| Aset lancar lainnya            |                   | 66.763.900               | 66.763.900                       | Other current assets                  |
| <b>Total Aset Lancar</b>       |                   | <b>2.144.701.549.729</b> | <b>2.261.115.896.471</b>         | <b>Total Current Assets</b>           |
| <b>ASET TIDAK LANCAR</b>       |                   |                          |                                  | <b>NON-CURRENT ASSETS</b>             |
| Uang muka pembelian aset tetap | 12                | 11.507.866.227           | 4.103.248.039                    | Advance for purchases of fixed assets |
| Investasi jangka panjang       | 16                | 190.006.366.110          | 76.364.882.225                   | Long-term investments                 |
| Aset tetap - Neto              | 13                | 436.617.481.240          | 433.859.085.201                  | Fixed assets - Net                    |
| Aset tak berwujud              | 15                | 83.885.431               | 111.426.615                      | Intangible assets                     |
| Aset hak guna – Neto           | 14                | 42.665.414.211           | 35.177.649.987                   | Right-of-use asset – Net              |
| Aset pajak tangguhan - Neto    | 27                | 4.876.169.598            | 5.494.170.209                    | Deferred tax assets – Net             |
| Tagihan restitusi pajak        | 27                | 1.402.088.533            | 9.020.972.973                    | Claim for tax refund                  |
| Aset tidak lancar lainnya      |                   | -                        | 84.000.000                       | Other non-current assets              |
| Deposito Berjangka             | 17                | 5.000.000.000            | -                                | Time Deposits                         |
| <b>Total Aset Tidak Lancar</b> |                   | <b>692.159.271.350</b>   | <b>564.215.435.249</b>           | <b>Total Non-Current Assets</b>       |
| <b>TOTAL ASET</b>              |                   | <b>2.836.860.821.079</b> | <b>2.825.331.331.720</b>         | <b>TOTAL ASSETS</b>                   |

Lihat Catatan atas Laporan Keuangan Konsolidasian  
pada Ekshibit E terlampir yang merupakan bagian yang tidak  
terpisahkan dari Laporan Keuangan Konsolidasian secara keseluruhan

See accompanying Notes to the Consolidated Financial  
Statements on Exhibit E which are an integral part of  
the Consolidated Financial Statements taken as a whole

Ekshibit A/2

Exhibit A/2

**PT JAYAMAS MEDICA INDUSTRI Tbk DAN ENTITAS ANAK**  
**LAPORAN POSISI KEUANGAN KONSOLIDASIAN**  
**PER 30 JUNI 2025**  
**(Disajikan dalam Rupiah, kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI Tbk AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**  
**AS OF JUNE 30, 2025**  
**(Expressed in Rupiah, unless otherwise stated)**

|                                                                                  | Catatan/<br>Notes | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                                                       |
|----------------------------------------------------------------------------------|-------------------|--------------------------|----------------------------------|-------------------------------------------------------|
| <b>LIABILITAS DAN EKUITAS</b>                                                    |                   |                          |                                  | <b>LIABILITIES AND EQUITY</b>                         |
| <b>LIABILITAS JANGKA PENDEK</b>                                                  |                   |                          |                                  | <b>CURRENT LIABILITIES</b>                            |
| Utang usaha                                                                      |                   |                          |                                  | Trade payables                                        |
| Pihak berelasi                                                                   | 18                | 5.457.682.137            | 5.040.794.082                    | Related parties                                       |
| Pihak ketiga                                                                     | 18                | 94.001.740.962           | 85.553.309.972                   | Third parties                                         |
| Utang non-usaha                                                                  |                   |                          |                                  | Non-trade payables                                    |
| Pihak berelasi                                                                   | 19                | 1.348.102.758            | 16.153.800                       | Related parties                                       |
| Pihak ketiga                                                                     | 19                | 7.197.002.465            | 3.876.696.148                    | Third parties                                         |
| Uang muka dari pelanggan                                                         | 20                | 1.839.524.651            | 1.342.962.666                    | Advances from customers                               |
| Beban masih harus dibayar                                                        | 21                | 5.449.333.055            | 8.889.867.741                    | Accrued expenses                                      |
| Utang pajak                                                                      | 27                | 19.454.707.313           | 18.693.598.856                   | Taxes payable                                         |
| Liabilitas jangka panjang<br>yang akan jatuh tempo<br>dalam satu tahun:          |                   |                          |                                  | Current maturities of<br>long-term liabilities:       |
| Liabilitas sewa                                                                  | 22                | 11.989.936.291           | 11.926.541.615                   | Lease liabilities                                     |
| Surat utang jangka menengah                                                      | 24                | -                        | 159.916.759.651                  | Medium-term notes                                     |
| Pinjaman bank                                                                    | 23                | 1.790.258.963            | -                                | Bank loan                                             |
| Hutang dividen                                                                   | 27                | 100.600.094.500          | -                                | Dividend payables                                     |
| <b>Total Liabilitas Jangka Pendek</b>                                            |                   | <b>249.128.383.095</b>   | <b>295.256.684.531</b>           | <b>Total Current Liabilities</b>                      |
| <b>LIABILITAS JANGKA PANJANG</b>                                                 |                   |                          |                                  | <b>NON-CURRENT LIABILITIES</b>                        |
| Liabilitas jangka panjang,<br>setelah dikurangi jatuh<br>tempo dalam satu tahun: |                   |                          |                                  | Long-term liabilities, net of<br>current maturities:  |
| Liabilitas sewa                                                                  | 22                | 14.303.725.318           | 13.683.411.015                   | Lease liabilities                                     |
| Pinjaman bank                                                                    | 23                | 2.916.666.663            | -                                | Bank loan                                             |
| Liabilitas pajak tangguhan                                                       | 27                | 1.395.663.108            | 1.972.422.636                    | Deferred tax liabilities                              |
| Liabilitas diestimasi imbalan paska-kerja                                        | 25                | 21.190.385.616           | 18.730.107.652                   | Estimated liabilities for<br>post-employment benefits |
| <b>Total Liabilitas Jangka Panjang</b>                                           |                   | <b>39.806.440.705</b>    | <b>34.385.941.303</b>            | <b>Total Non-Current Liabilities</b>                  |
| <b>Total Liabilitas</b>                                                          |                   | <b>288.934.823.800</b>   | <b>329.642.625.834</b>           | <b>Total Liabilities</b>                              |

Lihat Catatan atas Laporan Keuangan Konsolidasian  
pada Ekshibit E terlampir yang merupakan bagian yang tidak  
terpisahkan dari Laporan Keuangan Konsolidasian secara keseluruhan

See accompanying Notes to the Consolidated Financial  
Statements on Exhibit E which are an integral part of  
the Consolidated Financial Statements taken as a whole

Ekshibit A/3

Exhibit A/3

**PT JAYAMAS MEDICA INDUSTRI Tbk DAN ENTITAS ANAK**  
**LAPORAN POSISI KEUANGAN KONSOLIDASIAN**  
**PER 30 JUNI 2025**  
(Disajikan dalam Rupiah, kecuali dinyatakan lain)

**PT JAYAMAS MEDICA INDUSTRI Tbk AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**  
**AS OF JUNE 30, 2025**  
(Expressed in Rupiah, unless otherwise stated)

|                                                                                                                                             | Catatan<br>/<br>Notes | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                                                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|--------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>LIABILITAS DAN EKUITAS (Lanjutan)</b>                                                                                                    |                       |                          |                                  | <b>LIABILITIES AND EQUITY (Continued)</b>                                                                                                           |
| <b>E K U I T A S</b>                                                                                                                        |                       |                          |                                  | <b>E Q U I T Y</b>                                                                                                                                  |
| Modal saham – dengan nilai nominal Rp 25 per saham – periode Juni 2025 dan tahun 2024                                                       |                       |                          |                                  | Share capital –<br>Rp 25 par value per share in June 2025 and in 2024                                                                               |
| Modal dasar - 92.000.000.000 saham, Modal ditempatkan dan disetor penuh 27.058.850.000 saham pada tanggal 30 Juni 2025 dan 31 Desember 2024 | 26                    | 676.471.250.000          | 676.471.250.000                  | Authorized shares –<br>92,000,000,000 shares,<br>Issued and fully paid capital -<br>27,058,850,000 shares as of June 30, 2025 and December 31, 2024 |
| Saham treasuri                                                                                                                              | 26                    | ( 1.842.632.147 )        | -                                | Treasury stock                                                                                                                                      |
| Tambahan modal disetor                                                                                                                      | 28                    | 223.188.269.200          | 223.188.269.200                  | Additional paid-in capital                                                                                                                          |
| Akumulasi rugi aktuarial atas imbalan paska-kerja                                                                                           |                       | ( 17.341.752.576 )       | ( 17.341.752.576 )               | Accumulated actuarial<br>loss on post-employment<br>benefit liabilities                                                                             |
| Saldo laba                                                                                                                                  | 25                    |                          |                                  | Retained earnings                                                                                                                                   |
| Telah ditentukan penggunaannya                                                                                                              |                       | 120.000.000.000          | 120.000.000.000                  | Appropriated                                                                                                                                        |
| Belum ditentukan penggunaannya                                                                                                              |                       | 1.516.149.801.535        | 1.459.018.580.223                | Unappropriated                                                                                                                                      |
| Total ekuitas yang diatribusikan kepada pemilik entitas induk                                                                               |                       | 2.516.624.936.012        | 2.461.336.346.847                | Total equity attributable<br>to owners of the parent company                                                                                        |
| Kepentingan nonpengendali                                                                                                                   | 40                    | 31.301.061.267           | 34.352.359.039                   | Non-controlling interests                                                                                                                           |
| <b>Total Ekuitas</b>                                                                                                                        |                       | <b>2.547.925.997.279</b> | <b>2.495.688.705.886</b>         | <b>Total Equity</b>                                                                                                                                 |
| <b>TOTAL LIABILITAS DAN EKUITAS</b>                                                                                                         |                       | <b>2.836.860.821.079</b> | <b>2.825.331.331.720</b>         | <b>TOTAL LIABILITIES AND EQUITY</b>                                                                                                                 |

Lihat Catatan atas Laporan Keuangan Konsolidasian pada Ekshibit E terlampir yang merupakan bagian yang tidak terpisahkan dari Laporan Keuangan Konsolidasian secara keseluruhan

See accompanying Notes to the Consolidated Financial Statements on Exhibit E which are an integral part of the Consolidated Financial Statements taken as a whole

Sidoarjo, 29 Juli/July 29, 2025



Herlien Sri Ariani  
Direktur Utama/President Director




Eka Suwignyo  
Direktur Keuangan/Finance Director

Ekshibit B

Exhibit B

PT JAYAMAS MEDICA INDUSTRI Tbk DAN ENTITAS ANAK  
LAPORAN LABA RUGI DAN PENGHASILAN  
KOMPREHENSIF LAIN KONSOLIDASIAN  
UNTUK PERIODE TIGA BULAN YANG BERAKHIR PADA  
30 JUNI 2025  
(Disajikan dalam Rupiah, kecuali dinyatakan lain)

PT JAYAMAS MEDICA INDUSTRI Tbk AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF PROFIT OR LOSS  
AND OTHER COMPREHENSIVE INCOME  
FOR THE THREE-MONTHS PERIOD ENDED  
JUNE 30, 2025  
(Expressed in Rupiah, unless otherwise stated)

|                                                                | Catatan/<br>Notes | 30 Juni/<br>June<br>2025 | 30 Juni/<br>June<br>2024 |                                                      |
|----------------------------------------------------------------|-------------------|--------------------------|--------------------------|------------------------------------------------------|
| <b>PENJUALAN NETO</b>                                          | <b>30</b>         | 925.846.133.453          | 879.648.060.816          | <b>NET SALES</b>                                     |
| <b>BEBAN POKOK PENJUALAN</b>                                   | <b>31</b>         | ( 613.077.155.012)       | ( 587.600.809.069)       | <b>COST OF GOODS SOLD</b>                            |
| <b>LABA BRUTO</b>                                              |                   | 312.768.978.441          | 292.047.251.747          | <b>GROSS PROFIT</b>                                  |
| Beban penjualan dan pemasaran                                  | <b>32</b>         | ( 84.194.711.148)        | ( 71.684.679.548)        | Selling and marketing expenses                       |
| Beban umum dan administrasi                                    | <b>33</b>         | ( 65.865.947.553)        | ( 60.446.567.918)        | General and administrative expenses                  |
| Pendapatan (beban) operasi lain-lain                           | <b>34</b>         | 6.625.066.328            | 5.086.249.200            | Other operating income (expenses)                    |
| <b>LABA DARI OPERASI</b>                                       |                   | 169.333.386.068          | 165.002.253.481          | <b>PROFIT FROM OPERATIONS</b>                        |
| Pendapatan keuangan                                            | <b>35</b>         | 31.385.997.536           | 26.848.397.564           | Finance income                                       |
| Beban keuangan                                                 | <b>36</b>         | ( 7.491.341.441)         | ( 9.574.859.620)         | Finance expenses                                     |
| <b>LABA SEBELUM PAJAK</b>                                      |                   | <b>193.228.042.163</b>   | <b>182.275.791.425</b>   | <b>PROFIT BEFORE TAX</b>                             |
| <b>BEBAN PAJAK</b>                                             |                   |                          |                          | <b>TAX EXPENSES</b>                                  |
| K ini                                                          | <b>29</b>         | ( 38.506.783.040)        | ( 37.395.833.860)        | Current                                              |
| Tangguhan                                                      |                   | ( 41.241.083)            | 358.928.133              | Deferred                                             |
| <b>Beban pajak - Neto</b>                                      |                   | <b>( 38.548.024.123)</b> | <b>( 37.036.905.727)</b> | <b>Income tax expense - Net</b>                      |
| <b>LABA TAHUN BERJALAN</b>                                     |                   | <b>154.680.018.040</b>   | <b>145.238.885.698</b>   | <b>PROFIT FOR THE YEAR</b>                           |
| <b>PENGHASILAN KOMPREHENSIF LAIN:</b>                          |                   |                          |                          | <b>OTHER COMPREHENSIVE INCOME:</b>                   |
| Pos yang tidak akan direklasifikasi ke dalam laporan laba rugi |                   | -                        | -                        | Item that will not be reclassified to profit or loss |
| Pengukuran kembali atas liabilitas imbalan paska-kerja         |                   | -                        | -                        | Remeasurement of post-employment benefit obligations |
| Pajak penghasilan terkait                                      |                   | -                        | -                        | Related income tax                                   |
| <b>PENGHASILAN (BEBAN) KOMPREHENSIF LAIN</b>                   |                   | <b>-</b>                 | <b>-</b>                 | <b>OTHER COMPREHENSIVE INCOME (EXPENSE)</b>          |
| <b>TOTAL LABA KOMPREHENSIF TAHUN BERJALAN</b>                  |                   | <b>154.680.018.040</b>   | <b>145.238.885.698</b>   | <b>TOTAL COMPREHENSIVE INCOME FOR THE YEAR</b>       |

Lihat Catatan atas Laporan Keuangan Konsolidasian pada Ekshibit E terlampir yang merupakan bagian yang tidak terpisahkan dari Laporan Keuangan Konsolidasian secara keseluruhan

See accompanying Notes to the Consolidated Financial Statements on Exhibit E which are an integral part of the Consolidated Financial Statements taken as a whole

Ekshibit B/2

Exhibit B/2

**PT JAYAMAS MEDICA INDUSTRI Tbk DAN ENTITAS ANAK**  
**LAPORAN LABA RUGI DAN PENGHASILAN**  
**KOMPREHENSIF LAIN KONSOLIDASIAN**  
**UNTUK PERIODE TIGA BULAN YANG BERAKHIR PADA**  
**30 JUNI 2025**  
**(Disajikan dalam Rupiah, kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI Tbk AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF PROFIT OR LOSS**  
**AND OTHER COMPREHENSIVE INCOME**  
**FOR THE THREE-MONTHS PERIOD ENDED**  
**JUNE 30, 2025**  
**(Expressed in Rupiah, unless otherwise stated)**

|                                                                        | Catatan/<br>Notes | 30 Juni/<br>June<br>2025 | 30 Juni/<br>June<br>2024 |                                                    |
|------------------------------------------------------------------------|-------------------|--------------------------|--------------------------|----------------------------------------------------|
| <b>Laba tahun berjalan yang dapat diatribusikan kepada:</b>            |                   |                          |                          | <b>Profit for the year attributable to:</b>        |
| Pemilik entitas induk                                                  |                   | 153.731.315.812          | 143.948.846.175          | Owners of the parent entity                        |
| Kepentingan nonpengendali                                              |                   | 948.702.228              | 1.290.039.523            | Non-controlling interests                          |
| <b>Jumlah</b>                                                          |                   | <b>154.680.018.040</b>   | <b>145.238.885.698</b>   | <b>Total</b>                                       |
| <b>Jumlah laba komprehensif tahun yang dapat diatribusikan kepada:</b> |                   |                          |                          | <b>Total comprehensive income attributable to:</b> |
| Pemilik entitas                                                        |                   | 153.731.315.812          | 143.948.846.175          | Owners of the entity                               |
| Kepentingan nonpengendali                                              |                   | 948.702.228              | 1.290.039.523            | Non-controlling interests                          |
| <b>Jumlah</b>                                                          |                   | <b>154.680.018.040</b>   | <b>145.238.885.698</b>   | <b>Total</b>                                       |
| <b>DASAR LABA PER SAHAM</b>                                            |                   | <b>5,68</b>              | <b>5,32</b>              | <b>BASIC EARNINGS PER SHARE</b>                    |

Lihat Catatan atas Laporan Keuangan Konsolidasian pada Ekshibit E terlampir yang merupakan bagian yang tidak terpisahkan dari Laporan Keuangan Konsolidasian secara keseluruhan

See accompanying Notes to the Consolidated Financial Statements on Exhibit E which are an integral part of the Consolidated Financial Statements taken as a whole

Sidoarjo, 29 Juli/July 29, 2025



**Hertien Sri Ariani**  
Direktur Utama/President Director




**Eka Suwignyo**  
Direktur Keuangan/Finance Director

The original consolidated financial statements included herein are in the Indonesian language

Ekshibit C

Exhibit C

PT JAYAMAS MEDICA INDUSTRI Tbk DAN ENTITAS ANAK  
LAPORAN PERUBAHAN EKUITAS KONSOLIDASIAN  
UNTUK PERIODE TIGA BULAN YANG BERAKHIR PADA  
30 JUNI 2025  
(Disajikan dalam Rupiah, kecuali dinyatakan lain)

PT JAYAMAS MEDICA INDUSTRI Tbk AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY  
FOR THE THREE-MONTHS PERIOD ENDED  
JUNE 30, 2025  
(Expressed in Rupiah, unless otherwise stated)

| Diatribusikan kepada pemilik entitas induk/Attributable to owners of the parent |                                                                       |                                                             |                                                                                                                                 |                                          |                                                   |                   |                                                         |                                 |
|---------------------------------------------------------------------------------|-----------------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|---------------------------------------------------|-------------------|---------------------------------------------------------|---------------------------------|
|                                                                                 | Modal ditempatkan dan disetor penuh/<br>Issued and fully paid capital | Tambahan modal disetor/<br>Additional paid-in Capital - net | Akumulasi laba (rugi) actuarial atas imbalan Kerjal<br>Accumulated actuarial gain (loss) on post-employment benefit liabilities | Laba ditahan/Retained Earnings           |                                                   | Jumlah/<br>Total  | Kepentingan nonpengendali/<br>Non-controlling interests | Jumlah ekuitas/<br>Total equity |
|                                                                                 |                                                                       |                                                             |                                                                                                                                 | Ditentukan penggunaannya/<br>Appropriate | Belum ditentukan penggunaannya/<br>Unappropriated |                   |                                                         |                                 |
| Saldo per 1 Januari 2024                                                        | 676.471.250.000                                                       | 223.188.269.200                                             | ( 16.715.011.046)                                                                                                               | 120.000.000.000                          | 1.215.274.605.898                                 | 2.218.219.114.052 | 27.188.847.889                                          | 2.245.407.961.941               |
| Setoran modal dari kepentingan Non-pengendali JWM (Catatan 1)                   | -                                                                     | -                                                           | -                                                                                                                               | -                                        | -                                                 | -                 | 4.900.000.000                                           | 4.900.000.000                   |
| Dividen yang telah ditetapkan (Catatan 27)                                      | -                                                                     | -                                                           | -                                                                                                                               | -                                        | ( 77.929.488.000)                                 | ( 77.929.488.000) | -                                                       | ( 77.929.488.000)               |
| Laba periode berjalan                                                           | -                                                                     | -                                                           | -                                                                                                                               | -                                        | 143.948.846.175                                   | 143.948.846.175   | 1.290.039.523                                           | 145.238.885.698                 |
| Saldo per 30 Juni 2024                                                          | 676.471.250.000                                                       | 223.188.269.200                                             | ( 16.715.011.046)                                                                                                               | 120.000.000.000                          | 1.281.293.964.073                                 | 2.284.238.472.227 | 33.378.887.412                                          | 2.317.617.359.639               |

Lihat Catatan atas Laporan Keuangan Konsolidasian pada Ekshibit E terlampir yang merupakan bagian yang tidak terpisahkan dari Laporan Keuangan Konsolidasian secara keseluruhan

See accompanying Notes to the Consolidated Financial Statements on Exhibit E which are an integral part of the Consolidated Financial Statements taken as a whole

The original consolidated financial statements included herein are in the Indonesian language

Ekshibit C/2

Exhibit C/2

PT JAYAMAS MEDICA INDUSTRI Tbk DAN ENTITAS ANAK  
LAPORAN PERUBAHAN EKUITAS KONSOLIDASIAN  
UNTUK PERIODE TIGA BULAN YANG BERAKHIR PADA  
30 JUNI 2025  
(Disajikan dalam Rupiah, kecuali dinyatakan lain)

PT JAYAMAS MEDICA INDUSTRI Tbk AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY  
FOR THE THREE-MONTHS PERIOD ENDED  
JUNE 30, 2025  
(Expressed in Rupiah, unless otherwise stated)

|                                               | Modal<br>Ditempatkan<br>dan disetor<br>penuh/<br><i>Issued and fully<br/>paid capital</i> | Tambahan<br>modal<br>disetor/<br><i>Additional paid-in<br/>Capital - net</i> | Saham<br>Tresuri/<br>Treasury<br>Stock | Akumulasi laba<br>(rugi) actuarial<br>atas imbalan<br>Kerjal/<br><i>Accumulated<br/>Actuarial gain<br/>(loss) on<br/>post-employment<br/>benefit<br/>liabilities</i> | Ditentukan<br>penggunaannya/<br><i>Appropriate</i> | Belum<br>ditentukan<br>penggunaannya/<br><i>Unappropriated</i> | Jumlah/<br><i>Total</i> | Kepentingan<br>nonpengendali/<br><i>Non-controlling<br/>interests</i> | Jumlah ekuitas/<br><i>Total equity</i> |                             |
|-----------------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------|-------------------------|-----------------------------------------------------------------------|----------------------------------------|-----------------------------|
| Saldo per 1 Januari 2025                      | 676.471.250.000                                                                           | 223.188.269.200                                                              |                                        | ( 17.341.752.576)                                                                                                                                                    | 120.000.000.000                                    | 1.459.018.580.223                                              | 2.461.336.346.847       | 34.352.359.039                                                        | 2.495.688.705.886                      | Balance per 1 January 2025  |
| Saham tresuri (Catatan 26)                    |                                                                                           |                                                                              | ( 1.842.632.147)                       |                                                                                                                                                                      |                                                    |                                                                | ( 1.842.632.147)        |                                                                       | ( 1.842.632.147)                       | Treasury stock (Note 26)    |
| Dividen yang telah<br>ditetapkan (Catatan 27) |                                                                                           |                                                                              |                                        |                                                                                                                                                                      |                                                    | ( 96.600.094.500)                                              | ( 96.600.094.500)       | ( 4.000.000.000)                                                      | ( 100.600.094.500)                     | Dividend declared (Note 27) |
| Laba tahun berjalan                           | -                                                                                         | -                                                                            |                                        | -                                                                                                                                                                    | -                                                  | 153.731.315.812                                                | 153.731.315.812         | 948.702.228                                                           | 154.680.018.040                        | Profit for the year         |
| Saldo per 30 Juni 2025                        | 676.471.250.000                                                                           | 223.188.269.200                                                              | ( 1.842.632.147)                       | ( 17.341.752.576)                                                                                                                                                    | 120.000.000.000                                    | 1.516.149.801.535                                              | 2.516.624.936.012       | 31.301.061.267                                                        | 2.547.925.997.279                      | Balance as of 30 June 2025  |

Lihat Catatan atas Laporan Keuangan Konsolidasian  
pada Ekshibit E terlampir yang merupakan bagian yang tidak terpisahkan  
dari Laporan Keuangan Konsolidasian secara keseluruhan

See accompanying Notes to the Consolidated Financial Statements  
on Exhibit E which are an integral part of  
the Consolidated Financial Statements taken as a whole

Ekshibit D

Exhibit D

**PT JAYAMAS MEDICA INDUSTRI Tbk DAN ENTITAS ANAK**  
**LAPORAN ARUS KAS KONSOLIDASIAN**  
**UNTUK PERIODE YANG BERAKHIR PADA**  
**30 JUNI 2025**  
**(Disajikan dalam Rupiah, kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI Tbk AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**FOR THE PERIOD ENDED**  
**JUNE 30, 2025**  
**(Expressed in Rupiah, unless otherwise stated)**

|                                                                       | Catatan/<br>Notes          | 30 Juni/<br>June<br>2025 | 30 Juni/<br>June<br>2024 |                                                            |
|-----------------------------------------------------------------------|----------------------------|--------------------------|--------------------------|------------------------------------------------------------|
| <b>ARUS KAS DARI AKTIVITAS OPERASI</b>                                |                            |                          |                          | <b>CASH FLOWS FROM OPERATING ACTIVITIES</b>                |
| Penerimaan kas dari pelanggan                                         |                            | 897.295.668.712          | 821.990.242.927          | Cash receipts from customers                               |
| Penerimaan kas dari pendapatan bunga                                  |                            | 29.219.958.039           | 27.574.627.850           | Cash receipt from interest income                          |
| Pembayaran kepada pemasok                                             | ( 543.469.038.306)         | ( 543.469.038.306)       | ( 548.828.058.640)       | Payments to suppliers                                      |
| Pembayaran untuk beban operasional                                    | ( 82.697.524.641)          | ( 82.697.524.641)        | ( 71.224.855.982)        | Payment for operating expenses                             |
| Pembayaran untuk gaji dan imbalan kerja karyawan                      | ( 90.516.077.943)          | ( 90.516.077.943)        | ( 83.960.683.086)        | Payment for salaries and employee benefits                 |
| Pembayaran beban bunga                                                | ( 9.060.302.917)           | ( 9.060.302.917)         | ( 8.710.244.027)         | Payment of interest expenses                               |
| Penerimaan dari tagihan pajak penghasilan                             |                            | 6.062.852.129            | 56.313.981.775           | Cash receipt from claim for tax refunds                    |
| Pembayaran pajak penghasilan                                          | ( 42.103.909.891)          | ( 42.103.909.891)        | ( 28.826.535.593)        | Payment income tax                                         |
| <b>Kas netto diperoleh dari (digunakan untuk) aktivitas operasi</b>   |                            | <u>164.731.625.182</u>   | <u>164.328.475.224</u>   | <b>Net cash provided by operating activities</b>           |
| <b>ARUS KAS DARI AKTIVITAS INVESTASI</b>                              |                            |                          |                          | <b>CASH FLOWS FROM INVESTING ACTIVITIES</b>                |
| Perolehan dari aset tetap                                             | 2l,12,14 ( 11.280.604.567) | ( 11.280.604.567)        | ( 38.837.039.456)        | Acquisition of fixed assets                                |
| Perolehan dari aset tak berwujud                                      | 2m,13 ( - )                | ( - )                    | ( 19.387.753)            | Acquisition of intangible assets                           |
| Peningkatan investasi jangka panjang                                  | 2g,15 ( 113.641.483.885)   | ( 113.641.483.885)       | ( 11.071.522.404)        | Acquisition of long-term investment                        |
| Pencairan (Peningkatan) Investasi jangka pendek                       | 2g,5 55.037.931.788        | 55.037.931.788           | ( 35.527.484.262)        | Withdrawal (acquisition) of short-term Investment          |
| Penambahan uang muka aset tetap                                       | ( 15.899.121.273)          | ( 15.899.121.273)        | ( 6.499.598.824)         | Additional of advance for purchases of fixed assets        |
| Penerimaan dari penjualan aset tetap                                  |                            | 5.541.667                | 963.463                  | Proceeds from sales of fixed assets                        |
| <b>Kas netto diperoleh dari (digunakan untuk) aktivitas investasi</b> |                            | <u>( 85.777.736.270)</u> | <u>( 91.954.069.236)</u> | <b>Net cash provided by (used in) investing activities</b> |

Lihat Catatan atas Laporan Keuangan Konsolidasian pada Ekshibit E terlampir yang merupakan bagian yang tidak terpisahkan dari Laporan Keuangan Konsolidasian secara keseluruhan

See accompanying Notes to the Consolidated Financial Statements on Exhibit E which are an integral part of the Consolidated Financial Statements taken as a whole

Ekshibit D/2

Exhibit D/2

**PT JAYAMAS MEDICA INDUSTRI Tbk DAN ENTITAS ANAK**  
**LAPORAN ARUS KAS KONSOLIDASIAN**  
**UNTUK TAHUN YANG BERAKHIR PADA**  
**30 JUNI 2025**  
**(Disajikan dalam Rupiah, kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI Tbk AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**FOR THE YEAR ENDED**  
**JUNE 30, 2025**  
**(Expressed in Rupiah, unless otherwise stated)**

|                                                                | Catatan/<br>Notes | 30 Juni/<br>June<br>2025  | 30 Juni/<br>June<br>2024 |                                                                                |
|----------------------------------------------------------------|-------------------|---------------------------|--------------------------|--------------------------------------------------------------------------------|
| <b>ARUS KAS DARI AKTIVITAS<br/>PENDANAAN</b>                   |                   |                           |                          | <b>CASH FLOWS FROM<br/>FINANCING ACTIVITIES</b>                                |
| Pembayaran liabilitas sewa                                     | 20                | ( 15.684.666.669)         | ( 13.912.776.000)        | Payment of lease liabilities                                                   |
| Pembayaran surat utang jk. menengah                            |                   | ( 160.000.000.000)        | -                        | Medium term-notes payment                                                      |
| Pembelian kembali saham                                        |                   | ( 1.842.632.147)          | -                        | Stocks repurchased                                                             |
| Pembayaran pinjaman bank                                       |                   | ( 477.474.451)            | -                        | Bank loan payment                                                              |
| <b>Kas neto digunakan untuk<br/>aktivitas pendanaan</b>        |                   | <b>( 178.004.773.267)</b> | <b>( 13.912.776.000)</b> | <b>Net cash used in<br/>Activities</b>                                         |
| <b>KENAIKAN<br/>KAS DAN SETARA KAS</b>                         |                   | <b>( 99.050.884.355)</b>  | <b>58.461.629.988</b>    | <b>INCREASE IN CASH<br/>AND CASH EQUIVALENTS</b>                               |
| Pengaruh neto perubahan nilai<br>tukar pada kas dan setara kas |                   | 4.704.068.553             | 7.030.860.361            | The net effect of changes in<br>exchange rates on cash<br>and cash equivalents |
| <b>KAS DAN SETARA KAS<br/>AWAL TAHUN</b>                       |                   | <b>1.224.705.775.933</b>  | <b>1.120.572.328.713</b> | <b>CASH AND CASH EQUIVALENTS<br/>AT THE BEGINNING OF YEAR</b>                  |
| <b>KAS DAN SETARA KAS<br/>AKHIR TAHUN</b>                      | 2g, i,4           | <b>1.130.358.960.131</b>  | <b>1.186.064.819.062</b> | <b>CASH AND CASH EQUIVALENTS<br/>AT END OF YEAR</b>                            |

Lihat Catatan atas Laporan Keuangan Konsolidasian  
pada Ekshibit E terlampir yang merupakan bagian yang tidak  
terpisahkan  
dari Laporan Keuangan Konsolidasian secara keseluruhan

See accompanying Notes to the Consolidated Financial  
Statements on Exhibit E which are an integral part of  
the Consolidated Financial Statements taken as a whole

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**1. UMUM**

**a. Pendirian dan Informasi Umum**

PT Jayamas Medica Industri ("Perusahaan") didirikan berdasarkan akta Notaris No. 5 tanggal 15 Desember 2000 yang dibuat dihadapan Devi Chrisnawati, S.H., Notaris di Surabaya. Akta Pendirian telah mendapat pengesahan dari Menteri Kehakiman Republik Indonesia dalam Surat Keputusan No. C-09367.HT.01.01.Th 2001, tanggal 27 September 2001 dan telah diumumkan dalam Berita Negara No. 105 Tambahan No. 041636 tanggal 31 Desember 2021.

Anggaran dasar Perusahaan telah mengalami beberapa kali perubahan, dengan perubahan terakhir melalui akta Notaris No. 2 tanggal 3 September 2024 yang dibuat dihadapan Dr. Susanti, S.H., M.Kn., Notaris di Surabaya mengenai ruang lingkup Perusahaan dan telah diterima dan dicatat oleh Kementerian Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-0186635.AH.01.11.TAHUN 2024 tanggal 3 September 2024.

Sesuai dengan Pasal 3 anggaran dasar Perusahaan, ruang lingkup kegiatan Perusahaan terutama bergerak dalam bidang industri pengolahan, perdagangan besar dan eceran alat kesehatan.

Perusahaan dan pabriknya berdomisili di Jalan By Pass Krian, Desa Sidomojo Krian, Sidoarjo Jawa Timur dan memiliki pabrik lain yang terletak di Jalan A Yani, Kecamatan Mojoagung, Jombang - Jawa Timur.

Perusahaan Induk adalah PT Intisumber Hasil Sempurna, didirikan di Republik Indonesia pada tanggal 4 Maret 1992. Pemegang saham utama PT Intisumber Hasil Sempurna adalah sekelompok individu (keluarga).

**b. Penawaran Umum Saham**

Berdasarkan akta Notaris No. 77 tanggal 7 April 2022 yang dibuat dihadapan Jose Dima Satria, SH., M.Kn., Notaris di Jakarta, akta Notaris tersebut telah diberitahukan dan diterima oleh Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dengan Surat Keputusan No. AHU-0070244.AH.01.11.TAHUN 2022 tanggal 8 April 2022 tentang:

- Menyetujui perubahan status Perusahaan dari Perseroan Terbatas Tertutup menjadi Perseroan Terbatas Terbuka dan karenanya mengubah nama PT Jayamas Medica Industri menjadi PT Jayamas Medica Industri Tbk.

**1. GENERAL**

**a. Establishment and General Information**

*PT Jayamas Medica Industri (the "Company") was established based on Notarial deed No. 5 dated December 15, 2000 of Devi Chrisnawati, S.H., Notary in Surabaya. The Deed of Establishment was approved by the Minister of Justice of the Republic of Indonesia in its Decision Letter No. C-09367.HT.01.01.Th 2001 dated September 27, 2001 and was published in the State Gazette No. 105 Supplement No. 041636 dated December 31, 2021.*

*The Company's articles of association has been amended several times, with the latest amendment being made by Notarial deed No. 2 dated September 3, 2024 of Dr. Susanti, S.H., M.Kn., Notary in Surabaya regarding the scope of the Company's activities and the changes received and registered by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-0186635.AH.01.11.TAHUN 2024 dated September 3, 2024.*

*In accordance with Article 3 of the Company's articles of association, the scope of the Company's activities are primarily engaged in manufacturing, wholesale and retail trade of medical devices.*

*The Company's office and its plants are located at Jalan By Pass Krian, Desa Sidomojo Krian, Sidoarjo Jawa Timur and has another plant which is located at Jalan A Yani, Kecamatan Mojoagung, Jombang - Jawa Timur.*

*The Parent Company is PT Intisumber Hasil Sempurna, established in Republic Indonesia on 4 March 1992. The ultimate shareholders of the PT Intisumber Hasil Sempurna are a group of individuals (a family).*

**b. Public Offering Shares**

*Based on Notarial deed No. 77 dated April 7, 2022 drawn up before Jose Dima Satria, SH., M.Kn., Notary in Jakarta, the Notarial deed have been notified and accepted by the Minister of Law and Human Rights of the Republic of Indonesia by its Decision Letter No. AHU-0070244.AH.01.11.TAHUN 2022 dated April 8, 2022 concerning:*

- *Approved the change in the Company's status from a Closed Company to a Public Limited Liability Company and therefore changed the name of PT Jayamas Medica Industri to PT Jayamas Medica Industri Tbk.*

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

- Menyetujui Penawaran Umum Perdana Saham (*Initial Public Offering/IPO*) Perusahaan melalui pengeluaran saham baru dari dalam simpanan (*portepel*) Perusahaan sebanyak banyaknya sebesar 5.048.800.000 (lima miliar empat puluh delapan juta delapan ratus ribu) saham dengan nilai nominal per saham Rp 25 (dua puluh lima rupiah), untuk ditawarkan kepada masyarakat baik di wilayah Republik Indonesia dan /atau secara internasional dan untuk dicatatkan di Bursa Efek Indonesia. Pemegang saham Perusahaan dengan ini mengesampingkan haknya untuk mengambil bagian atas saham baru yang dikeluarkan tersebut.

Perusahaan menyampaikan Pernyataan Pendaftaran kepada Otoritas Jasa Keuangan Indonesia (OJK) dalam rangka Penawaran Umum Saham Perdana pada tanggal 8 Juli 2022 melalui surat No. 006/JMI-DIR/VII/22. Pada tanggal 31 Oktober 2022, Perusahaan memperoleh pernyataan efektif dari OJK melalui surat No. S-223/D.04/2022 perihal Pemberitahuan Efektifnya Pernyataan Pendaftaran dalam rangka Penawaran Umum Perdana Saham Biasa Perusahaan.

Perusahaan menawarkan 4.058.850.000 saham, atau 15,00% dari jumlah saham yang ditempatkan Perusahaan, kepada masyarakat pada harga penawaran sebesar Rp 204 per saham. Saham yang ditawarkan merupakan saham dengan harga nominal Rp 25 per saham. Selisih lebih antara harga penawaran per saham dengan nilai nominal per saham dicatat sebagai tambahan modal disetor setelah dikurangi biaya emisi saham, yang disajikan pada bagian ekuitas pada laporan posisi keuangan konsolidasian.

Perusahaan memberikan program alokasi saham kepada karyawan Perusahaan (*Employee Share Allocation*) dengan jumlah sebanyak banyaknya 2% (dua persen) dari jumlah saham yang telah ditawarkan oleh Perusahaan melalui Penawaran Umum Saham Perdana ("Program ESA") dengan memperhatikan peraturan BEI dan perundang-undangan yang berlaku. Selanjutnya memberikan wewenang dan kuasa kepada Direksi untuk melakukan segala tindakan yang diperlukan dalam melaksanakan yang diperlukan dalam melaksanakan Program ESA, termasuk namun tidak terbatas pada menentukan kepastian jumlah saham Program ESA, menentukan kriteria karyawan yang berhak menerima saham Program ESA, dan jumlah karyawan yang akan menerima saham Program ESA.

- Approved the Company's Initial Public Offering (IPO) through the issuance of new shares from the Company's deposit (*portepel*) in the amount of 5,048,800,000 (five billion forty eight million eight hundred thousand) shares with a nominal value per share of Rp 25 (twenty five rupiahs), to be offered to the public both within the territory of the Republic of Indonesia and/or internationally and to be listed on the Indonesia Stock Exchange. The shareholders of the Company hereby waive their rights to subscribe for the new shares issued.

The Company submitted a registration statement to Indonesian Financial Services Authority (OJK) related to Public Offering of Ordinary Shares through letter dated July 8, 2022 No. 006/JMI-DIR/VII/22. On October 31, 2022, the Company received effective statement from OJK through letter No. S-223/D.04/2022 about Notification of effectiveness Registration of the Company's Public Offering of Ordinary Shares.

The Company offered 4,058,850,000 shares, or 15.00% of the total of the Company's issued shares, to the public at an offering price of Rp 204 per share. The offered shares are shares with par value of Rp 25 per share. The excess of the share offering price over the par value per share are recognized as additional paid-in capital after deducting shares issuance costs, which is presented under the equity section of the consolidated statement of financial position.

The Company provide a share allocation program to the Company's employees (*Employee Share Allocation*) with a maximum amount of 2% (two percent) of the number of shares that have offered by the Company through an Initial Public Offering ("ESA Program") with due observance of IDX regulations and laws – applicable invitation Furthermore, granting authority and power to the Board of Directors to take all necessary actions in carrying out those required in implementing the ESA Program, including but not limited to determining the certainty of the number of ESA Program shares, determining the criteria for employees who are entitled to receive ESA Program shares, and the number of employees who will receive ESA Program shares.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Perusahaan mengeluarkan saham baru dalam rangka program Opsi Saham Management dan Karyawan (*Management and Employee Stock Option Plan*) ("Program MESOP") dengan jumlah sebanyak banyaknya 126.219.600 (seratus dua puluh enam juta dua ratus sembilan belas ribu enam ratus) saham. Program MESOP ditetapkan lebih lanjut oleh Dewan Komisaris Perusahaan dengan memperhatikan peraturan perundang-undangan yang berlaku.

Berdasarkan akta Notaris No. 31 tanggal 8 Desember 2022 yang dibuat dihadapan Jose Dima Satria, S.H., M.Kn., Notaris di Jakarta, Perusahaan telah melakukan peningkatan modal ditempatkan dan modal disetor sebanyak 4.058.850.000 saham atau dengan nilai nominal sebesar Rp 101.471.250.000 untuk masyarakat. Akta Notaris tersebut telah diberitahukan dan diterima oleh Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dengan Surat Keputusan No. AHU-0249168.AH.01.11.TAHUN 2022 tanggal 12 Desember 2022

**Pembelian Kembali Saham**

Pada tanggal 19 Mei 2025, Perusahaan mengumumkan untuk melakukan pembelian kembali saham (buyback) sesuai dengan peraturan Otoritas Jasa Keuangan (OJK) No. 13/POJK.04/2023 tentang Kebijakan dalam Menjaga Kinerja dan Stabilitas Pasar Modal pada Kondisi Pasar yang Berfluktuasi secara Signifikan. Pembelian kembali saham tersebut dilakukan selama periode 20 Mei 2025 sampai dengan 20 Agustus 2025 dalam rangka meningkatkan stabilitas harga saham. Seluruh kegiatan pembelian kembali saham telah dilaporkan kepada OJK dan Laporan Informasi atau Fakta Material Pembelian Kembali Saham Perseroan dalam Kondisi Pasar yang Berfluktuasi secara Signifikan telah diumumkan kepada publik sebagai bagian dari keterbukaan informasi dan prinsip tata kelola perusahaan yang baik (catatan 26).

Berdasarkan Rapat Umum Pemegang Saham Luar Biasa tanggal 26 Juni 2025, yang berita acaranya dituangkan dalam Akta Notaris No. 18 tanggal 26 Juni 2025 dari Notaris Dr. Susanti, S.H., MKn., para pemegang saham menyetujui untuk melakukan pembelian kembali saham maksimal senilai Rp. 5.000.000.000 dari kas internal dalam rangka mengalokasikan program kepemilikan saham Perusahaan bagi pegawai yang akan berlangsung dari 27 Juni 2025 hingga 27 Juni 2026.

The Company have issued new shares in the framework of the Management and Employee Stock Option Plan ("MESOP Program") with a total of 126,219,600 (one hundred twenty six million two hundred nineteen thousand six hundred) shares. The MESOP program is further determined by the Company's Board of Commissioners with due observance of the prevailing laws and regulations.

Based on Notarial deed No. 31 dated December 8, 2022 drawn up before Jose Dima Satria, S.H., M.Kn., Notary in Jakarta, the Company has increased the issued and paidup capital of 4,058,850,000 shares or with a nominal value of Rp 101,471,250,000 for public. The Notarial deed have been notified and accepted by the Minister of Law and Human Rights of the Republic of Indonesia by its Decision Letter no. AHU-0249168.AH.01.11.TAHUN 2022 dated 12 December 2022.

**Share Buyback**

On May 19, 2025, The Company has announced to conduct stock repurchased based on the Financial Services Authority (OJK) Regulation No. 13/POJK.04/2023 concerning Policies to Maintain Market Performance and Stability Under Significantly Fluctuating Market Conditions. The share buy-back carried out starting from May 20, 2025 to August 20, 2025, with the objective of supporting the stability of the Company's share price. All buyback activities have been reported to OJK and Material Information or Fact of Repurchased Stocks have disclosed to the public as part of the Company's commitment to transparency and good corporate governance (Note 26).

Based on Extraordinary General Shareholders Meeting dated on June 26, 2025, which was notarized by Notarial Deed No. 18 dated on June 26, 2025, of Notary Dr. Susanti, S.H., MKn., the shareholders agreed to repurchase the shares with a maximum amount of Rp. 5,000,000,000 using internal cash to allocate shares for the Corporate's employee stock ownership program which will be held from June 27, 2025 to June 27, 2026.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**c. Dewan Komisaris dan Direksi, Komite Audit dan Karyawan**

Pada tanggal 30 Juni 2025 dan 31 Desember 2024, susunan anggota Dewan Komisaris dan Direksi Perusahaan adalah sebagai berikut:

**Dewan Komisaris**

|                 |   |                        |   |
|-----------------|---|------------------------|---|
| Komisaris Utama | : | Yacobus Jemmy Hartanto | : |
| Komisaris       | : | Siane Soetanto         | : |
| Komisaris       | : | David Allen Worth      | : |

**Direksi**

|                   |   |                          |   |
|-------------------|---|--------------------------|---|
| Presiden Direktur | : | Herlien Sri Ariani       | : |
| Direktur          | : | Leonard Hariadi Hartanto | : |
| Direktur          | : | Louis Krisnadi Hartanto  | : |
| Direktur          | : | Eka Suwignyo             | : |

Susunan Komite Audit Perusahaan pada tanggal 30 Juni 2025 dan 31 Desember 2024 adalah sebagai berikut:

**Komite Audit**

|         |   |                   |   |
|---------|---|-------------------|---|
| Ketua   | : | David Allen Worth | : |
| Anggota | : | Ronny Budisantoso | : |
| Anggota | : | Lie, Ryan Limanto | : |

Pada tanggal 31 Desember 2022, Perusahaan telah menunjuk Daniel Kurniawan sebagai sekretaris perusahaan.

Personel manajemen kunci Perusahaan adalah orang-orang yang mempunyai kewenangan dan tanggung jawab untuk merencanakan, memimpin dan mengendalikan aktivitas Perusahaan. Seluruh anggota Dewan Komisaris dan Direksi dianggap sebagai manajemen kunci Perusahaan.

Pada tanggal 30 Juni 2025 dan 31 Desember 2024, Perusahaan dan entitas anak memiliki jumlah karyawan sebanyak 1.257 dan 1.220 (tidak diaudit).

Berdasarkan keputusan Rapat Umum Pemegang Saham Luar Biasa (RUPSLB) tanggal 3 September 2024, David Allen Worth diangkat sebagai Komisaris Independen Perseroan menggantikan Brigjen (Purn) Dr. Supriyanto, Sp.P, MARS, efektif 3 September 2024. Berdasarkan Surat Keputusan Dewan Komisaris pada tanggal 4 September 2024, David Allen Worth diangkat sebagai Ketua Komite Audit menggantikan Brigjen (Purn) Dr. Supriyanto, Sp.P, MARS, efektif 4 September 2024.

**c. Boards of Commissioners and Directors, Audit Committee and Employees**

As at June 30, 2025 and December 31, 2024, the composition of the Company's Boards of Commissioners and Directors is as follows:

**Board of Commissioners**

|                        |
|------------------------|
| President Commissioner |
| Commissioner           |
| Commissioner           |

**Directors**

|                    |
|--------------------|
| President Director |
| Director           |
| Director           |
| Director           |

The composition of the Company's Audit Committee as at June 30, 2025 and December 31, 2024 is as follows:

**Audit Committee**

|          |
|----------|
| Chairman |
| Member   |
| Member   |

As of December 31, 2022, the Company has appointed Daniel Kurniawan as corporate secretary.

Key management personnel of the Company are those persons having the authority and responsibility for planning, directing and controlling the activities of the Company. All members of the Boards of Commissioners and Directors are considered as key management personnel of the Company.

As of June 30, 2025 and December 31, 2024, the Company and its Subsidiaries have 1,257 and 1,220 employees, respectively (unaudited).

Based on a resolution of the Extraordinary General Meeting of Shareholders on 3 September 2024, David Allen Worth was appointed as Independent Commissioner of the Company replacing Brigadier General (Ret.) Dr. Supriyanto, Sp.P, MARS, effective 3 September 2024. Based on the Resolution Letter of the Board of Commissioners on 4 September 2024, David Allen Worth was appointed as an Audit Committee Chairman replacing Brigadier General (Ret.) Dr. Supriyanto, Sp.P, MARS, effective 4 September 2024.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**d. Entitas Anak yang Dikonsolidasikan**

Pada tanggal akhir periode pelaporan, rincian entitas anak dari Grup adalah sebagai berikut:

| Entitas Anak/<br>Subsidiaries                  | Tempat<br>kedudukan/<br>Domicile | Ruang<br>lingkup usaha/<br>Scope of<br>activities                                                                                                                                                              | Tahun dimulai<br>kegiatan<br>komersial/<br>Start of<br>commercial<br>year | Jumlah aset sebelum eliminasi/<br>Total assets before elimination |      |                          |                                  |
|------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------|------|--------------------------|----------------------------------|
|                                                |                                  |                                                                                                                                                                                                                |                                                                           | Percentage<br>of<br>ownership                                     |      | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |
|                                                |                                  |                                                                                                                                                                                                                |                                                                           | 2025                                                              | 2024 |                          |                                  |
| PT Intisumber Hasil Sempurna Global (IHSG) (1) | Surabaya                         | Perdagangan besar alat laboratorium farmasi dan kedokteran, pergudangan dan penyimpanan, aktivitas pengepakan/ Wholesale of pharmaceutical and medical laboratory equipment, warehousing and storage, packing. | 2021                                                                      | 99%                                                               | 99%  | 1.162.364.623.005        | 1.230.522.567.074                |
| PT Inti Medicom Retailindo (2)                 | Surabaya                         | Pengadaan, pemeliharaan, perbaikan alat-alat kesehatan dan perdagangan/ Procurement, maintenance, repair of medical devices, trade.                                                                            | 2012                                                                      | 75%                                                               | 75%  | 104.365.183.462          | 96.928.477.658                   |
| PT Jayamas Wellong Medical (1)                 | Jombang                          | Industri dan perdagangan alat-alat kesehatan dan bahan medis habis pakai/ Manufacturing and selling of medical equipment and medical disposable                                                                | 2024                                                                      | 51%                                                               | 51%  | 9.341.331.717            | 9.598.959.037                    |

Pemilikan langsung oleh/ *Equity interest directly held by:*

1. Perusahaan / *The Company*
2. PT Intisumber Hasil Sempurna Global

**PT Intisumber Hasil Sempurna Global (IHSG)**

PT Intisumber Hasil Sempurna Global didirikan di Republik Indonesia berdasarkan akta Notaris Julia Seloadji, S.H., No. 59 tanggal 28 November 2019 dengan modal dasar sebesar Rp 1.000.000.000 ditempatkan dan disetor sebesar Rp 250.000.000.

Tahun 2023, Perusahaan melakukan peningkatan investasi ke PT Intisumber Hasil Sempurna Global sebesar Rp 50.000.000.000 dan telah diaktakan dengan Akta Notaris No. 17 tanggal 21 Juni 2023 yang dibuat dihadapan Dr. Susanti, S.H., M.Kn., dan telah disahkan oleh Menteri Kehakiman Republik Indonesia dalam Surat Keputusan No. AHU-0116420.AH.01. Tahun 2023 tanggal 21 Juni 2023.

PT Intisumber Hasil Sempurna Global bergerak dalam bidang perdagangan besar alat laboratorium, farmasi dan kedokteran, pergudangan dan penyimpanan, aktivitas pengepakan. Kegiatan utama Perusahaan adalah berusaha dalam distribusi perdagangan besar alat laboratorium, farmasi dan kedokteran. Perusahaan berdomisili di Kompleks Darmo Park II Blok IV No. 14, Jl. Mayjend Sungkono, Kelurahan Dukuh Pakis, Kecamatan Dukuh Pakis, Surabaya.

**d. Consolidated Subsidiaries**

As at the end of the reporting period, details of the Group's subsidiaries are as follows:

**PT Intisumber Hasil Sempurna Global (IHSG)**

PT Intisumber Hasil Sempurna Global (IHSG) was established in the Republic of Indonesia based on Notarial deed of Julia Seloadji, S.H., No. 59 dated November 28, 2019 with an authorized capital of Rp 1,000,000,000 and issued and paid-up capital amounting to Rp 250,000,000.

In 2023, the Company increased its investment in PT Intisumber Hasil Sempurna Global amounted to Rp 50,000,000,000 and was notarized effected Notarial deed No. 17 dated June 21, 2023 of Dr. Susanti, S.H., M.Kn and has approved by the Minister of Justice of the Republic of Indonesia in Decision No. AHU-0116420.AH.01. Year 2023 dated June 21, 2023.

PT Intisumber Hasil Sempurna Global is engaged in wholesale trading of laboratory equipment, pharmaceuticals and medicine, warehousing and storage, packaging activities. The main activity of the Company is to engage in wholesale trading of laboratory, pharmaceutical and medical equipment. The Company is domiciled in Kompleks Darmo Park II Blok IV No. 14, Jl. Mayjend Sungkono, Kelurahan Dukuh Pakis, Kecamatan Dukuh Pakis, Surabaya.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**PT Inti Medicom Retailindo (IMR)**

PT Inti Medicom Retailindo (IMR) didirikan berdasarkan akta Notaris No. 55 tanggal 15 Desember 2012 dari DR. J. Andy Hartanto, S.H., M.H., I.R., M.M.T., Notaris di Surabaya dengan modal dasar Rp 1.000.000.000 ditempatkan dan disetor penuh sebesar Rp 250.000.000.

Berdasarkan akta No. 21 tanggal 26 Juni 2023, Notaris Dr. Susanti S.H., M.Kn., PT Intisumber Hasil Sempurna Global melakukan penyertaan modal tambahan sebesar Rp 489.000.000 untuk modal saham dengan melakukan setoran modal secara tunai sebesar Rp 42.009.980.220, yang mana selisih setoran sebesar Rp 41.520.980.220 dicatat sebagai agio saham sehingga secara efektif Perusahaan telah mengakuisisi 75% kepemilikan atas IMR. Akta tersebut telah mendapat pengesahan dari Menteri Kehakiman Republik Indonesia dengan Surat Keputusan No. AHU 0119982.AH.01.11. tahun 2023 tanggal 26 Juni 2023.

IMR bergerak dalam bidang pengadaan, pemeliharaan dan perbaikan alat kesehatan, menjalankan usaha di bidang perdagangan pada umumnya, termasuk ekspor, impor, lokal dan antar pulau semua barang yang diproduksi sendiri atau diproduksi oleh perusahaan lain, termasuk menjadi agen, grosir, pemasok dan distributor semua jenis diperdagangkan tetapi tidak terbatas pada perdagangan alat kesehatan. IMR berdomisili di Surabaya.

**PT Jayamas Wellong Medical (JWM)**

PT Jayamas Wellong Medical (JWM) didirikan di Republik Indonesia berdasarkan akta Notaris Julia Seloadji, S.H., No. 60 tanggal 24 November 2023 dengan modal dasar sebesar Rp 25.000.000.000 ditempatkan dan disetor sebesar Rp 10.001.000.000. Akta tersebut telah mendapat pengesahan dari Menteri Kehakiman Republik Indonesia dengan Surat Keputusan No. AHU-0091078.AH.01.01.TAHUN 2023 tanggal 29 November 2023.

Perusahaan melakukan penyertaan atas 51% saham pada JWM sebesar Rp. 5.101.000.000. Perusahaan telah melakukan penyeteroran modal tunai kepada PT Jayamas Wellong Medical pada 28 Juni 2024. Wellong International Limited telah melakukan penyeteroran modal tunai pada PT Jayamas Wellong Medical pada tanggal 3 Desember 2024

JWM bergerak dalam bidang produksi dan penjualan alat Kesehatan dan Badan Medis Habis Pakai untuk export. JWM berdomisili di Jombang.

**PT Inti Medicom Retailindo (IMR)**

PT Inti Medicom Retailindo (IMR) was established based on Notarial deed No. 55 dated December 15, 2012 of DR. J. Andy Hartanto, S.H., M.H., I.R., M.M.T., Notary in Surabaya with an authorized capital of Rp 1,000,000,000 and issued and paid-up capital amounting to Rp 250,000,000.

Based on Deed No. 21 dated June 26, 2023, Notary Dr. Susanti S.H., M.Kn., PT Intisumber Hasil Sempurna Global invested an additional capital of Rp 489,000,000 for share capital by making a cash deposit of Rp 42,009,980,220. The difference in the deposit, amounting to Rp 41,520,980,220, is recorded as share premium, effectively resulting in the company acquiring a 75% ownership on IMR. This deed has been authorized by the Minister of Justice of the Republic of Indonesia with Decree No. AHU 0119982.AH.01.11. year 2023 dated June 26, 2023.

IMR is engaged in the procurement, maintenance and repair of medical devices, conducting business in the trade sector in general, including export, import, local and inter-island of all goods produced by themselves or produced by other companies, including being agents, wholeseller, suppliers and distributors of all kinds traded but not limited to trading in medical devices. IMR is domiciled at Surabaya.

**PT Jayamas Wellong Medical (JWM)**

PT Jayamas Wellong Medical (JWM) was established based on Notarial deed No. 60 dated November 24, 2023 of Julia Seloadji, S.H., Notary in Surabaya with an authorized capital of Rp 25,000,000,000 and issued and paid-up capital amounting to Rp 10,001,000,000. This deed has been authorized by the Minister of Justice of the Republic of Indonesia with Decree No. AHU-0091078.AH.01.01. year 2023 dated November 29, 2023.

The Company has a portion of a 51% equity interest in JWM amounting Rp. 5,101,000,000. The Company has paid up the share capital to PT Jayamas Wellong Medical on June 28, 2024. Wellong Internation Limited has not yet paid up the share capital to PT Jayamas Wellong Medica dated December 3, 2024.

JWM is engaged in manufacturing and selling medical equipment and medical disposable for export. JWM is domiciled in Jombang.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**2. PENERAPAN PERNYATAAN STANDAR AKUNTANSI KEUANGAN (PSAK) BARU DAN REVISI DAN INTERPRETASI STANDAR AKUNTANSI KEUANGAN (ISAK)**

**a. Perubahan Nomenklatur Standar Akuntansi Keuangan Indonesia**

Sejalan dengan pengesahan Kerangka Standar Pelaporan Keuangan Indonesia, Dewan Standar Akuntansi Keuangan Ikatan Akuntan Indonesia (DSAK-IAI) menyetujui perubahan nomenklatur Standar Akuntansi Keuangan Indonesia yang mengatur penomoran Pernyataan Standar Akuntansi Keuangan (PSAK) dan Interpretasi atas Standar Akuntansi Keuangan (ISAK). Hal ini bertujuan untuk membedakan antara PSAK dan ISAK yang diadopsi dari International Financial Reporting Standards (IFRS) dan yang tidak. Perubahan nomenklatur Standar Akuntansi Keuangan Indonesia yang berlaku efektif pada 1 Januari 2025, tidak akan mempengaruhi isi masing-masing PSAK dan ISAK.

**b. Amendemen/Penyesuaian Standar yang Berlaku Efektif pada Tahun Berjalan**

Dalam tahun berjalan, Grup telah menerapkan sejumlah amendemen/penyesuaian PSAK yang relevan dengan operasinya dan efektif untuk periode akuntansi yang dimulai pada atau setelah 1 Januari 2025. Penerapan atas PSAK revisi tidak mengakibatkan perubahan atas kebijakan akuntansi Grup dan tidak memiliki dampak material terhadap jumlah yang dilaporkan pada tahun berjalan atau tahun-tahun sebelumnya:

Efektif untuk periode yang dimulai pada atau setelah tanggal 1 Januari 2025:

- PSAK 117, "Kontrak Asuransi"

PSAK 117 mengatur relaksasi beberapa ketentuan antara lain berupa penambahan pengecualian ruang lingkup, penyesuaian penyajian laporan keuangan, penerapan opsi mitigasi risiko dan beberapa modifikasi pada ketentuan transisi. PSAK 117 juga mensyaratkan pemisahan yang jelas antara pendapatan yang dihasilkan dari bisnis asuransi dengan yang berasal dari kegiatan investasi.

- PSAK 117 (Amendemen), "Kontrak Asuransi", Penerapan Awal PSAK 117 dan PSAK 109 - Informasi Komparatif

Amendemen ini memperjelas pengaturan bagi entitas industri asuransi yang akan melakukan penerapan awal PSAK 117 dan PSAK 109

**2. ADOPTION OF NEW AND REVISED STATEMENTS OF FINANSIAL ACCOUNTING STANDARDS (SFAS) AND INTERPRETATIONS OF FINANSIAL ACCOUNTING STANDARDS (IFAS)**

**a. Change in the Indonesian Financial Accounting Standards Nomenclature**

In line with the ratification of the Indonesian Financial Reporting Standards Framework, the Financial Accounting Standards Board of the Indonesian Institute of Accountants ("DSAK-IAI") approved the change in the Indonesian Financial Accounting Standards nomenclature which regulates the numbering of Statements of Financial Accounting Standards ("SFAS") and Interpretations of Financial Accounting Standards ("ISAK"). This aims to differentiate between PSAK and ISAK which are adopted from International Financial Reporting Standards (IFRS) and to those which are not. The change in the Indonesian Financial Accounting Standards nomenclature, which is effective on January 1, 2025, does not affect the contents of each PSAK and ISAK.

**b. Amendments/Improvements to Standards Effective in the Current Year**

In the current year, the Group has applied amendments/improvements to SFAS that are relevant to its operations and effective for accounting period beginning on or after January 1, 2025. The adoption of these revised SFAS' does not result in changes to the Group's accounting policies and has no material effect on the amounts reported for the current or prior years.

Effective for periods beginning on or after January 1, 2025:

- SFAS 117, "Insurance Contracts"

SFAS 117 regulates the relaxation of several provisions, including the addition of scope exceptions, adjustments to the presentation of financial statements, application of risk mitigation options and some modifications to transitional provisions. SFAS 117 also requires a clear separation between income generated from the insurance business and from investment activities.

- SFAS 117 (Amendment), "Insurance Contract", Initial Application of SFAS 117 and SFAS 109 - Comparative Information

This amendment clarifies the arrangements for insurance industry entities that will carry out the initial adoption of SFAS 117 and SFAS

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

dalam periode bersamaan. Amandemen ini juga mengatasi isu penerapan yang terkait dengan informasi komparatif yang akan disajikan pada penerapan awal untuk aset keuangan.

- PSAK 221 (Amendemen), "Pengaruh Perubahan Kurs Valuta Asing": Kekurangan Ketertukaran"

Amandemen ini mensyaratkan entitas untuk menerapkan pendekatan yang konsisten dalam menilai apakah suatu mata uang dapat ditukar dengan mata uang lain dan, jika tidak, dalam menentukan nilai tukar yang akan digunakan dan pengungkapan yang harus diberikan.

Efektif untuk periode yang dimulai pada atau setelah tanggal 1 Januari 2026:

- Amandemen PSAK 109, "Instrumen Keuangan" dan PSAK 107, "Instrumen Keuangan: Pengungkapan": Klasifikasi dan Pengukuran Instrumen Keuangan

Amandemen tersebut mengklarifikasi persyaratan yang terkait dengan tanggal penghentian pengakuan aset keuangan dan liabilitas keuangan, dengan pengecualian untuk penghentian pengakuan liabilitas keuangan yang diselesaikan melalui transfer elektronik; persyaratan untuk menilai karakteristik arus kas kontraktual dari aset keuangan, dengan panduan tambahan tentang penilaian fitur kontinjensi; dan karakteristik pinjaman *non-recourse* dan instrumen yang terkait secara kontraktual. Amandemen tersebut juga memperkenalkan persyaratan pengungkapan tambahan untuk instrumen ekuitas yang diukur pada nilai wajar melalui penghasilan komprehensif lain dan untuk instrumen keuangan dengan fitur kontinjensi.

- Penyesuaian Tahunan 2024 terhadap PSAK 107, "Instrumen Keuangan: Pengungkapan", PSAK 109, "Instrumen Keuangan", PSAK 110, "Laporan Keuangan Konsolidasian" dan PSAK 207, "Laporan Arus Kas".

Penyesuaian tahunan ini terbatas pada amandemen yang mengklarifikasi susunan kata (*wording*) atau pembetulan minor atas konsekuensi yang tidak diintensikan, kekeliruan, atau persyaratan yang bertentangan dalam standar.

Efektif untuk periode yang dimulai pada atau setelah tanggal 1 Januari 2027:

- PSAK 413, "Penurunan Nilai"

PSAK 413 mengatur tentang penurunan nilai

109 in the same period. This amendment also addresses application issues related to the comparative information that will be presented on initial application to financial assets.

- SFAS 221 (Amendment), "The Effects of Changes in Foreign Exchange Rates": Lack of Exchangeability

This amendment requires an entity to apply a consistent approach to assessing whether a currency is exchangeable into another currency and, when it is not, to determining the exchange rate to use and the disclosures to provide.

Effective for periods beginning on or after January 1, 2026:

- Amendments to SFAS 109, "Financial Instruments" and SFAS 107, "Financial Instruments: Disclosure": Classification and Measurement of Financial Instrument

The amendments clarify the requirements related to the date of recognition and derecognition of financial assets and financial liabilities, with an exception for derecognition of financial liabilities settled via an electronic transfer; the requirements for assessing contractual cash flow characteristics of financial assets, with additional guidance on assessment of contingent features; and the characteristics of non-recourse loans and contractually linked instruments. The amendments also introduce additional disclosure requirements for equity instruments at fair value through other comprehensive income and for financial instruments with contingent features.

- 2024 Annual Improvements to SFAS 107, "Financial Instruments: Disclosures", SFAS 109, "Financial Instruments", SFAS 110, "Consolidated Financial Statements" and SFAS 207, "Statement of Cash Flows".

These annual improvements are limited to amendments that either clarify the wording or correct relatively minor unintended consequences, oversights or conflicts between requirements in the standards.

Effective for periods beginning on or after January 1, 2027:

- SFAS 413, "Impairment"

SFAS 413 regulates the impairment of sharia

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

atas aset keuangan syariah dan pengakuan provisi *kafalah* penjaminan risiko kredit. PSAK 413 menggunakan konsep ekspektasi kerugian (*expected loss*) yang mensyaratkan pengakuan penyisihan untuk ekspektasi kerugian penurunan nilai. Perhitungannya mencerminkan jumlah tidak bias dan probabilitas tertimbang dan informasi wajar dan tersokong, serta tidak mencerminkan nilai waktu atas uang.

financial assets and the recognition of *kafalah* provisions for credit risk guarantees. SFAS 413 uses the concept of expected loss which requires the recognition of provisions for expected impairment losses. The calculation reflects the unbiased and probability-weighted amount and reasonable and supportable information, and does not reflect the time value of money.

Sampai dengan tanggal penerbitan laporan keuangan konsolidasian, dampak dari penerapan standar dan amendemen tersebut terhadap laporan keuangan konsolidasian tidak dapat diketahui atau diestimasi oleh manajemen.

As at the issuance date of the consolidated financial statements, the effects of adopting these standard and amendments on the consolidated financial statements are not known nor reasonably estimable by management.

**3. INFORMASI KEBIJAKAN AKUNTANSI MATERIAL**

**a. Pernyataan Kepatuhan**

Laporan keuangan konsolidasian Grup disusun sesuai dengan Standar Akuntansi Keuangan di Indonesia yang meliputi PSAK dan ISAK yang diterbitkan oleh Dewan Standar Akuntansi Keuangan – Ikatan Akuntan Indonesia (DSAK-IAI), serta peraturan Pasar Modal yang berlaku antara lain Peraturan Otoritas Jasa Keuangan/Badan Pengawas Pasar Modal dan Lembaga Keuangan (OJK/Bapepam-LK) No. VIII.G.7 tentang pedoman penyajian laporan keuangan, keputusan Ketua Bapepam-LK No. KEP347/BL/2012 tentang penyajian laporan keuangan emiten atau Perusahaan publik.

**b. Dasar Penyusunan dan Pengukuran Laporan Keuangan Konsolidasian**

Dasar pengukuran laporan keuangan konsolidasian ini adalah konsep biaya perolehan (*historical cost*), kecuali beberapa akun tertentu disusun berdasarkan pengukuran lain, sebagaimana diuraikan dalam kebijakan akuntansi masing-masing akun tersebut. Laporan keuangan konsolidasian ini disusun dengan metode akrual, kecuali laporan arus kas konsolidasian.

Laporan arus kas konsolidasian disusun dengan menggunakan metode langsung dengan mengelompokkan arus kas dalam aktivitas operasi, investasi dan pendanaan.

Kebijakan akuntansi yang diterapkan dalam penyusunan laporan keuangan konsolidasian adalah selaras dengan kebijakan akuntansi yang diterapkan dalam penyusunan laporan keuangan konsolidasian Grup untuk tahun yang berakhir pada tanggal 31 Desember 2024, kecuali bagi penerapan beberapa SAK yang telah direvisi. Seperti diungkapkan dalam catatan 2, beberapa standar

**3. MATERIAL ACCOUNTING POLICY INFORMATION**

**a. Statement of Compliance**

The consolidated financial statements of the Group have been prepared in accordance with Indonesian Financial Accounting Standards which include the SFAS and ISAK issued by the Financial Accounting Standards Board of the Indonesian Institute of Accountant ("DSAK-IAI"), and regulations in the Capital Market including Regulations of Financial Services Authority/ Capital Market and Supervisory Board and Financial Institutions (OJK/Bapepam-LK) No. VIII.G.7 regarding guidelines for the presentation of financial statements, decree of Chairman of Bapepam-LK No. KEP347/BL/2012 regarding presentation and disclosure of financial statements of the issuer or public company.

**b. Basis of Preparation and Measurement of Consolidated Financial Statements**

The consolidated financial statement have been prepared on the historical cost basis, except for certain accounts which are measured on the bases described in the related accounting policies. The consolidated financial statements, except for the consolidated statement of cash flows, are prepared under the accrual basis of accounting.

The consolidated statement of cash flows are prepared using the direct method with classifications of cash flows into operating, investing and financing activities.

The accounting policies adopted in the preparation of the consolidated financial statements are consistent with those made in the preparation of the Group's consolidated financial statements for the year ended December 31, 2024, except for the adoption of several amended SAKs. As disclosed in Note 2a, several amended and published

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

akuntansi yang telah direvisi dan diterbitkan, diterapkan efektif tanggal 1 Januari 2024.

Grup telah menyusun laporan keuangan konsolidasian dengan dasar bahwa Grup akan terus mempertahankan kelangsungan usaha

Mata uang yang digunakan dalam penyusunan dan penyajian laporan keuangan konsolidasian adalah mata uang Rupiah.

**c. Prinsip Konsolidasian**

Laporan keuangan konsolidasian meliputi laporan keuangan Perusahaan dan entitas-entitas yang dikendalikan secara langsung ataupun tidak langsung oleh Perusahaan.

Secara spesifik, Perusahaan mengendalikan *investee* jika dan hanya jika Perusahaan memiliki seluruh hal berikut ini:

- Kekuasaan atas *investee* (misal, hak yang ada memberikan kemampuan kini untuk mengarahkan aktivitas relevan *investee*).
- Eksposur atau hak atas imbal hasil variabel dari keterlibatannya dengan *investee*.
- Kemampuan untuk menggunakan kekuasaannya atas *investee* untuk mempengaruhi jumlah imbal hasil investor.

Perusahaan menilai kembali apakah investor mengendalikan *investee* jika fakta dan keadaan mengindikasikan adanya perubahan terhadap satu atau lebih dari tiga elemen pengendalian

Ketika Perusahaan memiliki kurang dari hak suara mayoritas, Perusahaan dapat mempertimbangkan semua fakta dan keadaan yang relevan dalam menilai apakah memiliki kekuasaan atas *investee* tersebut:

- Pengaturan kontraktual dengan pemilik hak suara yang lain.
- Hak yang timbul dari pengaturan kontraktual lain.
- Hak suara dan hak suara potensial Perusahaan.

Konsolidasi atas entitas anak dimulai ketika Perusahaan memiliki pengendalian atas entitas anak dan berhenti ketika Perusahaan kehilangan pengendalian atas entitas anak. Aset, liabilitas, penghasilan dan beban atas entitas anak yang diakuisisi atau dilepas selama periode termasuk dalam laporan keuangan konsolidasi dari tanggal Perusahaan memperoleh pengendalian sampai dengan tanggal Perusahaan menghentikan pengendalian atas entitas anak

accounting standards were adopted effective January 1, 2024.

The Group has prepared the consolidated financial statements on the basis that it will continue to operate as a going concern

The currency used in the preparation and presentation of the consolidated financial statements is the Indonesian Rupiah.

**c. Principles of Consolidation**

The consolidated financial statements incorporate the financial statements of the Company and entities in which the Company has the ability to directly or indirectly exercise control.

Specifically, the Company controls an investee if and only if the Company has:

- Power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee).
- Exposure, or rights, to variable returns from its involvement with the investee, and
- The ability to use its power over the investee to affect its returns.

The Company re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control.

When the Company has less than a majority of the voting or similar right of an investee, the Company considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- The contractual arrangement with the other vote holders of the investee.
- Rights arising from other contractual arrangements.
- The Company's voting rights and potential voting rights.

Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the period are included in the consolidated financial statements from the date the Company gains control until the date the Company ceases to control the subsidiary.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Laporan keuangan entitas anak disusun dengan periode pelaporan yang sama dengan Perusahaan. Kebijakan akuntansi yang digunakan dalam penyajian laporan keuangan konsolidasian telah diterapkan secara konsisten oleh Grup, kecuali dinyatakan lain.

Semua aset dan liabilitas, ekuitas, penghasilan, beban dan arus kas berkaitan dengan transaksi antar anggota Grup juga akan dieliminasi secara penuh dalam proses konsolidasi.

Kepentingan nonpengendali mencerminkan bagian atas laba atau rugi dan aset neto dari entitas anak yang tidak dapat diatribusikan, secara langsung maupun tidak langsung, pada Perusahaan, yang masing-masing disajikan dalam laporan laba rugi dan penghasilan komprehensif lain konsolidasian dan dalam ekuitas pada laporan posisi keuangan konsolidasian, terpisah dari bagian yang dapat diatribusikan kepada pemilik Perusahaan.

Kepentingan nonpengendali pada awalnya dapat diukur sebesar nilai wajar atau bagian proporsional kepentingan nonpengendali atas nilai wajar aset neto teridentifikasi pihak yang diakuisisi. Pilihan pengukuran dibuat untuk masing-masing akuisisi. Kepentingan nonpengendali lain awalnya diukur sebesar nilai wajar. Setelah akuisisi, jumlah tercatat kepentingan nonpengendali adalah jumlah kepentingan tersebut pada pengakuan awal ditambah bagian kepentingan nonpengendali dari perubahan selanjutnya di ekuitas

Laba atau rugi dan setiap komponen atas penghasilan komprehensif lain diatribusikan pada pemegang saham entitas induk Perusahaan dan pada kepentingan nonpengendali, walaupun hasil di kepentingan nonpengendali mempunyai saldo defisit.

Perubahan kepemilikan pada entitas anak, tanpa kehilangan pengendalian, dihitung sebagai transaksi ekuitas. Jumlah tercatat dari kepemilikan Grup dan kepentingan nonpengendali disesuaikan untuk mencerminkan perubahan kepentingan relatifnya dalam entitas anak. Selisih antara jumlah tercatat kepentingan nonpengendali yang disesuaikan dan nilai wajar imbalan yang dibayar atau diterima diakui secara langsung dalam ekuitas dan diatribusikan kepada pemilik entitas induk.

Jika Grup kehilangan pengendalian atas entitas anak, maka Grup:

- menghentikan pengakuan aset (termasuk setiap *goodwill*) dan liabilitas entitas anak;
- menghentikan pengakuan jumlah tercatat setiap kepentingan nonpengendali;

*The financial statements of the subsidiaries are prepared for the same reporting period as the Company. The accounting policies adopted in preparing the consolidated financial statements have been consistently applied by the Group, unless otherwise stated.*

*All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.*

*Non-controlling Interest represents the portion of the profit or loss and net assets of the subsidiary not attributable directly or indirectly to the Company, which are presented in the consolidated statement of profit or loss and other comprehensive income and under the equity section of the consolidated statement of financial position, respectively, separately from the corresponding portion attributable to the owner of the Company.*

*Non-controlling interest may initially be measured at fair value or at the non-controlling interests' proportionate share of the fair value of the acquiree's identifiable net assets. The choice of measurement is made on an acquisition-by-acquisition basis. Other non-controlling interests are initially measured at fair value. Subsequent to acquisition, the carrying amount of non-controlling interests is the amount of those interests at initial recognition plus the non-controlling interests' share of subsequent changes in equity.*

*Profit or loss and each component of other comprehensive income are attributed to the equity holders of the Company and to the non-controlling interest, even if this results in the NCI having a deficit balance.*

*A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. The carrying amounts of the Group's interest and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the owners of the Company.*

*If the Group loses control over a subsidiary, it:*

- and liabilities of the subsidiary;*
- derecognizes the carrying amount of any non-controlling interest;*

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

- c. menghentikan pengakuan akumulasi selisih penjabaran, yang dicatat di ekuitas, bila ada;
- d. mengakui nilai wajar pembayaran yang diterima;
- e. mengakui setiap sisa investasi pada nilai wajarnya;
- f. mengakui setiap perbedaan yang dihasilkan sebagai keuntungan atau kerugian sebagai laba rugi; dan
- g. mereklasifikasi ke laba rugi proporsi keuntungan dan kerugian yang telah diakui sebelumnya dalam penghasilan komprehensif lain atau saldo laba, begitu pula menjadi persyaratan jika Grup akan melepas secara langsung aset atau liabilitas yang terkait.

Jumlah tercatat dari kepemilikan Grup dan kepentingan nonpengendali disesuaikan untuk mencerminkan perubahan kepentingan relatifnya dalam entitas anak. Selisih antara jumlah tercatat kepentingan nonpengendali yang disesuaikan dan nilai wajar imbalan yang dibayar atau diterima diakui secara langsung dalam ekuitas dan diatribusikan kepada pemilik Perusahaan.

Nilai wajar setiap sisa investasi pada entitas anak terdahulu pada tanggal hilangnya pengendalian dianggap sebagai nilai wajar pada saat pengakuan awal untuk perlakuan akuntansi berikutnya dalam PSAK 109, "Instrumen Keuangan", ketika berlaku, biaya perolehan pada saat pengakuan awal dari investasi pada entitas asosiasi atau ventura<sup>1</sup> bersama.

**d. Kombinasi Bisnis Entitas Sepengendali**

Kombinasi bisnis antara entitas sepengendali diperlakukan sesuai dengan PSAK 338. Berdasarkan PSAK tersebut, transaksi kombinasi bisnis entitas sepengendali, berupa pengalihan bisnis yang dilakukan dalam rangka reorganisasi entitas-entitas yang berada di dalam suatu Grup yang sama, bukan merupakan perubahan kepemilikan dalam arti substansi ekonomi, sehingga transaksi tersebut tidak menimbulkan laba atau rugi bagi Grup secara keseluruhan ataupun bagi entitas individu dalam Grup tersebut

Metode penyatuan kepemilikan diterapkan seolah-olah entitas-entitas tersebut telah bergabung sejak periode dimana entitas yang bergabung berada dalam sepengendalian. Selisih antara imbalan yang dialihkan dan nilai tercatat aset neto pihak yang diakuisisi disajikan dalam "tambahan modal disetor" dan tidak direklasifikasi ke laba rugi atau

- c. derecognizes the cumulative translation differences, recorded in equity, if any;
- d. recognizes the fair value of the consideration received;
- e. recognizes the fair value of any investment retained;
- f. recognizes any surplus or deficit in profit or loss; and
- g. reclassifies the parent's share of components previously recognized in other comprehensive income to profit or loss or retained earnings, as appropriate, as would be required if the Group had directly disposed of the related assets or liabilities

*The carrying amounts of the Group's interest and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the owners of the Company.*

*The fair value of any investment retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under SFAS 109, "Financial Instruments", when applicable, the cost on initial recognition of an investment in an associate or a joint venture.*

**d. Business Combination of Entities Under Common Control**

*Business combination involving entities under common control is accounted in accordance with PSAK 338. Under this PSAK, business combination of entities under common control transactions, such as transfers of business conducted within the framework of the reorganization of the entities that are in the same group, is not a change of ownership in terms of economic substance, hence, the transaction does not result in a gain or loss for the Group as a whole or for individual entities within the Group*

*The pooling-of-interest method is applied as if the entities had been combined from the period when the merging entities were placed under common control. The difference between the consideration transferred and the book value of the net assets of the acquiree is presented under "additional paid-in capital" and is not recycled to profit or loss nor*

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

direklasifikasi ke saldo laba ketika pengendalian hilang.

*reclassified to retained earnings when control is lost.*

**e. Transaksi dalam Mata Uang Asing dan Translasi Saldo**

Mata uang penyajian yang digunakan pada laporan keuangan konsolidasian adalah Rupiah, yang juga merupakan mata uang fungsional setiap entitas dalam Grup. Tiap entitas dalam Grup menentukan mata uang fungsionalnya masing-masing dan laporan keuangannya masing-masing diukur menggunakan mata uang fungsional tersebut.

Transaksi dalam mata uang asing dicatat ke dalam Rupiah berdasarkan kurs yang berlaku pada saat transaksi dilakukan. Pada tanggal pelaporan, aset dan liabilitas moneter dalam mata uang asing disajikan ke dalam mata uang Rupiah berdasarkan kurs tengah Bank Indonesia yang berlaku pada tanggal tersebut. Laba atau rugi kurs yang timbul dikreditkan atau dibebankan pada usaha tahun berjalan.

Pada akhir periode pelaporan, kurs konversi yakni kurs tengah Bank Indonesia yang digunakan oleh Grup, adalah sebagai berikut:

|                         | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |
|-------------------------|-----------------------------------|-------------------------------------------|
| 1 Punds Inggris         | 22.298,48                         | 20.332,61                                 |
| 1 Euro Eropa            | 19.008,85                         | 16.851,32                                 |
| 1 Dolar Amerika Serikat | 16.233,00                         | 16.162,00                                 |
| 1 Ringgit Malaysia      | 3.843,97                          | 3.616,48                                  |
| 1 Yuan China            | 2.264,87                          | 2.214,17                                  |
| 1 Yen Jepang            | 112,68                            | 102,36                                    |
| 1 Singapura Dollar      | 12.748,28                         | 11.919,34                                 |

Akun-akun dari entitas anak luar negeri dijabarkan dari mata uang pelaporannya menjadi Rupiah dengan dasar sebagai berikut:

- Aset dan liabilitas, baik moneter maupun non-moneter, dijabarkan dengan menggunakan kurs penutup.
- Pendapatan dan beban dijabarkan dengan menggunakan kurs yang berlaku pada tanggal transaksi atau, bila memenuhi syarat, kurs rata-rata periode tersebut.
- Selisih kurs yang terjadi disajikan sebagai "Penghasilan Komprehensif Lain - Selisih Kurs atas Penjabaran Akun-akun Kegiatan Usaha Luar Negeri" sebagai bagian dari ekuitas sampai pelepasan investasi neto yang bersangkutan.

**e. Foreign Currency Transactions and Balances Translation**

*The presentation currency used in the consolidated financial statements is Indonesian Rupiah, which is also the functional currency of each entity in the Group. Each entity in the Group determines its own functional currency and their financial statements are measured using that functional currency.*

*Transactions involving foreign currencies are recorded in Indonesian Rupiah at the rates of exchange prevailing at the time the transactions are made. At the reporting date, monetary assets and liabilities denominated in foreign currency are adjusted to Rupiah at middle rates of exchange issued by Bank of Indonesia at such date. Any resulting gains or losses are credited or charged to operations of the current year.*

*As at the end of the reporting period, the conversion rates used by the Group was the middle rate of Bank Indonesia as follows:*

|                        |
|------------------------|
| 1 United Kingdom Punds |
| 1 European Euro        |
| 1 United States Dollar |
| 1 Ringgit Malaysia     |
| 1 Chinese Yuan         |
| 1 Japan Yen            |
| 1 Singapore Dollar     |

*The accounts of foreign subsidiary are translated from its respective reporting currency into Indonesian Rupiah on the following basis:*

- Assets and liabilities, both monetary and non-monetary, are translated using the closing rate of exchange.*
- Revenues and expenses are translated using transactions date exchange rate or, if applicable, the average rate for the period.*
- The resulting exchange difference is presented as "Other Comprehensive Income - Exchange Differences on Translation of the Accounts of Foreign Operations" in the equity section until disposal of the net investment.*

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Pada pelepasan kegiatan usaha luar negeri (yaitu pelepasan dari seluruh kepentingan Grup pada kegiatan usaha luar negeri, atau pelepasan yang melibatkan hilangnya pengendalian pada entitas anak yang mencakup kegiatan usaha luar negeri, atau pelepasan parsial atas kepentingan dalam pengaturan bersama atau entitas asosiasi yang mencakup kegiatan operasi luar negeri, merupakan aset keuangan yang mencakup kegiatan usaha luar negeri), seluruh selisih kurs terakumulasi di ekuitas yang terkait dengan kegiatan usaha luar negeri yang telah diatribusikan ke pemilik Perusahaan direklasifikasi ke laba rugi.

Selanjutnya, dalam pelepasan sebagian dari entitas anak yang mencakup kegiatan usaha luar negeri, yang tidak mengakibatkan hilangnya pengendalian Grup atas entitas anak, bagian proporsional dari akumulasi selisih kurs diatribusikan kembali kepada kepentingan nonpengendali dan tidak diakui dalam laba rugi. Untuk seluruh pelepasan sebagian kepentingan lainnya (yaitu pelepasan sebagian dari entitas asosiasi atau pengaturan bersama yang tidak mengakibatkan hilangnya pengaruh signifikan atau pengendalian bersama Grup), bagian proporsional dari jumlah kumulatif selisih kurs direklasifikasi ke laba rugi.

Pada konsolidasi, selisih kurs yang berasal dari penjabaran atas investasi neto entitas luar negeri (termasuk pos-pos moneter yang secara substansi membentuk bagian investasi neto entitas luar negeri), dan atas pinjaman dan instrumen mata uang lainnya yang ditetapkan sebagai lindung nilai atas investasi tersebut, diakui dalam penghasilan komprehensif lain dan diakumulasikan dalam komponen ekuitas yang terpisah di bawah judul "cadangan selisih kurs atas penjabaran akun-akun kegiatan usaha luar negeri".

*Goodwill* dan penyesuaian nilai wajar yang timbul dari akuisisi dari kegiatan usaha luar negeri diperlakukan sebagai aset dan liabilitas dari kegiatan usaha luar negeri dan dijabarkan pada kurs tutup buku. Selisih kurs yang timbul diakui pada penghasilan komprehensif lain.

*On the disposal of a foreign operation (i.e. a disposal of the Group's entire interest in a foreign operation, or a disposal involving loss of control over a subsidiary that includes a foreign operation, or a partial disposal of an interest in a joint arrangement or an associate that includes a foreign operation of which the retained interest becomes a financial asset), all of the exchange differences accumulated in equity in respect of that operation attributable to the owners of the Company are reclassified to profit or loss.*

*In addition, in relation to a partial disposal of a subsidiary that includes a foreign operation that does not result in the Group losing control over the subsidiary, the proportionate share of accumulated exchange differences are re-attributed to non-controlling interests and are not recognized in profit or loss. For all other partial disposals (i.e. partial disposal of associates or joint arrangements that do not result in the Group losing significant influence or joint control), the proportionate share of the accumulated exchange differences is reclassified to profit or loss.*

*On consolidation, exchange differences arising from the translation of the net investment in foreign entities (including monetary items that, in substance, form part of the net investment in foreign entities), and of borrowings and other currency instruments designated as hedges of such investments, are recognized in other comprehensive income and accumulated in a separate component of equity under the header of "reserve for exchange differences on translation of accounts of foreign operation".*

*Goodwill and fair value adjustments arising on the acquisition of a foreign operation are treated as assets and liabilities of the foreign operation and translated at the closing rate. Exchange differences arising are recognized in other comprehensive income*

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**f. Transaksi dengan Pihak-pihak Berelasi**

Pihak-pihak berelasi adalah orang atau entitas yang terkait dengan Grup:

- a) Orang atau anggota keluarga dekatnya mempunyai relasi dengan entitas pelapor jika orang tersebut:
  - i. memiliki pengendalian atau pengendalian bersama atas entitas pelapor;
  - ii. memiliki pengaruh signifikan atas entitas pelapor; atau
  - iii. merupakan personil manajemen kunci entitas pelapor atau entitas induk dari entitas pelapor.
- b) Suatu entitas berelasi dengan entitas pelapor jika memenuhi salah satu hal berikut:
  - i. Entitas dan entitas pelapor adalah anggota dari Perusahaan dan Entitas Anak yang sama (artinya entitas induk, Entitas Anak dan Entitas Anak berikutnya terkait dengan entitas lain);
  - ii. Satu entitas adalah entitas asosiasi atau ventura bersama dari entitas lain (atau entitas asosiasi atau ventura bersama) yang merupakan anggota suatu Perusahaan dan Entitas Anak, yang mana entitas lain tersebut adalah anggotanya;
  - iii. Kedua entitas tersebut adalah ventura bersama dari pihak ketiga yang sama
  - iv. Satu entitas adalah ventura bersama dari entitas ketiga dan entitas yang lain adalah entitas asosiasi dari entitas ketiga;
  - v. Entitas tersebut adalah suatu program imbalan pasca-kerja untuk imbalan kerja dari salah satu entitas pelapor atau entitas yang terkait dengan entitas pelapor. Jika entitas pelapor adalah entitas yang menyelenggarakan program tersebut, maka entitas sponsor juga berelasi dengan entitas pelapor.
  - vi. Entitas yang dikendalikan atau dikendalikan bersama oleh orang yang diidentifikasi dalam paragraf (i), (ii) dan (iii);
  - vii. Orang yang diidentifikasi dalam sub-paragraf (i) (a) memiliki pengaruh signifikan atas entitas atau personil manajemen kunci entitas (atau entitas induk dari entitas);
  - viii. Entitas, atau anggota dari kelompok yang mana entitas merupakan bagian dari kelompok tersebut, menyediakan jasa personal manajemen kunci kepada entitas pelapor atau kepada entitas induk dari entitas pelapor.

**f. Transaction with Related Parties**

A related party is a person or entity that is related to the Group:

- a) A person or a close member of that person's family is related to a reporting entity if that person:
  - i. has control or joint control over the reporting entity;
  - ii. has significant influence over the reporting entity; or
  - iii. is a member of the key management personnel of the reporting entity or of a parent entity of the reporting entity.
- b) An entity is related to the reporting entity if any of the following conditions applies:
  - i. The entity and the reporting entity are members of the same business the Company and its Subsidiaries (i.e. a parent, subsidiaries and entities associated with the next subsidiaries of another entity);
  - ii. One entity is an associate or joint venture of the other entity (or an associate or joint venture) of a member of a business the Company and its Subsidiaries, which the other entity is a member;
  - iii. Both entities are joint ventures of the same third party;
  - iv. One entity is a joint venture of a third entity and the other entity is an associate of the third entity;
  - v. The entity has a post-employment benefits plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related entities to the reporting entity;
  - vi. Entities controlled or jointly controlled by a person identified in paragraph in (i), (ii) and (iii);
  - vii. Person identified in sub-paragraph (i) (a) has significant influence over the entity or the key management personnel of the entity (or the entity's parent entity);
  - viii. The entity, or any member of a group of which it is a part, provides key management personal services to the reporting entity or to the parent of the reporting entity.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Transaksi signifikan yang dilakukan dengan pihak-pihak berelasi, baik dilakukan dengan kondisi dan persyaratan yang sama dengan pihak ketiga maupun tidak, diungkapkan pada laporan keuangan konsolidasian.

*Significant transactions with related parties, whether or not made at similar terms and conditions as those done with third parties, are disclosed in the consolidated financial statements.*

**g. Instrumen Keuangan**

Instrumen keuangan adalah setiap kontrak yang menimbulkan aset keuangan dari satu entitas dan liabilitas keuangan atau instrumen ekuitas dari entitas lain.

**g. Financial Instruments**

*A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.*

Klasifikasi

Classification

**Aset Keuangan**

**Financial Assets**

Aset keuangan diklasifikasikan, pada pengakuan awal, yang selanjutnya diukur pada biaya perolehan diamortisasi, nilai wajar melalui penghasilan komprehensif lain (FVOCI), dan nilai wajar melalui laba rugi (FVTPL).

*Financial assets are classified, at initial recognition, and subsequently measured at amortized cost, fair value through other comprehensive income (FVOCI), and fair value through profit or loss (FVTPL).*

Grup mengukur aset keuangan pada biaya perolehan diamortisasi jika kedua kondisi berikut terpenuhi:

*The Group measures financial assets at amortized cost if both of the following conditions are met:*

- Aset keuangan dimiliki dalam model bisnis dengan tujuan untuk memiliki aset keuangan dalam rangka mengumpulkan arus kas kontraktual, dan
- Persyaratan kontraktual dari aset keuangan menimbulkan arus kas pada tanggal tertentu yang hanya merupakan pembayaran pokok dan bunga dari jumlah pokok terutang

- *The financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows, and*
- *The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding*

Untuk aset keuangan yang diklasifikasikan dan diukur pada biaya perolehan diamortisasi atau FVOCI, aset keuangan harus menimbulkan arus kas yang 'semata-mata pembayaran pokok dan bunga (SPPI)' dari jumlah pokok terutang. Penilaian ini disebut sebagai tes SPPI dan dilakukan pada tingkat instrumen

*In order for a financial asset to be classified and measured at amortized cost or FVOCI, it needs to give rise to cash flows that are 'solely payments of principal and interest (SPPI)' on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level.*

Model bisnis Grup untuk mengelola aset keuangan mengacu pada bagaimana Perusahaan mengelola aset keuangannya untuk menghasilkan arus kas. Model bisnis menentukan apakah arus kas akan dihasilkan dari pengumpulan arus kas kontraktual, penjualan aset keuangan, atau keduanya

*The Group's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both.*

Aset keuangan Grup yang diukur dengan biaya perolehan diamortisasi meliputi kas dan bank, piutang usaha, piutang lain-lain dan deposito berjangka yang dibatasi penggunaannya dan uang jaminan. Grup tidak memiliki aset keuangan yang diukur pada FVTPL dan FVOCI.

*The Group's financial assets at amortized cost consist of cash on hand and in banks, trade receivables, other receivables and restricted time deposits classified as financial assets at amortized cost. The group has no financial assets measured at FVTPL and FVOCI.*

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Pengakuan dan Pengukuran

Aset keuangan, kecuali piutang usaha yang diukur sesuai harga transaksi, dan liabilitas keuangan pada awalnya diukur pada nilai wajar. Biaya transaksi yang dapat diatribusikan secara langsung dengan perolehan atau penerbitan aset keuangan dan liabilitas keuangan ditambahkan atau dikurangkan dari nilai wajar aset keuangan dan liabilitas keuangan, jika diperlukan, pada pengakuan awal. Biaya transaksi yang dapat diatribusikan secara langsung dengan perolehan aset keuangan dan liabilitas keuangan pada nilai wajar melalui laba rugi diakui langsung pada laba rugi.

Pembelian atau penjualan aset keuangan yang memerlukan penyerahan aset dalam jangka waktu yang ditetapkan oleh regulasi atau konvensi dipasar (perdagangan reguler) diakui pada tanggal perdagangan, yaitu tanggal Grup berkomitmen untuk membeli atau menjual aset.

Aset keuangan yang diukur dengan biaya perolehan diamortisasi selanjutnya diukur dengan menggunakan metode suku bunga efektif (EIR) dan mengalami penurunan nilai. Keuntungan dan kerugian diakui dalam laba rugi pada saat aset dihentikan pengakuannya, dimodifikasi atau diturunkan nilainya.

Penghentian Pengakuan

Suatu aset keuangan, atau mana yang berlaku, bagian dari aset keuangan atau bagian dari kelompok aset keuangan sejenis, dihentikan pengakuannya pada saat:

- a. hak kontraktual atas arus kas yang berasal dari aset keuangan tersebut berakhir; atau
- b. Grup mengalihkan hak kontraktual untuk menerima arus kas yang berasal dari aset keuangan atau menanggung kewajiban untuk membayar arus kas yang diterima tanpa penundaan yang material kepada pihak ketiga melalui suatu kesepakatan penyerahan dan (i) secara substansial mengalihkan seluruh risiko dan manfaat atas kepemilikan aset keuangan tersebut, atau (ii) secara substansial tidak mengalihkan dan tidak mempertahankan seluruh risiko dan manfaat atas kepemilikan aset keuangan tersebut, namun telah mengalihkan pengendalian atas aset keuangan tersebut.

Recognition and Measurement

Financial assets, except for trade receivables which are measured at transaction price, and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities are added to or deducted from the fair value of the financial assets and financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in profit or loss.

Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Group commits to purchase or sell the asset.

Financial assets at amortized cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognized in profit or loss when the asset is derecognized, modified or impaired

Derecognition

A financial asset, or where applicable a part of a financial asset or part of a group of similar financial assets, is derecognized when:

- a. the contractual rights to receive cash flows from the financial asset have expired; or
- b. the Group has transferred its contractual rights to receive cash flows from the financial asset or has assumed an obligation to pay them in full without material delay to a third party under a "pass-through" arrangement and either (i) has transferred substantially all the risks and rewards of the financial asset, or (ii) has neither transferred nor retained substantially all the risks and rewards of the financial asset, but has transferred control of the financial asset.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Ketika Grup telah mentransfer hak untuk menerima arus kas dari aset atau telah menandatangani perjanjian *pass-through*, dan tidak mentransfer maupun tidak memiliki secara substansial seluruh risiko dan manfaat atas aset keuangan atau pengendalian ditransfer dari aset, aset tersebut diakui apabila besar kemungkinannya Grup melanjutkan aset keuangan tersebut. Keterlibatan berkelanjutan yang berbentuk pemberian jaminan atas aset yang ditransfer diukur sebesar jumlah terendah dari jumlah tercatat asli aset dan jumlah maksimum pembayaran Grup.

Dalam hal ini, Grup juga mengakui liabilitas terkait. Aset yang dialihkan dan liabilitas terkait diukur dengan dasar yang mencerminkan hak dan liabilitas yang masih dipertahankan Grup.

Pada penghentian pengakuan aset keuangan yang diukur pada biaya perolehan diamortisasi, perbedaan antara nilai tercatat aset dan jumlah imbalan yang diterima dan piutang diakui dalam laba rugi.

#### Liabilitas keuangan

##### Klasifikasi

Grup mengklasifikasikan liabilitas keuangannya pada pengakuan awal sebagai liabilitas keuangan diukur pada biaya perolehan diamortisasi

Liabilitas keuangan Grup meliputi utang bank jangka pendek, utang usaha, utang lain-lain, beban masih harus dibayar, utang bank jangka panjang, utang pembiayaan dan utang pembiayaan konsumen. Grup tidak memiliki liabilitas keuangan yang diukur pada FVTPL.

##### Pengakuan dan Pengukuran

Grup mengakui liabilitas keuangan pada saat timbulnya liabilitas kontraktual untuk menyerahkan kas atau aset keuangan lainnya kepada entitas lain

Liabilitas keuangan yang bukan merupakan 1) imbalan kontingen dari pihak pengakuisisi dalam kombinasi bisnis, 2) dimiliki untuk diperdagangkan, atau 3) ditetapkan sebagai FVTPL, selanjutnya diukur pada biaya perolehan diamortisasi dengan menggunakan metode suku bunga efektif.

##### Penghentian Pengakuan

Liabilitas keuangan dihentikan pengakuannya ketika liabilitas yang ditetapkan dalam kontrak dihentikan atau dibatalkan atau kedaluwarsa.

When the Group have transferred their rights to receive cash flows from an asset or has entered into a pass-through arrangement, and has neither transferred nor retained substantially all the risks and rewards of the asset nor the transferred control of the asset, the asset is recognized to the extent of the Group continuing involvement in the asset. Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay.

In that case, the Group also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

On derecognition of a financial asset measured at amortized cost, the difference between the asset's carrying amount and the sum of the consideration received and receivable is recognized in profit or loss.

#### Financial Liabilities

##### Classification

The Group classifies its financial liabilities, at initial recognition, as financial liabilities measured at amortized cost.

The Group's financial liabilities include short-term bank loans, trade payables, other payables, accrued expenses, long-term bank loan, consumer financing payables and lease liabilities. The Group has no financial liabilities measured at FVTPL.

##### Recognition and Measurement

Financial liabilities are recognized when the Group has a contractual obligation to transfer cash or other financial assets to other entities.

Financial liabilities that are not 1) contingent consideration of an acquirer in a business combination, 2) held-for-trading, or 3) designated as at FVTPL, are subsequently measured at amortized cost using the effective interest method.

##### Derecognition

A financial liability is derecognized when the obligation specified in the contract is discharged or cancelled or expired.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Ketika liabilitas keuangan saat ini digantikan dengan yang lain dari pemberi pinjaman yang sama dengan persyaratan yang berbeda secara substansial, atau modifikasi secara substansial atas ketentuan liabilitas keuangan yang saat ini ada, maka pertukaran atau modifikasi tersebut dicatat sebagai penghapusan liabilitas keuangan awal dan pengakuan liabilitas keuangan baru.

Selisih antara jumlah tercatat liabilitas keuangan yang dihentikan pengakuannya dan imbalan yang dibayarkan dan utang diakui dalam laba rugi.

Metode Suku Bunga Efektif

Metode suku bunga efektif adalah metode yang digunakan untuk menghitung biaya perolehan diamortisasi dari liabilitas keuangan dan metode untuk mengalokasikan biaya bunga selama periode yang relevan. Suku bunga efektif adalah suku bunga yang secara tepat mendiskontokan estimasi pembayaran kas masa depan (mencakup seluruh komisi dan bentuk lain yang dibayarkan dan diterima yang merupakan bagian yang tak terpisahkan dari suku bunga efektif, biaya transaksi dan premium dan diskonto lainnya) selama perkiraan umur liabilitas keuangan, atau (jika lebih tepat) digunakan periode yang lebih singkat untuk memperoleh nilai tercatat neto pada saat pengakuan awal.

Saling Hapus antar Instrumen Keuangan

Aset keuangan dan liabilitas keuangan disalinghapuskan dan nilai netonya disajikan dalam laporan posisi keuangan konsolidasian jika grup tersebut memiliki hak yang dapat dipaksakan secara hukum untuk melakukan saling hapus atas jumlah yang telah diakui; dan berintensitas untuk menyelesaikan secara neto atau untuk merealisasikan aset dan menyelesaikan liabilitasnya secara simultan. Hak saling hapus harus ada pada saat ini dan tidak bersifat kontingen atas terjadinya suatu peristiwa di masa depan dan harus dapat dieksekusi oleh pihak lawan, baik dalam situasi bisnis normal dan dalam peristiwa gagal bayar, peristiwa kepailitan atau kebangkrutan.

**h. Penentuan Nilai Wajar**

Nilai wajar adalah harga yang akan diterima untuk menjual suatu aset atau harga yang akan dibayar untuk mengalihkan suatu liabilitas dalam transaksi teratur di antara pelaku pasar pada tanggal pengukuran. Pengukuran nilai wajar didasarkan pada asumsi bahwa transaksi untuk menjual aset atau mengalihkan liabilitas akan terjadi:

*When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability.*

*The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable is recognized in profit or loss.*

Effective Interest Method

*Effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or (where appropriate) a shorter period to the net carrying amount on initial recognition.*

Offsetting Financial Instruments

*Financial assets and financial liabilities are offset and the net amount presented in the consolidated statement of financial position when the Group has a legally enforceable right to set off the recognized amounts; and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. A right to set-off must be available today rather than being contingent on a future event and must be exercisable by any of the counterparties, both in the normal course of business and in the event of default, insolvency or bankruptcy.*

**h. Fair Value Measurement**

*Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:*

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

1. di pasar utama untuk aset atau liabilitas tersebut atau;
2. jika tidak terdapat pasar utama, di pasar yang paling menguntungkan untuk aset atau liabilitas tersebut.

Grup harus memiliki akses ke pasar utama atau pasar yang paling menguntungkan.

Pengukuran nilai wajar aset nonkeuangan memperhitungkan kemampuan pelaku pasar untuk menghasilkan manfaat ekonomik dengan menggunakan aset dalam penggunaan tertinggi dan terbaiknya, atau dengan menjualnya kepada pelaku pasar lain yang akan menggunakan aset tersebut dalam penggunaan tertinggi dan terbaiknya.

**i. Penurunan Nilai Aset Keuangan**

Grup mengakui cadangan untuk kerugian kredit ekspektasian ("ECL") atas instrumen utang diukur pada biaya perolehan diamortisasi atau pada FVTOCI, piutang sewa, aset kontrak maupun kontrak jaminan keuangan [dan komitmen pinjaman].

**j. Penurunan Nilai Aset Keuangan**

Grup mengakui cadangan untuk kerugian kredit ekspektasian ("ECL") atas instrumen utang diukur pada biaya perolehan diamortisasi atau pada FVTOCI, piutang sewa, aset kontrak maupun kontrak jaminan keuangan [dan komitmen pinjaman].

Pengukuran kerugian kredit ekspektasian merupakan fungsi dari *probability of default*, *loss given default* (yaitu besarnya kerugian jika terjadi gagal bayar) dan eksposur pada gagal bayar. Penilaian *probability of default* dan *loss given default* berdasarkan data historis yang disesuaikan dengan informasi masa depan seperti dijelaskan di atas. Adapun eksposur atas gagal bayar, untuk aset keuangan, diwakili oleh nilai tercatat bruto aset pada tanggal pelaporan; untuk kontrak jaminan keuangan, eksposur mencakup jumlah yang ditarik pada tanggal pelaporan, ditambah dengan jumlah yang diperkirakan akan ditarik di masa depan sebelum tanggal gagal bayar yang ditentukan berdasarkan tren historis, pemahaman Grup mengenai kebutuhan pembiayaan masa depan yang spesifik dari debiturnya, dan informasi perkiraan masa depan lainnya yang relevan.

1. in the principal market for the asset or liability or;
2. in the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible to the Group.

A fair value measurement of a nonfinancial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

**i. Impairment of Financial Assets**

The Group recognizes an allowance for expected credit losses (ECL) on investments in debt instruments that are measured at amortized cost or at FVTOCI, lease receivables, contract assets as well as on financial guarantee contracts [and loan commitments].

**j. Impairment of Financial Assets**

The Group recognizes an allowance for expected credit losses (ECL) on investments in debt instruments that are measured at amortized cost or at FVTOCI, lease receivables, contract assets as well as on financial guarantee contracts [and loan commitments].

The measurement of expected credit losses is a function of the probability of default, loss given default (i.e. the magnitude of the loss if there is a default) and the exposure at default. The assessment of the probability of default and loss given default is based on historical data adjusted by forward-looking information as described above. As for the exposure at default, for financial assets, this is represented by the assets' gross carrying amount at the reporting date; for financial guarantee contracts, the exposure includes the amount drawn down as at the reporting date, together with any additional amounts expected to be drawn down in the future by default date determined based on historical trend, the Group's understanding of the specific future financing needs of the debtors, and other relevant forward-looking information.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

ECL didasarkan pada perbedaan antara arus kas kontraktual yang tertuang dalam kontrak dan seluruh arus kas yang diharapkan akan diterima Grup, didiskontokan menggunakan suku bunga efektif awal. Arus kas yang diharapkan akan diterima tersebut mencakup arus kas dari penjualan agunan yang dimiliki atau perluasan perbaikan risiko-kredit lainnya yang merupakan bagian integral dari persyaratan kontrak.

ECL diakui dalam dua tahap. Untuk risiko kredit atas instrumen keuangan yang tidak mengalami peningkatan secara signifikan sejak pengakuan awal, ECL dilakukan untuk kerugian kredit yang diakibatkan oleh peristiwa gagal bayar yang mungkin terjadi dalam 12 bulan ke depan (ECL 12 bulan). Untuk risiko kredit atas instrumen keuangan yang mengalami peningkatan secara signifikan sejak pengakuan awal, penyisihan kerugian dilakukan sepanjang sisa umurnya, terlepas dari waktu terjadinya gagal bayar (ECL sepanjang umurnya).

Dalam menilai apakah risiko kredit pada instrumen keuangan telah meningkat secara signifikan sejak pengakuan awal, Grup membandingkan risiko gagal bayar yang terjadi pada instrumen keuangan pada tanggal pelaporan dengan risiko gagal bayar yang terjadi pada instrumen keuangan pada tanggal pengakuan awal. Dalam melakukan penilaian, Grup mempertimbangkan baik informasi kuantitatif maupun kualitatif yang wajar dan mendukung, termasuk pengalaman historis dan informasi bersifat perkiraan masa depan, yang tersedia tanpa biaya atau upaya berlebihan. Informasi masa depan yang dipertimbangkan mencakup prospek masa depan industri di mana debitur Grup beroperasi, yang diperoleh dari laporan ahli ekonomi, analisis keuangan, badan pemerintah, lembaga terkait, dan organisasi serupa lainnya, serta pertimbangan berbagai sumber eksternal aktual dan prakiraan informasi ekonomi yang terkait dengan operasi inti Grup.

Secara khusus, informasi berikut diperhitungkan ketika menilai apakah risiko kredit telah meningkat secara signifikan sejak pengakuan awal: (a) indikasi pihak peminjam atau kelompok pihak peminjam mengalami kesulitan keuangan signifikan, (b) wanprestasi atau tunggakan pembayaran bunga atau pokok, (c) kemungkinan bahwa mereka akan dinyatakan pailit atau melakukan reorganisasi keuangan lainnya dan (d) di mana data yang dapat diobservasi mengindikasikan bahwa ada terukur penurunan arus kas estimasi masa mendatang, seperti perubahan tunggakan atau kondisi ekonomi yang berkorelasi dengan wanprestasi.

ECL are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECL are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECL are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

In assessing whether the credit risk on a financial instrument has increased significantly since initial recognition, the Group compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition. In making this assessment, the Group considers both quantitative and qualitative information that is reasonable and supportable, including historical experience and forward-looking information that is available without undue cost or effort. Forward-looking information considered includes the future prospects of the industries in which the Group's debtors operate, obtained from economic expert reports, financial analysts, governmental bodies, relevant think-tanks and other similar organizations, as well as consideration of various external sources of actual and forecast economic information that relate to the Group's core operations.

In particular, the following information is taken into account when assessing whether credit risk has increased significantly since initial recognition: (a) indications that the debtors or a group of debtors is experiencing significant financial difficulty, (b) default or delinquency in interest or principal payments, (c) the probability that they will enter bankruptcy or other financial reorganization and (d) where observable data indicate that there is a measurable decrease in the estimated future cash flows, such as changes in arrears or economic conditions that correlate with defaults.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Grup mengakui keuntungan atau kerugian penurunan nilai dalam laba rugi untuk semua instrumen keuangan dengan penyesuaian terkait ke jumlah tercatat melalui akun cadangan kerugian dan tidak mengurangi nilai tercatat aset keuangan pada laporan posisi keuangan konsolidasian.

The Group recognizes an impairment gain or loss in profit or loss for all financial instruments with a corresponding adjustment to their carrying amount through a loss allowance account and does not reduce the carrying amount of the financial asset in the consolidated statement of financial position.

**k. Kas dan Setara Kas**

Kas dan setara kas terdiri dari kas dan bank yang tidak dibatasi penggunaannya dan tidak dijaminkan sebagai jaminan utang

**k. Cash and Cash Equivalents**

Cash and Cash Equivalent consist of all unrestricted cash on hand and in banks that are not pledged as collateral to loans.

Untuk tujuan laporan arus kas konsolidasian, kas dan bank terdiri dari kas dan bank setelah dikurangi saldo cerukan bank yang harus dibayar sesuai permintaan dan merupakan bagian yang tidak terpisahkan dari pengelolaan kas Grup. Dalam laporan posisi keuangan konsolidasian, cerukan disajikan sebagai utang bank jangka pendek pada liabilitas jangka pendek.

For purposes of consolidated statement of cash flows, cash on hand and in banks consist of cash on hand and in banks net of outstanding bank overdrafts which are repayable on demand and form an integral part of Group's cash management. In the consolidated statement of financial position, bank overdrafts are shown within short-term bank loan under current liabilities.

**l. Deposito Berjangka**

Deposito berjangka dibatasi penggunaannya disajikan sebagai aset tidak lancar jika pembatasan kontrak diperpanjang lebih dari 12 bulan setelah akhir periode pelaporan.

**l. Time Deposits**

Time deposits which are restricted in use are presented as non-current assets, if contractual restriction extends beyond 12 months after the end of reporting period.

**m. Persediaan**

Persediaan dinilai berdasarkan nilai terendah antara biaya perolehan atau nilai realisasi bersih (NRV), dimana biaya perolehan ditentukan dengan metode rata-rata tertimbang. Nilai realisasi bersih merupakan estimasi harga jual persediaan dikurangi seluruh estimasi biaya penyelesaian dan biaya yang diperlukan untuk melakukan penjualan. Penyisihan penurunan nilai persediaan dibentuk berdasarkan penelaahan terhadap kondisi persediaan pada akhir periode.

**m. Inventories**

Inventories are valued at the lower of cost or net realizable value (NRV), whereby cost is determined by weighted average method. Net realizable value represents the estimated selling price for inventories less all estimated costs of completion and costs necessary to make the sale. Allowance for decline in value of inventories is provided based on a review of the condition of inventories at the end of the period.

**n. Uang Muka dan Biaya Dibayar di Muka**

Uang Muka

Uang muka pada awalnya dicatat sebesar biaya transaksi, dan selanjutnya dicatat sebesar biaya perolehan dikurangi kerugian penurunan nilai, jika ada

**n. Prepaid Expenses**

Advances

Advances are initially recorded at transaction cost, and subsequently recorded at cost less impairment loss, if any.

Biaya Dibayar di Muka

Biaya dibayar di muka diamortisasi selama manfaat masing-masing biaya dengan menggunakan metode garis lurus.

Prepaid Expenses

Prepaid expenses are amortized over their beneficial periods using the straight-line method.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**o. Sewa**

Sebagai Penyewa

Perusahaan menilai apakah sebuah kontrak mengandung sewa, pada tanggal inisiasi kontrak. Perusahaan mengakui aset hak-guna dan liabilitas sewa terkait sehubungan dengan seluruh kesepakatan sewa di mana Perusahaan merupakan penyewa, kecuali untuk sewa jangka-pendek (yang didefinisikan sebagai sewa yang memiliki masa sewa 12 bulan atau kurang) dan sewa yang aset dasarnya bernilai-rendah. Untuk sewa-sewa tersebut, Perusahaan mengakui pembayaran sewa sebagai beban operasi secara garis lurus selama masa sewa kecuali dasar sistematis lainnya lebih merepresentasikan pola konsumsi manfaat penyewa dari aset sewa.

Liabilitas sewa awalnya diukur pada nilai kini pembayaran sewa masa depan yang belum dibayarkan pada tanggal permulaan, yang didiskontokan menggunakan suku bunga implisit dalam sewa. Jika suku bunga ini tidak dapat ditentukan, Perusahaan menggunakan suku bunga pinjaman inkremental khusus untuk penyewa.

Bunga pinjaman inkremental bergantung pada jangka waktu, mata uang dan tanggal mulai sewa, dan ditentukan berdasarkan serangkaian input, termasuk: tingkat bebas risiko berdasarkan suku bunga obligasi pemerintah; penyesuaian risiko khusus negara; penyesuaian risiko kredit berdasarkan imbal hasil obligasi; dan penyesuaian khusus entitas ketika profil risiko entitas yang melakukan perjanjian sewa berbeda dengan Perusahaan dan sewa tersebut tidak memperoleh manfaat atas jaminan dari Perusahaan.

Pembayaran sewa yang diperhitungkan dalam pengukuran liabilitas sewa terdiri atas:

- Pembayaran tetap (termasuk pembayaran tetap secara-substansi), dikurangi insentif sewa;
- Pembayaran sewa variabel yang bergantung ada indeks atau suku bunga yang pada awalnya diukur dengan menggunakan indeks atau suku bunga pada tanggal permulaan;
- Jumlah yang diperkirakan akan dibayarkan oleh penyewa dalam jaminan nilai residual;
- Harga eksekusi opsi beli jika penyewa cukup pasti untuk mengeksekusi opsi tersebut; dan pembayaran penalti karena penghentian sewa, jika masa sewa merefleksikan penyewa mengeksekusi opsi untuk menghentikan sewa.

**o. Leases**

As Lessee

The Company assesses whether a contract is or contains a lease, at the inception of the contract. The Company recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. For these leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Company uses the incremental borrowing rate specific to the lessee.

The incremental borrowing rate depends on the term, currency and start date of the lease and is determined based on a series of inputs including: the risk-free rate based on government bond rates; a country-specific risk adjustment; a credit risk adjustment based on bond yields; and an entity-specific adjustment when the risk profile of the entity that enters into the lease is different to that of the Company and the lease does not benefit from a guarantee from the Company.

Lease payments included in the measurement of the lease liability comprise:

- Fixed lease payments (including in-substance fixed payments), less any lease incentives;
- Variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date;
- The amount expected to be payable by the lessee under residual value guarantees;
- The exercise price of purchase options, if the lessee is reasonably certain to exercise the options; and payments of penalties for terminating the lease, if the lease term reflects the exercise of an option to terminate the lease.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Liabilitas sewa disajikan sebagai pos terpisah dalam laporan posisi keuangan.

Liabilitas sewa selanjutnya diukur dengan meningkatkan jumlah tercatat untuk merefleksikan bunga atas liabilitas sewa (menggunakan metode suku bunga efektif) dan dengan mengurangi jumlah tercatat untuk merefleksikan sewa yang telah dibayar.

Setiap pembayaran sewa dialokasikan antara liabilitas dan biaya keuangan. Biaya keuangan dibebankan pada laba rugi selama periode sewa sehingga menghasilkan tingkat suku bunga periodik yang konstan atas saldo liabilitas untuk setiap periode.

Perusahaan mengukur kembali liabilitas sewa (dan melakukan penyesuaian terkait terhadap aset hak-guna) jika:

- Terdapat perubahan dalam masa sewa atau perubahan dalam penilaian atas eksekusi opsi pembelian, di mana liabilitas sewa diukur dengan mendiskontokan pembayaran sewa revisian menggunakan tingkat diskonto revisian;
- Terdapat perubahan sewa masa depan sebagai akibat dari perubahan indeks atau perubahan perkiraan pembayaran berdasarkan nilai residual jaminan di mana liabilitas sewa diukur kembali dengan mendiskontokan pembayaran sewa revisian menggunakan tingkat diskonto awal (kecuali jika pembayaran sewa berubah karena perubahan suku bunga mengambang, di mana tingkat diskonto revisian digunakan); atau kontrak sewa dimodifikasi dan modifikasi sewa tidak dicatat sebagai sewa terpisah, di mana liabilitas sewa diukur dengan mendiskontokan pembayaran sewa revisian menggunakan tingkat diskonto revisian.

Perusahaan tidak melakukan penyesuaian tersebut selama periode yang disajikan.

Aset hak-guna terdiri dari pengukuran awal atas liabilitas sewa, pembayaran sewa yang dilakukan pada saat atau sebelum permulaan sewa dan biaya langsung awal. Aset hak-guna selanjutnya diukur sebesar biaya dikurangi akumulasi penyusutan dan kerugian penurunan nilai.

Jika Perusahaan dibebankan kewajiban atas biaya membongkar dan memindahkan aset sewa, merestorasi tempat di mana aset berada atau merestorasi aset pendasar ke kondisi yang disyaratkan oleh syarat dan ketentuan sewa, provisi diakui dan diukur sesuai PSAK 237. Biaya tersebut diperhitungkan dalam aset hak-guna terkait, kecuali jika biaya tersebut terjadi untuk memproduksi persediaan.

The lease liability is presented as a separate line in the statement of financial position.

The lease liability is subsequently measured by increasing the carrying amount to reflect the interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made.

Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

The Company remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use assets) whenever:

- The lease term has changed or there is a change in the assessment of the exercise of a purchase option, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate;
- The lease payments change due to changes in an index or rate or a change in expected payment under a guaranteed residual value, in which cases the lease liability is remeasured by discounting the revised lease payments using the initial discount rate (unless the lease payments change is due to a change in a floating interest rate, in which case a revised discount rate is used); or a lease contract is modified and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate.

The Company did not make such any adjustment during the periods presented.

The right-of-use assets comprise the initial measurements of the corresponding lease liability, lease payments made at or before the commencement day and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Whenever the Company incurs an obligation for costs to dismantle and remove a leased asset, restore the site on which it is located or restore the underlying assets to the conditions required by the terms and conditions of the lease, a provision is recognized and measured under PSAK 237. The costs are included in the related right-of-use asset, unless those costs are incurred to produce inventories.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Aset hak-guna disusutkan secara garis lurus selama jangka waktu sewa yang lebih pendek dan estimasi masa manfaat aset, sebagai berikut:

*Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets, as follows:*

**Tahun/Years**

Tanah dan Bangunan  
Kendaraan

3 dan/and 80  
2 dan/and 3

*Landrights and Buildings  
Vehicles*

Jika sewa mengalihkan kepemilikan aset pendasar atau jika biaya perolehan aset hak-guna merefleksikan Perusahaan akan mengeksekusi opsi beli, aset hak-guna disusutkan selama masa manfaat aset pendasar. Penyusutan dimulai pada tanggal permulaan sewa.

*If a lease transfers ownership of the underlying assets or the cost of the right-of-use assets reflects that of the Company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying assets. The depreciation starts at the commencement date of the lease.*

Aset hak-guna disajikan sebagai pos terpisah di laporan posisi keuangan.

*The right-of-use assets are presented as a separate line in the statement of financial position.*

**p. Aset Tetap**

**p. Fixed Assets**

Aset tetap dinyatakan sebesar biaya perolehan dikurangi akumulasi penyusutan (kecuali tanah yang tidak disusutkan) dan rugi penurunan nilai, jika ada. Biaya perolehan termasuk biaya penggantian bagian aset tetap saat biaya tersebut terjadi, jika memenuhi kriteria pengakuan. Selanjutnya, pada saat inspeksi yang signifikan dilakukan, biaya inspeksi itu diakui ke dalam nilai tercatat aset tetap sebagai suatu penggantian jika memenuhi kriteria pengakuan. Semua biaya pemeliharaan dan perbaikan yang tidak memenuhi kriteria pengakuan diakui dalam laporan laba rugi dan penghasilan komprehensif lain pada saat terjadinya.

*Fixed assets are stated at cost less accumulated depreciation (except for land that is not depreciated) and impairment losses, if any. Such cost includes the cost of replacing part of the fixed assets when that cost is incurred, if the recognition criteria are met. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the fixed assets as a replacement if the recognition criteria are satisfied. All other repairs and maintenance costs that do not meet the recognition criteria are recognized in the statement of profit or loss and other comprehensive income as incurred.*

Penyusutan dihitung dengan menggunakan metode garis lurus untuk bangunan dan metode saldo menurun ganda untuk mesin, kendaraan, perlengkapan, dan peralatan kantor dengan menggunakan tarif sebagai berikut:

*Depreciation is calculated using the straight-line method for buildings and the double-declining balance method for machinery, vehicles, and supplies and office equipments using the following useful life:*

**Tahun/Years**

Bangunan

10 dan/and 20

*Buildings*

Mesin

4 dan/and 16

*Machineries*

Kendaraan

8

*Vehicles*

Perlengkapan dan peralatan kantor

4 dan/and 8

*Supplies and office equipments*

Aset dalam penyelesaian dinyatakan sebesar biaya perolehan dan disajikan sebagai bagian dari "Aset Tetap - Neto" dalam laporan posisi keuangan. Akumulasi biaya perolehan untuk aset dalam penyelesaian akan dipindahkan ke masing-masing aset tetap yang bersangkutan pada saat aset tersebut selesai dikerjakan dan siap digunakan sesuai dengan tujuannya.

*Construction in progress is stated at cost and presented as part of "Fixed Assets - Net" in the statement of financial position. The accumulated costs will be reclassified to the appropriate fixed asset account when the construction is substantially completed and the constructed asset is ready for its intended use.*

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Jumlah tercatat aset tetap dihentikan pengakuannya pada saat dilepaskan atau saat tidak ada manfaat ekonomis masa depan yang diharapkan dari penggunaan atau pelepasannya. Laba atau rugi yang timbul dari penghentian pengakuan aset (dihitung sebagai perbedaan antara jumlah neto hasil pelepasan dan jumlah tercatat dari aset) dimasukkan dalam laporan laba rugi dan penghasilan komprehensif lain pada tahun aset tersebut dihentikan pengakuannya.

Pada setiap akhir tahun buku, nilai residu, umur manfaat dan metode penyusutan ditelaah, dan jika sesuai dengan keadaan, disesuaikan secara prospektif.

**q. Aset Tak berwujud**

Aset takberwujud yang diperoleh secara terpisah diukur pada pengakuan awal sebesar biaya perolehan. Setelah pengakuan awal, aset takberwujud dicatat sebesar biaya perolehan dikurangi akumulasi amortisasi dan akumulasi kerugian penurunan nilai. Aset takberwujud yang dihasilkan secara internal, tidak termasuk biaya pengembangan yang dikapitalisasi, tidak dikapitalisasi dan pengeluaran terkait tercermin dalam laba rugi pada periode ketika pengeluaran terjadi.

Masa manfaat aset takberwujud dinilai baik terbatas atau tidak terbatas.

Aset takberwujud dengan masa manfaat terbatas diamortisasi selama masa manfaat ekonomis dan dinilai untuk penurunan nilai setiap ada indikasi bahwa aset takberwujud tersebut mungkin mengalami penurunan nilai. Periode amortisasi dan metode amortisasi untuk aset takberwujud dengan masa manfaat terbatas dikaji paling lambat pada setiap akhir periode pelaporan.

Perubahan dalam masa manfaat yang diharapkan atau pola konsumsi yang diharapkan dari manfaat ekonomi masa depan yang terkandung dalam aset dianggap memodifikasi periode atau metode amortisasi, sebagaimana mestinya, dan diperlakukan sebagai perubahan dalam estimasi akuntansi.

Beban amortisasi atas aset takberwujud dengan umur terbatas diakui dalam laba rugi dalam kategori biaya yang konsisten dengan fungsi dari aset takberwujud.

*An item of fixed asset is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit or loss and other comprehensive income in the year the asset is derecognized.*

*Residual values, useful lives and method of depreciation are reviewed, and adjusted prospectively, if appropriate, at each financial year end.*

**q. Intangible Assets**

*Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. Internally generated intangibles, excluding capitalised development costs, are not capitalised and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred*

*The useful lives of intangible assets are assessed as either finite or indefinite.*

*Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible assets may be impaired. The amortization period and the amortization method for an intangible assets with a finite useful life are reviewed at least at the end of each reporting period.*

*Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortization period or method, as appropriate, and are treated as changes in accounting estimates.*

*The amortization expense on intangible assets with finite life is recognized in the statement of profit or loss in the expense category that is consistent with the function of the intangible assets.*

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Aset takberwujud dengan masa manfaat tidak terbatas tidak diamortisasi, tetapi diuji untuk penurunan setiap tahun, baik secara individu atau pada tingkat unit penghasil kas. Penilaian masa manfaat yang tidak terbatas ditinjau setiap tahun untuk menentukan apakah masa manfaat yang tidak terbatas tetap dapat didukung. Jika tidak, perubahan dalam masa manfaat dari tidak terbatas menjadi terbatas dilakukan secara prospektif.

Keuntungan atau kerugian yang timbul dari penghentian pengakuan suatu aset takberwujud diukur sebagai perbedaan antara jumlah neto hasil pelepasan dan jumlah tercatat dari aset dan diakui dalam laba rugi ketika aset dihentikan pengakuannya.

Ringkasan kebijakan yang diterapkan pada aset takberwujud Perusahaan adalah, sebagai berikut:

**Perangkat lunak/  
Software**

|                   |                                     |                     |
|-------------------|-------------------------------------|---------------------|
| Umur manfaat      | 4 tahun/years                       | Useful lives        |
| Metode amortisasi | Saldo menurun /<br>double-declining | Amortization method |
| Cara perolehan    | Akuisisi/Acquisition                | Acquired by         |

**r. Penurunan Nilai Aset Non-keuangan**

Pada setiap akhir periode pelaporan, Perusahaan menilai apakah terdapat indikasi suatu aset mengalami penurunan nilai. Jika terdapat indikasi tersebut atau pada saat pengujian penurunan nilai diperlukan, maka Perusahaan membuat estimasi jumlah terpulihkan aset tersebut.

Jumlah terpulihkan yang ditentukan untuk aset individual adalah jumlah yang lebih tinggi antara nilai wajar aset atau Unit Penghasil Kas ("UPK") dikurangi biaya untuk menjual dengan nilai pakainya, kecuali aset tersebut tidak menghasilkan arus kas masuk yang sebagian besar independen dari aset atau kelompok aset lain. Jika nilai tercatat aset lebih besar daripada nilai terpulihkannya, maka aset tersebut mengalami penurunan nilai dan nilai tercatat aset diturunkan menjadi sebesar nilai terpulihkannya.

Rugi penurunan nilai dari operasi yang dilanjutkan diakui pada laporan laba rugi dan penghasilan komprehensif lain sebagai "Rugi Penurunan Nilai".

Dalam menghitung nilai pakai, estimasi arus kas masa depan neto didiskontokan ke nilai kini dengan menggunakan tingkat diskonto sebelum pajak yang menggambarkan penilaian pasar terkini atas nilai waktu dari uang dan risiko spesifik dari aset. Jika tidak terdapat transaksi tersebut, Perusahaan menggunakan model penilaian yang sesuai untuk menentukan nilai wajar aset. Perhitungan-

*Intangible assets with indefinite useful lives are not amortised, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.*

*Gains or losses arising from derecognition of an intangible assets are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit or loss when the asset is derecognized.*

*A summary of the policies applied to the Company's intangible assets is, as follows:*

**r. Impairment of Non-financial Assets**

*The Company assesses at each reporting period, whether there is an indication that an asset may be impaired. If any such indication exists or when annual impairment testing for an asset is required, the Company makes an estimate of the asset's recoverable amount.*

*An asset's recoverable amount is the higher of the asset's or Cash Generating Unit's ("CGU") fair value less costs to sell and its value in use, and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or Companies of assets. Where the carrying amount of an asset exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.*

*Impairment losses of continuing operations are recognized in the statement of profit or loss and other comprehensive income as "Impairment Losses".*

*In assessing the value in use, the estimated net future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. If no such transactions can be identified, the Company used an appropriate valuation model to determine the fair value of the assets. These calculations are*

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

perhitungan ini dikuatkan oleh penilaian berganda atau indikasi nilai wajar yang tersedia.

Dalam mengukur nilai wajar dikurangi biaya pelepasan, digunakan harga penawaran pasar terakhir, jika tersedia. Kerugian penurunan nilai dari operasi yang dilanjutkan, jika ada, diakui dalam laporan laba rugi dan penghasilan komprehensif lain sesuai dengan kategori beban yang konsisten dengan fungsi dari aset yang diturunkan nilainya.

Penilaian dilakukan pada akhir setiap periode pelaporan tahunan apakah terdapat indikasi bahwa rugi penurunan nilai yang telah diakui dalam periode sebelumnya mungkin tidak ada lagi atau mungkin telah menurun. Jika indikasi dimaksud ditemukan, maka entitas mengestimasi jumlah terpulihkan aset tersebut. Kerugian penurunan nilai yang telah diakui dalam periode sebelumnya dibalik hanya jika terdapat perubahan asumsi-asumsi yang digunakan untuk menentukan jumlah terpulihkan aset sejak rugi penurunan nilai terakhir diakui.

Dalam hal ini, jumlah tercatat aset dinaikkan ke jumlah terpulihkannya. Pembalikan tersebut dibatasi sehingga jumlah tercatat aset tidak melebihi jumlah terpulihkannya maupun jumlah tercatat, neto setelah penyusutan, seandainya tidak ada rugi penurunan nilai yang telah diakui untuk aset tersebut pada tahun sebelumnya. Pembalikan rugi penurunan nilai diakui dalam laporan laba rugi dan penghasilan komprehensif lain. Setelah pembalikan tersebut, penyusutan aset tersebut disesuaikan di periode mendatang untuk mengalokasikan jumlah tercatat aset yang direvisi, dikurangi nilai sisanya, dengan dasar yang sistematis selama sisa umur manfaatnya.

**s. Imbalan Kerja Karyawan**

Imbalan kerja jangka pendek adalah imbalan kerja yang jatuh tempo dalam jangka waktu dua belas bulan setelah akhir periode pelaporan dan diakui pada saat pekerja telah memberikan jasa kerjanya. Kewajiban diakui ketika karyawan memberikan jasa kepada Grup dimana semua perubahan pada nilai bawaan dari kewajiban diakui pada laba rugi

Imbalan Pascakerja Program Imbalan Pasti

Grup mengakui kewajiban imbalan kerja yang tidak didanai sesuai dengan Peraturan Pemerintah Pengganti Undang-Undang (Perppu) No. 2 tahun 2022 tentang Cipta Kerja yang kemudian disahkan menjadi Undang-Undang No. 6 tahun 2023. Beban pensiun berdasarkan program dana pensiun manfaat pasti Grup ditentukan melalui perhitungan aktuarial secara periodik dengan menggunakan metode *projected-unit credit* dan menerapkan asumsi atas

*corroborated by valuation multiples or other available fair value indicators.*

*In measurement of fair value less costs of disposal, recent market transactions are taken into account, if available. Impairment losses of continuing operations, if any, are recognized in the statement of profit or loss and other comprehensive income under expense categories that are consistent with the functions of the impaired assets.*

*An assessment is made at each annual reporting period as to whether there is any indication that previously recognized impairment losses recognized for an asset may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognized impairment loss for an asset is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognized.*

*If that is the case, the carrying amount of the asset is increased to its recoverable amount. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceeds the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Reversal of an impairment loss is recognized in the statement of profit or loss and other comprehensive income. After such a reversal, the depreciation charge on the said asset is adjusted in future periods to allocate the asset's revised carrying amount, less any residual value, on a systematic basis over its remaining useful life.*

**s. Employee Benefits**

*Short term employee benefits are employee benefits which are due for payment within twelve months after the reporting period and recognized when the employees have rendered this related service. Liabilities are recognized when the employee renders services to the Group where all changes in the carrying amount of the liability are recognized in profit or loss.*

Defined Benefit Plan

*The Group recognized unfunded employee benefits liability in accordance with Government Regulation in Lieu of Law ("Perppu") No. 2 of 2022 on Job Creation which was later passed into Law No. 6 in 2023. Pension costs under the Group's defined benefit pension plans are determined by periodic actuarial calculation using the projected-unit-credit method and applying the assumptions on discount rate, return on plan assets and annual rate of increase in compensation.*

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

tingkat diskonto, hasil atas aset program dan tingkat kenaikan manfaat pasti pensiun tahunan.

Pengukuran kembali, terdiri dari keuntungan dan kerugian aktuarial, dampak perubahan pada batas atas aset (jika ada) dan imbal hasil atas aset program (tidak termasuk bunga), yang tercermin langsung dalam laporan posisi keuangan konsolidasian yang dibebankan atau dikreditkan diakui dalam penghasilan komprehensif lain pada periode terjadinya untuk mencerminkan aset atau liabilitas pensiun neto yang diakui pada laporan keuangan konsolidasian untuk mencerminkan nilai penuh dari defisit dan surplus program. Pengukuran kembali diakui dalam penghasilan komprehensif lain tercermin segera dalam saldo laba dan tidak akan direklasifikasi ke laba rugi.

Biaya jasa lalu diakui dalam laba rugi ketika terjadi amendemen program atau kurtailmen, atau ketika Grup mengakui biaya restrukturisasi terkait atau pesangon, jika lebih dahulu.

Bunga neto dihitung dengan menggunakan tingkat diskonto terhadap liabilitas atau aset imbalan pasti neto. Biaya imbalan pasti dikategorikan sebagai berikut:

- Biaya jasa (termasuk biaya jasa kini, biaya jasa lalu serta keuntungan dan kerugian kurtailmen dan penyelesaian)
- Beban atau pendapatan bunga neto Pengukuran kembali

Grup menyajikan dua komponen pertama dari biaya imbalan pasti di laba rugi, Keuntungan dan kerugian kurtailmen dicatat sebagai biaya jasa lalu

Kewajiban imbalan pensiun yang diakui pada laporan posisi keuangan konsolidasian merupakan defisit atau surplus aktual dalam program imbalan pasti Grup. Surplus yang dihasilkan dari perhitungan ini terbatas pada nilai kini manfaat ekonomis yang tersedia dalam bentuk pengembalian dana program dan pengurangan iuran masa depan atas program.

**t. Pengakuan pendapatan dan beban**

Perusahaan menerapkan PSAK 115 yang mensyaratkan pengakuan pendapatan harus memenuhi lima langkah analisa sebagai berikut:

1. Identifikasi kontrak dengan pelanggan;
2. Identifikasi kewajiban pelaksanaan dalam kontrak. Kewajiban pelaksanaan merupakan janji-janji dalam kontrak untuk menyeragkan barang atau jasa yang memiliki karakteristik berbeda ke pelanggan;

*Remeasurement, comprising actuarial gains and losses, the effect of the changes to the asset ceiling (if applicable) and the return on plan assets (excluding interest), is reflected immediately in the consolidated statement of financial position with a charge or credit recognized in other comprehensive income in the period in which they occur in order for the net pension asset or liability recognized in the consolidated statement of financial position to reflect the full value of the plan deficit and surplus. Remeasurement recognized in other comprehensive income is reflected immediately in retained earnings and will not be reclassified to profit or loss.*

*Past service cost is recognized in profit or loss when the plan amendment or curtailment occurs, or when the Group recognizes related restructuring costs or termination benefits, if earlier.*

*Net interest is calculated by applying the discount rate to the net defined benefit liability or asset. Defined benefit costs are categorized as follows*

- *Service cost (including current service cost, past service cost, as well as gains and losses on curtailments and settlements)*
- *Net interest expense or income Remeasurement*

*The Group presents the first two components of defined benefit costs in profit or loss. Curtailment gains and losses are accounted for as past service costs.*

*The retirement benefit obligation recognized in the consolidated statement of financial position represents the actual deficit or surplus in the Group's defined benefit plans. Any surplus resulting from this calculation is limited to the present value of any economic benefits available in the form of refunds from the plans or reductions in future contributions to the plans.*

**t. Revenue and expense recognition**

*The Company have adopted PSAK 115, which, requires revenue recognition to fulfill five steps of assessment:*

1. *Identify contract(s) with a customer;*
2. *Identify the performance obligation in the contract. Performance obligations are promises in a contract to transfer to a customer goods or service that are distinct;*

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

3. Penetapan harga transaksi. Harga transaksi merupakan jumlah imbalan yang berhak diperoleh suatu entitas sebagai kompensasi atas penyerahannya barang atau jasa yang dijanjikan ke pelanggan. Jika imbalan yang dijanjikan di kontrak mengandung suatu jumlah yang bersifat variabel, maka Perusahaan membuat estimasi jumlah imbalan tersebut sebesar jumlah yang diharapkan berhak diterima atas penyerahannya barang atau jasa yang dijanjikan ke pelanggan yang akan dibayarkan selama periode kontrak; dan
4. Alokasi harga transaksi ke setiap kewajiban pelaksanaan dengan menggunakan dasar harga jual berdiri sendiri relatif dari setiap barang atau jasa berbeda yang dijanjikan di kontrak. Ketika tidak dapat diamati secara langsung, harga jual berdiri sendiri relatif diperkirakan berdasarkan biaya yang diharapkan ditambah margin; dan
5. Pengakuan pendapatan ketika kewajiban pelaksanaan telah dipenuhi dengan menyerahkan barang atau jasa yang dijanjikan ke pelanggan (ketika pelanggan telah memiliki kendali atas barang atau

Kewajiban pelaksanaan dapat dipenuhi:

- Pada suatu titik waktu (umumnya janji untuk menyerahkan barang ke pelanggan); atau
- Suatu periode waktu (umumnya janji untuk menyerahkan jasa ke pelanggan). Untuk kewajiban pelaksanaan yang dipenuhi dalam suatu periode waktu, Perusahaan memilih ukuran penyelesaian yang sesuai untuk penentuan jumlah pendapatan yang harus diakui telah terpenuhinya kewajiban pelaksanaan.

Berikut ini kriteria khusus pengakuan yang harus dipenuhi sebelum pendapatan diakui:

Penjualan barang

Pendapatan dari penjualan barang yang timbul dari pengiriman fisik produk-produk Perusahaan diakui bila kontrol yang signifikan telah dipindahkan kepada pembeli, yang umumnya bersamaan waktunya dengan pengiriman dan penerimaannya

Pendapatan/beban bunga

Untuk semua instrumen keuangan yang diukur pada biaya perolehan diamortisasi, pendapatan atau beban bunga dicatat dengan menggunakan metode Suku Bunga Efektif ("SBE"), yaitu suku bunga yang secara tepat mendiskontokan estimasi pembayaran atau penerimaan kas di masa datang selama perkiraan umur dari instrumen keuangan, atau jika lebih tepat, digunakan periode yang lebih singkat,

3. Determine the transaction price. Transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods or services to a customer which will be paid during the contract period; and
4. Allocate the transaction price to each performance obligation on the basis of the relative stand-alone selling prices of each distinct good or service promised in the contract. Where these are not directly observable, the relative stand-alone selling prices are estimated based on expected cost plus margin; and
5. Recognise revenue when the performance obligation is satisfied by transferring a promised good or service to a customer (which is when the customer obtains control of that good or service).

A performance obligation may be satisfied:

- At a point in time (typically for promises to transfer goods to a customer); or
- Over time (typically for promises to transfer service to a customer). For a performance obligation satisfied over time, the Company select an appropriate measure of progress to determine the amount of revenue that should be recognised as the performance obligation is satisfied.

The following specific recognition criteria must also be fulfilled before revenue is recognized:

Sales of goods

Revenue from sales arising from physical delivery of the Company products is recognized at the time the transfer of control have been passed to the buyer, which generally coincides with their delivery and acceptance.

Interest income/expense

For all financial instruments measured at amortized cost, interest income or expense is recorded using the Effective Interest Rate ("EIR"), which is the rate that exactly discounts the estimated future cash payments or receipts through the expected life of the financial instrument or a shorter period, where appropriate, to the net carrying amount of the financial asset or liabilities.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

untuk nilai tercatat neto dari aset atau liabilitas keuangan.

Beban

Beban diakui pada saat terjadinya (akrual).

Saldo kontrak yang timbul dari pendapatan dengan kontrak pelanggan adalah sebagai berikut:

Piutang usaha

Piutang merupakan hak Perusahaan atas imbalan yang tidak bersyarat (yaitu, hanya berlalunya waktu yang diperlukan sebelum pembayaran jatuh tempo).

Uang muka dari pelanggan

Uang muka dari pelanggan mengacu pada pembayaran dari pelanggan sebelum pengiriman barang. Uang muka dari pelanggan merupakan kewajiban untuk menyerahkan barang kepada pelanggan dimana Perusahaan telah menerima imbalan dari pelanggan. Uang muka dari pelanggan akan digunakan untuk saling hapus dengan piutang usaha pada saat Perusahaan menyerahkan barang berdasarkan kontrak. Uang muka pelanggan diklasifikasikan sebagai liabilitas kontrak dari perjanjian pendapatan dengan pelanggan.

Tidak ada aset kontrak dalam perjanjian pendapatan Perusahaan dengan pelanggan.

Perusahaan juga menilai pengaturan pendapatannya untuk menentukan apakah bertindak sebagai prinsipal atau sebagai agen. Perusahaan telah menilai bahwa ia bertindak sebagai prinsipal dalam pengaturan pendapatannya.

**u. Perpajakan**

Pajak Kini

Aset dan liabilitas pajak kini untuk tahun berjalan diukur sebesar jumlah yang diharapkan dapat direstitusi dari atau dibayarkan kepada otoritas perpajakan.

Beban pajak kini ditentukan berdasarkan laba kena pajak tahun berjalan yang dihitung berdasarkan tarif pajak yang berlaku.

Koreksi terhadap liabilitas perpajakan diakui pada saat surat ketetapan pajak diterima atau, jika diajukan keberatan, pada saat keputusan atas keberatan ditetapkan.

Expense

Expense are recognized when incurred (Accrual basis).

Contract balances arising from revenue with customer contract are as follow:

Trade receivables

A receivable represents the Company's right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due).

Advances from customers

Advances from customers refer to payment from customers prior to delivery of the goods. Advances from customers represent the obligation to transfer goods to a customer for which the Company has received consideration from the customer. Advances from customers will be used to offset to trade reivables when the Company delivers the goods under the contract. Advances from customers were classified as contract liabilities from revenue arrangements with customers.

There were no contract assets in the Company's revenue arrangements with customers.

The Company also assess its revenue arrangements to determine if it is acting as a principal or as an agent. The Company has assessed that it acts as principal in its revenue arrangements.

**u. Taxation**

Current Tax

Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authority.

Current tax expense is determined based on the taxable profit for the year computed using the prevailing tax rates.

Amendments to tax obligations are recorded when a tax assessment letter is received or, if appealed against, when the result of the appeal is determined.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Kekurangan/kelebihan pembayaran pajak penghasilan beserta bunga dan denda, jika ada, dicatat sebagai bagian dari "Beban Pajak Penghasilan - Neto" dalam laporan laba rugi dan penghasilan komprehensif lain.

*Underpayment/overpayment of income tax with interest and penalty, if any, are recorded as part of "Income Tax Expense - Net" in the statement of profit or loss and other comprehensive income.*

Pajak Tangguhan

Deferred Tax

Aset dan liabilitas pajak tangguhan diakui menggunakan metode liabilitas atas konsekuensi pajak pada masa mendatang yang timbul dari perbedaan jumlah tercatat aset dan liabilitas menurut laporan keuangan dengan dasar pengenaan pajak aset dan liabilitas pada setiap tanggal pelaporan. Liabilitas pajak tangguhan diakui untuk semua perbedaan temporer kena pajak dan aset pajak tangguhan diakui untuk perbedaan temporer yang boleh dikurangkan dan akumulasi rugi fiskal, sepanjang besar kemungkinan perbedaan temporer yang boleh dikurangkan dan akumulasi rugi fiskal tersebut dapat dimanfaatkan untuk mengurangi laba kena pajak pada masa depan.

*Deferred tax assets and liabilities are recognized using the liability method for the future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities in the financial statements and their respective tax bases at each reporting date. Deferred tax liabilities are recognized for all taxable temporary differences and deferred tax assets are recognized for deductible temporary differences and accumulated fiscal losses to the extent that it is probable that taxable profit will be available in future years against which the deductible temporary differences and accumulated fiscal losses can be utilized.*

Jumlah tercatat aset pajak tangguhan ditelaah ulang pada akhir setiap periode pelaporan dan diturunkan apabila laba fiskal mungkin tidak memadai untuk mengkompensasi sebagian atau semua manfaat aset pajak tangguhan tersebut. Pada akhir setiap periode pelaporan, Grup menilai kembali aset pajak tangguhan yang tidak diakui. Grup mengakui aset pajak tangguhan yang sebelumnya tidak diakui apabila besar kemungkinan bahwa laba fiskal pada masa depan akan tersedia untuk pemulihannya.

*The carrying amount of a deferred tax asset is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow the benefit of part or all of that deferred tax asset to be utilized. At the end of each reporting period, the Group reassesses unrecognized deferred tax assets. The Group recognizes a previously unrecognized deferred tax assets to the extent that it has become probable that future taxable profit will allow the deferred tax assets to be recovered.*

Pajak tangguhan dihitung dengan menggunakan tarif pajak yang berlaku atau secara substansial telah berlaku pada tanggal pelaporan.

*Deferred tax is calculated at the tax rates that have been enacted or substantively enacted at the reporting date.*

Perubahan nilai tercatat aset dan liabilitas pajak tangguhan yang disebabkan oleh perubahan tarif pajak dibebankan pada usaha periode berjalan, kecuali untuk transaksi-transaksi yang sebelumnya telah langsung dibebankan atau dikreditkan ke ekuitas.

*Changes in the carrying amount of deferred tax assets and liabilities due to a change in tax rates are charged to current period operations, except to the extent that they relate to items previously charged or credited to equity.*

Aset dan liabilitas pajak tangguhan disajikan secara saling hapus dalam laporan posisi keuangan, kecuali aset dan liabilitas pajak tangguhan untuk entitas yang berbeda, sesuai dengan penyajian aset dan liabilitas pajak kini.

*Deferred tax assets and liabilities are offset in the statement of financial position, except if they are for different legal entities, consistent with the presentation of current tax assets and liabilities.*

Pajak Pertambahan Nilai ("PPN")

Value Added Tax ("VAT")

Pendapatan, beban dan aset diakui neto atas jumlah PPN, kecuali:

*Revenues, expenses and assets are recognized net of the amount of VAT, except:*

- Ketika PPN yang terjadi sehubungan dengan pembelian aset atau jasa tidak dapat dikreditkan menurut ketentuan perpajakan. Dalam hal ini PPN diakui sebagai bagian dari biaya perolehan

- Where the VAT incurred on purchase of assets or services is not recoverable according to tax regulations. In which case the VAT is recognized as the part of the cost of acquisition

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

aset atau sebagai bagian dari beban yang bersangkutan.

- Piutang dan utang yang disajikan termasuk dengan jumlah PPN.

Jumlah PPN neto yang terpulihkan dari, atau terutang kepada, kantor pajak termasuk sebagai bagian dari piutang atau utang pada laporan posisi keuangan.

**v. Informasi Segmen**

Segmen operasi diidentifikasi berdasarkan laporan internal mengenai komponen dari Grup yang secara regular direviu oleh "pengambil keputusan operasional" dalam rangka mengalokasikan sumber daya dan menilai kinerja segmen operasi.

Segmen operasi adalah suatu komponen dari entitas:

- yang terlibat dalam aktivitas bisnis untuk memperoleh pendapatan dan menimbulkan beban (termasuk pendapatan dan beban terkait dengan transaksi dengan komponen lain dari entitas yang sama);
- yang hasil operasinya dikaji ulang secara regular oleh pengambil keputusan operasional untuk membuat keputusan tentang sumber daya yang dialokasikan pada segmen tersebut dan menilai kinerjanya; dan
- dimana tersedia informasi keuangan yang dapat dipisahkan.

Informasi yang digunakan oleh pengambil keputusan operasional dalam rangka alokasi sumber daya dan penilaian kinerja mereka terfokus pada kategori dari setiap produk.

Pendapatan, beban, hasil, aset dan liabilitas segmen termasuk hal-hal yang dapat diatribusikan secara langsung kepada suatu segmen serta hal-hal yang dapat dialokasikan dengan dasar yang memadai untuk segmen tersebut. Segmen ditentukan sebelum saldo dan transaksi antar grup dieliminasi sebagai bagian dari proses konsolidasi.

**w. Laba per Saham**

Laba per saham dasar dihitung dengan membagi laba bersih tahun berjalan dengan rata-rata tertimbang jumlah saham yang beredar pada periode yang bersangkutan.

**x. Dividen**

Pembagian dividen kepada para pemegang saham Grup diakui sebagai liabilitas dalam laporan keuangan konsolidasian pada periode ketika dividen tersebut disetujui oleh para pemegang saham Grup.

of the asset or as the part of the related expense item.

- Receivables and payables that are stated with the amount of VAT included.

The net amount of VAT recoverable from, or payable to, the taxation authorities is included as part of receivables or payables in the statement of financial position.

**v. Segment Information**

Operating segments are identified on the basis of internal reports about components of the Group that are regularly reviewed by the "chief operating decision maker" in order to allocate resources to the segments and to assess their performances.

An operating segment is a component of an entity:

- that engages in business activities from which it may earn revenues and incurred expenses (including revenues and expenses relating to the transactions with other components of the same entity);
- whose operating results are reviewed regularly by the entity's chief operating decision maker to make decision about resources to be allocated to the segments and assess its performance; and
- for which discrete financial information is available.

Information reported to the chief operating decision maker for the purpose of resource allocation and assessment of performance is more specifically focused on the category of each product.

Segment revenue, expenses, results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis to that segment. They are determined before intra-group balances and intragroup transactions are eliminated.

**w. Earning per Share**

Basic earnings per share is computed by dividing net profit for the year with the weighted average number of shares outstanding during the period.

**x. Dividends**

Dividend distribution to the Group's shareholders is recognized as a liability in the consolidated financial statements in the period in which the dividends are approved by the Group's shareholders.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**y. Provisi dan Kontinjensi**

Provisi diakui ketika Grup memiliki kewajiban kini (baik bersifat hukum maupun bersifat konstruktif) sebagai akibat peristiwa masa lalu, kemungkinan besar Grup diharuskan menyelesaikan kewajiban dan estimasi yang andal mengenai jumlah kewajiban tersebut dapat dibuat.

Jumlah yang diakui sebagai provisi adalah hasil estimasi terbaik pengeluaran yang diperlukan untuk menyelesaikan kewajiban kini pada akhir periode pelaporan, dengan mempertimbangkan risiko dan ketidakpastian yang meliputi kewajibannya. Apabila suatu provisi diukur menggunakan arus kas yang diperkirakan untuk menyelesaikan kewajiban kini, maka nilai tercatatnya adalah nilai kini dari arus kas (ketika pengaruh nilai waktu uang bersifat material).

Tingkat diskonto yang digunakan untuk menentukan nilai kini adalah tingkat sebelum pajak yang mencerminkan penilaian pasar saat ini atas nilai waktu uang dan risiko spesifik terhadap liabilitas. Peningkatan provisi karena berlalunya waktu diakui sebagai beban bunga.

Ketika beberapa atau seluruh manfaat ekonomi untuk penyelesaian provisi yang diharapkan dapat dipulihkan dari pihak ketiga, piutang diakui sebagai aset apabila terdapat kepastian bahwa penggantian akan diterima dan jumlah piutang dapat diukur secara andal.

Aset dan liabilitas kontinjensi tidak diakui dalam laporan keuangan konsolidasian. Liabilitas kontinjensi diungkapkan dalam laporan keuangan konsolidasian, kecuali kemungkinan arus keluar sumber daya yang mewujudkan manfaat ekonomi bersifat kecil. Aset kontinjensi diungkapkan dalam laporan keuangan konsolidasian di mana kemungkinan besar terjadi arus masuk manfaat ekonomi.

**z. Peristiwa Setelah Periode Pelaporan**

Peristiwa setelah akhir tahun yang memberikan tambahan informasi mengenai posisi keuangan Perusahaan pada tanggal pelaporan (peristiwa penyesuaian), jika ada, dicerminkan dalam laporan keuangan konsolidasian. Peristiwa setelah akhir tahun yang bukan peristiwa penyesuaian diungkapkan dalam Catatan atas laporan keuangan konsolidasian, jika material.

**aa. Aset Lancar Lainnya**

Aset lancar lainnya merupakan jaminan yang diberikan Grup untuk sewa jangka pendek dan dicatat berdasarkan jumlah yang dibayarkan oleh Grup.

**y. Provisions and Contingencies**

Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that the Group will be required to settle the obligations, and a reliable estimate can be made of the amount of the obligation.

The amount recognized as a provisions is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of time value of money is material).

The discount rate used to determine the present value is a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The increase in the provision due to the passage of time is recognized as interest expense.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognized as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Contingent assets and liabilities are not recognized in the consolidated financial statements. Contingent liabilities are disclosed in the consolidated financial statements, unless the possibility of an outflow of resources embodying economic benefits is remote. Contingent assets are disclosed in the consolidated financial statements where inflow of economic benefits is probable.

**z. Events After the Reporting Period**

Events after the reporting period that provide additional information about the Group position at the reporting period (adjusting events) are reflected in the consolidated financial statements. Events after the reporting period that are not adjusting events are disclosed in the notes to the consolidated financial statements when material.

**aa. Other Current Asset**

Aset lancar lainnya merupakan jaminan yang diberikan Grup untuk sewa jangka pendek dan dicatat berdasarkan jumlah yang dibayarkan oleh Grup.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**bb. Instrumen Ekuitas**

Instrumen ekuitas adalah setiap kontrak yang memberikan hak residual atas aset Grup setelah dikurangi dengan seluruh liabilitasnya. Instrumen ekuitas yang diterbitkan oleh Grup dicatat sebesar hasil penerimaan neto setelah dikurangi biaya penerbitan langsung.

Ketika entitas Grup membeli modal saham ekuitas Entitas (saham treasuri), imbalan yang dibayar, termasuk biaya tambahan yang secara langsung dapat diatribusikan (dikurangi pajak penghasilan) dikurangkan dari ekuitas yang diatribusikan kepada pemilik ekuitas entitas sampai saham tersebut dibatalkan atau diterbitkan kembali. Ketika saham biasa tersebut selanjutnya diterbitkan kembali, imbalan yang diterima, dikurangi biaya tambahan transaksi yang terkait dan dampak pajak penghasilan yang terkait, diakui pada ekuitas.

**bb. Equity Instruments**

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Group are recorded at the proceeds received, net of direct issue costs.

Where any Group company purchases the Company's equity share capital (treasury shares), the consideration paid, including any directly attributable incremental costs (net of income taxes) is deducted from equity attributable to the Company's equity holders until the shares are cancelled or reissued. Where such ordinary shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effect, is recognized in equity.

**4. PERTIMBANGAN KRITIS AKUNTANSI DAN SUMBER UTAMA KETIDAKPASTIAN ESTIMASI**

Dalam penerapan kebijakan akuntansi Perusahaan, yang dijelaskan dalam Catatan 3, direksi diwajibkan untuk membuat penilaian, estimasi dan asumsi tentang jumlah tercatat aset dan liabilitas yang tidak tersedia dari sumber lain. Estimasi dan asumsi yang terkait didasarkan pada pengalaman historis dan faktor-faktor lain yang dianggap relevan. Hasil aktualnya mungkin berbeda dari estimasi tersebut.

Estimasi dan asumsi yang mendasari ditelaah secara berkelanjutan. Revisi estimasi akuntansi diakui dalam periode yang perkiraan tersebut direvisi jika revisi hanya mempengaruhi periode itu, atau pada periode revisi dan periode masa depan jika revisi mempengaruhi kedua periode saat ini dan masa depan.

**Pertimbangan Kritis dalam Penerapan Kebijakan Akuntansi**

Dalam penerapan kebijakan akuntansi, yang dijelaskan dalam Catatan 3, manajemen tidak membuat pertimbangan kritis yang memiliki pengaruh signifikan terhadap jumlah yang diakui dalam laporan keuangan konsolidasian selain dari yang melibatkan estimasi.

**Sumber Utama Estimasi Ketidakpastian**

Asumsi utama masa depan dan ketidakpastian sumber estimasi utama yang lain pada tanggal pelaporan yang memiliki risiko signifikan bagi penyesuaian yang material terhadap nilai tercatat aset dan liabilitas untuk tahun berikutnya diungkapkan di bawah ini. Grup mendasarkan asumsi dan estimasi pada parameter yang tersedia pada saat laporan keuangan konsolidasian disusun. Asumsi dan situasi mengenai perkembangan masa depan

**4. CRITICAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY**

In the application of the Company's accounting policies, which are described in Note 3, the directors are required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

**Critical Judgments in Applying Accounting Policies**

In the process of applying the accounting policies described in Note 3, management has not made any critical judgement that has a significant effect on the amounts recognized in the consolidated financial statements, apart from those involving estimates

**Key Sources of Uncertainty Estimation**

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Group based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

mungkin berubah akibat perubahan pasar atau situasi di luar kendali Grup. Perubahan tersebut dicerminkan dalam asumsi terkait pada saat terjadinya.

circumstances and assumptions about future developments however, may change due to market changes or circumstances arising beyond the control of the Group. Such changes are reflected in the assumptions when they occur.

Perhitungan cadangan kerugian piutang usaha

Calculation of loss allowance on trade accounts receivables

Grup menggunakan matriks provisi untuk menghitung ECL piutang usaha. Tingkat provisi didasarkan pada hari lewat jatuh tempo untuk pengelompokan berbagai segmen pelanggan yang memiliki pola kerugian yang serupa (yaitu, menurut geografi, jenis produk, jenis dan peringkat pelanggan, dan pertanggungan berdasarkan surat kredit dan bentuk asuransi kredit lainnya).

The Group uses a provision matrix to calculate ECLs for trade receivables. The provision rates are based on days past due for groupings of various customer segments that have similar loss patterns (i.e., by geography, product type, customer type and rating, and coverage by letters of credit and other forms of credit insurance).

Matriks provisi awalnya didasarkan pada tingkat *default* yang diamati secara historis Grup. Grup akan mengkalibrasi matriks untuk menyesuaikan pengalaman kerugian kredit historis dengan informasi berwawasan ke depan. Misalnya, jika prakiraan kondisi ekonomi (yaitu, *product domestic bruto*) diperkirakan akan memburuk selama tahun depan yang dapat menyebabkan peningkatan jumlah *default*, maka tingkat *default* historis disesuaikan. Pada setiap tanggal pelaporan, tingkat *default* yang diamati secara historis diperbarui dan perubahan dalam estimasi berwawasan ke depan dianalisis.

The provision matrix is initially based on the Group's historical observed default rates. The Group will calibrate the matrix to adjust the historical credit loss experience with forward-looking information. For instance, if forecast economic conditions (i.e., gross domestic product) are expected to deteriorate over the next year which can lead to an increased number of defaults, the historical default rates are adjusted. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analyzed.

Penilaian korelasi antara tingkat *default* yang diamati secara historis, prakiraan kondisi ekonomi, dan ECL adalah estimasi signifikan. Jumlah ECL sensitif terhadap perubahan keadaan dan prakiraan kondisi ekonomi. Pengalaman kerugian kredit historis Grup dan prakiraan kondisi ekonomi mungkin tidak mewakili *default* aktual pelanggan di masa depan. Cadangan kerugian piutang usaha masing-masing diungkapkan pada Catatan 7.

The assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate. The amount of ECLs is sensitive to changes in circumstances and of forecast economic conditions. The Group's historical credit loss experience and forecast of economic conditions may also not be representative of customer's actual default in the future. The loss allowance for trade receivables is disclosed in Note 7

Penyisihan Penurunan Nilai Pasar dan Kusangan Persediaan

Allowance for Decline in Market Values and Obsolescence of Inventories

Penyisihan penurunan nilai pasar dan keusangan persediaan diestimasi berdasarkan fakta dan situasi terbaik yang tersedia, termasuk namun tidak terbatas kepada, kondisi fisik persediaan yang dimiliki, harga jual pasar, estimasi biaya penyelesaian dan estimasi biaya yang timbul untuk penjualan. Provisi dievaluasi kembali dan disesuaikan jika terdapat tambahan informasi yang mempengaruhi jumlah yang diestimasi. Nilai tercatat persediaan diungkapkan dalam Catatan 9.

Allowance for decline in market values and obsolescence of inventories is estimated based on the best available facts and circumstances, including but not limited to, the inventories' own physical conditions, their market selling prices, estimated costs of completion and estimated costs to be incurred for their sales. The provisions are re-evaluated and adjusted as additional information received affects the amount estimated. The carrying amounts of inventories are disclosed in Note 9.

Taksiran Masa Manfaat Ekonomis Aset Tetap

Estimated Useful Lives of Fixed Asset

Masa manfaat setiap aset tetap Grup ditentukan berdasarkan kegunaan yang diharapkan dari asset tersebut. Estimasi ini ditentukan berdasarkan evaluasi teknis internal dan pengalaman atas asset sejenis. Masa manfaat setiap aset direvisi secara periodik dan

The useful life of each item of the Group's Fixed Asset are estimated based on the period over which the asset is expected to be available for use. Such estimation is based on internal technical evaluation and experience with similar assets. The estimated useful life of each

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

disesuaikan apabila prakiraan berbeda dengan estimasi sebelumnya karena keausan, keusangan teknis dan komersial, hukum atau keterbatasan lainnya atas pemakaian aset. Namun terdapat kemungkinan bahwa hasil operasi dimasa mendatang dapat dipengaruhi secara signifikan oleh perubahan atas jumlah serta periode pencatatan biaya yang diakibatkan karena perubahan faktor yang disebutkan di atas.

Perubahan masa manfaat aset tetap dapat mempengaruhi jumlah biaya penyusutan yang diakui dan merubah nilai tercatat aset tersebut. Perubahan masa manfaat aset tetap dapat mempengaruhi jumlah biaya penyusutan yang diakui dan merubah nilai tercatat aset tersebut.

Nilai tercatat aset tetap diungkapkan dalam Catatan 13.

Amortisasi Aset Tak berwujud

Perusahaan dan Anak Perusahaan melakukan penelaahan berkala atas masa manfaat ekonomis aset takberwujud berdasarkan faktor-faktor yang relevan, antara lain, kondisi teknis dan perkembangan teknologi di masa depan. Perubahan tingkat pemakaian dan perkembangan teknologi dapat memengaruhi masa manfaat ekonomis dan nilai sisa aset, dan karenanya biaya amortisasi masa depan mungkin direvisi.

Nilai tercatat aset tak berwujud diungkapkan dalam Catatan 14.

Estimasi Tingkat Suku Bunga Inkremental untuk Sewa

Grup tidak dapat langsung menentukan tingkat bunga implisit dalam sewa. Oleh karena itu, ia menggunakan suku bunga pinjaman inkremental yang relevan untuk mengukur liabilitas sewa.

Suku bunga pinjaman inkremental adalah suku bunga yang harus dibayar Grup untuk meminjam dalam jangka waktu yang sama dan dengan jaminan yang sama, dana yang diperlukan untuk memperoleh aset dengan nilai yang sama dengan aset hak-guna dalam lingkungan ekonomi yang serupa. Oleh karena itu, suku bunga pinjaman inkremental mencerminkan jumlah yang harus dibayar Grup, yang memerlukan estimasi ketika tidak tersedia suku bunga yang dapat diobservasi dan untuk membuat penyesuaian untuk mencerminkan syarat dan ketentuan sewa. Grup mengestimasi kenaikan suku bunga pinjaman menggunakan input yang dapat diobservasi (seperti suku bunga pasar) jika tersedia dan diharuskan untuk mempertimbangkan kontrak tertentu dan estimasi spesifik entitas.

asset is reviewed periodically and updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence and legal or other limits on the use of the asset. However, it is possible that future results of operations could be materially affected by changes in the amounts and timing of recorded expenses brought about by changes in the factors mentioned above.

A change in the estimated useful life of any item of property and equipment would affect the recorded depreciation expense and change the carrying amounts of these assets.

The carrying amounts of property and equipment are disclosed in Note 13.

Amortization of Intangible Assets

The Company and its subsidiaries performs review of the useful lives of the intangible assets periodically, based on relevant factors, among others, technical condition and technological development in the future. Changes in the expected level of usage and technological development could impact the economic useful lives and the residual values of these assets, and therefore future amortization charges could be revised.

The carrying amounts of intangible assets are disclosed in Note 14.

Estimating The Incremental Borrowing Rate for Leases

The Group cannot readily determine the interest rate implicit in the leases. Therefore, it uses its relevant incremental borrowing rate to measure lease liability.

The incremental borrowing rate is the rate of interest that the Group would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The incremental borrowing rate, therefore, reflects what the Group would have to pay, which requires estimation when no observable rates are available and to make adjustments to reflect the terms and conditions of the lease. The Group estimates the incremental borrowing rate using observable inputs (such as market interest rates) when available and is required to consider certain contract and entity specific estimates.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Imbalan Pasca Kerja dan Pensiun

Penentuan utang dan biaya pensiun dan liabilitas imbalan kerja Grup bergantung pada pemilihan asumsi yang digunakan oleh aktuaris independen dalam menghitung jumlah-jumlah tersebut. Asumsi tersebut termasuk antara lain, tingkat diskonto, tingkat kenaikan gaji tahunan, tingkat pengunduran diri karyawan tahunan, tingkat kecacatan, umur pensiun dan tingkat kematian. Hasil aktual yang berbeda dari asumsi yang ditetapkan Grup diakui segera pada laporan posisi keuangan konsolidasian dengan debit atau kredit ke saldo laba melalui penghasilan komprehensif lain dalam periode terjadinya. Sementara Grup berkeyakinan bahwa asumsi tersebut adalah wajar dan sesuai, perbedaan signifikan pada hasil aktual atau perubahan signifikan dalam asumsi yang ditetapkan Grup dapat mempengaruhi secara material liabilitas diestimasi atas pensiun dan imbalan kerja dan beban imbalan kerja neto. Nilai tercatat liabilitas imbalan kerja diungkapkan pada Catatan 25.

Pajak Penghasilan

Pertimbangan signifikan dilakukan dalam menentukan provisi atas pajak penghasilan badan. Terdapat transaksi dan perhitungan tertentu yang penentuan pajak akhirnya adalah tidak pasti dalam kegiatan usaha normal. Grup mengakui liabilitas atas pajak penghasilan badan berdasarkan estimasi apakah akan terdapat tambahan pajak penghasilan badan. Penjelasan lebih rinci diungkapkan dalam Catatan 29.

Aset/Kewajiban Pajak Tangguhan

Aset pajak tangguhan diakui atas [perbedaan temporer yang dapat dikurangkan dan] seluruh rugi fiskal yang belum digunakan sepanjang besar kemungkinannya bahwa penghasilan kena pajak akan tersedia sehingga rugi fiskal tersebut dapat digunakan. Estimasi signifikan oleh manajemen diharuskan dalam menentukan jumlah aset pajak tangguhan yang dapat diakui, berdasarkan saat penggunaan dan tingkat penghasilan kena pajak serta strategi perencanaan pajak masa depan. Rincian lebih lanjut diungkapkan dalam Catatan 29.

Pension and Employee Benefits

Penentuan utang dan biaya pensiun dan liabilitas imbalan kerja Grup bergantung pada pemilihan asumsi yang digunakan oleh aktuaris independen dalam menghitung jumlah-jumlah tersebut. Asumsi tersebut termasuk antara lain, tingkat diskonto, tingkat kenaikan gaji tahunan, tingkat pengunduran diri karyawan tahunan, tingkat kecacatan, umur pensiun dan tingkat kematian. Hasil aktual yang berbeda dari asumsi yang ditetapkan Grup diakui segera pada laporan posisi keuangan konsolidasian dengan debit atau kredit ke saldo laba melalui penghasilan komprehensif lain dalam periode terjadinya. Sementara Grup berkeyakinan bahwa asumsi tersebut adalah wajar dan sesuai, perbedaan signifikan pada hasil aktual atau perubahan signifikan dalam asumsi yang ditetapkan Grup dapat mempengaruhi secara material liabilitas diestimasi atas pensiun dan imbalan kerja dan beban imbalan kerja neto. Nilai tercatat liabilitas imbalan kerja diungkapkan pada Catatan 25.

Income Tax

Significant judgment is involved in determining the provision for corporate income tax. There are certain transactions and computation for which the ultimate tax determination is uncertain during the ordinary course of business. The Group recognizes liabilities for expected corporate income tax issues based on estimates of whether additional corporate income tax will be due. Further details are disclosed in Note 29.

Deferred Tax Assets/Liabilities

Deferred tax assets are recognized for [deductible temporary difference and] all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Significant management estimates are required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies. Further details are disclosed in Note 29.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**5. KAS DAN SETARA KAS**

|                                                                      | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |
|----------------------------------------------------------------------|-----------------------------------|-------------------------------------------|
| <b>K a s</b>                                                         |                                   |                                           |
| Rupiah                                                               | 593.297.625                       | 357.355.070                               |
| <b>B a n k</b>                                                       |                                   |                                           |
| <b>Dalam Rupiah</b>                                                  |                                   |                                           |
| PT Bank Mandiri (Persero) Tbk                                        | 87.820.259.775                    | 107.247.836.541                           |
| PT Bank CIMB Niaga Tbk                                               | 56.658.001.175                    | 28.585.674.403                            |
| PT Bank Pan Indonesia Tbk                                            | 51.017.433.757                    | 38.708.267.078                            |
| PT Bank Central Asia Tbk                                             | 22.571.211.359                    | 11.449.064.623                            |
| PT Bank HSBC Indonesia                                               | 22.489.655.300                    | 7.997.052.394                             |
| PT Bank IBK Indonesia Tbk                                            | 12.040.463.597                    | 4.011.555.610                             |
| PT Bank Rakyat Indonesia<br>(Persero) Tbk                            | 2.878.097.169                     | 610.552.266                               |
| PT Bank Danamon Indonesia Tbk                                        | 2.069.339.283                     | 10.698.310.748                            |
| PT Bank BPD Jateng                                                   | 732.901.931                       | 280.315.839                               |
| PT Bank Jatim                                                        | 704.349.778                       | 133.857.616                               |
| PT Bank Negara Indonesia<br>(Persero) Tbk                            | 627.313.283                       | 597.838.931                               |
| PT Bank Tabungan Negara Tbk                                          | 516.894.982                       | 317.599.691                               |
| PT Bank BPD Sulawesi Tengah                                          | 386.434.544                       | 925.704.784                               |
| PT Bank SMBC Indonesia                                               | 374.306.306                       | 100.000.000                               |
| PT Bank Pembangunan Daerah<br>Jawa Barat dan Banten Tbk              | 251.655.666                       | 27.093.403.175                            |
| PT Bank Pembangunan<br>Daerah Jambi                                  | 224.055.402                       | 1.151.257.279                             |
| PT OCBC Tbk                                                          | 157.468.840                       | 1.606.762.522                             |
| PT Bank UOB                                                          | 92.857.565                        | 3.295.585                                 |
| PT Bank Index Selindo                                                | 67.049.598                        | 86.685.992                                |
| PT Bank DKI                                                          | 21.583.273                        | 215.040.715                               |
| PT Bank Mayapada<br>Internasional Tbk                                | 21.536.268                        | 21.441.984                                |
| PT Bank Pembangunan<br>Daerah Sulawesi Selatan<br>dan Sulawesi Barat | 16.086.389                        | 245.518.076                               |
| PT Bank Maspion Tbk                                                  | 5.909.012                         | 4.887.099                                 |
| PT Bank Maybank                                                      | 4.815.771                         | 1.604.122.041                             |
| PT Bank KB Bukopin Tbk                                               | 1.736.290                         | 1.812.138                                 |
| <b>Yuan China</b>                                                    |                                   |                                           |
| PT Bank Maybank                                                      | 41.262.504.674                    | 52.178.342.263                            |
| PT Bank Central Asia Tbk                                             | 19.184.439.826                    | 13.295.474.779                            |
| PT Bank HSBC Indonesia                                               | 11.720.486.408                    | 8.493.411.535                             |
| PT Bank CIMB Niaga Tbk                                               | 1.561.129.594                     | 1.526.648.073                             |
| PT Bank Danamon                                                      | 783.776.428                       | 1.930.435.606                             |
| PT UOB Bank                                                          | 40.840.634                        | 39.926.401                                |
| <b>Dolar Amerika Serikat</b>                                         |                                   |                                           |
| PT Bank Central Asia Tbk                                             | 56.117.108.939                    | 29.706.969.120                            |
| PT Bank Maybank                                                      | 47.373.577.173                    | 102.143.840.000                           |
| PT Bank HSBC Indonesia                                               | 20.779.138.010                    | 22.822.899.203                            |
| PT Bank CIMB Niaga Tbk                                               | 12.066.275.737                    | 2.480.252.359                             |
| PT Bank Danamon Indonesia Tbk                                        | 9.781.747.208                     | 4.282.228.246                             |
| PT Bank Pan Indonesia Tbk                                            | 3.197.713.996                     | 1.567.327.728                             |
| PT OCBC Tbk                                                          | 1.461.063.340                     | -                                         |
| PT Bank Rakyat Indonesia Tbk                                         | 95.379.102                        | 95.389.740                                |
| PT Bank IBK Indonesia Tbk                                            | 65.432.301                        | 71.413.736                                |
| PT Bank Mandiri (Persero) Tbk                                        | 19.515.637                        | 3.252.053.800                             |
| PT Bank Mayada                                                       | 18.245.892                        | 18.650.948                                |
| PT Bank UOB Indonesia Tbk                                            | 15.496.184                        | 15.585.986                                |
| Sub-total                                                            | 487.295.287.396                   | 487.618.706.653                           |

**5. CASH AND CASH EQUIVALENTS**

|                                                                      |  |
|----------------------------------------------------------------------|--|
| <b>Cash on hands</b><br>Rupiah                                       |  |
| <b>B a n k</b><br><b>In Rupiah</b>                                   |  |
| PT Bank Mandiri (Persero) Tbk                                        |  |
| PT Bank CIMB Niaga Tbk                                               |  |
| PT Bank Pan Indonesia Tbk                                            |  |
| PT Bank Central Asia Tbk                                             |  |
| PT Bank HSBC Indonesia                                               |  |
| PT Bank IBK Indonesia Tbk                                            |  |
| PT Bank Rakyat Indonesia<br>(Persero) Tbk                            |  |
| PT Bank Danamon Indonesia Tbk                                        |  |
| PT Bank BPD Jateng                                                   |  |
| PT Bank Jatim                                                        |  |
| PT Bank Negara Indonesia<br>(Persero) Tbk                            |  |
| PT Bank Tabungan Negara Tbk                                          |  |
| PT Bank BPD Sulawesi Tengah                                          |  |
| PT Bank SMBC Indonesia                                               |  |
| PT Bank Pembangunan Daerah<br>Jawa Barat dan Banten Tbk              |  |
| PT Bank Pembangunan Daerah<br>Jambi                                  |  |
| PT OCBC Tbk                                                          |  |
| PT Bank UOB                                                          |  |
| PT Bank Index Selindo                                                |  |
| PT Bank DKI                                                          |  |
| PT Bank Mayapada<br>Internasional Tbk                                |  |
| PT Bank Pembangunan Daerah<br>Sulawesi Selatan dan<br>Sulawesi Barat |  |
| PT Bank Maspion Tbk                                                  |  |
| PT Bank Maybank                                                      |  |
| PT Bank KB Bukopin Tbk                                               |  |
| <b>Chinese Yuan</b>                                                  |  |
| PT Bank Maybank                                                      |  |
| PT Bank Central Asia Tbk                                             |  |
| PT Bank HSBC Indonesia                                               |  |
| PT Bank CIMB Niaga Tbk                                               |  |
| PT Bank Danamon                                                      |  |
| PT UOB Bank                                                          |  |
| <b>United States Dollar</b>                                          |  |
| PT Bank Central Asia Tbk                                             |  |
| PT Bank Maybank                                                      |  |
| PT Bank HSBC Indonesia                                               |  |
| PT Bank CIMB Niaga Tbk                                               |  |
| PT Bank Danamon Indonesia Tbk                                        |  |
| PT Bank Pan Indonesia Tbk                                            |  |
| PT OCB Tbk                                                           |  |
| PT Bank Rakyat Indonesia Tbk                                         |  |
| PT Bank IBK Indonesia Tbk                                            |  |
| PT Bank Mandiri (Persero) Tbk                                        |  |
| PT Bank Mayapada                                                     |  |
| PT Bank UOB Indonesia Tbk                                            |  |
| Sub-total                                                            |  |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

|                                           | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                                           |
|-------------------------------------------|-----------------------------------|-------------------------------------------|-------------------------------------------|
| <b>Total (Pindahan)</b>                   | 487.295.287.396                   | 487.618.706.653                           | <b>Total (brought forward)</b>            |
| <b>Reksadana</b>                          |                                   |                                           | <b>Mutual Funds</b>                       |
| <b>Dolar Amerika Serikat</b>              |                                   |                                           | <b>United States Dollar</b>               |
| PT Manulife Aset Manajemen Indonesia      | 811.650.000                       | -                                         | PT Manulife Aset Manajemen Indonesia      |
| <b>Deposito berjangka</b>                 |                                   |                                           | <b>Time deposits</b>                      |
| <b>Dalam Rupiah</b>                       |                                   |                                           | <b>Rupiah</b>                             |
| PT Bank Rakyat Indonesia (Persero) Tbk    | 150.000.000.000                   | 200.000.000.000                           | PT Bank Rakyat Indonesia (Persero) Tbk    |
| PT Bank Mayapada Internasional Tbk        | 143.912.174.520                   | 191.923.808.207                           | PT Bank Mayapada Internasional Tbk        |
| PT Bank Tabungan Negara Tbk               | 85.000.000.000                    | 71.100.000.000                            | PT Bank Tabungan Negara Tbk               |
| PT Bank Pan Indonesia Tbk                 | 68.000.000.000                    | 40.000.000.000                            | PT Bank Pan Indonesia Tbk                 |
| PT Bank Danamon Indonesia Tbk             | 50.000.000.000                    | 40.000.000.000                            | PT Bank Danamon Indonesia Tbk             |
| PT Bank Mandiri Tbk                       | 27.621.452.054                    | -                                         | PT Bank Mandiri Tbk                       |
| PT Bank Maspion Indonesia Tbk             | 20.000.000.000                    | 30.000.000.000                            | PT Bank Maspion Indonesia Tbk             |
| PT Bank Index Selindo                     | 6.000.000.000                     | 16.020.547.936                            | PT Bank Index Selindo                     |
| PT Bank IBK Indonesia Tbk                 | 1.602.000.000                     | 3.027.000.000                             | PT Bank IBK Indonesia Tbk                 |
| PT Bank Pembangunan Daerah Jawa Timur Tbk | -                                 | 38.530.000.000                            | PT Bank Pembangunan Daerah Jawa Timur Tbk |
| PT Bank Negara Indonesia (Persero) Tbk    | 22.500.000.000                    | 25.000.000.000                            | PT Bank Negara Indonesia (Persero) Tbk    |
| PT Bank SMBC                              | -                                 | 10.000.000.000                            | PT Bank SMBC                              |
| PT Bank Shinhan Indonesia                 | -                                 | 5.000.000.000                             | PT Bank Shinhan Indonesia                 |
| <b>Dolar Amerika Serikat</b>              |                                   |                                           | <b>United States Dollar</b>               |
| PT Bank HSBC Indonesia                    | 32.466.000.000                    | 32.324.000.000                            | PT Bank HSBC Indonesia                    |
| PT Bank BTPN Tbk                          | 17.733.217.336                    | 17.409.625.267                            | PT Bank BTPN Tbk                          |
| PT Bank IBK Indonesia Tbk                 | 16.823.881.200                    | 16.394.732.800                            | PT Bank IBK Indonesia Tbk                 |
| <b>Sub-total</b>                          | <b>642.470.375.110</b>            | <b>736.729.714.210</b>                    | <b>Sub-total</b>                          |
| <b>Jumlah</b>                             | <b>1.130.358.960.131</b>          | <b>1.224.705.775.933</b>                  | <b>Total</b>                              |

Kisaran tingkat suku bunga tahunan deposito berjangka adalah sebagai berikut:

The ranges of the annual interest rates of time deposits are as follows:

|                       | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                      |
|-----------------------|-----------------------------------|-------------------------------------------|----------------------|
| Rupiah                | 5,7%-7,5%                         | 5,00%-7,50%                               | Rupiah               |
| Dolar Amerika Serikat | 4,50%-5,45%                       | 4,75%-5,50%                               | United States Dollar |

Pendapatan bunga deposito berjangka masing-masing sebesar Rp 18.380.749.652 dan Rp 36.051.415.278 untuk tahun yang berakhir pada 30 Juni 2025 dan 31 Desember 2024.

Interest income from time deposits amounted to Rp 18,380,749,652 and Rp 36,051,415,278 respectively for years ended June 30, 2025 and December 31, 2024.

Semua setara kas ditempatkan pada pihak ketiga atau tidak ada setara kas yang ditempatkan pada pihak berelasi.

All cash equivalents are allocated in third parties or there are no cash equivalents allocated in related parties.

Pada tanggal 30 Juni 2025, saldo kas dan setara kas mencakup investasi dalam reksa dana pasar uang sebesar Rp 811.650.000, yang mewakili 49.815,682 unit. Investasi ini diukur pada nilai wajar dan mencakup keuntungan belum terealisasi

As of June 30, 2025, the balance of cash and cash equivalents includes investments in money market mutual funds amounting to Rp 811,650,000 representing 49,815.682 units. These investments are measured at fair value and include unrealized profit

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**6. INVESTASI JANGKA PENDEK**

**6. SHORT TERM INVESTMENT**

|                               | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                               |
|-------------------------------|--------------------------|----------------------------------|-------------------------------|
| <b>Obligasi</b>               |                          |                                  | <b>Bonds</b>                  |
| <b>Dalam Rupiah</b>           |                          |                                  | <b>Rupiah</b>                 |
| PT Bank Danamon Indonesia Tbk | 19.476.350.848           | 26.260.378.318                   | PT Bank Danamon Indonesia Tbk |
| PT Bank CIMB Niaga Tbk        | 14.982.449.010           | 29.934.342.595                   | PT Bank CIMB Niaga Tbk        |
| PT Bank Central Asia Tbk      | -                        | 5.000.000.000                    | PT Bank Central Asia Tbk      |
| <b>Dolar Amerika Serikat</b>  |                          |                                  | <b>United States Dollar</b>   |
| PT Bank Central Asia Tbk      | -                        | 16.173.350.828                   | PT Bank Central Asia Tbk      |
| PT CIMB Niaga Tbk             | -                        | 8.889.529.883                    | PT CIMB Niaga Tbk             |
| PT Bank Danamon Indonesia Tbk | -                        | 3.239.130.022                    | PT Bank Danamon Indonesia Tbk |
| <b>Jumlah</b>                 | <b>34.458.799.858</b>    | <b>89.496.731.646</b>            | <b>Total</b>                  |

Aset keuangan diukur pada biaya perolehan diamortisasi sesuai dengan kondisi persyaratan kontraktual dari aset keuangan menghasilkan arus kas pada tanggal tertentu yang semata dari pembayaran pokok dan bunga dari jumlah pokok terutang yang dirincikan sebagai berikut:

Financial assets are measured at amortized cost in accordance with the contractual terms of the financial assets generating cash flows at a certain date which are solely payments of principal and interest on the principal amount payable, which are detailed as follows:

| 30 Juni/June 2025                                |                          |                           |                       |
|--------------------------------------------------|--------------------------|---------------------------|-----------------------|
| Seri produk/Product series                       | Suku bunga/Interest rate | Jatuh tempo/Maturity date | Jumlah/Total          |
| <b>Obligasi/Bonds</b>                            |                          |                           |                       |
| <b>Dalam Rupiah/In Rupiah</b>                    |                          |                           |                       |
| PBS036                                           | 5,38%                    | 15 Agustus/August 2025    | 26.964.368.447        |
| ORI022                                           | 5,95%                    | 15 Oktober/October 2025   | 7.494.431.411         |
| <b>Jumlah/Total</b>                              |                          |                           | <b>34.458.799.858</b> |
| 31 Desember/December 2024                        |                          |                           |                       |
| Seri produk/Product series                       | Suku bunga/Interest rate | Jatuh tempo/Maturity date | Jumlah/Total          |
| <b>Obligasi/Bonds</b>                            |                          |                           |                       |
| <b>Dalam Rupiah/In Rupiah</b>                    |                          |                           |                       |
| FR0081                                           | 6,50%                    | 15 Juni/June 2025         | 26.878.508.305        |
| PBS036                                           | 5,38%                    | 15 Agustus/August 2025    | 26.830.972.989        |
| ORI022                                           | 5,95%                    | 15 Oktober/October 2025   | 7.485.239.619         |
|                                                  |                          |                           | <b>61.194.720.913</b> |
| <b>Dolar Amerika Serikat/United State Dollar</b> |                          |                           |                       |
| INDOIS25                                         | 4,33%                    | 28 Mei/May 2025           | 19.412.480.850        |
| INDOIS2.3%                                       | 2,30%                    | 23 Juni/June 2025         | 8.889.529.883         |
|                                                  |                          |                           | <b>28.302.010.733</b> |
| <b>Jumlah/Total</b>                              |                          |                           | <b>89.496.731.646</b> |

Perusahaan telah mencairkan investasi jangka pendek atas INDOIS24NEW pada tanggal 20 Agustus 2024 dengan nilai USD 3.140.060 atau setara dengan Rp 50.432.503.660.

The Company already settled the short-term investments of INDOIS24NEW on 20 August 2024 with value of USD 3,140,060 or equivalent to Rp 50,432,503,660.

Perusahaan telah mencairkan obligasi syariah SR015 pada tanggal 10 September 2024 dengan nilai Rp 5.019.625.000.

The Company already settled the Islamic bonds SR015 on 10 September 2024 with value of Rp 5,019,625,000.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Perusahaan telah melakukan penjualan atas obligasi seri FR090 tanggal 4 September 2024 senilai Rp 9.685.000.000.

The Company already settled the investments of FR090 on September 4, 2024 with value of Rp 9,685,000,000.

Perusahaan telah melakukan pencairan obligasi seri INDOIS25 pada tanggal 28 Mei 2025 senilai USD 1.200.000 atau setara dengan Rp 19.651.200.000

The Company already settled the bonds of INDOIS25 on May 28, 2025 with the value of USD 1,200,000 or equivalent to Rp 19,651,200,000

Perusahaan telah melakukan pencairan obligasi seri FR081 pada tanggal 16 Juni 2025 senilai Rp 26.870.000.000.

The Company already settled the bonds of FR081 on June 16, 2025 with the value of Rp 26,870,000,000.

Perusahaan telah melakukan pencairan obligasi seri INDOIS2.3 pada tanggal 26 Juni 2025 senilai USD 557.000 atau setara dengan Rp 9.061.276.000

The Company already settled the bonds of INDOIS2.3 on June 26, 2025 with the value of USD 557,000 or equivalent to Rp 9,061,276,000

**7. PIUTANG USAHA**

**7. TRADE RECEIVABLES**

|                                                   | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                                                   |
|---------------------------------------------------|--------------------------|----------------------------------|---------------------------------------------------|
| <b>Pihak berelasi (Catatan 35)</b>                | <b>937.751.050</b>       | <b>1.218.630.201</b>             | <b>Related parties (Note 35)</b>                  |
| <b>Pihak ketiga</b>                               |                          |                                  | <b>Third parties</b>                              |
| Sekretariat Ditjen Kefarmasian dan Alat Kesehatan | 12.267.522.800           | -                                | Sekretariat Ditjen Kefarmasian dan Alat Kesehatan |
| PT Inti Medika Sarana                             | 8.258.721.162            | 7.842.827.474                    | PT Inti Medika Sarana                             |
| PT Inti Hasil Medicatama                          | 7.995.290.971            | 6.105.343.318                    | PT Inti Hasil Medicatama                          |
| PT Fresenius Medical Care Indonesia               | 6.541.071.356            | 6.341.660.898                    | PT Fresenius Medical Care Indonesia               |
| RSUP Dr Wahidin Sudirohusodo                      | 5.667.336.842            | 1.514.883.945                    | RSUP Dr Wahidin Sudirohusodo                      |
| PT Sumbermas Medika                               | 4.131.033.504            | 263.892.584                      | PT Sumbermas Medika                               |
| PT Syifa Globalmed                                | 3.911.648.451            | 55.705.615                       | PT Syifa Globalmed                                |
| PT Sumber Rejeki Medika Jaya                      | 3.906.475.843            | 6.614.104.508                    | PT Sumber Rejeki Medika Jaya                      |
| PT Alphatirta Medica                              | 3.788.254.492            | 6.645.982.429                    | PT Alphatirta Medica                              |
| RSU Putri Bidadari Langkat                        | 3.662.703.495            | 390.908.700                      | RSU Putri Bidadari Langkat                        |
| PT Dimas Andalas Makmur                           | 3.640.990.520            | 7.467.409.032                    | PT Dimas Andalas Makmur                           |
| RSUP Dr Mohammad Hoesin Palembang                 | 3.592.740.258            | 2.861.571.859                    | RSUP Dr. Mohammad Hoesin Palembang                |
| PT Ridho Ilahi Farma                              | 3.370.642.563            | 3.783.187.749                    | PT Ridho Ilahi Farma                              |
| PT Suramando Mega Berkat                          | 3.344.911.460            | 3.353.721.760                    | PT Suramando Mega Berkat                          |
| PT Graha Papua Medika                             | 3.085.544.925            | 2.183.418.602                    | PT Graha Papua Medika                             |
| RSUD Dr Iskak                                     | 2.936.818.346            | 2.023.619.012                    | RSUD Dr Iskak                                     |
| PT Rusdi Medika                                   | 2.872.813.342            | 4.694.851.611                    | PT Rusdi Medika                                   |
| RSUP Dr. M. Djamil Padang                         | 2.335.498.091            | 2.182.921.136                    | RSUP Dr. M. Djamil Padang                         |
| PT Mutiara Farma                                  | 2.257.487.608            | 1.760.980.179                    | PT Mutiara Farma                                  |
| RSUD Dr. Saiful Anwar                             | 2.209.586.683            | 2.661.619.129                    | RSUD Dr. Saiful Anwar                             |
| RSUP Dr Hasan Sadikin                             | 2.200.648.257            | 3.559.793.017                    | RSUP Dr Hasan Sadikin                             |
| PT Global Sinar Medica                            | 2.115.325.813            | 1.895.629.363                    | PT Global Sinar Medica                            |
| RSUPN Dr. Cipto Mangunkusumo                      | 2.056.673.363            | 2.588.541.622                    | RSUPN Dr. Cipto Mangunkusumo                      |
| PT Mitra Medika Sejahtera Bersama                 | 1.880.778.954            | 2.054.528.079                    | PT Mitra Medika Sejahtera Bersama                 |
| PT Henso Jaya                                     | 1.572.190.627            | 2.047.497.167                    | PT Henso Jaya                                     |
| Lain-lain<br>(saldo di bawah Rp 2 miliar)         | 207.184.644.443          | 188.527.738.922                  | Others<br>(balances below Rp 2 billion)           |
| Sub-jumlah pihak ketiga                           | 306.787.354.169          | 269.422.337.710                  | Sub-total third parties                           |
| Jumlah                                            | 307.725.105.219          | 270.640.967.911                  | Total                                             |
| Cadangan kerugian penurunan nilai                 | ( 5.423.893.552)         | ( 5.448.970.460)                 | Allowance for impairment losses                   |
| <b>Neto</b>                                       | <b>302.301.211.667</b>   | <b>265.191.997.451</b>           | <b>Net</b>                                        |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Analisa berdasarkan umur piutang usaha pada tanggal 30 Juni 2025 dan 31 Desember 2024 adalah sebagai berikut:

The aging analysis of the trade receivables as June, 2025 and December 31, 2024 are as follows:

|                     | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                  |
|---------------------|--------------------------|----------------------------------|------------------|
| Belum jatuh tempo   | 234.625.660.734          | 209.101.784.113                  | Not yet due      |
| Jatuh tempo:        |                          |                                  | Overdue:         |
| 1 – 30 hari         | 38.784.351.360           | 43.804.162.375                   | 1 – 30 days      |
| 31 – 60 hari        | 16.773.309.807           | 7.468.258.284                    | 31 – 60 days     |
| 61 – 90 hari        | 5.921.504.890            | 3.811.627.450                    | 61 – 90 days     |
| 91 – 120 hari       | 2.132.957.018            | 2.478.760.189                    | 91 – 120 days    |
| Lebih dari 120 hari | 9.487.321.410            | 3.976.375.500                    | Over 120 days    |
| <b>Jumlah</b>       | <b>307.725.105.219</b>   | <b>270.640.967.911</b>           | <b>T o t a l</b> |

Mutasi cadangan kerugian penurunan nilai adalah sebagai berikut:

The movements of allowance for impairment losses are as follows:

|                                                                 | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                                                                    |
|-----------------------------------------------------------------|--------------------------|----------------------------------|--------------------------------------------------------------------|
| Saldo awal                                                      | 5.448.970.460            | 5.960.639.233                    | Beginning balance                                                  |
| Penambahan cadangan (pemulihan)<br>penurunan nilai (Catatan 34) | ( 25.076.908 )           | ( 511.668.773 )                  | Additional allowance (reversal)<br>for impairment losses (Note 34) |
| <b>Saldo akhir</b>                                              | <b>5.423.893.552</b>     | <b>5.448.970.460</b>             | <b>Ending balance</b>                                              |

Berdasarkan penelaahan atas piutang pada akhir periode, manajemen berpendapat bahwa cadangan penurunan nilai piutang usaha cukup untuk menutup kemungkinan kerugian atas tidak tertagihnya piutang.

Based on review of receivable accounts at the end of the period, management is of the opinion that the allowance for impairment of trade receivables is sufficient to cover any possible losses on uncollectible accounts.

Piutang usaha tidak dikenakan bunga, dan penyelesaiannya akan dilakukan secara tunai, dan umumnya dikenakan syarat pembayaran selama 1 sampai dengan 60 hari.

Trade receivables are non-interest bearing, and will be settled in cash and generally on 1 to 60 days term of payment.

Pada 30 Juni 2025 dan 31 Desember 2024, tidak terdapat piutang usaha Perusahaan dan Entitas Anak digunakan sebagai jaminan.

As of June 30, 2025 and December 31, 2024 there were no trade receivables of the Company and its Subsidiaries that were used as collateral.

Rincian piutang usaha berdasarkan mata uang adalah sebagai berikut:

The details of trade receivables based on currency denominations are as follows:

|                       | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                       |
|-----------------------|--------------------------|----------------------------------|-----------------------|
| Rupiah                | 306.711.327.097          | 270.062.090.540                  | Rupiah                |
| Dolar Amerika Serikat | 1.013.778.122            | 578.877.371                      | United States Dollar  |
| <b>Saldo akhir</b>    | <b>307.725.105.219</b>   | <b>270.640.967.911</b>           | <b>Ending balance</b> |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**8. PIUTANG NON-USAHA**

|                                    | 30 Juni/<br>June     | 31 Desember/<br>December |
|------------------------------------|----------------------|--------------------------|
|                                    | 2025                 | 2024                     |
| <b>Pihak berelasi</b> (Catatan 38) |                      |                          |
| PT Karya Indah Medika              | 239.000              | -                        |
| <b>Sub-jumlah pihak berelasi</b>   | 239.000              | -                        |
| <b>Pihak ketiga</b>                |                      |                          |
| Rupiah                             |                      |                          |
| Pendapatan bunga                   | 5.399.176.532        | 3.244.971.571            |
| Karyawan                           | 126.600.000          | 127.108.950              |
| Lain-lain                          | 11.834.536           | 384.877                  |
| <b>Sub-jumlah pihak ketiga</b>     | 5.537.611.068        | 3.372.465.398            |
| <b>Jumlah</b>                      | <u>5.537.850.068</u> | <u>3.372.465.398</u>     |

Piutang non-usaha sebagian besar merupakan piutang pendapatan bunga atas deposito dan obligasi, seluruh piutang non-usaha belum melewati batas jatuh temponya.

Pada tanggal 30 Juni 2025 dan 31 Desember 2024, tidak terdapat piutang non-usaha yang dijaminkan.

Rincian piutang non-usaha berdasarkan mata uang adalah sebagai berikut:

|                       | 30 Juni/<br>June     | 31 Desember/<br>December |
|-----------------------|----------------------|--------------------------|
|                       | 2025                 | 2024                     |
| Rupiah                | 3.066.001.048        | 2.992.389.117            |
| Dolar Amerika Serikat | 2.471.849.021        | 380.076.281              |
| <b>Saldo akhir</b>    | <u>5.537.850.068</u> | <u>3.372.465.398</u>     |

**Related parties** (Note 38)  
PT Karya Indah Medika  
**Sub-total related parties**

**Third parties**  
Rupiah  
Interest income  
Employee  
Others

**Sub-total third parties**

**T o t a l**

Non-trade receivables mostly represent interest income receivables on time deposits and bonds, all non-trade receivables have not yet reached their maturity date.

As of June 30, 2025 and December 31, 2024, Non-trade receivables were not pledged as collateral on loans.

The details of non-trade receivables based on currency denominations are as follows:

Rupiah  
United States Dollar  
**Ending balance**

**9. PERSEDIAAN**

|                                                                                   | 30 Juni/<br>June       | 31 Desember/<br>December |
|-----------------------------------------------------------------------------------|------------------------|--------------------------|
|                                                                                   | 2025                   | 2024                     |
| Barang jadi                                                                       | 377.841.486.182        | 374.000.654.574          |
| Bahan baku                                                                        | 167.448.078.790        | 168.667.811.041          |
| Barang dalam proses                                                               | 32.572.594.214         | 24.468.949.056           |
| Bahan kemasan                                                                     | 30.275.365.225         | 33.263.818.512           |
| Barang dalam perjalanan                                                           | 26.748.298.519         | 25.592.086.750           |
| Suku cadang                                                                       | 6.436.252.129          | 6.637.584.067            |
| Bahan pembantu                                                                    | 3.292.671.856          | 8.613.890.419            |
| <b>Jumlah</b>                                                                     | 644.614.746.915        | 641.244.794.419          |
| Dikurangi: cadangan kerugian<br>penurunan nilai pasar dan<br>keusangan persediaan | ( 3.822.455.818 )      | ( 1.265.671.538 )        |
| <b>Neto</b>                                                                       | <u>640.792.291.097</u> | <u>639.979.122.881</u>   |

**9. INVENTORIES**

Finished goods  
Raw materials  
Work in process  
Packing materials  
Goods in transit  
Spare parts  
Supporting materials

**T o t a l**

Less: allowance for impairment  
loss in market value and  
obsolescence of inventories

**N e t**

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Berdasarkan penelaahan atas persediaan pada 30 Juni 2025 dan 31 Desember 2024, manajemen berpendapat bahwa penyisihan penurunan nilai persediaan cukup untuk menutup kemungkinan kerugian persediaan usang atau rusak.

Based on review of inventories in June 30, 2025 and December 31, 2024, management believes that the allowance for impairment of inventories is sufficient to cover any possible loss on obsolete or damaged inventories.

Pada tanggal 30 Juni 2025 dan 31 Desember 2024, tidak terdapat persediaan yang dijaminkan.  
Mutasi cadangan penurunan nilai :

As of June 30, 2025 and December 31, 2024, inventories were not pledged as collateral on loans.  
Movements in the allowance for impairment:

|                                                          | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                                                       |
|----------------------------------------------------------|-----------------------------------|-------------------------------------------|-------------------------------------------------------|
| Saldo awal                                               | 1.265.671.538                     | 395.092.557                               | Beginning balance                                     |
| Penambahan cadangan<br>penurunan nilai (Catatan 31 & 34) | 2.556.784.280                     | 870.578.981                               | Additional allowance<br>for impairment (Note 31 & 34) |
| <b>Saldo akhir</b>                                       | <b>3.822.455.818</b>              | <b>1.265.671.538</b>                      | <b>Ending balance</b>                                 |

Pada tanggal 30 Juni 2025 dan 31 Desember 2024, persediaan diasuransikan terhadap risiko kerugian atas kebakaran dan risiko lainnya berdasarkan paket polis dengan nilai pertanggungan sebesar Rp 531.385.000.000. Manajemen berpendapat bahwa nilai pertanggungan asuransi cukup untuk menutupi kemungkinan kerugian atas persediaan yang dipertanggungkan.

As of June 30, 2025 and December 31, 2024, inventories are covered by insurance against losses from fire and other risks under blanket policies with a total coverage of amounting Rp 531,385,000,000. Management believes that the insurance coverage is adequate to cover possible losses insured inventories.

**10. BEBAN DIBAYAR DIMUKA**

**10. PREPAID EXPENSES**

|               | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |              |
|---------------|-----------------------------------|-------------------------------------------|--------------|
| Asuransi      | 631.295.342                       | 1.125.148.104                             | Insurance    |
| Sewa          | 311.472.219                       | 288.611.110                               | Rent         |
| Jaminan       | 296.136.346                       | 294.841.103                               | Guarantee    |
| Lainnya       | 569.577.559                       | 347.747.188                               | Others       |
| <b>Jumlah</b> | <b>1.808.481.466</b>              | <b>2.056.347.505</b>                      | <b>Total</b> |

Sewa merupakan pembayaran dimuka atas sewa gedung dan kendaraan di beberapa lokasi.

Rent represents prepayment on building and vehicle leases which are over several locations.

**11. UANG MUKA PEMBELIAN**

**11. ADVANCE FOR PURCHASE**

|                                | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                                       |
|--------------------------------|-----------------------------------|-------------------------------------------|---------------------------------------|
| Uang muka pembelian persediaan |                                   |                                           | Advances for purchases of inventories |
| Impor                          | 23.910.450.824                    | 25.560.450.081                            | Import                                |
| Lokal                          | 3.955.840.557                     | 5.992.289.021                             | Local                                 |
| <b>Jumlah</b>                  | <b>27.866.291.381</b>             | <b>31.552.739.102</b>                     | <b>Total</b>                          |

Uang muka pembelian didenominasi dalam laporan posisi keuangan konsolidasian dalam mata uang berikut:

Advances for purchases are denominated in the consolidated statement of financial position in the following currencies:

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

|                       | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                      |
|-----------------------|-----------------------------------|-------------------------------------------|----------------------|
| Rupiah                | 3.955.840.557                     | 5.992.289.021                             | Rupiah               |
| Yuan China            | 8.021.446.305                     | 12.360.573.054                            | Chinese Yuan         |
| Dolar Amerika Serikat | 14.377.242.215                    | 12.167.368.091                            | United States Dollar |
| Euro Eropa            | 1.511.762.304                     | 1.032.508.936                             | European Euro        |
| <b>Jumlah</b>         | <b>27.866.291.381</b>             | <b>31.552.739.102</b>                     | <b>Total</b>         |

**12. UANG MUKA PEMBELIAN ASET TETAP**

**12. ADVANCE FOR PURCHASE OF FIXED ASSET**

|                                | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                                       |
|--------------------------------|-----------------------------------|-------------------------------------------|---------------------------------------|
| Uang muka pembelian aset tetap |                                   |                                           | Advances for purchases of fixed asset |
| Impor                          | 8.500.414.277                     | 2.032.453.056                             | Import                                |
| Lokal                          | 3.007.451.950                     | 2.070.794.983                             | Local                                 |
| <b>Jumlah</b>                  | <b>11.507.866.227</b>             | <b>4.103.248.039</b>                      | <b>Total</b>                          |

Uang muka pembelian didenominasi dalam laporan posisi keuangan konsolidasian dalam mata uang berikut:

Advances for purchases are denominated in the consolidated statement of financial position in the following currencies:

|                       | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                      |
|-----------------------|-----------------------------------|-------------------------------------------|----------------------|
| Yuan China            | 5.355.203.907                     | 1.558.841.900                             | Chinese Yuan         |
| Dolar Amerika Serikat | 3.145.210.370                     | 473.611.156                               | United States Dollar |
| Rupiah                | 3.007.451.950                     | 2.070.794.983                             | Rupiah               |
| <b>Jumlah</b>         | <b>11.507.866.227</b>             | <b>4.103.248.039</b>                      | <b>Total</b>         |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**13. ASET TETAP**

**13. FIXED ASSETS**

|                                    |                                | 30 Juni/June 2025                   |                          |                            |                                    |                                   |
|------------------------------------|--------------------------------|-------------------------------------|--------------------------|----------------------------|------------------------------------|-----------------------------------|
|                                    |                                | Saldo awal/<br>Beginning<br>balance | Penambahan/<br>Additions | Pengurangan/<br>Deductions | Reklasifikasi/<br>Reclassification | Saldo akhir/<br>Ending<br>balance |
| <b>Harga perolehan</b>             | <b>Kepemilikan langsung</b>    |                                     |                          |                            |                                    | <b>Cost</b>                       |
|                                    | <i>Tanah</i>                   | 106.807.616.918                     | -                        | -                          | -                                  | 106.807.616.918                   |
|                                    | <i>Bangunan</i>                | 131.131.274.096                     | 747.807.477              | ( 290.365.500 )            | 43.186.575.861                     | 174.775.291.934                   |
|                                    | <i>Mesin</i>                   | 228.142.300.037                     | 5.223.298.777            | ( 1.900.328.417 )          | 11.331.012.592                     | 242.796.282.989                   |
|                                    | <i>Kendaraan</i>               | 4.902.998.215                       | 39.000.000               | -                          | 210.811.224                        | 5.152.809.439                     |
|                                    | <i>Inventaris</i>              | 56.500.553.928                      | 3.368.259.862            | ( 326.384.931 )            | 704.488.139                        | 60.246.916.998                    |
|                                    | <i>Sub-jumlah</i>              | <u>527.484.743.194</u>              | <u>9.378.366.116</u>     | <u>( 2.517.078.848 )</u>   | <u>55.432.887.816</u>              | <u>589.778.918.278</u>            |
|                                    | <b>Aset dalam penyelesaian</b> |                                     |                          |                            |                                    | <b>Construction-in-progress</b>   |
|                                    | <i>Bangunan</i>                | 73.690.966.844                      | 12.411.011.713           | -                          | ( 43.186.575.861 )                 | 42.915.402.696                    |
|                                    | <i>Mesin</i>                   | 41.668.433.863                      | 4.359.598.325            | -                          | ( 11.397.140.329 )                 | 34.630.891.859                    |
|                                    | <i>Lainnya</i>                 | <u>2.024.357.895</u>                | <u>471.513.179</u>       | <u>-</u>                   | <u>( 849.171.626 )</u>             | <u>1.646.699.448</u>              |
|                                    | <i>Sub-jumlah</i>              | <u>117.383.758.602</u>              | <u>17.242.123.217</u>    | <u>-</u>                   | <u>( 55.432.887.816 )</u>          | <u>79.192.994.003</u>             |
| <b>Jumlah harga perolehan</b>      |                                | <u>644.868.501.796</u>              | <u>26.620.489.333</u>    | <u>( 2.517.078.848 )</u>   | <u>-</u>                           | <u>668.971.912.281</u>            |
|                                    | <b>Akumulasi penyusutan</b>    |                                     |                          |                            |                                    | <b>Accumulated depreciation</b>   |
|                                    | <b>Kepemilikan langsung</b>    |                                     |                          |                            |                                    | <b>Direct ownership</b>           |
|                                    | <i>Bangunan</i>                | 29.032.670.927                      | 4.624.846.551            | ( 261.032.167 )            | -                                  | 33.396.485.311                    |
|                                    | <i>Mesin</i>                   | 136.932.686.799                     | 14.478.950.593           | ( 1.693.486.045 )          | -                                  | 149.718.151.347                   |
|                                    | <i>Kendaraan</i>               | 4.078.406.757                       | 188.073.849              | -                          | -                                  | 4.266.480.606                     |
|                                    | <i>Inventaris</i>              | <u>40.965.652.112</u>               | <u>4.312.368.130</u>     | <u>( 304.706.465 )</u>     | <u>-</u>                           | <u>44.973.313.777</u>             |
| <b>Jumlah akumulasi penyusutan</b> |                                | <u>211.009.416.595</u>              | <u>23.604.239.123</u>    | <u>( 2.259.224.677 )</u>   | <u>-</u>                           | <u>232.354.431.041</u>            |
| <b>Nilai tercatat</b>              |                                | <u>433.859.085.201</u>              |                          |                            |                                    | <u>436.617.481.240</u>            |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

| 31 Desember/December 2024                                    |                                     |                          |                            |                                    |                                   |                                      |
|--------------------------------------------------------------|-------------------------------------|--------------------------|----------------------------|------------------------------------|-----------------------------------|--------------------------------------|
|                                                              | Saldo awal/<br>Beginning<br>balance | Penambahan/<br>Additions | Pengurangan/<br>Deductions | Reklasifikasi/<br>Reclassification | Saldo akhir/<br>Ending<br>balance | Cost                                 |
| <b>Harga perolehan<br/>Kepemilikan<br/>langsung</b>          |                                     |                          |                            |                                    |                                   | <b>Direct ownership</b>              |
| Tanah                                                        | 106.807.616.918                     | -                        | -                          | -                                  | 106.807.616.918                   | Land                                 |
| Bangunan                                                     | 113.070.014.174                     | 15.465.475.015           | -                          | 2.595.784.907                      | 131.131.274.096                   | Buildings                            |
| Mesin                                                        | 198.683.270.995                     | 29.417.278.913           | ( 1.062.800.341 )          | 1.104.550.470                      | 228.142.300.037                   | Machineries                          |
| Kendaraan                                                    | 4.598.480.488                       | 315.017.727              | ( 10.500.000 )             | -                                  | 4.902.998.215                     | Vehicles                             |
| Inventaris                                                   | 44.743.028.623                      | 11.774.724.401           | ( 267.807.656 )            | 250.608.560                        | 56.500.553.928                    | Furniture and fixtures               |
| Sub-jumlah                                                   | 467.902.411.198                     | 56.972.496.056           | ( 1.341.107.997 )          | 3.950.943.937                      | 527.484.743.194                   | Sub-total                            |
| <b>Aset dalam<br/>penyelesaian</b>                           |                                     |                          |                            |                                    |                                   | <b>Construction-in-<br/>progress</b> |
| Bangunan                                                     | 39.071.854.586                      | 36.936.534.063           | -                          | ( 2.317.421.805 )                  | 73.690.966.844                    | Buildings                            |
| Mesin                                                        | 1.279.550.470                       | 41.493.433.863           | -                          | ( 1.104.550.470 )                  | 41.668.433.863                    | Machineries                          |
| Lainnya                                                      | 606.809.499                         | 1.946.520.058            | -                          | ( 528.971.662 )                    | 2.024.357.895                     | Machineries                          |
| Sub-jumlah                                                   | 40.958.214.555                      | 80.376.487.984           | -                          | ( 3.950.943.937 )                  | 117.383.758.602                   | Sub-total                            |
| <b>Jumlah harga<br/>perolehan</b>                            | <b>508.860.625.753</b>              | <b>137.348.984.040</b>   | <b>( 1.341.107.997 )</b>   | <b>-</b>                           | <b>644.868.501.796</b>            | <b>Total cost</b>                    |
| <b>Akumulasi<br/>penyusutan<br/>Kepemilikan<br/>langsung</b> |                                     |                          |                            |                                    |                                   | <b>Accumulated<br/>depreciation</b>  |
| Bangunan                                                     | 22.347.044.751                      | 6.685.626.176            | -                          | -                                  | 29.032.670.927                    | Buildings                            |
| Mesin                                                        | 110.057.152.404                     | 27.804.988.742           | ( 929.454.347 )            | -                                  | 136.932.686.799                   | Machineries                          |
| Kendaraan                                                    | 3.709.770.577                       | 379.136.180              | ( 10.500.000 )             | -                                  | 4.078.406.757                     | Vehicles                             |
| Inventaris                                                   | 32.884.959.430                      | 8.342.990.804            | ( 262.298.122 )            | -                                  | 40.965.652.112                    | Furniture and fixtures               |
| Jumlah akumulasi<br>penyusutan                               | 168.998.927.162                     | 43.212.741.902           | ( 1.202.252.469 )          | -                                  | 211.009.416.595                   | Total accumulated<br>depreciation    |
| <b>Nilai tercatat</b>                                        | <b>339.861.698.591</b>              |                          |                            |                                    | <b>433.859.085.201</b>            | <b>Carrying value</b>                |

Beban penyusutan dialokasikan pada:

Depreciation expense which were charged to:

|                                               | 30 Juni/<br>June<br>2025 | 30 Juni/<br>June<br>2024 |                                                  |
|-----------------------------------------------|--------------------------|--------------------------|--------------------------------------------------|
| Beban pokok penjualan<br>(Catatan 31)         | 20.682.351.312           | 18.246.209.765           | Cost of goods sold<br>(Note 31)                  |
| Beban penjualan dan pemasaran<br>(Catatan 32) | 3.428.784                | 3.428.781                | Selling and marketing expenses<br>(Note 32)      |
| Beban umum dan administrasi<br>(Catatan 33)   | 2.918.459.027            | 2.050.036.404            | General and administrative expenses<br>(Note 33) |
| <b>Jumlah</b>                                 | <b>23.604.239.123</b>    | <b>20.299.674.950</b>    | <b>Total</b>                                     |

Pada 30 Juni 2025 jumlah harga perolehan aset tetap yang telah disusutkan penuh dan masih digunakan adalah sebesar Rp 68.152.602.867 (2024: Rp 62.296.979.433).

As of June 30, 2025 the cost of fixed assets which have been fully depreciated and are still being used was amounted to Rp 68,152,602,867 (2024: Rp 62,296,979,433).

Pada 30 Juni 2025 dan 31 Desember 2024 tidak terdapat aset tetap yang tidak dipakai sementara.

As of June 30, 2025 and December 31, 2024 there are no fixed assets that are not used temporary.

Pada 30 Juni 2025 dan 31 Desember 2024 tidak terdapat aset tetap yang dihentikan dari penggunaan aktif dan diklasifikasikan sebagai tersedia untuk dijual.

As of June 30, 2025 and December 31, 2024 there are no fixed assets that are discontinued from active use and classified as held for sale.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Rincian laba atas penjualan aset tetap sebagai berikut:

Detail of gain on sales fixed assets are as follows:

|                                               | 30 Juni/<br>June<br>2025 | 30 Juni/<br>June<br>2024 |                                          |
|-----------------------------------------------|--------------------------|--------------------------|------------------------------------------|
| Harga jual                                    | 5.541.667                | 963.462                  | Selling price                            |
| Harga perolehan                               | 45.756.470               | 1.333.333                | C o s t                                  |
| Akumulasi penyusutan                          | ( 36.993.299 )           | ( 263.889 )              | Accumulated depreciation                 |
| <b>Nilai tercatat</b>                         | <b>8.763.171</b>         | <b>1.069.444</b>         | <b>Carrying value</b>                    |
| (Rugi) atas penjualan aset tetap (Catatan 34) | ( 3.221.504 )            | ( 105.982 )              | (Loss) on sale of fixed assets (Note 34) |

Perhitungan rugi atas penghapusan aset tetap sebagai berikut:

The computation of loss on the write-off property, plant and equipment are as follows:

|                                               | 30 Juni/<br>June<br>2025 | 30 Juni/<br>June<br>2024 |                                            |
|-----------------------------------------------|--------------------------|--------------------------|--------------------------------------------|
| Harga perolehan                               | 2.471.322.378            | 778.534.546              | C o s t                                    |
| Akumulasi penyusutan                          | ( 2.222.231.378 )        | ( 643.708.311 )          | Accumulated depreciation                   |
| Rugi atas penghapusan aset tetap (Catatan 34) | 249.091.000              | 134.826.235              | Loss on disposal of fixed assets (Note 34) |

Manajemen berkeyakinan bahwa tidak terdapat kondisi atau peristiwa yang menimbulkan indikasi penurunan nilai atas jumlah tercatat aset tetap, sehingga tidak diperlukan cadangan kerugian penurunan nilai untuk aset tetap pada tanggal 30 Juni 2025 dan 31 Desember 2024.

Management believes that there were no conditions or events that indicate impairment in the carrying amount of its property, plant and equipment, and therefore an allowance for impairment losses of property, plant and equipment was not considered necessary as of June 30, 2025 and December 31, 2024.

### Perusahaan

Perusahaan memiliki hak atas tanah dengan luas 21.000 m2 terletak di By Pass Krian Kilometer 28, Desa Sidomojo, Kecamatan Krian, Sidoarjo, bersertifikat Hak Guna Bangunan (HGB) No. 2 tanggal 13 Mei 1996 yang berlaku sampai dengan tahun 2026. Manajemen berpendapat bahwa masa manfaat hak atas tanah tersebut dapat diperbaharui/diperpanjang pada saat jatuh tempo.

Perusahaan memiliki hak atas tanah dengan luas 58.636 m2 terletak di Kebonsari, Karangwinongan, Kec. Mojoagung, Kabupaten Jombang, Jawa Timur, sampai dengan laporan keuangan ini diterbitkan Hak Guna Bangunan (HGB) masih dalam proses.

Pada 30 Juni 2025 dan 31 Desember 2024, tidak ada aset tetap Perusahaan dan Entitas Anak digunakan sebagai jaminan atas utang bank.

Aset tetap, kecuali hak atas tanah, telah diasuransikan kepada PT Asuransi Multi Artha Guna Tbk, PT MNC Insurance Indonesia, PT China Taiping Insurance Indonesia, PT Asuransi Bina Dana Arta Tbk, PT Great Eastern General Insurance Indonesia, PT Asuransi Maximus Graha Persada Tbk, PT Asuransi Sahabat Artha Proteksi, PT Zurich General Takaful Indonesia,

### Company

The Company has the right to land with an area of about 21,000 m2 located in By Pass Krian Kilometer 28, Desa Sidomojo, Kecamatan Krian, Sidoarjo, certified of Usage Right for Building (HGB) No. 2 dated May 13, 1996, which is valid until 2026. Management believes that the term of the landrights can be renewed/extended upon maturity.

The Company has the right to land with an area of about 58,636 m2 located in By Kebonsari, Karangwinongan, Kec. Mojoagung, Kabupaten Jombang, Jawa Timur, up to the date of this report Usage Right for Building (HGB) still in process.

As of June 30, 2025 and December 31, 2024, there were no fixed assets of the Company and its Subsidiaries that were used as collateral bank loans.

Fixed assets, except for land rights, were insured with PT Asuransi Multi Artha Guna Tbk, PT MNC Insurance Indonesia, PT China Taiping Insurance Indonesia, PT Asuransi Bina Dana Arta Tbk, PT Great Eastern General Insurance Indonesia, PT Asuransi Maximus Graha Persada Tbk, PT Asuransi Sahabat Artha Proteksi, PT Zurich General Takaful Indonesia,

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

PT Asuransi Chubb Syariah Indonesia, PT Asuransi Tugu Pratama Indonesia Tbk, PT Sunday Insurance Indonesia, PT Chubb General Insurance Indonesia, terhadap kerugian kebakaran dan risiko lain berdasarkan suatu paket polis dengan nilai pertanggungan sebesar Rp 691.875.105.886 pada tanggal 30 Juni 2025 dan 31 Desember 2024, dimana manajemen berpendapat bahwa nilai pertanggungan tersebut cukup untuk menutup kemungkinan kerugian atas resiko-resiko tersebut.

PT Asuransi Chubb Syariah Indonesia, PT Asuransi Tugu Pratama Indonesia Tbk, PT Sunday Insurance Indonesia, PT Chubb General Insurance Indonesia, Indonesia against fire and other risks under a policy package with a total coverage of Rp 691,875,105,886 as of June 30, 2025 and December 31, 2024, wherein the Company's management believes that the insurance coverage is adequate to cover possible losses from these risks.

Pada tanggal 30 Juni 2025, tingkat penyelesaian aset dalam pembangunan adalah sebagai berikut:

The completion stage of construction in progress as of June 30, 2025 is as follows:

|                     | <b>Persentase<br/>Penyelesaian/<br/>Completion<br/>percentage</b> | <b>Estimasi tahun<br/>Penyelesaian/<br/>Estimated<br/>completion year</b> |                      |
|---------------------|-------------------------------------------------------------------|---------------------------------------------------------------------------|----------------------|
| <b>30 Juni 2025</b> |                                                                   |                                                                           | <b>June 30, 2025</b> |
| Bangunan            | 81%                                                               | 2025                                                                      | Building             |
| Mesin               | 92%                                                               | 2025                                                                      | Machineries          |
| Lainnya             | 74%                                                               | 2025                                                                      | Others               |

**14. ASET TAK BERWUJUD**

**14. INTANGIBLE ASET**

| <b>30 Juni/June 2025</b>         |                                  |                          |                                |  |                                 |
|----------------------------------|----------------------------------|--------------------------|--------------------------------|--|---------------------------------|
| <b>Saldo awal/<br/>Beginning</b> |                                  | <b>Pengurangan<br/>/</b> | <b>Saldo akhir/<br/>Ending</b> |  |                                 |
| <b>balance</b>                   | <b>Penambahan/<br/>Additions</b> | <b>Deductions</b>        | <b>balance</b>                 |  |                                 |
| <b>Harga perolehan</b>           |                                  |                          |                                |  | <b>Cost</b>                     |
| <u>Kepemilikan langsung</u>      |                                  |                          |                                |  | <u>Direct ownership</u>         |
| Software komputer dan lisensi    | 2.922.105.690                    | -                        | 2.922.105.690                  |  | Computer software and license   |
| <b>Akumulasi amortisasi</b>      |                                  |                          |                                |  | <b>Accumulated amortization</b> |
| <u>Kepemilikan langsung</u>      |                                  |                          |                                |  | <u>Direct ownership</u>         |
| Software komputer dan lisensi    | (2.810.679.075)                  | (27.541.184)             | (2.838.220.259)                |  | Computer software and license   |
| <b>Nilai tercatat</b>            | <b>111.426.615</b>               |                          | <b>83.885.431</b>              |  | <b>Carrying value</b>           |
| <b>31 Desember/December 2024</b> |                                  |                          |                                |  |                                 |
| <b>Saldo awal/<br/>Beginning</b> |                                  | <b>Pengurangan<br/>/</b> | <b>Saldo akhir/<br/>Ending</b> |  |                                 |
| <b>balance</b>                   | <b>Penambahan/<br/>Additions</b> | <b>Deductions</b>        | <b>balance</b>                 |  |                                 |
| <b>Harga perolehan</b>           |                                  |                          |                                |  | <b>Cost</b>                     |
| <u>Kepemilikan langsung</u>      |                                  |                          |                                |  | <u>Direct ownership</u>         |
| Software komputer dan lisensi    | 2.902.717.937                    | 19.387.753               | 2.922.105.690                  |  | Computer software and license   |
| <b>Akumulasi amortisasi</b>      |                                  |                          |                                |  | <b>Accumulated amortization</b> |
| <u>Kepemilikan langsung</u>      |                                  |                          |                                |  | <u>Direct ownership</u>         |
| Software komputer dan lisensi    | (2.735.232.473)                  | (75.446.602)             | (2.810.679.075)                |  | Computer software and license   |
| <b>Nilai tercatat</b>            | <b>167.485.464</b>               |                          | <b>111.426.615</b>             |  | <b>Carrying value</b>           |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Pada 30 Juni 2025 dan 2024, biaya amortisasi yang dibebankan pada beban umum dan administrasi sebesar Rp 27.541.184 dan Rp. 37.521.348 (Catatan 33).

As of June 30, 2025 and 2024, amortization expenses are charged to general and administrative expenses amounted to Rp 27,541,184 and Rp. 37,521,348 (Note 33).

Berdasarkan penilaian manajemen, tidak ada kejadian kejadian atau perubahan-perubahan keadaan yang mengindikasikan adanya penurunan nilai aset takberwujud pada tanggal-tanggal 30 Juni 2025 dan 31 Desember 2024.

Based on the evaluation of the management, there are no events or changes in circumstances which may indicate impairment in value of intangible assets as of June 30, 2025 and December 31, 2024.

**15. ASET HAK GUNA**

**15. RIGHT-OF-USE ASSET**

| 30 Juni/June 2025           |                                     |                                    |                            |                          |                                   |
|-----------------------------|-------------------------------------|------------------------------------|----------------------------|--------------------------|-----------------------------------|
|                             | Saldo awal/<br>Beginning<br>balance | Reklasifikasi/<br>Reclassification | Pengurangan/<br>Deductions | Penambahan/<br>Additions | Saldo akhir/<br>Ending<br>balance |
| <b>Harga perolehan</b>      |                                     |                                    |                            |                          |                                   |
| Tanah                       | 24.384.592.796                      |                                    | -                          | -                        | 24.384.592.796                    |
| Bangunan                    | 39.315.058.772                      | 19.871.625.887                     | (10.937.777.776)           | 16.309.277.780           | 64.558.184.663                    |
| Kendaraan                   | 19.871.625.887                      | (19.871.625.887)                   | -                          | -                        | -                                 |
|                             | 83.571.277.455                      | -                                  | (10.937.777.776)           | 16.309.277.780           | 88.942.777.459                    |
| <b>Akumulasi amortisasi</b> |                                     |                                    |                            |                          |                                   |
| Tanah                       | 856.736.013                         |                                    | -                          | 151.792.621              | 1.008.528.634                     |
| Bangunan                    | 27.208.439.941                      | 20.328.451.514                     | (10.937.777.776)           | 8.669.720.935            | 45.268.834.614                    |
| Kendaraan                   | 20.328.451.514                      | (20.328.451.514)                   | -                          | -                        | -                                 |
|                             | 48.393.627.468                      | -                                  | (10.937.777.776)           | 8.821.513.556            | 46.277.363.248                    |
| <b>Nilai tercatat</b>       | <u>35.177.649.987</u>               |                                    |                            |                          | <u>42.665.414.211</u>             |
| 31 Desember/December 2024   |                                     |                                    |                            |                          |                                   |
|                             | Saldo awal/<br>Beginning<br>balance | Reklasifikasi/<br>Reclassification | Pengurangan/<br>Deductions | Penambahan/<br>Additions | Saldo akhir/<br>Ending<br>balance |
| <b>Harga perolehan</b>      |                                     |                                    |                            |                          |                                   |
| Tanah                       | 27.523.439.721                      | -                                  | (3.138.846.925)            | -                        | 24.384.592.796                    |
| Bangunan                    | 45.998.206.236                      | -                                  | (20.886.065.906)           | 14.202.918.442           | 39.315.058.772                    |
| Kendaraan                   | 20.685.611.453                      | -                                  | (1.195.985.566)            | 382.000.000              | 19.871.625.887                    |
|                             | 94.207.257.410                      | -                                  | (25.220.898.397)           | 14.584.918.442           | 83.571.277.455                    |
| <b>Akumulasi amortisasi</b> |                                     |                                    |                            |                          |                                   |
| Tanah                       | 516.064.495                         | -                                  | -                          | 340.671.518              | 856.736.013                       |
| Bangunan                    | 34.447.955.335                      | -                                  | (20.963.165.344)           | 13.723.649.950           | 27.208.439.941                    |
| Kendaraan                   | 19.331.567.480                      | -                                  | (500.738.877)              | 1.497.622.911            | 20.328.451.514                    |
|                             | 54.295.587.310                      | -                                  | (21.463.904.221)           | 15.561.944.379           | 48.393.627.468                    |
| <b>Nilai tercatat</b>       | <u>39.911.670.100</u>               |                                    |                            |                          | <u>35.177.649.987</u>             |

**Cost**  
Landrights  
Buildings  
Vehicles

**Accumulated amortization**  
Landrights  
Buildings  
Vehicles

**Carrying value**

**Cost**  
Landrights  
Buildings  
Vehicles

**Accumulated amortization**  
Landrights  
Buildings  
Vehicles

**Carrying value**

Perusahaan memiliki hak atas tanah dengan luas 41.325 m2 terletak di Kedawung, Kecamatan Banyuputih, Batang bersertifikat Hak Guna Bangunan (HGB) No. 56 tanggal 28 Juni 2022 yang berlaku selama 80 tahun sampai dengan tahun 2102. Manajemen berpendapat bahwa masa manfaat hak atas tanah tersebut dapat diperbaharui/diperpanjang pada saat jatuh tempo.

The Company has the right to land with an area of about 41,325 m2 located in Kedawung, Kecamatan Banyuputih, Batang, certified of Usage Right for Building (HGB) No. 56 dated June 28, 2022, which is valid for 80 years until 2102. Management believes that the term of the landrights can be renewed/extended upon maturity.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Beban amortisasi yang dibebankan kepada:

Amortization expense which were charged to:

|                                               | 30 Juni/<br>June<br>2025 | 30 Juni/<br>June<br>2024 |                                             |
|-----------------------------------------------|--------------------------|--------------------------|---------------------------------------------|
| Beban pokok penjualan<br>(Catatan 31)         | 151.792.621              | 172.021.501              | Cost of goods sold<br>(Note 31)             |
| Beban penjualan dan pemasaran<br>(Catatan 32) | 8.669.720.935            | 7.023.052.823            | Selling and marketing expenses<br>(Note 32) |
| <b>Jumlah</b>                                 | <b>8.821.513.556</b>     | <b>7.195.074.324</b>     | <b>T o t a l</b>                            |

Berdasarkan penilaian manajemen, tidak ada kejadian kejadian atau perubahan-perubahan keadaan yang mengindikasikan adanya penurunan nilai aset hak-guna pada tanggal 30 Juni 2025 dan 31 Desember 2024.

Based on the evaluation of the management, there are no events or changes in circumstances which may indicate impairment in value of right-of-use assets as of June 30, 2025 and December 31, 2024.

**16. INVESTASI JANGKA PANJANG**

**16. LONG TERM INVESTMENT**

**a. Obligasi**

**a. Bonds**

|                               | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                               |
|-------------------------------|--------------------------|----------------------------------|-------------------------------|
| <b>Dalam Rupiah</b>           |                          |                                  | <b>Rupiah</b>                 |
| PT Bank CIMB Niaga Tbk        | 49.922.872.689           | -                                | PT Bank CIMB Niaga Tbk        |
| PT Bank Central Asia Tbk      | 16.873.799.446           | 9.782.712.003                    | PT Bank Central Asia Tbk      |
| PT Bank Danamon Indonesia Tbk | 16.104.164.824           | 15.860.348.116                   | PT Bank Danamon Indonesia Tbk |
| PT UOB Bank                   | 2.022.613.723            | -                                | PT UOB Bank                   |
| PT Bank Pan Indonesia Tbk     | 3.000.000.000            | 7.986.269.826                    | PT Bank Pan Indonesia Tbk     |
| <b>Sub total</b>              | <b>87.923.450.682</b>    | <b>33.629.329.945</b>            | <b>Sub total</b>              |
| <b>Dolar Amerika Serikat</b>  |                          |                                  | <b>US Dollars</b>             |
| PT Bank Central Asia Tbk      | 47.804.711.239           | 16.986.104.148                   | PT Bank Central Asia Tbk      |
| PT Bank Danamon Indonesia Tbk | 33.760.539.852           | 8.520.955.543                    | PT Bank Danamon Indonesia Tbk |
| PT Bank CIMB Niaga Tbk        | 20.267.664.337           | 16.978.195.590                   | PT BankCIMB Niaga Tbk         |
| <b>Sub-total</b>              | <b>101.832.915.428</b>   | <b>42.485.255.281</b>            | <b>Sub-total</b>              |
| <b>Jumlah</b>                 | <b>189.756.366.110</b>   | <b>76.114.585.226</b>            | <b>Total</b>                  |

Aset keuangan diukur pada biaya perolehan diamortisasi sesuai dengan kondisi persyaratan kontraktual dari aset keuangan menghasilkan arus kas pada tanggal tertentu yang semata dari pembayaran pokok dan bunga dari jumlah pokok terutang yang dirincikan sebagai berikut:

Financial assets are measured at amortized cost in accordance with the contractual terms of the financial assets generating cash flows at a certain date which are solely payments of principal and interest on the principal amount payable, which are detailed as follows:

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

| 30 Juni/June 2025                                       |                            |                             |                        |
|---------------------------------------------------------|----------------------------|-----------------------------|------------------------|
| Seri produk/Product series                              | Suku bunga / Interest rate | Jatuh tempo/Maturity date   | Jumlah/Total           |
| <b>Obligasi/Bonds</b>                                   |                            |                             |                        |
| <b><u>Dalam Rupiah/In Rupiah</u></b>                    |                            |                             |                        |
| FR0071                                                  | 9,00%                      | 15 Maret/March 2029         | 21.441.625.886         |
| FR0092                                                  | 7,13%                      | 15 Juni/June 2042           | 10.157.346.404         |
| FR0059                                                  | 7,00%                      | 15 Mei/May 2027             | 10.067.998.893         |
| FR0082                                                  | 7,00%                      | 15 September/September 2030 | 9.970.260.506          |
| FR0064                                                  | 6,13%                      | 15 Mei/May 2028             | 9.811.600.184          |
| FR0056                                                  | 8,38%                      | 15 September/September 2026 | 8.689.929.860          |
| FR0076                                                  | 7,13%                      | 15 Mei/May 2048             | 5.204.871.507          |
| MERDEKA COPPER GOLD                                     | 8,75%                      | 25 Februari/February 2028   | 5.056.332.637          |
| OBLIGASI BERKELANJUTAN IV                               | 7,25%                      | 1 Oktober/October 2029      | 3.000.000.000          |
| FR0097                                                  | 7,13%                      | 15 Juni/June 2043           | 2.536.222.371          |
| FR0101                                                  | 6,88%                      | 15 April/April 2029         | 1.987.262.434          |
|                                                         |                            |                             | <b>87.923.450.682</b>  |
| <b><u>Dollar Amerika Serikat/US Dollars</u></b>         |                            |                             |                        |
| INDON42                                                 | 5,25%                      | 17 Januari/January 2042     | 62.951.574.527         |
| INDON53                                                 | 5,65%                      | 11 Januari/January 2053     | 16.099.149.449         |
| INDON46                                                 | 5,95%                      | 8 Januari/January 2046      | 13.361.959.880         |
| INDOIS54NEW                                             | 5,65%                      | 25 November/November 2054   | 6.321.202.391          |
| INDON45                                                 | 5,13%                      | 15 Januari/January 2045     | 3.099.029.181          |
|                                                         |                            |                             | <b>101.832.915.428</b> |
| <b>Jumlah/Total</b>                                     |                            |                             | <b>189.756.366.110</b> |
| 31 Desember/December 2024                               |                            |                             |                        |
| Seri produk/Product series                              | Suku bunga Interest rate   | Jatuh tempo/Maturity date   | Jumlah/Total           |
| <b>Obligasi/Bonds</b>                                   |                            |                             |                        |
| <b><u>Dalam Rupiah/In Rupiah</u></b>                    |                            |                             |                        |
| FR0082                                                  | 7,00%                      | 15 September/September 2030 | 9.968.258.904          |
| FR0071                                                  | 9,00%                      | 15 Maret/March 2029         | 10.878.656.037         |
| FR0064                                                  | 6,13%                      | 15 Mei/May 2028             | 9.782.712.003          |
| OBLIGASI BERKELANJUTAN IV                               | 7,25%                      | 1 Oktober/October 2029      | 3.000.000.000          |
|                                                         |                            |                             | <b>33.629.626.944</b>  |
| <b><u>Dolar Amerika Serikat/United State Dollar</u></b> |                            |                             |                        |
| INDON42                                                 | 5,25%                      | 17 Januari/January 2042     | 42.485.255.281         |
|                                                         |                            |                             | <b>42.485.255.281</b>  |
| <b>Jumlah/Total</b>                                     |                            |                             | <b>76.114.882.225</b>  |

**b. Investasi pada instrumen ekuitas – metode biaya perolehan diamortisasi**

**b. Investment in equity instruments – amortised cost**

|                                 | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                                |
|---------------------------------|--------------------------|----------------------------------|--------------------------------|
| Saldo awal                      | 250.000.000              | 5.351.000.000                    | Beginning balance              |
| Reklasifikasi ke Metode Ekuitas | ( - )                    | ( 5.101.000.000 )                | Reclassified to equity methods |
| <b>Saldo akhir</b>              | <b>250.000.000</b>       | <b>250.000.000</b>               | <b>Ending balance</b>          |

Perusahaan melakukan penyertaan atas 1% saham pada PT Jayatex Nonwoven Industri sebesar Rp 5.000.000. Investasi pada PT Jayatex Nonwoven Industri dimaksudkan untuk memperoleh keuntungan

The Company have a portion of 1% equity interest in PT Jayatex Nonwoven Industri amounting Rp 5,000,000. Investment in PT Jayatex Nonwoven Industri is held primary for long-term

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

dalam jangka panjang yang tidak memiliki kuotasi harga di pasar.

Berdasarkan akta Notaris No. 28 tanggal 6 Maret 2023 dari Notaris Julia Seloadji, S.H., yang telah diterima dan dicatat oleh Kementerian Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-0014192.AH.01.02.TAHUN 2023 tanggal 7 Maret 2023, Perusahaan telah melakukan peningkatan atas investasi saham pada PT Jayatex Nonwoven Industri menjadi 250 lembar saham atau sebesar Rp 250.000.000 dengan persentase kepemilikan sebesar 1%.

Perusahaan melakukan penyertaan atas 51% saham pada PT Jayamas Wellong Medical sebesar Rp 5.101.000.000. Investasi pada PT Jayamas Wellong Medical dimaksudkan untuk memperoleh keuntungan dalam jangka panjang yang tidak memiliki kuotasi harga di pasar.

Pada tanggal 28 Juni 2024, Perusahaan telah melakukan penyertaan modal. Oleh karena itu, laporan keuangan konsolidasian menerapkan metode ekuitas (Catatan 1d).

growth potential and no readily available fair value of the shares.

Based on Notarial deed No. 28 dated March 6, 2023 of Notary Julia Seloadji, S.H., that have been notified and accepted by the Minister of Law and Human Rights of the Republic of Indonesia by its Decision Letter No. AHU-0014192.AH.01.02.TAHUN 2023 dated March 7, 2023, the Company has increased its share investment in PT Jayatex Nonwoven Industri to 250 shares or Rp 250,000,000 with an ownership percentage of 1%.

The Company have a portion of 51% equity interest in PT Jayamas Wellong Medical amounting Rp 5,101,000,000. Investment in PT Jayamas Wellong Medical is held primary for long-term growth potential and no readily available fair value of the shares.

On June 28, 2024, the Company has paid up the shares capital. Thus, the consolidated financial statements applied the equity method (Notes 1d).

**17. DEPOSITO BERJANGKA**

**17. TIME DEPOSITS**

|                    | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |               |
|--------------------|-----------------------------------|-------------------------------------------|---------------|
| Deposito Berjangka | <u>5.000.000.000</u>              | <u>-</u>                                  | Time Deposits |

**PT Bank Index Selindo**

Berdasarkan perjanjian gadai atas deposito berjangka no. 09/SBY/111/2025 pada tanggal 17 Maret 2025, Perusahaan menggadaikan deposito berjangka No.DC-0069691 sebesar Rp. 5.000.000.000 (lima miliar rupiah) sebagai jaminan. Deposito berjangka diserahkan pada tanggal 17 Maret 2025. Deposito berjangka yang digadaikan akan dikembalikan setelah Perusahaan menyelesaikan kewajiban yang timbul akibat perjanjian ini (Catatan 23)

**PT Bank Index Selindo**

Based on pawn agreement on Time Deposits No 09/SBY/111/2025 dated March 17, 2025, The Company committed a time deposit No.DC-0069691 amounting to Rp. 5,000,000,000 (five billion rupiah) as collateral. The deposit was placed on March 17, 2025. The collateral time deposit will be released upon full settlement of the Company's obligations as a result from this agreement (Note 23).

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**18. UTANG USAHA**

**18. TRADE PAYABLES**

|                                                               | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                                                               |
|---------------------------------------------------------------|-----------------------------------|-------------------------------------------|---------------------------------------------------------------|
| <b>Pihak berelasi (Catatan 38)</b>                            | <b>5.457.682.137</b>              | <b>5.040.794.082</b>                      | <b>Related parties (Note 38)</b>                              |
| <b>Pihak ketiga</b>                                           |                                   |                                           | <b>Third parties</b>                                          |
| Jiangsu Yuyue Medical Equipment                               | 12.252.851.579                    | 8.649.920.805                             | Jiangsu Yuyue Medical Equipment                               |
| Zhejiang Renon Medical Instrument                             | 8.811.952.263                     | 2.117.404.941                             | Zhejiang Renon Medical Instrument                             |
| Sri Trang Gloves                                              | 5.514.938.546                     | -                                         | Sri Trang Gloves                                              |
| Anhui Hongyu Wuxhou Import & Export<br>public company limited | 6.579.199.439                     | 1.023.206.720                             | Anhui Hongyu Wuxhou Import & Export<br>public company limited |
| PT Anugrah Argon Medica                                       | 3.575.363.930                     | 2.933.777.693                             | PT Anugrah Argon Medica                                       |
| Besmed Health Corp                                            | 3.111.249.246                     | 205.331.455                               | Besmed Health Corp                                            |
| PT Molindo Raya                                               | 2.734.250.000                     | 3.508.710.000                             | PT Molindo Raya                                               |
| CV Aman                                                       | 2.383.924.958                     | 1.814.805.451                             | CV Aman                                                       |
| Shanghai Yencom                                               | 2.280.226.896                     | 602.713.468                               | Shanghai Yencom                                               |
| PT Riken Indonesia (Rapindo)                                  | 2.235.624.000                     | 917.748.000                               | PT Riken Indonesia (Rapindo)                                  |
| PT Shanghai Honsun International Trade                        | 2.070.100.239                     | 2.853.372.095                             | PT Shanghai Honsun International Trade                        |
| PT I Flex Indonesia                                           | 1.779.102.778                     | 1.062.309.405                             | PT I Flex Indonesia                                           |
| PT Asterindo Plast                                            | 1.660.886.157                     | 1.180.662.741                             | PT Asterindo Plast                                            |
| PT Sinar Garuda Makmurindo                                    | 1.649.767.475                     | 868.701.393                               | PT Sinar Garuda Makmurindo                                    |
| PT Sun Paper Source                                           | 1.598.974.185                     | -                                         | PT Sun Paper Source                                           |
| Jiangsu Pakion Medical                                        | 1.553.834.409                     | 2.337.767                                 | Jiangsu Pakion Medical                                        |
| Daiwha Corporation, Ltd                                       | 1.542.135.000                     | -                                         | Daiwha Corporation, Ltd                                       |
| CGN Dasheng Electron                                          | 1.396.937.250                     | 5.630.709.600                             | CGN Dasheng Electron                                          |
| PT Grand Kemindo Pratama                                      | 1.284.040.250                     | 714.653.086                               | PT Grand Kemindo Pratama                                      |
| Nichiban Thailand, Co. Ltd                                    | 1.170.719.415                     | 535.285.440                               | Nichiban Thailand, Co. Ltd                                    |
| Yangzhou Medline Industries Co. Ltd                           | 1.109.786.300                     | -                                         | Yangzhou Medline Industries Co. Ltd                           |
| Hexa Medika Pratama                                           | 1.078.975.500                     | 647.749.769                               | Hexa Medika Pratama                                           |
| PT Duta Budi Tulusrejo                                        | 1.073.814.000                     | 628.260.000                               | PT Duta Budi Tulusrejo                                        |
| Allmed Medical Products                                       | 934.534.748                       | 1.829.703.735                             | Allmed Medical Products                                       |
| PT Global Energy Alkesinco                                    | 983.778.925                       | 1.644.425.040                             | PT Global Energy Alkesinco                                    |
| PT Tatarasa Primatama                                         | 988.883.715                       | 1.452.625.987                             | PT Tatarasa Primatama                                         |
| PT Andalan Bangun Bhuana Baru                                 | 335.043.886                       | 3.987.260.948                             | PT Andalan Bangun Bhuana Baru                                 |
| PT Fresenius Kabi Indonesia                                   | 155.177.137                       | 4.023.595.444                             | PT Fresenius Kabi Indonesia                                   |
| Dominion                                                      | -                                 | 3.084.891.264                             | Dominion                                                      |
| Foshan Dongfang Medical Equipment, Ltd                        | -                                 | 2.438.407.853                             | Foshan Dongfang Medical Equipment, Ltd                        |
| Billerud Korsnas                                              | -                                 | 2.421.746.404                             | Billerud Korsnas                                              |
| PT Universal Gloves                                           | -                                 | 2.120.145.000                             | PT Universal Gloves                                           |
| Terumo                                                        | -                                 | 2.090.255.843                             | Terumo                                                        |
| Zhejiang Wellong                                              | -                                 | 1.425.318.243                             | Zhejiang Wellong                                              |
| Lain-lain (saldo di bawah Rp 1 miliar)                        | 22.155.668.736                    | 23.137.274.382                            | Others (Balance below Rp 1 billion)                           |
| <b>Sub-total</b>                                              | <b>94.001.740.962</b>             | <b>85.553.309.972</b>                     | <b>Sub-total</b>                                              |
| <b>Jumlah</b>                                                 | <b>99.459.423.099</b>             | <b>90.594.104.054</b>                     | <b>Total</b>                                                  |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Pada tanggal 30 Juni 2025 dan 31 Desember 2024, rincian utang usaha berdasarkan jenis mata uang adalah sebagai berikut:

As of June 30, 2025 and December 31, 2024, the details of trade payables based on currencies are as follows:

|                       | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                      |
|-----------------------|-----------------------------------|-------------------------------------------|----------------------|
| Rupiah                | 46.165.351.049                    | 51.814.500.768                            | Rupiah               |
| Yuan China            | 26.616.705.850                    | 23.810.386.368                            | Chinese Yuan         |
| Dolar Amerika Serikat | 26.454.603.718                    | 12.874.158.653                            | United States Dollar |
| Euro Eropa            | 222.762.482                       | -                                         | European Euro        |
| Jepang Yen            | -                                 | 2.095.058.265                             | Japanese Yen         |
| <b>Jumlah</b>         | <b>99.459.423.099</b>             | <b>90.594.104.054</b>                     | <b>Total</b>         |

Analisa berdasarkan umur utang usaha pada tanggal 30 Juni 2025 dan 31 Desember 2024 adalah sebagai berikut:

The aging analysis of the trade payables as of June 30, 2025 and December 31, 2024 are as follows:

|                    | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |              |
|--------------------|-----------------------------------|-------------------------------------------|--------------|
| Belum jatuh tempo  | 53.276.627.847                    | 46.236.561.142                            | Not yet due  |
| Jatuh tempo:       |                                   |                                           | Overdue:     |
| 1 – 30 hari        | 30.925.513.258                    | 38.874.825.151                            | 1 – 30 days  |
| 31 – 60 hari       | 8.331.581.326                     | 3.837.197.401                             | 31 – 60 days |
| 61 – 90 hari       | 1.971.458.430                     | 1.503.627.387                             | 61 – 90 days |
| Lebih dari 90 hari | 4.954.242.238                     | 141.892.973                               | Over 90 days |
| <b>Jumlah</b>      | <b>99.459.423.099</b>             | <b>90.594.104.054</b>                     | <b>Total</b> |

Utang usaha tidak dijamin, tidak dikenakan bunga dan umumnya dengan jangka waktu pembayaran 1 sampai 30 hari. Penjelasan atas manajemen risiko likuiditas Perusahaan dan Entitas Anak diungkapkan pada Catatan 42.

Trade payables are unsecured, non-interest bearing and generally on 1 to 30 days terms of payment. Explanations on the Company and its Subsidiaries' liquidity risk management were disclosed in Note 42.

**19. UTANG NON-USAHA**

**19. NON-TRADE PAYABLES**

|                             | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                           |
|-----------------------------|-----------------------------------|-------------------------------------------|---------------------------|
| Pihak ketiga                | 7.197.002.465                     | 3.876.696.148                             | Third parties             |
| Pihak berelasi (Catatan 38) | 1.348.102.758                     | 16.153.800                                | Related parties (Note 38) |
| <b>Jumlah</b>               | <b>8.545.105.223</b>              | <b>3.892.849.948</b>                      | <b>Total</b>              |

Pada tanggal 30 Juni 2025 dan 31 Desember 2024, rincian utang non-usaha berdasarkan jenis mata uang adalah sebagai berikut:

As of June 30, 2025 and December 31, 2024, the details of non-trade payables based on currencies are as follows:

|                       | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                      |
|-----------------------|-----------------------------------|-------------------------------------------|----------------------|
| Rupiah                | 4.552.549.180                     | 3.714.972.522                             | Rupiah               |
| Yuan China            | 3.011.811.993                     | 108.756.139                               | Chinese Yuan         |
| Dolar Amerika Serikat | 966.284.466                       | 69.119.037                                | United States Dollar |
| Euro                  | 14.459.584                        | -                                         | Euro                 |
| <b>Jumlah</b>         | <b>8.545.105.223</b>              | <b>3.892.849.948</b>                      | <b>Total</b>         |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**20. UANG MUKA DARI PELANGGAN**

Pada tanggal 30 Juni 2025 dan 31 Desember 2024, uang muka dari pelanggan dirincikan sebagai berikut:

|                                  | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |
|----------------------------------|-----------------------------------|-------------------------------------------|
| RSUPN Dr Ciptomangunkusumo       | 185.007.066                       | -                                         |
| RSUD Andi Makassar Parepare      | 162.942.190                       | -                                         |
| PT Selaras Multi Packing         | 89.650.442                        | 103.484.089                               |
| PT Gomotoride Master Indonesia   | -                                 | 316.914.591                               |
| Lain-lain (di bawah Rp 100 juta) | <u>1.401.924.953</u>              | <u>922.563.986</u>                        |
| <b>Jumlah</b>                    | <b><u>1.839.524.651</u></b>       | <b><u>1.342.962.666</u></b>               |

Pada tanggal 30 Juni 2025 dan 31 Desember 2024, rekonsiliasi saldo awal dan pendapatan yang diakui untuk uang muka dari pelanggan adalah sebagai berikut:

|                           | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |
|---------------------------|-----------------------------------|-------------------------------------------|
| Saldo awal                | 1.342.962.666                     | 710.900.760                               |
| Penambahan                | 203.718.719.462                   | 371.542.211.696                           |
| Diakui sebagai pendapatan | <u>( 203.222.157.478 )</u>        | <u>( 370.910.149.790 )</u>                |
| <b>Jumlah</b>             | <b><u>1.839.524.650</u></b>       | <b><u>1.342.962.666</u></b>               |

RSUPN Dr Ciptomangunkusumo  
RSUD Andi Makassar Parepare  
PT Selaras Multi Packing  
PT Gomotoride Master Indonesia  
Others (below Rp 100 million)

**T o t a l**

**20. ADVANCE FROM CUSTOMER**

As of June 30, 2025 and December 31, 2024, detailed advances from customers are as follows:

As of June 30, 2025 and December 31, 2024, the reconciliation of opening balance and revenue recognized for the advance from customer were as follow:

Beginning Balance  
Additions  
Recognized as revenue

**T o t a l**

**21. BEBAN AKRUAL**

|                | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |
|----------------|-----------------------------------|-------------------------------------------|
| Bunga          | -                                 | 1.910.727.029                             |
| Gaji           | 4.337.429.855                     | 5.733.541.559                             |
| Listrik        | 1.097.911.734                     | 1.019.620.059                             |
| Jasa konsultan | -                                 | 163.500.000                               |
| Pemasaran      | -                                 | 50.000.000                                |
| Lain-lain      | <u>13.991.466</u>                 | <u>12.479.094</u>                         |
| <b>Jumlah</b>  | <b><u>5.449.333.055</u></b>       | <b><u>8.889.867.741</u></b>               |

Lain-lain di atas pada umumnya terdiri dari beban administrasi dan pembelian kebutuhan kantor.

**21. ACCRUED EXPENSE**

Others above generally consist of administrative expenses and office supplies purchased.

Interest  
Salaries  
Electricity  
Professional fee  
Marketing  
Others

**T o t a l**

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**22. LIABILITAS SEWA**

**22. LEASE LIABILITY**

|                                                     | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                          |
|-----------------------------------------------------|--------------------------|----------------------------------|--------------------------|
| Saldo awal                                          | 25.609.952.630           | 29.497.751.943                   | Beginning balance        |
| Penambahan                                          | 16.309.277.779           | 10.574.806.431                   | Additions                |
| Beban bunga                                         | 683.708.979              | 2.802.428.825                    | Interest expense         |
| Pembayaran                                          | ( 16.309.277.779 )       | ( 17.265.034.569 )               | Payments                 |
| Saldo akhir                                         | 26.293.661.609           | 25.609.952.630                   | Ending balance           |
| Dikurangi: bagian yang jatuh tempo dalam satu tahun | ( 11.989.936.291 )       | ( 11.926.541.615 )               | Less: current portion    |
| <b>Bagian jangka panjang</b>                        | <b>14.303.725.318</b>    | <b>13.683.411.015</b>            | <b>Long-term portion</b> |

Untuk sewa yang sebelumnya diklasifikasikan sebagai sewa pembiayaan, Perusahaan dan Entitas Anak menentukan nilai tercatat liabilitas sewa segera sebelum transisi sebagai nilai tercatat liabilitas sewa pada tanggal penerapan awal PSAK 116.

For lease previously classified as finance lease, the Company and its Subsidiaries determined the carrying amount of the lease liabilities immediately before the transition as the carrying amount of the lease liabilities at the date of initial application of PSAK 116.

Komitmen sewa Perusahaan dan Entitas Anak sehubungan dengan perjanjian sewa tanah, gedung dan kendaraan memenuhi PSAK 116 untuk pengakuan aset hak-guna dan liabilitas sewa. Perjanjian sewa biasanya memiliki periode tetap dari 2 sampai 80 tahun.

The Company and its Subsidiaries' lease commitments with respect to its lease of landrights, building and vehicle agreements qualify under PSAK 116 for the recognition of right-of-use assets and lease liabilities. Rental agreements are usually have fixed periods of 2 until 80 years.

Sewa untuk beberapa mesin dengan pembayaran sewa tahunan dianggap bernilai rendah atau masa sewa kurang dari satu tahun seperti sewa Gondola yang memiliki masa sewa normal kurang dari 6 bulan dibebankan selama tahun tersebut.

Lease for several machine with annual lease payments considered as low-value or lease term of less than one year such as rental for Gondola which has a normal lease period of less than 6 months were expensed during the year.

Pada tanggal 28 Juni 2022, Perusahaan menandatangani sertifikat Hak Guna Bangunan (HGB) dengan PT Kawasan Industri Terpadu Batang untuk tanah seluas 41.325 m<sup>2</sup> yang berlokasi di Kedawung, Kecamatan Banyuputih, Kabupaten Batang sebesar Rp 35.126.250.000 untuk 2 kali angsuran serta dibebani bunga per tahun sebesar 8,90%. Transaksi ini menimbulkan sewa-balik aset hak-guna sebesar Rp 27.523.439.721 (Catatan 15).

On June 28, 2022, the Company signed a certificate of Usage Right of Building (HGB) with PT Kawasan Industri Terpadu Batang for a land area of 41,325 m<sup>2</sup> located in Kedawung, Kecamatan Banyuputih, Kabupaten Batang in the amount of Rp 35,126,250,000 for 2 installments and bears annual interest of 8.90%. This transaction resulted in a leaseback of right-of-use assets in the amount of Rp 27,523,439,721 (Note 15).

Pada tanggal 4 Desember 2024, Perusahaan menandatangani akta adendum Pemanfaatan Tanah Industri dengan PT Kawasan Industri Terpadu Batang sepakat bahwa luas keseluruhan tanah kaveling industri seluruhnya seluas 35.650m<sup>2</sup> yang berlokasi di Kedawung, Kecamatan Banyuputih, Kabupaten Batang sebesar Rp 30.302.500.000 untuk 2 kali angsuran serta dibebani bunga per tahun sebesar 8,90%. Transaksi ini menimbulkan sewa-balik aset hak-guna sebesar Rp 24.384.592.796 (Catatan 15).

On December 4, 2024, the Company signed an addendum deed for the Utilization of Industrial Land with PT Kawasan Industri Terpadu Batang, agreeing that the total area of the industrial land is 35,650 m<sup>2</sup>, located in Kedawung, Banyuputih District, Batang Regency, with a total value of Rp 30,302,500,000 payable in two installments and subject to an annual interest rate of 8.90%. This transaction resulted in a leaseback of right-of-use assets amounting to Rp 24,384,592,796 (Note 15).

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Laporan laba rugi konsolidasian menyajikan saldo berikut berkaitan dengan sewa:

The consolidated statement of profit or loss show the following amounts related to leases:

|                                              | 30 Juni/<br>June<br>2025 | 30 Juni/<br>June<br>2024 |                                         |
|----------------------------------------------|--------------------------|--------------------------|-----------------------------------------|
| Beban bunga (Catatan 36)                     | 683.708.979              | 886.315.544              | Interest expenses (Note 36)             |
| Beban sewa jangka pendek (Catatan 32)        | 10.042.665.128           | 7.564.281.154            | Short-term rent expenses (Note 32)      |
| Beban sewa aset bernilai rendah (Catatan 32) | -                        | -                        | Low value assets rent expense (Note 32) |

**23. HUTANG BANK**

**23. BANK LOAN**

|                                                     | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                                |
|-----------------------------------------------------|--------------------------|----------------------------------|--------------------------------|
| <b>Hutang Bank<br/>Dalam Rupiah</b>                 |                          |                                  | <b>Bank Loan<br/>In Rupiah</b> |
| PT Bank Index Selindo                               | 4.583.333.333            | -                                | PT Bank Index Selindo          |
| PT Bank Central Asia                                | 123.592.293              | -                                | PT Bank Central Asia           |
| <b>Total</b>                                        | 4.706.925.626            | -                                | <b>Total</b>                   |
| Dikurangi: bagian yang jatuh tempo dalam satu tahun | ( 1.790.258.963 )        | -                                | Less: current portion          |
| <b>Bagian jangka panjang</b>                        | <u>2.916.666.663</u>     | <u>-</u>                         | <b>Long-term portion</b>       |

**PT Bank Index Selindo**

Berdasarkan perjanjian fasilitas kredit No. 08/SBY/III/2025 tanggal 17 Maret 2025, Perusahaan mendapatkan fasilitas pinjaman modal kerja sebesar Rp. 5.000.000.000. Pinjaman ini jatuh tempo pada tanggal 17 Maret 2028 dan dikenakan bunga 0%.

Fasilitas kredit diatas dijamin dengan deposito berjangka atas nama Perusahaan sebesar Rp. 5.000.000.000, yang digadaikan selama periode hutang fasilitas kredit (Catatan 17).

**PT Bank Central Asia**

Berdasarkan perjanjian pembiayaan No. 9650003136-PK-004 tanggal 26 Maret 2025, Perusahaan mendapatkan fasilitas pembiayaan multiguna/investasi dengan cara pembelian dengan pembayaran secara angsuran sebesar Rp 184.400.077. Pinjaman ini jatuh tempo pada tanggal 26 Februari 2026 dengan bunga 2,68%.

**PT Bank Index Selindo**

Based on credit agreement No.08/SBY/III/2025 dated March 17, 2025, the Company obtained working capital loan facility amounting to Rp. 5,000,000,000. This facility will mature on March 17, 2028 and bears interest at 0%.

Above facility secured by time deposit under the Company amounted to Rp. 5,000,000,000, which was collateralized throughout the term of the credit facility (refer to Note 17).

**PT Bank Central Asia**

Based on financing agreement No. 9650003136-PK-004 on March 26, 2025, the Company obtained multi-purpose financing/investment facility by means of purchase with payment in installments with the value of Rp 184.400.077. This facility will mature on February 26, 2026 and bears interest at 2.68%

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**24. SURAT UTANG JANGKA MENENGAH**

|                                            | <b>30 Juni/<br/>June<br/>2025</b> |
|--------------------------------------------|-----------------------------------|
| Surat utang jangka menengah                | 160.000.000.000                   |
| Biaya transaksi yang belum<br>diamortisasi | -                                 |
| Pembayaran                                 | <u>(160.000.000.000)</u>          |
| <b>Jumlah</b>                              | <b>-</b>                          |

Berdasarkan akta Notaris No. 18 tanggal 12 Mei 2020 dari Notaris Jose Dima Satria, S.H., M.Kn., PT Intisumber Hasil Sempurna Global, Entitas Anak, menerbitkan Surat Utang Jangka Menengah/Medium-Term Note (MTN) dengan nilai pokok sebesar Rp 160.000.000.000. Surat utang jangka menengah tersebut telah dibayar pada tanggal 14 Mei 2025, dengan tingkat suku bunga 10,50% per tahun. Biaya transaksi 0,5% atau sebesar Rp 800.000.000. Penggunaan dana hasil penerbitan surat utang jangka menengah digunakan untuk pembiayaan operasional PT Intisumber Hasil Sempurna Global sebagai Entitas Anak.

Pada 30 Juni 2025, biaya bunga surat utang jangka menengah sebesar Rp 6.492.972.973 (30 Juni 2024: Rp 8.379.158.175) (Catatan 36).

Pada tanggal 30 Juni 2025, amortisasi biaya transaksi adalah sebesar Rp 83.240.349 (30 Juni 2024: Rp 90.857.174) (Catatan 36).

Penerbitan surat utang jangka menengah dijamin dengan corporate guarantee dari PT Intisumber Hasil Sempurna, pemegang saham Perusahaan.

Tidak ada kewajiban covenant atas pinjaman jangka panjang surat utang jangka menengah.

**25. LIABILITAS DIESTIMASI IMBALAN PASKA-KERJA**

Perusahaan dan Entitas Anak mencatat liabilitas imbalan kerja sesuai Peraturan Pemerintah No. 35/2021 dan Peraturan Pemerintah Pengganti Undang-Undang No. 2 tanggal 30 Desember 2022 tentang Cipta Kerja dan Undang-undang Ketenagakerjaan No. 13/2003 yang dihitung oleh aktuaris independen KKA Nurichwan dan PT Sigma Prima Solusindo, pada tanggal 31 Desember 2024 dan 2023 dengan menggunakan metode "Projected Unit Credit". Pada 30 Juni 2025 dan 31 Desember 2024, Perusahaan dan Entitas Anak menerapkan Peraturan Pemerintah No. 35 tahun 2021 tentang Cipta Kerja.

Asumsi dasar yang digunakan dalam menentukan liabilitas imbalan kerja pada tanggal 30 Juni 2025 dan 31 Desember 2024 berdasarkan metode "Projected Unit Credit" adalah sebagai berikut:

**24. MEDIUM-TERM NOTE**

|  | <b>31 Desember/<br/>December<br/>2024</b> |                              |
|--|-------------------------------------------|------------------------------|
|  | 160.000.000.000                           | Medium-term note             |
|  | ( 83.240.349 )                            | Unamortized transaction cost |
|  | <u>-</u>                                  | Payments                     |
|  | <b>159.916.759.651</b>                    | <b>Total</b>                 |

Based on Notarial deed No. 18 dated May 12, 2020 of Notary Jose Dima Satria, S.H., M.Kn., PT Intisumber Hasil Sempurna Global, a Subsidiary issued a Medium-Term Note (MTN) with a principal amount of Rp 160,000,000,000. Medium Term Note was paid on May 14, 2025, bears interest rates at 10.50% per annum. The transaction cost is 0.5% or amounted to Rp 800,000,000. The use of the proceeds from Medium Term Note issuance is to finance the operations of PT Intisumber Hasil Sempurna Global, as the Subsidiary.

As of June 30, 2025, the interest expense for Medium Term Note amounted to Rp 6,492,972,973 (30 June 2024: Rp 8,379,158,175) (Note 36).

As of June 30, 2025, the amortization of transaction costs amounted to Rp 83,240,349 (30 June 2024: Rp 90,857,174) (Note 36).

The issuance of Medium Term Note is guaranteed by a corporate guarantee from PT Intisumber Hasil Sempurna, the Company's shareholder.

There is no covenant obligation for long-term Medium Term Note loans.

**25. ESTIMATED LIABILITIES FOR POST-EMPLOYMENT BENEFITS**

The Company and its Subsidiaries recorded employee benefits liability according to Government Regulation No. 35/2021 and Government Regulation in Lieu of Law (Perpu) No. 2 dated December 30, 2022 regarding Job Creation and Labor Law No. 13/2003 which computed by independent actuaries KKA Nurichwan and PT Sigma Prima Solusindo as of December 31, 2024 and 2023 by using the "Projected Unit Credit". On June 30, 2025 and December 31, 2024, the Company and its Subsidiaries implemented Government Regulation No. 35 year 2021 concerning Job Creation.

The basic assumptions used in determining employee benefits liabilities on June 30, 2025 and December 31, 2024 based on the "Projected Unit Credit" method are as follows:

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

|                                                                                                             | <b>Perusahaan/Company</b>                                                                              |                                           |                                                 |
|-------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-------------------------------------------|-------------------------------------------------|
|                                                                                                             | <b>30 Juni/<br/>June<br/>2025</b>                                                                      | <b>31 Desember/<br/>December<br/>2024</b> |                                                 |
| Tingkat diskonto                                                                                            | 7,11%                                                                                                  | 7,11%                                     | Discount rate                                   |
| Tingkat kenaikan gaji                                                                                       | 10%                                                                                                    | 10%                                       | Salary increment rate                           |
| Umur pensiun                                                                                                | 56                                                                                                     | 56                                        | Pension age                                     |
|                                                                                                             | <b>Entitas Anak/Subsidiaries</b>                                                                       |                                           |                                                 |
|                                                                                                             | <b>30 Juni/<br/>June<br/>2025</b>                                                                      | <b>31 Desember/<br/>December<br/>2024</b> |                                                 |
| Tingkat diskonto                                                                                            | 7,11% - 7,12%                                                                                          | 7,11% - 7,12%                             | Discount rate                                   |
| Tingkat kenaikan gaji                                                                                       | 6% - 10%                                                                                               | 6% - 10%                                  | Salary increment rate                           |
| Umur pensiun                                                                                                | 55 - 60                                                                                                | 55 - 60                                   | Pension age                                     |
| Liabilitas imbalan kerja karyawan Perusahaan dan Entitas Anak adalah sebagai berikut:                       | Estimated employee benefit liabilities of the Company and its Subsidiaries are as follows:             |                                           |                                                 |
|                                                                                                             | <b>30 Juni/<br/>June<br/>2025</b>                                                                      | <b>31 Desember/<br/>December<br/>2024</b> |                                                 |
| Nilai kini liabilitas imbalan kerja karyawan                                                                | 42.241.571.345                                                                                         | 39.237.351.452                            | Present value of employee benefit liabilities   |
| Nilai wajar aset program                                                                                    | ( 21.051.185.729 )                                                                                     | ( 20.507.243.800 )                        | Fair value of plan assets                       |
| Jumlah liabilitas imbalan kerja karyawan                                                                    | <u>21.190.385.616</u>                                                                                  | <u>18.730.107.652</u>                     | Total employee benefit liabilities              |
| Mutasi liabilitas imbalan kerja karyawan Perusahaan dan Entitas Anak adalah sebagai berikut:                | Movements in employee benefit liabilities of the Company and its Subsidiaries are as follows:          |                                           |                                                 |
| Mutasi liabilitas imbalan kerja karyawan Perusahaan dan Entitas Anak adalah sebagai berikut:                | Movements in employee benefit liabilities of the Company and its Subsidiaries are as follows:          |                                           |                                                 |
|                                                                                                             | <b>30 Juni/<br/>June<br/>2025</b>                                                                      | <b>31 Desember/<br/>December<br/>2024</b> |                                                 |
| Saldo awal tahun                                                                                            | 39.237.351.452                                                                                         | 34.667.270.132                            | Balance at the beginning of the year            |
| Penyisihan imbalan kerja selama tahun berjalan                                                              | 3.004.219.893                                                                                          | 5.758.705.759                             | Provision for employee benefits during the year |
| Beban/(Pendapatan) komprehensif lain                                                                        | -                                                                                                      | 633.081.869                               | Other comprehensive (income)/expenses           |
| Pembayaran imbalan kerja                                                                                    | -                                                                                                      | ( 1.821.706.308 )                         | Payments of employee benefits                   |
| <b>Saldo akhir</b>                                                                                          | <u>42.241.571.345</u>                                                                                  | <u>39.237.351.452</u>                     | <b>Ending balance</b>                           |
| Beban imbalan kerja untuk tahun yang berakhir 30 Juni 2025 dan 30 Juni 2024 dengan rincian sebagai berikut: | Employee benefits expenses for the year ended June 30, 2025 and June 30, 2024 with details as follows: |                                           |                                                 |
|                                                                                                             | <b>30 Juni/<br/>June<br/>2025</b>                                                                      | <b>30 Juni/<br/>June<br/>2024</b>         |                                                 |
| Beban jasa kini                                                                                             | 1.687.552.386                                                                                          | 4.431.328.074                             | Current service cost                            |
| Beban bunga                                                                                                 | 1.316.667.508                                                                                          | -                                         | Interest expense                                |
| <b>Beban imbalan karyawan (Catatan 33)</b>                                                                  | <u>3.004.219.894</u>                                                                                   | <u>4.431.328.074</u>                      | <b>Employee benefit expenses (Note 33)</b>      |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Berikut nilai wajar asset program adalah sebagai berikut:

The following is the fair value of the plan assets as follows:

|                                   | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                                         |
|-----------------------------------|--------------------------|----------------------------------|-----------------------------------------|
| Saldo awal                        | ( 20.507.243.800)        | ( 10.333.739.762)                | Beginning balance                       |
| Kontribusi pemberi kerja          | -                        | ( 10.000.000.000)                | Contribution from the employer          |
| Beban komprehensif lainnya        | -                        | 190.052.842                      | Other comprehensive expenses            |
| Penarikan Dana dari Asset Program | -                        | 406.461.600                      | Fund Withdrawal from Program Asset      |
| Bunga                             | ( 543.941.929)           | ( 770.018.480)                   | Interest                                |
| <b>Nilai wajar aset program</b>   | <b>( 21.051.185.729)</b> | <b>( 20.507.243.800)</b>         | <b>Fair value of plan asset program</b> |

**Analisis sensitivitas**

Analisis sensitivitas di bawah telah ditentukan berdasarkan kemungkinan perubahan yang cukup untuk asumsi yang signifikan atas nilai kini kewajiban imbalan kerja pada akhir periode pelaporan, dengan asumsi bahwa seluruh asumsi lain digunakan secara tetap:

**Sensitivity analysis**

The sensitivity analysis below has been determined based on the possible changes that enough for any significant assumptions on the present value of employee benefits at the end of the reporting period, assuming that all other assumptions are used regularly:

|                        | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                        |
|------------------------|--------------------------|----------------------------------|------------------------|
| Tingkat diskonto:      |                          |                                  | Discount rate:         |
| Kenaikan 1%            | 35.455.967.062           | 35.455.967.062                   | Increase 1%            |
| Penurunan 1%           | 43.695.752.604           | 43.695.752.604                   | Decrease 1%            |
| Tingkat kenaikan gaji: |                          |                                  | Salary increment rate: |
| Kenaikan 1%            | 43.518.182.303           | 43.518.182.303                   | Increase 1%            |
| Penurunan 1%           | 35.524.607.285           | 35.524.607.285                   | Decrease 1%            |

Pembayaran kontribusi yang diharapkan dari liabilitas imbalan kerja pada periode mendatang adalah sebagai berikut:

The expected contribution payments from the employee benefit liabilities in the future periods are as follows:

| <b>Nilai Kini Atas Kewajiban Imbalan<br/>Kerja Karyawan/<br/>Present value of defined benefit<br/>obligation</b> |                                  |                |                            |
|------------------------------------------------------------------------------------------------------------------|----------------------------------|----------------|----------------------------|
| 30 Juni/<br>June<br>2025                                                                                         | 31 Desember/<br>December<br>2024 |                |                            |
| Kurang dari satu tahun                                                                                           | -                                | 6.738.274.000  | Less than a year           |
| Antara satu sampai dua tahun                                                                                     | -                                | 594.015.385    | Between one and two years  |
| Antara dua sampai lima tahun                                                                                     | -                                | 3.180.520.851  | Between two and five years |
| Lebih dari lima tahun                                                                                            | -                                | 49.687.248.680 | More than five years       |

Durasi rata-rata tertimbang dari liabilitas program pensiun imbalan pasti masing-masing pada 30 Juni 2025 dan 31 Desember 2024 adalah antara 22,16 tahun.

The weighted average duration of the defined benefit pension obligation at June 30, 2025 and December 31, 2024 is between 22,16 years.

**Strategi Pencocokan Aset-liabilitas untuk Mengelola Risiko**

Perusahaan dan Entitas Anak memiliki program pensiun formal dan oleh karena itu memiliki aset program untuk ditandingkan dengan liabilitas di bawah kewajiban pensiun.

**Asset-liability Matching Strategies to Manage Risks**

The Company and its Subsidiaries have a formal retirement plan and therefore has plan assets to match against the liabilities under the retirement obligation.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**Pengaturan Pendanaan**

Perusahaan dan Entitas Anak memiliki program pensiun formal, klaim manfaat atas kewajiban pensiun dibayarkan langsung oleh Perusahaan dan Entitas Anak pada saat jatuh tempo.

**Omnibus Law**

Pada akhir tahun 2021, Presiden Republik Indonesia memberlakukan Undang-Undang Nomor 11 Tahun 2020 ("Omnibus Law") tentang "Cipta Kerja" yang dimana pada tanggal 30 Desember 2022 telah digantikan dengan Peraturan Pemerintah Pengganti Undang-Undang (Perpu) No. 2 tahun 2022. Peraturan pelaksanaan terkait dengan perhitungan imbalan kerja minimum diatur dalam Peraturan Pemerintah Nomor 35 Tahun 2021 yang diterbitkan pada Februari 2021.

Dalam menentukan perhitungan kewajiban imbalan kerja karyawan, Perusahaan dan anak perusahaan memperhatikan undang-undang yang berlaku dan Perjanjian Kerja Bersama/Peraturan Perusahaan.

**26. MODAL SAHAM**

Pada tanggal 30 Juni 2025 dan 31 Desember 2024, modal dasar Perusahaan adalah sebagai berikut:

|                                                       | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |
|-------------------------------------------------------|-----------------------------------|-------------------------------------------|
| <b>Modal dasar</b>                                    |                                   |                                           |
| Saham biasa – (2025 dan 2024:<br>Rp 25 dan Rp 25)     | <u>2.300.000.000.000</u>          | <u>2.300.000.000.000</u>                  |
| <b>Jumlah saham modal dasar<br/>Untuk diterbitkan</b> |                                   |                                           |
| Saham biasa                                           | <u>92.000.000.000</u>             | <u>92.000.000.000</u>                     |

Berdasarkan akta Notaris No. 31 tanggal 8 Desember 2022 yang dibuat dihadapan Jose Dima Satria, S.H., M.Kn., Notaris di Jakarta, tentang peningkatan modal ditempatkan dan modal disetor dari publik menjadi 27.058.850.000 saham atau dengan nilai nominal seluruhnya sebesar Rp 676.471.250.000.

Berdasarkan akta Notaris No. 77 tanggal 7 April 2022 yang dibuat dihadapan Jose Dima Satria, S.H., M.Kn., Notaris di Jakarta, tentang:

- Pemecahan nilai nominal modal saham dari semula nilai nominal Rp 50 per saham menjadi nilai nominal Rp 25 per saham sehingga saham dasar Perusahaan menjadi 60.000.000.000 dari 30.000.000.000 saham yang keduanya setara menjadi Rp 1.500.000.000.000.
- Peningkatan modal dasar dari semula Rp 1.500.000.000.000 yang terdiri

**Funding Arrangements**

The Company and its Subsidiaries have a formal retirement plan, benefit claims under the retirement obligations are paid directly by the Company and its Subsidiaries when they become due.

**Omnibus Law**

In late 2021, the President of the Republic of Indonesia enacted Undang-Undang Nomor 11 Tahun 2020 (the "Omnibus Law") regarding "Job Creation", which has replaced by Government Regulation in Lieu of Law (Perpu) No. 2 year 2022. The implementing regulations related to the calculation of the minimum benefit are stipulated in Peraturan Pemerintah Nomor 35 Tahun 2021 issued in February 2021.

In determining the calculation of the employee benefit obligations, the Company and its Subsidiaries considers the prevailing regulations and the Collective Labor Agreement/Company Regulations.

**26. SHARE CAPITAL**

As of June 30, 2025 and December 31, 2024, the Company's authorized share capital is as follow:

|                                                     |
|-----------------------------------------------------|
| <b>Authorized share capital</b>                     |
| Common shares – (2025 and 2024:<br>Rp 25 and Rp 25) |
| <b>Number of shares authorized<br/>for issue</b>    |
| Common shares                                       |

Based on Notarial deed No. 31 dated December 8, 2022 drawn up before Jose Dima Satria, S.H., M.Kn., Notary in Jakarta, concerning the increase in issued and paid-up capital from public to 27,058,850,000 shares or with a total nominal value of Rp 676,471,250,000.

Based on Notarial deed No. 77 dated April 7, 2022 made before Jose Dima Satria, S.H., M.Kn., Notary in Jakarta, concerning:

- The stock split of the nominal value of the shares from the original Rp 50 par value per share to Rp 25 par value per share so that the authorized shares of the Company will be 60,000,000,000 shares from 30,000,000,000 shares, which are both equivalent to Rp 1,500,000,000,000.
- The increase in the authorized capital of the Company from Rp 1,500,000,000,000 consisting of

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

dari 60.000.000.000 saham menjadi  
Rp 2.300.000.000.000 yang terdiri dari  
92.000.000.000 saham.

60,000,000,000 shares to Rp 2,300,000,000,000  
consisting of 92,000,000,000 shares.

Akta Notaris tersebut telah diberitahukan dan diterima oleh Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dengan Surat Keputusan No. AHU-0070244.AH.01.11.TAHUN 2022 tanggal 8 April 2022.

The Notarial deed have been notified and accepted by the Minister of Law and Human Rights of the Republic of Indonesia by its Decision Letter No. AHU-0070244.AH.01.11.TAHUN 2022 dated April 8, 2022.

Berdasarkan akta Notaris No. 87 tanggal 30 September 2021 yang dibuat dihadapan Julia Seloadji, S.H., Notaris di Surabaya, tentang penambahan modal saham dan disetor penuh dari Rp 375.000.000.000 menjadi Rp 575.000.000.000 dan dengan jumlah saham dari 7.500.000.000 menjadi 11.500.000.000, dimana terjadi peningkatan modal ditempatkan/disetor atau timbul sebagai akibat dari pembagian dividen saham yang dialihkan oleh Perusahaan kepada pemegang saham. Akta Notaris tersebut telah diberitahukan dan diterima oleh Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dengan Surat Keputusan No. AHU-0187117.AH.01.11.TAHUN 2021 tanggal 27 Oktober 2021 dan telah diumumkan dalam Berita Negara No. 004 Tambahan No. 001522 tanggal 14 Januari 2022.

Based on Notarial deed No. 87 dated September 30, 2021 drawn up before Julia Seloadji, S.H., Notary in Surabaya, concerning the increase of share capital and fully paid from Rp 375,000,000,000 to Rp 575,000,000,000 and with the number of shares from 7,500,000,000 to 11,500,000,000, where the increase in issued/paid-up capital occurs or arises as a result of the distribution of share dividends transferred by the Company to shareholders. The Notarial deed have been notified and accepted by the Minister of Law and Human Rights of the Republic of Indonesia by its Decision Letter No. AHU-0187117.AH.01.11.TAHUN 2021 dated 27 October 2021 and was published in the State Gazette No. 004 Supplement No. 001522 dated January 14, 2022.

Berdasarkan akta Notaris No. 28 tanggal 29 Juni 2021 yang dibuat dihadapan Julia Seloadji, S.H., Notaris di Surabaya, tentang penambahan modal saham dan disetor penuh dari Rp 4.500.000.000 menjadi Rp 375.000.000.000 dan dengan jumlah saham dari 9.000 menjadi 7.500.000.000, dimana terjadi peningkatan modal ditempatkan/disetor atau timbul sebagai akibat dari pembagian dividen saham yang dialihkan oleh Perusahaan kepada pemegang saham. Akta Notaris tersebut telah diberitahukan dan diterima oleh Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dengan Surat Keputusan No. AHU-0123394.AH.01.11.TAHUN 2021 tanggal 15 Juli 2021. dan telah diumumkan dalam Berita Negara No. 004 Tambahan No. 001523 tanggal 14 Januari 2022.

Based on Notarial deed No. 28 dated 29 June 2021 drawn up before Julia Seloadji, S.H., Notary in Surabaya, concerning the increase of share capital and fully paid from Rp 4,500,000,000 to Rp 375,000,000,000 and with the number of shares from 9,000 to 7,500,000,000, where the increase in issued/paid-up capital occurs or arises as a result of the distribution of share dividends transferred by the Company to shareholders. The Notarial deed have been notified and accepted by the Minister of Law and Human Rights of the Republic of Indonesia by its Decision Letter No. AHU-0123394.AH.01.11.TAHUN 2021 dated 15 July 2021 and was published in the State Gazette No. 004 Supplement No. 001523 dated January 14, 2022.

Susunan kepemilikan saham pemegang saham Perusahaan masing-masing berdasarkan pencatatan yang dilakukan oleh biro administrasi efek yaitu PT Datindo Entrycom pada tanggal 30 Juni 2025 dan 31 Desember 2024 adalah sebagai berikut:

The composition of the Company's shareholders based on the record of the securities agency namely PT Datindo Entrycom as of June 30, 2025 and December 31, 2024 are as follows:

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

| <b>30 Juni/June 2025</b>                       |                                                                                                              |                                                                   |                            |                                      |
|------------------------------------------------|--------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|----------------------------|--------------------------------------|
| <b><u>Pemegang saham</u></b>                   | <b>Jumlah saham ditempatkan dan disetor penuh/<br/><i>Number of shares capital issued and fully paid</i></b> | <b>Persentase kepemilikan/<br/><i>Percentage of ownership</i></b> | <b><u>Jumlah/Total</u></b> | <b><u>Shareholders</u></b>           |
| PT Intisumber Hasil Sempurna                   | 22.540.000.000                                                                                               | 83,33%                                                            | 563.500.000.000            | PT Intisumber Hasil Sempurna         |
| Yacobus Jemmy Hartanto                         | 251.290.500                                                                                                  | 0,93%                                                             | 6.282.262.500              | Yacobus Jemmy Hartanto               |
| Siane Soetanto                                 | 242.708.000                                                                                                  | 0,90%                                                             | 6.067.700.000              | Siane Soetanto                       |
| Leonard Hariadi Hartanto (Direktur)            | 134.200                                                                                                      | 0,00%                                                             | 3.355.000                  | Leonard Hariadi Hartanto (Director)  |
| Publik (masing-masing kepemilikan di bawah 5%) | 4.014.183.300                                                                                                | 14,84%                                                            | 100.354.582.500            | Public (each ownership less than 5%) |
| <b>Jumlah</b>                                  | <b>27.048.316.000</b>                                                                                        | <b>100,00%</b>                                                    | <b>676.207.900.000</b>     | <b>Total</b>                         |
| Saham treasuri                                 | 10.534.000                                                                                                   |                                                                   | 263.350.000                | Treasury shares                      |
| <b>Jumlah</b>                                  | <b>27.058.850.000</b>                                                                                        | <b>100,00%</b>                                                    | <b>676.471.250.000</b>     | <b>Total</b>                         |

| <b>31 Desember/December 2024</b>               |                                                                                                              |                                                                   |                            |                                      |
|------------------------------------------------|--------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|----------------------------|--------------------------------------|
| <b><u>Pemegang saham</u></b>                   | <b>Jumlah saham ditempatkan dan disetor penuh/<br/><i>Number of shares capital issued and fully paid</i></b> | <b>Persentase kepemilikan/<br/><i>Percentage of ownership</i></b> | <b><u>Jumlah/Total</u></b> | <b><u>Shareholders</u></b>           |
| PT Intisumber Hasil Sempurna                   | 22.540.000.000                                                                                               | 83,30%                                                            | 563.500.000.000            | PT Intisumber Hasil Sempurna         |
| Yacobus Jemmy Hartanto                         | 242.108.800                                                                                                  | 0,89%                                                             | 6.052.720.000              | Yacobus Jemmy Hartanto               |
| Siane Soetanto                                 | 241.215.000                                                                                                  | 0,89%                                                             | 6.030.375.000              | Siane Soetanto                       |
| Publik (masing-masing kepemilikan di bawah 5%) | 4.035.526.200                                                                                                | 14,92%                                                            | 100.888.155.000            | Public (each ownership less than 5%) |
| <b>Jumlah</b>                                  | <b>27.058.850.000</b>                                                                                        | <b>100,00%</b>                                                    | <b>676.471.250.000</b>     | <b>Total</b>                         |

Menurut Undang-Undang Perseroan Terbatas No. 40 Tahun 2007, Perusahaan diharuskan untuk membuat penyisihan cadangan wajib sekurang-kurangnya 20% dari modal Perusahaan yang ditempatkan dan disetor. Pada tanggal 30 Maret 2022, Perusahaan menyetujui untuk menggunakan laba atas tahun buku 2021 sebesar Rp 120.000.000.000 sebagai dana cadangan yang paling sedikit 20% dari modal ditempatkan dan disetor Perseroan.

According to Limited Perseroan Law No. 40 Year 2007, the Company is required to make provision for mandatory reserves of at least 20% of the Company's issued and paid-up capital. On March 30, 2022, the Company approved to utilize the net profit for the 2021 financial year in the amount of Rp 120,000,000,000 as a fund reserve which is at least 20% of the Company's issued and paid-up capital.

**Saham treasuri**

Perusahaan telah melakukan pembelian kembali 10.534.000 lembar saham biasa Perusahaan melalui pembelian pada BEI dari tanggal 20 Mei 2025 sampai 30 Juni 2025. Jumlah pembayaran untuk mengakuisisi saham tersebut adalah Rp 1.842.632.147. Saham tersebut dicatat pada "saham treasuri".

**Treasury shares**

The Company repurchases 10,534,000 of its own ordinary shares through purchases on the IDX during May 20, 2025 to June 30, 2025. The total amount paid to acquire the shares was Rp 1,842,632,147. The shares are held as "treasury shares".

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**27. DIVIDEN**

**2025**

Berdasarkan akta notaris No. 17 tanggal 26 Juni 2025 yang dibuat di hadapan Dr. Susanti, S.H., M.Kn. notaris di Surabaya, Perusahaan membagikan dividen tunai kepada para pemegang saham sebesar Rp 3,57 per saham atau setara dengan Rp 96.600.094.500. Perusahaan akan membayar dividen tersebut pada tanggal 25 Juli 2025.

Berdasarkan akta notaris no.21 tanggal 24 Juni 2025, PT Intisumber Hasil Sempurna Global mengumumkan pembagian dividen tunai sebesar Rp400.000.000.000. Dalam laporan keuangan konsolidasian, sebesar Rp4.000.000.000 dari dividen yang diumumkan tersebut merupakan bagian kepentingan non-pengendali dan diakui sebagai hutang deviden pada tanggal 30 Juni 2025.

**2024**

Berdasarkan akta notaris No. 3 tanggal 7 Juni 2024 yang dibuat di hadapan Dr. Susanti, S.H., M.Kn. notaris di Surabaya, Perusahaan membagikan dividen tunai kepada para pemegang saham sebesar Rp 2,88 per saham atau setara dengan Rp 77.929.488.000. Perusahaan telah membayar dividen tersebut pada tanggal 10 Juli 2024.

**28. TAMBAHAN MODAL DISETOR**

Rincian tambahan modal disetor pada 30 Juni 2025 dan 31 Desember 2024 adalah sebagai berikut:

|                                                                                                                                              | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |
|----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|-------------------------------------------|
| Selisih nilai yang timbul dari restrukturisasi antara entitas sepengendali                                                                   | ( 456.717.535.402 )               | ( 456.717.535.402 )                       |
| Selisih lebih harga penawaran umum saham terbatas dengan nilai nominal saham – setelah dikurangi biaya emisi saham sebesar Rp 47.426.616.345 | 679.107.533.656                   | 679.107.533.656                           |
| Pengampunan pajak                                                                                                                            | 798.270.946                       | 798.270.946                               |
| Jumlah                                                                                                                                       | <u>223.188.269.200</u>            | <u>223.188.269.200</u>                    |

**Pengampunan pajak**

Terkait dengan UU.11 Tahun 2016 tentang pengampunan pajak, Perusahaan mengajukan permohonan pengampunan pajak dengan tanda terima No. 6400000016 dari Kantor Pelayanan Pajak tanggal 19 Agustus 2016.

Perusahaan sudah menerima surat keterangan pengampunan pajak dengan No. KET-235/PP/WPJ.24/2016. Aset yang di deklarasi oleh Perusahaan adalah kas sebesar Rp 798.270.946.

**27. DIVIDEND**

**2025**

Based on Notarial deed No. 17 dated June 26, 2025 drawn up before Dr. Susanti, S.H., M.Kn. notary in Surabaya, the Company paid the cash dividend to shareholders amounting to Rp 3.57 per shares or equivalent to Rp 96,600,094,500. The company will pay the dividend on July 25, 2025.

Based on Notarial deed no. 21 on June 24, 2025, PT Intisumber Hasil Sempurna Global declared cash dividends amounting to Rp 400,000,000,000. In the consolidated financial statements, Rp 4,000,000,000 of the declared dividends is attributable to non-controlling interests and is recognized as a dividend payable as of June 30, 2025.

**2024**

Based on Notarial deed No. 3 dated 3 June 2024 drawn up before Dr. Susanti, S.H., M.Kn. notary in Surabaya, the Company paid the cash dividend to shareholders amounting to Rp 2.88 per shares or equivalent to Rp 77,929,488,000. The company has paid the dividend on July 10, 2024.

**28. ADDITIONAL PAID-IN CAPITAL**

The details of additional paid-in capital as of June 30, 2025 and December 31, 2024 were as follows:

Difference in value arising from restructuring among entities under common control  
Excess of initial public offering share price over par value - net of share issuance costs amounting to  
Rp 47,426,616,345  
Tax amnesty

Total

**Tax amnesty**

In relation to Act.11 of year 2016 regarding tax amnesty, the Company submitted an application for tax amnesty with receipt No. 6400000016 from the Tax Service Office dated August 19, 2016.

The Company received a tax amnesty letter with No. KET-235/PP/WPJ.24/2016. Assets declared by the Company are cash of Rp 798,270,946.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**Selisih nilai yang timbul dari restrukturisasi antara entitas sepengendali**

**Bisnis Distribusi**

Pada tanggal 8 Januari 2019, PT Jayamas Medica Industri Tbk ("JMI"), Perusahaan Induk menjadi pemegang saham mayoritas PT Intisumber Hasil Sempurna ("IHS"). Pada 28 November 2019 Perusahaan didirikan untuk menangani usaha distribusi JMI dan Entitas Anak. IHS, JMI dan Perusahaan pada akhirnya dikendalikan oleh Bapak Yacobus Jemmy Hartanto dan Ibu Siane Soetanto (pasangan suami istri). Liabilitas bersih sebesar Rp 20.403.707.398 dikompensasikan dengan nilai transfer sebesar nihil yang mengakibatkan tambahan modal disetor Rp 20.403.707.398. Sebagai bagian dari IHS, bisnis distribusi bergantung pada IHS untuk semua modal kerja dan pembiayaan operasinya. Transaksi keuangan yang berkaitan dengan bisnis distribusi tercermin dalam laporan perubahan ekuitas konsolidasi terlampir sebagai "Penyesuaian dalam rangka restrukturisasi entitas sepengendali" dalam tambahan modal disetor.

**IMR**

Berdasarkan akta No. 21 tanggal 26 Juni 2023, Notaris Dr. Susanti, S.H., M.Kn., PT Intisumber Hasil Sempurna Global melakukan penyertaan modal tambahan sebesar Rp 489.000.000 untuk modal saham dan Rp 41.520.980.220 sebagai agio saham untuk secara efektif mengakuisisi 75% kepemilikan atas Perusahaan. Akta tersebut telah mendapat pengesahan dari Menteri Kehakiman Republik Indonesia dengan Surat Keputusan No. AHU.01.03-0083573 Tahun 2023 tanggal 26 Juni 2023.

Pada 29 Oktober 2021, IHSG menginvestasikan Rp 24.485.204.082 untuk mengakuisisi 51% kepemilikan saham atau mewakili 261 saham IMR. IMR secara mayoritas dimiliki oleh Yacobus Jemmy Hartanto dan Siane Soetanto, yang merupakan individu pengendali utama IHSG. Oleh karena itu, terdapat pengendalian bersama antara IHSG dan IMR, dan oleh karena itu, akuisisi tersebut dicatat dengan kombinasi bisnis entitas sepengendali. Aset bersih sebesar Rp 24.735.204.082 dikompensasikan dengan jumlah total investasi sebesar Rp 24.485.204.082 dan kepentingan nonpengendali sebesar Rp 12.101.371.860 yang mengakibatkan tambahan modal disetor sebesar Rp 11.851.371.860.

**Difference in value arising from restructuring among of entities under common control**

**Distribution Business**

On January 8, 2019, PT Jayamas Medica Industri Tbk ("JMI"), Parent Company, become the majority shareholder of PT Intisumber Hasil Sempurna ("IHS"). On November 28, 2019, the Company was established to handle the distribution business JMI and its Subsidiary. IHS, JMI and the Company were ultimately controlled by Mr. Yacobus Jemmy Hartanto and Mrs. Siane Soetanto (married couples). The net liability totalling toRp 20,403,707,398 was offset against the transfer consideration amount of nil which resulting in additional paid-in capital of Rp 20,403,707,398. As part of the IHS, the distribution business is dependent upon IHS for all of its working capital and financing of its operations. Financial transactions relating to the distribution business are reflected in the accompanying consolidated statement of changes in equity as "Adjustment in relation to restructuring among entities under common control" within additional paid-in capital.

**IMR**

According to Deed No. 21 dated June 26, 2023, by Notary Dr. Susanti, S.H., M.Kn., PT Intisumber Hasil Sempurna Global invested Rp 489,000,000 for the par value of share capital and Rp 41,520,980,220 as share premium to effectively acquire 75% ownership of the Company. The Deed of Establishment was approved by the Minister of Justice of the Republic of Indonesia in its Decision Letter No. AHU.01.03-0083573 Year 2023 dated June 26, 2023.

On October 29, 2021, IHSG invested Rp 24,485,204,082 to acquire 51% share ownership or representing 261 shares of IMR. IMR is majority owned by Yacobus Jemmy Hartanto and Siane Soetanto, which are the ultimate controlling individuals of the IHSG. Hence, common control exists between IHSG and IMR, and accordingly, the acquisition was accounted under business combination of entities under common control. The net assets totalling to Rp 24,735,204,082 was offset against the total investment amounting to Rp 24,485,204,082 and non-controlling interest amounting to Rp 12,101,371,860 which is resulting in an additional paid-in capital Rp 11,851,371,860.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**29. PERPAJAKAN**

**29. TAXATION**

**a. Pajak Dibayar Dimuka**

**a. Prepaid Taxes**

|                            | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                            |
|----------------------------|-----------------------------------|-------------------------------------------|----------------------------|
| <b><u>Perusahaan</u></b>   |                                   |                                           | <b><u>The Company</u></b>  |
| Pajak Pertambahan Nilai    | -                                 | 3.332.312.570                             | Value Added Tax            |
| <b><u>Entitas Anak</u></b> |                                   |                                           | <b><u>Subsidiaries</u></b> |
| Pajak Pertambahan Nilai    | 1.510.900.161                     | 1.361.640.085                             | Value Added Tax            |
| <b>Jumlah</b>              | <b>1.510.900.161</b>              | <b>4.693.952.655</b>                      | <b>Total</b>               |

**b. Utang Pajak**

**b. Taxes Payable**

|                            | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                            |
|----------------------------|-----------------------------------|-------------------------------------------|----------------------------|
| <b><u>Perusahaan</u></b>   |                                   |                                           | <b><u>The Company</u></b>  |
| Pajak penghasilan:         |                                   |                                           | Income tax:                |
| Pasal 4 (2)                | 135.331.304                       | 68.967.652                                | Article 4 (2)              |
| Pasal 21                   | 182.876.393                       | 456.113.900                               | Article 21                 |
| Pasal 23                   | 41.097.010                        | 81.652.105                                | Article 23                 |
| Pasal 26                   | 18.738.741                        | -                                         | Article 26                 |
| Pasal 25                   | 2.185.602.107                     | 2.358.944.333                             | Article 25                 |
| Pasal 29                   |                                   |                                           | Article 29                 |
| - Tahun pajak 2024         |                                   | 8.353.252.820                             | - 2024 Fiscal Year         |
| - Tahun pajak 2025         | 2.034.853.788                     | -                                         | - 2025 Fiscal Year         |
| Pajak Pertambahan Nilai    | 4.289.284.556                     | -                                         | Value Added Tax            |
| <b>Jumlah</b>              | <b>8.887.783.899</b>              | <b>11.318.930.810</b>                     | <b>Total</b>               |
| <b><u>Entitas Anak</u></b> |                                   |                                           | <b><u>Subsidiaries</u></b> |
| Pajak penghasilan:         |                                   |                                           | Income tax:                |
| Pasal 4 (2)                | 3.912.766                         | 58.017.332                                | Article 4 (2)              |
| Pasal 21                   | 433.160.585                       | 1.748.975.954                             | Article 21                 |
| Pasal 23                   | 173.349.570                       | 95.469.068                                | Article 23                 |
| Pasal 25                   | 1.137.116.229                     | -                                         | Article 25                 |
| Pasal 29                   |                                   |                                           | Article 29                 |
| - Tahun pajak 2024         | 2.569.973.683                     | 5.328.106.731                             | - 2024 Fiscal Year         |
| - Tahun pajak 2025         | 6.036.360.867                     | -                                         | - 2025 Fiscal Year         |
| Pajak Pertambahan Nilai    | 213.049.714                       | 144.098.961                               | Value Added Tax            |
| <b>Jumlah</b>              | <b>10.566.923.414</b>             | <b>7.374.668.046</b>                      | <b>Total</b>               |

**c. Beban Pajak Penghasilan**

**c. Income Tax Expenses**

|                         | <b>30 Juni/<br/>June<br/>2025</b> | <b>30 Juni/<br/>June<br/>2024</b> |                     |
|-------------------------|-----------------------------------|-----------------------------------|---------------------|
| Beban pajak penghasilan |                                   |                                   | Income tax expenses |
| Perusahaan              | 18.949.462.400                    | 21.126.232.600                    | Company             |
| Entitas Anak            | 19.557.320.640                    | 16.269.601.260                    | Subsidiaries        |
|                         | <b>38.506.783.040</b>             | <b>37.395.833.860</b>             |                     |

Rekonsiliasi antara laba konsolidasi sebelum pajak penghasilan interim yang disajikan dalam laporan laba rugi dan penghasilan komprehensif lain konsolidasian dengan taksiran laba fiskal interim untuk tahun yang berakhir pada tanggal 30 Juni 2025 dan 2024 adalah sebagai berikut:

A reconciliation between interim consolidated profit before income tax as presented in the consolidated statement of profit or loss and other comprehensive income and the estimated interim fiscal profit for years ended June 30, 2025 and 2024 are as follows:

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

|                                                                                                                  | 30 Juni/<br>June<br>2025 | 30 Juni/<br>June<br>2024 |                                                                                                               |
|------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|---------------------------------------------------------------------------------------------------------------|
| <b>Perusahaan</b>                                                                                                |                          |                          | <b>Company</b>                                                                                                |
| Laba sebelum pajak penghasilan menurut laporan laba rugi dan penghasilan komprehensif lain konsolidasian interim | 193.228.042.163          | 182.275.791.425          | Interim profit before income tax per consolidated statements of profit or loss and other comprehensive income |
| Laba Entitas Anak sebelum beban (manfaat) pajak penghasilan                                                      | ( 88.211.469.175)        | ( 69.361.923.302)        | Income of subsidiaries before income tax expense (benefit)                                                    |
| Laba sebelum beban pajak penghasilan - Perusahaan                                                                | 105.016.572.989          | 112.913.868.123          | Income before income tax expense - Company                                                                    |
| <b>Beda temporer:</b>                                                                                            |                          |                          | <b>Temporary differences:</b>                                                                                 |
| Penyisihan imbalan pasca - kerja - Neto                                                                          | 737.690.934              | 832.308.066              | Provision for post-employment benefits - Net                                                                  |
| Amortisasi ROU                                                                                                   | 151.792.621              | 172.021.501              | Amortization of ROU                                                                                           |
| Bunga aset hak guna                                                                                              | 683.708.979              | 793.293.381              | Interest from right-of-use assets                                                                             |
| Penyisihan penurunan persediaan                                                                                  | 1.375.429.749            | -                        | Allowance for inventories                                                                                     |
| Cicilan liabilitas sewa                                                                                          | 2.306.219                | -                        | Installment of Lease Liabilities                                                                              |
|                                                                                                                  | 2.950.928.502            | 1.625.601.447            |                                                                                                               |
| <b>Beda tetap:</b>                                                                                               |                          |                          | <b>Permanent differences:</b>                                                                                 |
| Pajak                                                                                                            | 70.109                   | 1.206.059.567            | Tax                                                                                                           |
| Sumbangan                                                                                                        | 27.036.720               | 23.704.300               | Donation                                                                                                      |
| Beban / (Pendapatan) lain-lain                                                                                   | ( 2.405.604.026)         | 40.058.899               | Other expense / (income)                                                                                      |
| Penghasilan bunga                                                                                                | ( 19.701.866.601)        | ( 20.129.229.799)        | Interest income                                                                                               |
| Entertainment                                                                                                    | -                        | 41.420.592               | Entertainment                                                                                                 |
| Penghapusan Aset Tetap                                                                                           | 246.782.542              | 134.826.235              | Loss on disposal of fixed assets                                                                              |
| Sub-jumlah                                                                                                       | ( 21.883.581.256)        | ( 18.511.138.705)        | Sub-total                                                                                                     |
|                                                                                                                  | ( 18.882.652.754)        | ( 16.885.537.258)        |                                                                                                               |
| <b>Taksiran laba kena pajak Perusahaan (dibulatkan)</b>                                                          | <b>86.133.920.000</b>    | <b>96.028.330.000</b>    | <b>Estimated taxable income – Current year (rounded)</b>                                                      |

Rekonsiliasi antara laba sebelum pajak penghasilan yang disajikan dalam laporan laba rugi dan penghasilan komprehensif lain konsolidasian dengan taksiran laba fiskal untuk tahun yang berakhir pada tanggal 30 Juni 2025 dan 2024 adalah sebagai berikut:

A reconciliation between profit before income tax as presented in the consolidated statement of profit or loss and other comprehensive income and the estimated fiscal profit for years ended June 30, 2025 and 2024 are as follows:

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

|                                                  | <b>30 Juni/<br/>June<br/>2025</b> | <b>30 Juni/<br/>June<br/>2024</b> |                                             |
|--------------------------------------------------|-----------------------------------|-----------------------------------|---------------------------------------------|
| Beban pajak penghasilan                          |                                   |                                   | Income tax expenses                         |
| Perusahaan                                       | 18.949.462.400                    | 21.126.232.600                    | Company                                     |
| Entitas Anak                                     | 19.557.320.640                    | 16.269.601.260                    | Subsidiaries                                |
|                                                  | <u>38.506.783.040</u>             | <u>37.395.833.860</u>             |                                             |
| Dikurangi pajak penghasilan dibayar dimuka:      |                                   |                                   | Less prepaid of income taxes:               |
| <b><u>Perusahaan</u></b>                         |                                   |                                   | <b><u>Company</u></b>                       |
| Pasal 22                                         | 3.280.763.998                     | 3.783.238.927                     | Article 22                                  |
| Pasal 23                                         | 205.294                           | 292.790                           | Article 23                                  |
| Pasal 25                                         | 13.633.639.320                    | 5.515.581.111                     | Article 25                                  |
| Sub-jumlah                                       | 16.914.608.612                    | 9.299.112.828                     | Sub-total                                   |
| <b><u>Entitas Anak</u></b>                       | <u>14.064.822.930</u>             | <u>13.953.725.624</u>             | <b><u>Subsidiaries</u></b>                  |
| <b>Jumlah</b>                                    | <u>30.979.431.542</u>             | <u>23.252.838.452</u>             | <b>Total</b>                                |
| Taksiran utang pajak penghasilan Pasal 29        |                                   |                                   | Estimated income tax payable-Article 29     |
| Perusahaan                                       | 2.034.853.788                     | -                                 | Company                                     |
| Entitas Anak                                     | 8.606.334.550                     | -                                 | Subsidiaries                                |
| <b>Jumlah</b>                                    | <u>10.641.188.338</u>             | <u>-</u>                          | <b>Total</b>                                |
| Taksiran Lebih bayar pajak penghasilan Pasal 28a |                                   |                                   | Estimated claim for tax refunds-Article 28a |
| Perusahaan                                       | -                                 | ( 11.827.119.772)                 | Company                                     |
| Entitas Anak                                     | ( 1.402.088.533)                  | ( 2.315.875.636)                  | Subsidiaries                                |
| <b>Jumlah</b>                                    | <u>( 1.402.088.533)</u>           | <u>( 14.142.995.408)</u>          | <b>Total</b>                                |

Dalam laporan keuangan konsolidasian interim ini, jumlah penghasilan kena pajak didasarkan atas perhitungan sementara, karena Perusahaan belum menyampaikan Surat Pemberitahuan Tahunan pajak penghasilan badan pada saat penyelesaian laporan keuangan konsolidasian interim. Oleh karena itu jumlah tersebut mungkin berbeda dari jumlah yang dilaporkan dalam SPT Pajak Penghasilan Badan.

In these interim consolidated financial statements, the amount of taxable income is based on preliminary calculations, as the Company has not yet submitted its corporate income tax when these interim consolidated financial statements were authorized. As a result, these amounts may differ from those reported in the corporate income tax returns.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**d. Aset Pajak Tangguhan**

|                                               | 1 Januari/<br>January<br>2025 | Dibebankan<br>ke laporan<br>laba rugi<br>komprehensif/<br>Charged to<br>statements of<br>comprehensive<br>income | Dibebankan<br>ke laporan<br>laba rugi/<br>Charged to<br>profit or loss | 30 Juni/<br>June 2025    |
|-----------------------------------------------|-------------------------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|--------------------------|
| <b>Perusahaan</b>                             |                               |                                                                                                                  |                                                                        |                          |
| <b>Kewajiban pajak tangguhan</b>              |                               |                                                                                                                  |                                                                        |                          |
| Liabilitas imbalan<br>pasca-kerja             | -                             | -                                                                                                                | 73.688.382                                                             | 73.668.382               |
| Liabilitas sewa                               | ( 1.858.127.265 )             | -                                                                                                                | 183.810.352                                                            | ( 1.674.316.913 )        |
| Penyisihan penurunan<br>nilai persediaan      | 133.273.245                   | -                                                                                                                | 302.594.545                                                            | 435.867.790              |
| <b>Sub-total</b>                              | <b>( 1.724.854.020 )</b>      |                                                                                                                  | <b>560.093.279</b>                                                     | <b>( 1.164.760.741 )</b> |
| <b>Anak Perusahaan</b>                        |                               |                                                                                                                  |                                                                        |                          |
| Aset pajak tangguhan                          | 5.494.170.209                 | -                                                                                                                | ( 618.000.611 )                                                        | 4.876.169.598            |
| Kewajiban pajak tangguhan                     | ( 247.568.616 )               | -                                                                                                                | 16.666.249                                                             | ( 230.902.368 )          |
| <b>Jumlah aset pajak tangguhan</b>            | <b>5.494.170.209</b>          | <b>-</b>                                                                                                         | <b>( 618.000.611 )</b>                                                 | <b>4.876.169.598</b>     |
| <b>Jumlah (kewajiban)<br/>pajak tangguhan</b> | <b>( 1.972.422.636 )</b>      | <b>-</b>                                                                                                         | <b>576.739.528</b>                                                     | <b>( 1.395.663.108 )</b> |

|                                         |
|-----------------------------------------|
| <b>The Company</b>                      |
| <b>Deferred tax liabilities</b>         |
| Employee benefits liabilities           |
| Lease liabilities                       |
| Allowance for Impairment of inventories |
| <b>Sub-Total</b>                        |
| <b>Subsidiaries</b>                     |
| Deferred tax assets                     |
| Deferred tax liabilities                |
| <b>Total deferred tax assets</b>        |
| <b>Total deferred tax (liabilities)</b> |

|                                               | 1 Januari/<br>January<br>2024 | (Dibebankan)<br>dikreditkan<br>ke laporan<br>laba rugi<br>komprehensif/<br>(Charged)<br>credited to<br>statements of<br>comprehensive<br>income | Dibebankan<br>ke laporan<br>laba rugi/<br>Charged to<br>profit or loss | 31 Desember/<br>December 2024 |
|-----------------------------------------------|-------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------------|
| <b>Perusahaan</b>                             |                               |                                                                                                                                                 |                                                                        |                               |
| <b>Kewajiban pajak tangguhan</b>              |                               |                                                                                                                                                 |                                                                        |                               |
| Liabilitas imbalan<br>pasca-kerja             | -                             | 205.902.669                                                                                                                                     | ( 205.902.669 )                                                        | -                             |
| Liabilitas sewa                               | ( 2.091.814.376 )             | 233.687.111                                                                                                                                     | -                                                                      | ( 1.858.127.265 )             |
| Penyisihan penurunan<br>nilai persediaan      | -                             | 133.273.245                                                                                                                                     | -                                                                      | -                             |
| <b>Sub-total</b>                              | <b>( 2.091.814.376 )</b>      | <b>572.863.025</b>                                                                                                                              | <b>( 205.902.669 )</b>                                                 | <b>( 1.724.854.020 )</b>      |
| <b>Anak Perusahaan</b>                        |                               |                                                                                                                                                 |                                                                        |                               |
| Aset pajak tangguhan                          | 6.714.764.384                 | ( 1.605.800.634 )                                                                                                                               | 385.206.459                                                            | 5.494.170.209                 |
| Kewajiban pajak tangguhan                     | ( 148.808.238 )               | ( 100.546.224 )                                                                                                                                 | 1.785.846                                                              | ( 247.568.616 )               |
| <b>Jumlah aset pajak tangguhan</b>            | <b>6.714.764.384</b>          | <b>( 1.605.800.634 )</b>                                                                                                                        | <b>385.206.459</b>                                                     | <b>5.494.170.209</b>          |
| <b>Jumlah (kewajiban)<br/>pajak tangguhan</b> | <b>( 2.240.622.614 )</b>      | <b>472.316.801</b>                                                                                                                              | <b>( 204.116.823 )</b>                                                 | <b>( 1.972.422.636 )</b>      |

|                                         |
|-----------------------------------------|
| <b>The Company</b>                      |
| <b>Deferred tax liabilities</b>         |
| Employee benefits liabilities           |
| Lease liabilities                       |
| Allowance for Impairment of inventories |
| <b>Sub-Total</b>                        |
| <b>Subsidiaries</b>                     |
| Deferred tax assets                     |
| Deferred tax liabilities                |
| <b>Total deferred tax assets</b>        |
| <b>Total deferred tax (liabilities)</b> |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**e. Tagihan Restitusi Pajak**

Rincian tagihan restitusi pajak adalah sebagai berikut:

|                        | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                             |
|------------------------|-----------------------------------|-------------------------------------------|-----------------------------|
| Entitas Anak           | <u>1.402.088.533</u>              | <u>9.020.972.973</u>                      | Subsidiaries                |
|                        | <u>1.402.088.533</u>              | <u>9.020.972.973</u>                      |                             |
|                        | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |                             |
| Belum/sedang diperiksa |                                   |                                           | Not yet audited/in progress |
| 2025                   | 543.863.157                       | -                                         | 2025                        |
| 2024                   | 858.225.376                       | 858.225.376                               | 2024                        |
| 2023                   | -                                 | 8.162.747.597                             | 2023                        |
| <b>Jumlah</b>          | <u>1.402.088.533</u>              | <u>9.020.972.973</u>                      | <b>Total</b>                |

Atas surat ketetapan pajak di atas, manajemen masih belum memperoleh keputusan dari DJP ataupun dari Pengadilan Pajak sampai dengan tanggal laporan keuangan konsolidasian ini.

**e. Claim For Tax Refund**

The details of claim for tax refunds are as follows:

Regarding the tax assessments above, management has not received any decision from the DGT or from the Tax Court up to the date of these consolidated financial statements.

**f. Hasil Pemeriksaan Pajak**

**Perusahaan**

Tanggal 23 April 2024, Perusahaan menerima surat Perintah Membayar Kelebihan Pajak dengan nomor 00340A terkait Pajak Penghasilan (PPh) Pasal 25/29 Badan tahun 2022 sebesar Rp. 26.996.348.956 dimana Perusahaan menerima pengembalian sebesar Rp.26.573.298.636 pada tanggal 25 April 2024. Atas sisa pengembalian PPh Badan yang tidak tertagih sebesar Rp. 423.050.320 dibebankan pada tahun 2024 sebagai bagian dari "beban pajak" pada biaya lain-lain pada laporan laba rugi dan penghasilan komprehensif lain konsolidasian.

Perusahaan menerima Surat Ketetapan Pajak Kurang Bayar tanggal 27 Maret 2024 atas Pajak Pertambahan Nilai (PPN), Pajak Penghasilan (PPh) Pasal 4 ayat 2, PPh pasal 23, PPh pasal 21 dengan jumlah total sebesar Rp. 765.354.220 sebagai bagian dari "beban pajak" pada biaya lain-lain pada laporan laba rugi dan penghasilan komprehensif lain konsolidasian dan Surat Tagihan Pajak atas PPN tanggal 27 Maret 2024 sebesar Rp. 17.638.027. Perusahaan telah membayar seluruh STP dan SKPKB pada tanggal 25 April 2024.

**f. Result of Tax Examination**

**Company**

On 23 April 2024, The Company received Tax Excess Payment Order No. 00340A related to Income Tax Art.25/29 for the period 2022 amounting to Rp 26,996,348,956, of which The company received a refund of Rp. 26,573,298,636 on April 25, 2024. The remaining uncollected Income Tax Art.25/29 amounting to Rp. 423,050,320 is charged as part of "Tax Expense" under other expenses in the consolidated statement of profit or loss and other comprehensive income

The Company received Tax Underpayment Decision Letter ("SKPKB") dated 27 March 2024 of Value Added Tax (VAT), Withholding Tax Art 4 section 2, Withholding Tax art 23, Withholding Tax Art 21 amounting Rp. 765,354,220 as part of "Tax Expense" under other expenses in the consolidated statement of profit or loss and other comprehensive income and a Tax Collection Letter (STP) of VAT dated on 27 March 2024 amounting Rp. 17,638,027. The company has made payment for the entire STP and SKPKB on 25 April 2024.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**PT Intisumber Hasil Sempurna Global**

Pada tanggal 25 Maret 2025, Perusahaan menerima Surat Keputusan Pengembalian Kelebihan Pajak (SKPKP) untuk Pajak Penghasilan (PPH) 25/29 periode 2023 dengan No. KEP-00028/KP-CT/KPP.1111/2025. Berdasarkan surat tersebut menetapkan bahwa Perusahaan akan menerima pengembalian atas kelebihan pembayaran pajak sebesar Rp 5.049.282.481 dan telah diterima oleh Perusahaan melalui Bank HSBC pada tanggal 14 April 2025.

Pada tanggal 25 Maret 2025, Perusahaan menerima Surat Keputusan Pengembalian Kelebihan Pembayaran Pajak (SKPKPP) untuk Pajak Pertambahan Nilai (PPN) periode 2023 dengan No. KEP-00030/KP-CT/KPP.1111/2025. Berdasarkan surat tersebut menetapkan bahwa Perusahaan akan menerima pengembalian atas kelebihan pembayaran pajak sebesar Rp 2.144.913.248 dan telah diterima oleh Perusahaan melalui Bank HSBC pada tanggal 9 April 2025.

Perusahaan menerima Surat Ketetapan Pajak Penghasilan 23 No. 00017/203/23/631/25 pada tanggal 12 Maret 2025 untuk masa pajak tahun 2023 sebesar Rp 100.195.580. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 28.054.762 dan telah dibayarkan tanggal 9 April 2025.

Pada tanggal 6 Juni 2024, Perusahaan menerima Surat Keputusan Pengembalian Pendahuluan Kelebihan Pajak (SKPPKP) untuk Pajak Pertambahan Nilai (PPN) periode 2022 dengan No. KEP-00131/PPN/KPP.1111/2024. Berdasarkan surat tersebut menetapkan bahwa Perusahaan akan menerima pengembalian atas kelebihan pembayaran pajak sebesar Rp 6.750.420.662 dan telah diterima oleh Perusahaan melalui Bank HSBC pada tanggal 8 Juni 2024.

Pada tanggal 6 Juni 2024, Perusahaan menerima Surat Keputusan Pengembalian Pendahuluan Kelebihan Pajak (SKPPKP) untuk Pajak Penghasilan (PPH) 25/29 periode 2022 dengan No. KEP-00069/PPNH/KPP.1111/2024. Berdasarkan surat tersebut menetapkan bahwa Perusahaan akan menerima pengembalian atas kelebihan pembayaran pajak sebesar Rp 29.906.994.348 dan telah diterima oleh Perusahaan melalui Bank HSBC pada tanggal 8 Juni 2024.

Berdasarkan berita acara permintaan penjelasan atas data dan/atau keterangan

**PT Intisumber Hasil Sempurna Global**

On March 25, 2025, the Company received a Decree of Preliminary Refund of Excess Tax (SKPKP) Corporate Income Tax Art. 25/29 period 2023 with No. KEP-00028/KP-CT/KPP.1111/2025.. Based on the letter, it was determined that Company will receive a refund of tax overpayment amounting to Rp 5,049,282,481 and has been received by the Company through HSBC Bank dated on April 14, 2025.

On March 25, 2025, the Company received a Decision Letter on Refund of Excess Tax (SKPKPP) for Value Added Tax (VAT) for the period of 2023 with No. KEP-00030/KP-CT/KPP.1111/2025. Based on the letter, it is determined that the Company will receive a refund of tax overpayment amounting to Rp 2,144,913,248 and has been received by the Company through HSBC Bank dated on April 9, 2025.

The Company received Income Tax Art 23 Assessment Letter No. 00017/203/23/631/25 on March 12, 2025 for the 2023 tax period in the amount of Rp 100,195,580. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 28,054,762 and has been paid on April 9, 2025.

On June 6, 2024, the Company received a Decision Letter on Preliminary Refund of Excess Tax (SKPPKP) for Value Added Tax (VAT) for the period of 2022 with No. KEP-00131/PPN/KPP.1111/2024. Based on the letter, it is determined that the Company will receive a refund of tax overpayment amounting to Rp 6,750,420,662 and has been received by the Company through HSBC Bank dated on June 8, 2024.

On June 6, 2024, the Company received a Decree of Preliminary Refund of Excess Tax (SKPPKP) Corporate Income Tax period 2022 with No. KEP-00069/PPNH/KPP.1111/2024.. Based on the letter, it was determined that Company will receive a refund of tax overpayment amounting to Rp 29,906,994,348 and has been received by the Company through HSBC Bank dated on June 8, 2024

Adhere to a minutes of request for data clarification and/or explanation, specifically No. BA-

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

No. BA-116/P2DK/KPP.111108/2024 tanggal 25 September 2024, terdapat kurang bayar atas PPh badan, PPh 4(2) dan PPh Pasal 23 masing-masing sebesar Rp 1.688.824.940, Rp 20.833.666 dan Rp 111.512.457. Perusahaan telah setuju dengan hasil pemeriksaan dan telah dibayarkan pada tanggal 27 September 2024.

Perusahaan menerima Surat Tagihan Pajak Penghasilan Final 4(2) No. 00014/140/21/631/24 pada tanggal 8 Oktober 2024 untuk masa pajak tahun 2021 sebesar Rp 4.700.075 dan telah dibayarkan tanggal 4 November 2024.

Perusahaan menerima Surat Tagihan Pajak Penghasilan 23 No. 00072/103/21/631/24 pada tanggal 8 Oktober 2024 untuk masa pajak tahun 2021 sebesar Rp 25.157.210 dan telah dibayarkan tanggal 4 November 2024.

Perusahaan menerima Surat Tagihan Pajak Penghasilan No. 00141/106/21/631/24 pada tanggal 11 Oktober 2024 untuk masa pajak tahun 2021 sebesar Rp 401.264.805 dan telah dibayarkan tanggal 4 November 2024.

Perusahaan menerima Surat Ketetapan Pajak Penghasilan Final 4(2) No. 00030/240/20/631/24 pada tanggal 1 November 2024 untuk masa pajak tahun 2020 sebesar Rp 12.117. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 5.119 dan telah dibayarkan tanggal 25 November 2024.

Perusahaan menerima Surat Ketetapan Pajak Penghasilan 21 No. 00057/207/20/631/24 pada tanggal 1 November 2024 untuk masa pajak tahun 2020 sebesar Rp 615.576.718. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 260.019.606 dan telah dibayarkan tanggal 25 November 2024.

Perusahaan menerima Surat Ketetapan Pajak Penghasilan 21 No. 00073/203/20/631/24 pada tanggal 1 November 2024 untuk masa pajak tahun 2020 sebesar Rp 12.122.845. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 5.207.309 dan telah dibayarkan tanggal 25 November 2024.

Perusahaan menerima Surat Ketetapan Pajak Pertambahan Nilai Barang dan Jasa No. 00158/207/20/631/24 pada tanggal 1 November 2024 untuk masa pajak tahun 2020 sebesar Rp 23.250.625. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 10.155.873 dan telah dibayarkan tanggal 25 November 2024.

Perusahaan menerima Surat Ketetapan Pajak Pertambahan Nilai Barang dan Jasa No. 00159/207/20/631/24 pada tanggal 1 November 2024 untuk masa pajak tahun 2020 sebesar

116/P2DK/KPP.111108/2024 dated September 25, 2024, there was an underpayment of corporate income tax, Tax Art. 4 (2) and Tax Art. 23 with amounting to Rp 1,688,824,940, Rp 20,833,666 and Rp 111,512,457. The company has agreed with the audit result and has been paid on September 27, 2024.

The Company received Final Income Tax Collection Letter 4(2) No. 00014/140/21/631/24 on October 8, 2024 for the tax period of 2021 in the amount of Rp 4,700,075 and has been paid on November 4, 2024.

The Company received Income Tax Collection Letter No. 00072/103/21/631/24 on October 8, 2024 for the 2021 tax period amounting to Rp 25,157,210 and has been paid on November 4, 2024.

The Company received Income Tax Collection Letter No. 00141/106/21/631/24 on October 11, 2024 for the 2021 tax period amounting to Rp 401,264,805 and has been paid on November 4, 2024.

The Company received Final Income Tax Assessment Letter 4(2) No. 00030/240/20/631/24 on November 1, 2024 for the 2020 tax period amounting to Rp 12,117. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 5,119 and has been paid on November 25, 2024.

The Company received Income Tax Assessment Letter No. 00057/207/20/631/24 on November 1, 2024 for the 2020 tax period in the amount of Rp 615,576,718. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 260,019,606 and has been paid on November 25, 2024.

The Company received Income Tax Assessment Letter No. 00073/203/20/631/24 on November 1, 2024 for the 2020 tax period in the amount of Rp 12,122,845. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 5,207,309 and has been paid on November 25, 2024.

The Company received Goods and Services Value Added Tax Assessment Letter No. 00158/207/20/631/24 on November 1, 2024 for the 2020 tax period amounting to Rp 23,250,625. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 10,155,873 and has been paid on November 25, 2024.

The Company received Goods and Services Value Added Tax Assessment Letter No. 00159/207/20/631/24 on November 1, 2024 for the 2020 tax period amounting to Rp 82,166,666.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Rp 82.166.666. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (3) KUP sebesar Rp 82.166.666 dan telah dibayarkan tanggal 25 November 2024.

Perusahaan menerima Surat Ketetapan Pajak Penghasilan 21 No. 00160/207/20/631/24 pada tanggal 1 November 2024 untuk masa pajak tahun 2020 sebesar Rp 4.000.000. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 1.747.200 dan telah dibayarkan tanggal 25 November 2024.

Perusahaan menerima Surat Ketetapan Pajak Penghasilan 21 No. 00161/207/20/631/24 pada tanggal 1 November 2024 untuk masa pajak tahun 2020 sebesar Rp 1.197.150. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 522.916 dan telah dibayarkan tanggal 25 November 2024.

Perusahaan menerima Surat Ketetapan Pajak Penghasilan 21 No. 00162/207/20/631/24 pada tanggal 1 November 2024 untuk masa pajak tahun 2020 sebesar Rp 2.592.384. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (3) huruf c KUP sebesar Rp 2.592.384 dan telah dibayarkan tanggal 25 November 2024.

Perusahaan menerima Surat Ketetapan Pajak Penghasilan 21 No. 00163/207/20/631/24 pada tanggal 1 November 2024 untuk masa pajak tahun 2020 sebesar Rp 57.327. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 25.041 dan telah dibayarkan tanggal 25 November 2024.

Perusahaan menerima Surat Ketetapan Pajak Penghasilan 21 No. 00164/207/20/631/24 pada tanggal 1 November 2024 untuk masa pajak tahun 2020 sebesar Rp 103.623.118. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (3) huruf c KUP sebesar Rp 103.623.118 dan telah dibayarkan tanggal 25 November 2024.

Perusahaan menerima Surat Ketetapan Pajak Pertambahan Nilai Barang dan Jasa No. 00157/207/20/631/24 pada tanggal 1 November 2024 untuk masa pajak tahun 2020 sebesar Rp 37.477.422. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 16.370.138 dan telah dibayarkan tanggal 25 November 2024.

**PT Inti Medicom Retailindo**

Perusahaan menerima Surat Ketetapan Pajak Penghasilan 21 No. 00024/201/23/631/25 pada tanggal 16 April 2025 untuk masa pajak tahun 2023 sebesar Rp 1.900.554. Perusahaan juga dikenakan

Company is also subject to administrative sanction of interest article 13 (3) KUP amounting to Rp 82,166,666 and has been paid on November 25, 2024.

The Company received Income Tax Assessment Letter No. 00160/207/20/631/24 on November 1, 2024 for the 2020 tax period in the amount of Rp 4,000,000. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 1,747,200 and has been paid on November 25, 2024.

The Company received Income Tax Assessment Letter No. 00161/207/20/631/24 on November 1, 2024 for the 2020 tax period in the amount of Rp 1,197,150. Company is also subject to administrative sanction of interest article 13 (2) KUP in the amount of Rp 522,916 and has been paid on November 25, 2024.

The Company received Income Tax Assessment Letter No. 00162/207/20/631/24 on November 1, 2024 for the 2020 tax period in the amount of Rp 2,592,384. Company is also subject to administrative sanction of interest article 13 (3) letter c KUP amounting to Rp 2,592,384 and has been paid on November 25, 2024.

The Company received Income Tax Assessment Letter No. 00163/207/20/631/24 on November 1, 2024 for the 2020 tax period in the amount of Rp 57,327. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 25,041 and has been paid on November 25, 2024.

The Company received Income Tax Assessment Letter No. 00164/207/20/631/24 on November 1, 2024 for the 2020 tax period in the amount of Rp 103,623,118. Company is also subject to administrative sanction of interest article 13 (3) letter c KUP in the amount of Rp 103,623,118 and has been paid on November 25, 2024.

The Company received Goods and Services Value Added Tax Assessment Letter No. 00157/207/20/631/24 on November 1, 2024 for the 2020 tax period amounting to Rp 37,477,422. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 16,370,138 and has been paid on November 25, 2024.

**PT Inti Medicom Retailindo**

The Company received Income Tax Art 21 Assessment Letter No. 00024/201/23/631/25 on April 16, 2025 for the 2023 tax period in the amount of Rp 1,900,554. Company is also subject to administrative sanction of interest article 13 (2)

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 547.360 dan telah dibayarkan tanggal 9 Mei 2025

KUP amounting to Rp 547,360 and has been paid on May 9, 2025.

Perusahaan menerima Surat Ketetapan Pajak Kurang Bayar Pajak Penghasilan Pasal 23 No. 00029/203/23/631/25 pada tanggal 16 April 2025 untuk masa pajak Desember 2023 sebesar Rp 25.320.083. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 7.292.185 dan telah dibayarkan pada tanggal 9 Mei 2025.

The Company received Income Tax Art 23 Underpayment Assessment Letter No. 00029/203/23/631/25 on April 16, 2025 for tax period of December 2023 amounting to Rp 25,320,083. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 7,292,185 and has been paid on May 9, 2025.

Tanggal 7 Mei 2025, Perusahaan menerima surat Perintah Membayar Kelebihan Pajak dengan nomor 00254A terkait Pajak Penghasilan (PPH) Pasal 25/29 Badan tahun 2023 sebesar Rp. 1.659.452.116 dimana Perusahaan menerima pengembalian sebesar Rp.1.592.563.096 pada tanggal 9 Mei 2025. Atas sisa pengembalian PPh Badan yang tidak tertagih sebesar Rp. 66.889.020 dibebankan pada tahun 2025 sebagai bagian dari "beban pajak" pada biaya lain-lain pada laporan laba rugi dan penghasilan komprehensif lain konsolidasian.

On May 7, 2025, The Company received Tax Excess Payment Order No. 00254A related to Income Tax Art.25/29 for the period 2023 amounting to Rp 1,659,452,116, of which The company received a refund of Rp. 1,592,563,096 on April 25, 2024. The remaining uncollected Income Tax Art.25/29 amounting to Rp. 66,889,020 is charged as part of "Tax Expense" under other expenses in the consolidated statement of profit or loss and other comprehensive income

Perusahaan menerima Surat Tagihan Pajak Penghasilan No. 00347/106/18/631/22 pada tanggal 15 Desember 2022 untuk masa pajak 2018 sebesar Rp 29.663.706 dan telah dibayarkan pada tanggal 2 April 2024.

The Company received Income Tax Collection Letter No. 00347/106/18/631/22 on December 15, 2022 for the 2018 tax period amounting to Rp 29,663,706 and has been paid on April 2, 2024.

Perusahaan menerima Surat Ketetapan Pajak Kurang Bayar No. 00003/243/22/631/24 pada tanggal 15 Maret 2024 untuk masa pajak 2022 sebesar Rp 7.125.104. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 1.955.842 dan telah dibayarkan pada tanggal 2 April 2024.

The Company received Tax Underpayment Assessment Letter No. 00003/243/22/631/24 on March 15, 2024 for tax period 2022 amounting to Rp 7,125,104. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 1,955,842 and has been paid on April 2, 2024.

Perusahaan menerima Surat Ketetapan Kurang Bayar Pajak Penghasilan Final Pasal 4 (2) No. 00006/240/22/631/24 pada tanggal 15 Maret 2024 untuk masa pajak 2022 sebesar Rp 18.407.556. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 5.502.874 dan telah dibayarkan pada tanggal 2 April 2024.

The Tax Company received Final Income Underpayment Letter Article 4 (2) No. 00006/240/22/631/24 on March 15, 2024 for tax period 2022 amounting to Rp 18,407,556. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 5,502,874 and has been paid on April 2, 2024.

Perusahaan menerima Surat Ketetapan Pajak Kurang Bayar No. 00010/201/22/631/24 pada tanggal 15 Maret 2024 untuk masa pajak 2022 sebesar Rp 11.542.952. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 3.168.541 dan telah dibayarkan pada tanggal 2 April 2024.

The Company received Tax Underpayment Assessment Letter No. 00010/201/22/631/24 on March 15, 2024 for tax period 2022 amounting to Rp 11,542,952. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 3,168,541 and has been paid on April 2, 2024.

Perusahaan menerima Surat Tagihan Pajak Pertambahan Nilai Barang dan Jasa No. 00011/107/22/631/24 pada tanggal 15 Maret 2024 untuk masa pajak 2022 sebesar Rp 18.232 dan telah dibayarkan pada tanggal 2 April 2024.

The Company received Goods and Services Value Added Tax Collection Letter No.00011/107/22/631/24 on March 15, 2024 for the tax period 2022 amounting to Rp 18,232 and has been paid on April 2, 2024.

Perusahaan menerima Surat Ketetapan Pajak Kurang Bayar No. 00013/203/22/631/24 pada tanggal 15 Maret 2024 untuk masa pajak 2022 sebesar Rp 71.658.585. Perusahaan juga dikenakan

The Company received Tax Underpayment Assessment Letter No. 00013/203/22/631/24 on March 15, 2024 for tax period 2022 amounting to Rp 71,658,585. Company is also subject to

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 19.670.282 dan telah dibayarkan pada tanggal 2 April 2024.

Perusahaan menerima Surat Ketetapan Pajak Pertambahan Nilai Barang dan Jasa No. 00043/207/22/631/24 pada tanggal 15 Maret 2024 untuk masa pajak 2022 sebesar Rp 200.555. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 88.084 dan telah dibayarkan pada tanggal 2 April 2024.

Perusahaan menerima Surat Ketetapan Pajak Kurang Bayar No. 0002/201/21/631/24 pada tanggal 15 Agustus 2024 untuk masa pajak 2021 sebesar Rp 8.067.022. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 3.426.871 dan telah dibayarkan pada tanggal 20 Agustus 2024.

Perusahaan menerima Surat Ketetapan Pajak Kurang Bayar No. 00021/206/21/631/24 pada tanggal 15 Agustus 2024 untuk masa pajak 2021 sebesar Rp 996.508.131. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 423.316.654 dan telah dibayarkan pada tanggal 20 Agustus 2024.

Perusahaan menerima Surat Ketetapan Pajak Kurang Bayar No. 00045/203/21/631/24 pada tanggal 15 Agustus 2024 untuk masa pajak 2021 sebesar Rp 3.937.129. Perusahaan juga dikenakan sanksi administrasi bunga pasal 13 (2) KUP sebesar Rp 1.672.493 dan telah dibayarkan pada tanggal 20 Agustus 2024.

**g. Tarif Pajak**

Pada tanggal 29 Oktober 2021, Pemerintah menerbitkan Undang-Undang Republik Indonesia No. 7 Tahun 2021 tentang Harmonisasi Peraturan Perpajakan. Peraturan tersebut telah menetapkan tarif pajak penghasilan untuk wajib pajak dalam negeri dan badan usaha sebesar 22% yang akan berlaku mulai Tahun Pajak 2022 dan selanjutnya penurunan tarif pajak sebesar 3% untuk wajib pajak dalam negeri yang memenuhi persyaratan tertentu.

**30. PENJUALAN NETO**

Disagregasi pendapatan

Perusahaan dan Entitas Anak telah mendisagregasi pendapatan ke dalam berbagai kategori dalam tabel berikut yang dimaksudkan untuk:

- menggambarkan bagaimana sifat, jumlah, waktu, dan ketidakpastian atas pendapatan dan arus kas yang dipengaruhi oleh tanggal ekonomi; dan
- memungkinkan pengguna untuk memahami hubungannya dengan informasi segmen pendapatan yang terdapat pada Catatan 45.

administrative sanction of interest article 13 (2) KUP amounting to Rp 19,670,282 and has been paid on April 2, 2024.

The Company received Goods and Services Value Added Tax Assessment Letter No. 00043/207/22/631/24 on March 15, 2024 for the tax period 2022 amounting to Rp 200,555. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 88,084 and has been paid on April 2, 2024.

The Company received Tax Underpayment Assessment Letter No. 0002/201/21/631/24 on August 15, 2024 for the 2021 tax period amounting to Rp 8,067,022. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 3,426,871 and has been paid on August 20, 2024.

The Company received Tax Underpayment Assessment Letter No. 00021/206/21/631/24 on August 15, 2024 for the 2021 tax period amounting to Rp 996,508,131. The company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 423,316,654 and has been paid on August 20, 2024.

The Company received Tax Underpayment Assessment Letter No. 00045/203/21/631/24 on August 15, 2024 for the 2021 tax period in the amount of Rp 3,937,129. Company is also subject to administrative sanction of interest article 13 (2) KUP amounting to Rp 1,672,493 and has been paid on August 20, 2024.

**g. Tax Rate**

On October 29, 2021, the Government issue Law of the Republic of Indonesia No. 7 year 2021 concerning Harmonization of Tax Regulations. The regulation has stipulated the income tax rate for domestic taxpayers and business establishments of 22% which will be effective from the Fiscal Year 2022 onwards and a further reduction of the tax rate by 3% for domestic taxpayers who meet certain requirements.

**30. NET SALES**

Disaggregation of revenue.

The Company and its Subsidiaries have disaggregated revenue into various categories in the following table which is intended to:

- depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic date; and
- enable users to understand the relationship with revenue segment information provided in Note 45.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Disagregasi pendapatan

Disaggregation of revenue.

|                                                | 30 Juni/<br>June 2025  | 30 Juni/<br>June 2024  |                                         |
|------------------------------------------------|------------------------|------------------------|-----------------------------------------|
| Medis sekali pakai dan<br>habis pakai          | 456.155.162.108        | 447.365.423.066        | Medical disposable and<br>consumables   |
| Perawatan Luka                                 | 151.599.138.117        | 136.878.815.439        | Wound care                              |
| Diagnostik dan peralatan                       | 105.688.258.096        | 99.194.425.852         | Diagnostic and equipment                |
| Antiseptik dan dialisis                        | 102.277.088.349        | 98.798.660.946         | Antiseptic and dialysis                 |
| Alat bantu jalan dan<br>perawatan rehabilitasi | 46.037.441.749         | 38.900.718.277         | Walking aids and<br>rehabilitation care |
| Bioteknologi dan laboratorium                  | 42.601.796.740         | 38.204.186.558         | Biotechnology and laboratory            |
| Perabotan rumah sakit                          | 21.053.160.253         | 20.182.619.562         | Hospital furniture                      |
| Lainnya                                        | 434.088.041            | 123.211.116            | Others                                  |
| <b>Jumlah</b>                                  | <b>925.846.133.453</b> | <b>879.648.060.816</b> | <b>T o t a l</b>                        |

30 Juni/June 2025

|                                      | Manufaktur/<br>Manufacturing | Distribusi/<br>Distribution | Eceran/<br>Retail     | Jumlah/<br>Total       |                                               |
|--------------------------------------|------------------------------|-----------------------------|-----------------------|------------------------|-----------------------------------------------|
| <b>Pasar geografi utama</b>          |                              |                             |                       |                        | <b>Primary geographical<br/>markets</b>       |
| Domestik                             | 18.240.766.300               | 804.460.658.296             | 99.830.869.141        | 922.532.293.737        | Domestic                                      |
| Luar negeri:                         |                              |                             |                       |                        | International:                                |
| Amerika Serikat dan<br>Amerika Latin | 3.313.839.716                | -                           | -                     | 3.313.839.716          | United States of America<br>and South America |
| <b>Jumlah</b>                        | <b>21.554.606.016</b>        | <b>804.460.658.296</b>      | <b>99.830.869.141</b> | <b>925.846.133.453</b> | <b>T o t a l</b>                              |

**Produk utama**

|                                                |                       |                        |                       |                        |                                         |
|------------------------------------------------|-----------------------|------------------------|-----------------------|------------------------|-----------------------------------------|
| Medis sekali pakai dan<br>habis pakai          | 3.548.585.047         | 412.260.865.060        | 40.345.712.001        | 456.155.162.108        | Medical disposable and<br>consumables   |
| Perawatan Luka                                 | 4.356.989.922         | 128.710.977.906        | 18.531.170.289        | 151.599.138.117        | Wound care                              |
| Diagnostik dan peralatan                       | 1.142.872.020         | 90.424.877.550         | 14.120.508.526        | 105.688.258.096        | Diagnostic and equipment                |
| Antiseptik dan dialisis                        | 12.383.780.600        | 80.299.966.953         | 9.593.340.796         | 102.277.088.349        | Antiseptic and dialysis                 |
| Alat bantu jalan dan<br>perawatan rehabilitasi | -                     | 37.972.054.004         | 8.065.387.745         | 46.037.441.749         | Walking aids and<br>rehabilitation care |
| Bioteknologi dan<br>laboratorium               | 9.797.585             | 34.381.255.635         | 8.210.743.520         | 42.601.796.740         | Biotechnology and<br>laboratory         |
| Perabotan rumah sakit                          | -                     | 20.089.153.989         | 964.006.264           | 21.053.160.253         | Hospital furniture                      |
| Lainnya                                        | 112.580.842           | 321.507.199            | -                     | 434.088.041            | Others                                  |
| <b>Jumlah</b>                                  | <b>21.554.606.016</b> | <b>804.460.658.296</b> | <b>99.830.869.141</b> | <b>925.846.133.453</b> | <b>T o t a l</b>                        |

**Waktu pengakuan  
pendapatan**

|                                            |                       |                        |                       |                        |                                           |
|--------------------------------------------|-----------------------|------------------------|-----------------------|------------------------|-------------------------------------------|
| Produk ditransfer pada satu<br>titik waktu | 21.554.606.016        | 804.460.658.296        | 99.830.869.141        | 925.846.133.453        | Product transferred<br>at a point in time |
| <b>Jumlah</b>                              | <b>21.554.606.016</b> | <b>804.460.658.296</b> | <b>99.830.869.141</b> | <b>925.846.133.453</b> | <b>T o t a l</b>                          |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

| 30 Juni/June 2024                        |                              |                             |                       |                        |                                              |
|------------------------------------------|------------------------------|-----------------------------|-----------------------|------------------------|----------------------------------------------|
|                                          | Manufaktur/<br>Manufacturing | Distribusi/<br>Distribution | Eceran/<br>Retail     | Jumlah/<br>Total       |                                              |
| <b><u>Pasar geografi utama</u></b>       |                              |                             |                       |                        | <b><u>Primary geographical markets</u></b>   |
| Domestik                                 | 23.953.314.794               | 779.515.511.573             | 74.759.378.401        | 878.228.204.768        | Domestic                                     |
| Luar negeri:                             |                              |                             |                       |                        | International:                               |
| Amerika Serikat dan                      |                              |                             |                       |                        | United States of America                     |
| Amerika Latin                            | 1.419.856.048                | -                           | -                     | 1.419.856.048          | and South America                            |
| <b>Jumlah</b>                            | <b>25.373.170.842</b>        | <b>779.515.511.573</b>      | <b>74.759.378.401</b> | <b>879.648.060.816</b> | <b>Total</b>                                 |
| <b><u>Produk utama</u></b>               |                              |                             |                       |                        | <b><u>Major products</u></b>                 |
| Medis sekali pakai dan                   |                              |                             |                       |                        | Medical disposable and                       |
| habis pakai                              | 3.325.221.648                | 414.300.018.978             | 29.740.182.440        | 447.365.423.066        | consumables                                  |
| Perawatan luka                           | 6.750.645.494                | 117.558.039.167             | 12.570.130.778        | 136.878.815.439        | Wound care                                   |
| Diagnostik dan peralatan                 | 339.614.300                  | 85.776.148.592              | 13.078.662.960        | 99.194.425.852         | Diagnostic and equipment                     |
| Antiseptik dan dialisis                  | 14.940.673.400               | 76.888.734.770              | 6.969.252.776         | 98.798.660.946         | Antiseptic and dialysis                      |
| Bioteknologi dan                         |                              |                             |                       |                        | Biotechnology and                            |
| laboratorium                             | 15.404.000                   | 32.004.947.338              | 6.183.835.220         | 38.204.186.558         | laboratory                                   |
| Alat bantu jalan dan                     |                              |                             |                       |                        | Walking aids and                             |
| perawatan rehabilitasi                   | -                            | 33.535.760.286              | 5.364.957.991         | 38.900.718.277         | rehabilitation care                          |
| Perabotan rumah sakit                    | 1.612.000                    | 19.328.651.326              | 852.356.236           | 20.182.619.562         | Hospital furniture                           |
| Lainnya                                  | -                            | 123.211.116                 | -                     | 123.211.116            | Others                                       |
| <b>Jumlah</b>                            | <b>25.373.170.842</b>        | <b>779.515.511.573</b>      | <b>74.759.378.401</b> | <b>879.648.060.816</b> | <b>Total</b>                                 |
| <b><u>Waktu pengakuan pendapatan</u></b> |                              |                             |                       |                        | <b><u>Timing of revenue recognitions</u></b> |
| Produk ditransfer pada satu              |                              |                             |                       |                        | Product transferred                          |
| titik waktu                              | 25.373.170.842               | 779.515.511.573             | 74.759.378.401        | 879.648.060.816        | at a point in time                           |
| <b>Jumlah</b>                            | <b>25.373.170.842</b>        | <b>779.515.511.573</b>      | <b>74.759.378.401</b> | <b>879.648.060.816</b> | <b>Total</b>                                 |

Penjualan kepada pihak berelasi untuk tahun-tahun yang berakhir pada 30 Juni 2025 sebesar Rp 6.031.018.396 (30 Juni 2024: Rp 4.947.529.250) (Catatan 38).

Sales to related parties for the years ended June 30, 2025 was Rp 6,031,018,396 (June 30, 2024: Rp 4,947,529,250) (Note 38).

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**31. BEBAN POKOK PENJUALAN**

**31. COST OF GOODS SOLD**

|                                                   | <u>30 Juni/<br/>June 2025</u> | <u>30 Juni/<br/>June 2024</u> |                                                |
|---------------------------------------------------|-------------------------------|-------------------------------|------------------------------------------------|
| Saldo awal bahan baku                             | 210.580.050.465               | 230.603.980.763               | Beginning balance – raw material               |
| Pembelian                                         | 324.286.940.276               | 302.602.840.867               | Purchases                                      |
| Saldo akhir bahan baku                            | ( 201.016.115.871)            | ( 197.910.524.347)            | Ending balance – raw material                  |
| <b>Bahan baku yang digunakan</b>                  | <b>333.850.874.870</b>        | <b>335.296.297.283</b>        | <b>Raw material – used</b>                     |
| Tenaga kerja langsung                             | 28.760.722.322                | 28.033.250.108                | Direct labour                                  |
| <b>Jumlah</b>                                     | <b>362.611.597.192</b>        | <b>363.329.547.391</b>        | <b>Total</b>                                   |
| Beban operasional pabrik                          |                               |                               | Factory overhead                               |
| Penyusutan aset tetap (Catatan 13)                | 20.682.351.312                | 18.246.209.765                | Depreciation of fixed assets (Note 13)         |
| Varians                                           | 20.601.800.722                | 28.618.305.161                | Variance                                       |
| Biaya transportasi                                | 12.905.805.191                | 12.397.787.921                | Transportation                                 |
| Gaji                                              | 7.186.007.829                 | 4.916.313.927                 | Salary                                         |
| Telpon, Listrik dan air                           | 6.798.693.911                 | 6.598.753.644                 | Telephone, Electricity and Water               |
| Subkontraktor                                     | 6.611.854.389                 | 6.413.900.117                 | Subcontractor                                  |
| Peralatan produksi                                | 2.327.382.592                 | 3.136.826.068                 | Production tools                               |
| Pemeliharaan                                      | 2.120.859.906                 | 2.766.748.389                 | Maintenance                                    |
| Konsumsi dan medis                                | 1.671.236.472                 | 2.004.895.996                 | Consumption and medical                        |
| Suku cadang                                       | 1.649.586.074                 | 1.060.735.212                 | Spare-part                                     |
| Penyisihan penurunan nilai persediaan (Catatan 9) | 1.375.429.749                 | -                             | Allowance for impairment of inventory (Note 9) |
| Asuransi                                          | 488.385.159                   | 410.211.311                   | Insurance                                      |
| Perlengkapan kantor                               | 125.229.487                   | 148.233.499                   | Stationary                                     |
| Amortisasi aset hak guna (Catatan 15)             | 151.792.621                   | 172.021.501                   | Amortization of right-of-use assets (Note 15)  |
| Lainnya                                           | 1.055.134.469                 | 883.210.643                   | Others                                         |
|                                                   | <u>85.751.549.883</u>         | <u>87.774.153.154</u>         |                                                |
| Sub-jumlah                                        | <u>448.363.147.075</u>        | <u>451.103.700.545</u>        | Sub-total                                      |
| Saldo awal barang dalam proses                    | 24.468.949.056                | 15.095.417.751                | Beginning balance working in process           |
| Pembelian                                         | 165.148.954.066               | 139.091.836.250               | Purchases                                      |
| Saldo akhir barang dalam proses                   | ( 32.572.594.214)             | ( 16.687.583.009)             | Ending balance working in process              |
| Harga pokok produksi                              | 605.408.455.983               | 588.603.371.537               | Cost of goods manufacture                      |
| Saldo awal barang jadi                            | 374.000.654.574               | 353.630.052.626               | Beginning balance finished goods               |
| Pembelian                                         | 11.509.530.637                | 28.059.720.355                | Purchases                                      |
| Saldo akhir barang jadi                           | ( 377.841.486.182)            | ( 382.692.335.449)            | Ending balance finished goods                  |
| <b>Beban Pokok Penjualan</b>                      | <b><u>613.077.155.012</u></b> | <b><u>587.600.809.069</u></b> | <b>Cost of goods sold</b>                      |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**32. BEBAN PENJUALAN DAN PEMASARAN**

|                                       | <u>30 Juni/<br/>June 2025</u> |
|---------------------------------------|-------------------------------|
| Pemasaran                             | 24.342.164.417                |
| Gaji                                  | 19.771.807.623                |
| Sewa (Catatan 22)                     | 10.042.665.128                |
| Pengiriman                            | 9.968.808.200                 |
| Amortisasi aset hak guna (Catatan 15) | 8.669.720.935                 |
| Pemeliharaan                          | 6.002.340.146                 |
| Transportasi dan Perjalanan Dinas     | 4.920.648.254                 |
| Asuransi                              | 453.257.805                   |
| Penyusutan aset tetap (Catatan 13)    | 3.428.784                     |
| Lainnya                               | 19.869.856                    |
| <b>Jumlah</b>                         | <b>84.194.711.148</b>         |

**32. SELLING AND MARKETING EXPENSES**

|               | <u>30 Juni/<br/>June 2024</u> |                                                |
|---------------|-------------------------------|------------------------------------------------|
|               | 20.162.460.374                | Marketing                                      |
|               | 18.712.429.686                | Salaries                                       |
|               | 7.564.281.154                 | Rent (Note 22)                                 |
|               | 9.859.483.959                 | Shipping                                       |
|               | 7.023.052.823                 | Amortization of right-of-use assets (Notes 15) |
|               | 2.782.291.932                 | Maintenance                                    |
|               | 5.113.458.014                 | Transportation and travelling                  |
|               | 451.320.482                   | Insurance                                      |
|               | 3.428.781                     | Depreciation of fixed assets (Note 13)         |
|               | 12.472.343                    | Others                                         |
| <b>Jumlah</b> | <b>71.684.679.548</b>         | <b>Total</b>                                   |

**33. BEBAN UMUM DAN ADMINISTRASI**

|                                               | <u>30 Juni/<br/>June 2025</u> |
|-----------------------------------------------|-------------------------------|
| Gaji, upah dan tunjangan karyawan             | 35.861.706.429                |
| Subkontraktor                                 | 8.831.219.974                 |
| Tenaga ahli                                   | 4.556.755.524                 |
| Manfaat karyawan (Catatan 25)                 | 3.004.219.894                 |
| Penyusutan aset tetap (Catatan 13)            | 2.918.459.027                 |
| Alat tulis kantor, materai dan pos percetakan | 2.872.599.611                 |
| Pemeliharaan kantor dan kendaraan             | 2.814.287.996                 |
| Telepon, Listrik & Air                        | 1.619.590.490                 |
| Perijinan dan lisensi                         | 1.532.806.096                 |
| Transportasi dan Perjalanan Dinas             | 1.083.570.299                 |
| Asuransi                                      | 44.094.470                    |
| Amortisasi aset takberwujud (Catatan 14)      | 27.541.184                    |
| Lainnya                                       | 699.096.559                   |
| <b>Jumlah</b>                                 | <b>65.865.947.553</b>         |

**33. GENERAL AND ADMINISTRATIVE EXPENSES**

|               | <u>30 Juni/<br/>June 2024</u> |                                             |
|---------------|-------------------------------|---------------------------------------------|
|               | 33.433.556.583                | Salaries, wages and allowances              |
|               | 6.860.010.783                 | Subcontractor                               |
|               | 3.700.299.934                 | Professional fee                            |
|               | 4.431.328.074                 | Employee benefits (Note 25)                 |
|               | 2.050.036.404                 | Depreciation of fixed assets (Note 13)      |
|               | 3.752.803.968                 | Office stationery, stamp and stamp duty     |
|               | 1.760.141.181                 | Office and vehicle maintenance              |
|               | 1.517.655.557                 | Telephone, Electricity and Water            |
|               | 1.476.993.447                 | Permit and licenses                         |
|               | 891.075.372                   | Transportation and travelling               |
|               | 44.896.816                    | Insurance                                   |
|               | 37.521.348                    | Amortization of intangible assets (Note 14) |
|               | 490.248.451                   | Others                                      |
| <b>Jumlah</b> | <b>60.446.567.918</b>         | <b>Total</b>                                |

Lainnya diatas pada umumnya terdiri dari biaya pendidikan dan pelatihan untuk pegawai.

Others above generally consist of education and training cost for employees.

**34. PENDAPATAN DAN BEBAN OPERASI LAIN-LAIN**

|                                  | <u>30 Juni/<br/>June 2025</u> |
|----------------------------------|-------------------------------|
| Laba selisih kurs                | 4.704.068.553                 |
| Pemulihan penyisihan piutang     | 25.076.908                    |
| Rugi atas penjualan aset tetap   | ( 3.221.504 )                 |
| Penghapusan piutang tak tertagih | ( 77.173.133 )                |
| Rugi atas penghapusan aset tetap | ( 249.091.000 )               |
| Penyisihan penurunan persediaan  | ( 1.181.354.531 )             |
| Beban pajak lainnya              | ( 1.725.352.507 )             |
| Lainnya                          | 5.132.113.542                 |
| <b>Jumlah</b>                    | <b>6.625.066.328</b>          |

**34. OTHER OPERATING INCOME AND EXPENSES**

|               | <u>30 Juni/<br/>June 2024</u> |                                          |
|---------------|-------------------------------|------------------------------------------|
|               | 7.030.860.361                 | Gain from foreign exchange               |
|               | -                             | Recovery allowance for trade receivables |
|               | ( 105.982 )                   | Loss on Sales of Fixed Assets            |
|               | ( 134.826.235 )               | Write-off trade receivables              |
|               | -                             | Loss on disposal of fixed assets         |
|               | ( 1.676.241.318 )             | Allowance for inventories                |
|               | ( 133.437.626 )               | Other tax expense                        |
|               |                               | Others                                   |
| <b>Jumlah</b> | <b>5.086.249.200</b>          | <b>Total</b>                             |

Lainnya di atas pada umumnya terdiri dari pendapatan pendukung promosi dan penjualan barang sample.

Others above generally consist of income from promotion support and sale of sample.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**35. PENDAPATAN KEUANGAN**

|                            | <u>30 Juni/<br/>June 2025</u> |
|----------------------------|-------------------------------|
| Pendapatan bunga deposito  | 18.380.749.652                |
| Pendapatan bunga jasa giro | 8.128.856.195                 |
| Pendapatan bunga obligasi  | 4.876.391.689                 |
| <b>Jumlah</b>              | <u>31.385.997.536</u>         |

**35. FINANCE INCOME**

|              | <u>30 Juni/<br/>June 2024</u> |                                  |
|--------------|-------------------------------|----------------------------------|
|              | 19.660.219.187                | Deposit interest income          |
|              | 4.065.037.078                 | Current accounts interest income |
|              | 3.123.141.299                 | Bonds interest income            |
| <b>Total</b> | <u>26.848.397.564</u>         |                                  |

**36. BEBAN KEUANGAN**

|                                                                             | <u>30 Juni/<br/>June 2025</u> |
|-----------------------------------------------------------------------------|-------------------------------|
| Bunga surat utang jangka menengah (Catatan 24)                              | 6.492.972.973                 |
| Bunga dari liabilitas sewa (Catatan 22)                                     | 683.708.979                   |
| Amortisasi beban ditangguhkan dari surat utang jangka menengah (Catatan 24) | 83.240.349                    |
| Administrasi bank                                                           | 229.186.769                   |
| Biaya bunga hutang bank                                                     | 2.233.371                     |
| <b>Jumlah</b>                                                               | <u>7.491.341.441</u>          |

**36. FINANCE COSTS**

|              | <u>30 Juni/<br/>June 2024</u> |                                                                 |
|--------------|-------------------------------|-----------------------------------------------------------------|
|              | 8.379.158.175                 | Interest from medium-term notes (Note 24)                       |
|              | 886.315.544                   | Interest from lease liabilities (Note 22)                       |
|              | 90.857.174                    | Amortization of deferred costs from medium-term notes (Note 24) |
|              | 218.528.727                   | Bank administration                                             |
|              | -                             | Bank loan interest                                              |
| <b>Total</b> | <u>9.574.859.620</u>          |                                                                 |

**37. LABA PER SAHAM**

|                                                                 | <u>30 Juni/<br/>June 2025</u> |
|-----------------------------------------------------------------|-------------------------------|
| Laba neto yang dapat diatribusikan kepada pemilik entitas induk | 153.731.315.812               |
| Rata-rata tertimbang jumlah saham biasa yang beredar            | 27.056.712.667                |
| <b>Laba per saham dasar</b>                                     | <u>5,68</u>                   |

**37. EARNING PER SHARE**

|                                 | <u>30 Juni/<br/>June 2024</u> |                                                         |
|---------------------------------|-------------------------------|---------------------------------------------------------|
|                                 | 143.948.846.175               | Net profit attributable to owners of the parent Company |
|                                 | 27.058.850.000                | Weighted average number of ordinary shares outstanding  |
| <b>Basic earnings per share</b> | <u>5,32</u>                   |                                                         |

Sebagaimana dinyatakan dalam PSAK 233, Laba per saham dimana perubahan struktur modal saham Perusahaan dan Entitas Anak mengakibatkan perubahan jumlah saham biasa yang diterbitkan tanpa perubahan sumber daya yang sesuai, perlu menyesuaikan dengan jumlah saham biasa yang diungkapkan untuk periode komparatif dalam mencerminkan perubahan ini, termasuk perubahan yang terjadi setelah periode pelaporan. Sebagai akibat dari pemecahan saham dan dividen saham pada tahun 2021 dan pemecahan saham di 2022, semua data historis per saham dan jumlah saham yang beredar disesuaikan secara retrospektif (Catatan 26).

As required by the PSAK 233, Earnings per share, where changes in the Company and its Subsidiaries' share capital structure result in changes to the number of common shares in issue without a corresponding change in resources, it is necessary to adjust the number of common shares disclosed for the comparative periods to reflect these changes, including changes that occur after the reporting period. As a result of the stock split and share dividend in 2021 and stock split in 2022, all historical per share data and number of shares outstanding were retrospectively adjusted (Notes 26).

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**38. SALDO DAN TRANSAKSI PIHAK BERELASI**

Dalam kegiatan usaha normal, Perusahaan dan Entitas Anak melakukan transaksi dengan pihak-pihak berelasi, antara lain berupa penjualan, pembelian dan pinjaman. Perusahaan-perusahaan tersebut mempunyai hubungan berelasi karena mempunyai kesamaan kepemilikan dan/atau pengurus dengan Perusahaan dan Entitas Anak.

- (i) Saldo dengan pihak berelasi pada 30 Juni 2025 dan 31 Desember 2024 adalah sebagai berikut:

**a. Piutang usaha (Catatan 7)**

|                                               | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |
|-----------------------------------------------|-----------------------------------|-------------------------------------------|
| PT Gehael Nusantara                           | 486.443.259                       | 313.886.776                               |
| PT Eka Husada Lestari                         | 337.297.263                       | 754.668.387                               |
| PT Karya Indah Medika                         | 114.010.528                       | 150.075.038                               |
| <b>Jumlah</b>                                 | <b>937.751.050</b>                | <b>1.218.630.201</b>                      |
| Persentase terhadap jumlah aset konsolidasian | 0,03%                             | 0,04%                                     |

**b. Piutang non-usaha (Catatan 8)**

|                                               | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |
|-----------------------------------------------|-----------------------------------|-------------------------------------------|
| PT Karya Indah Medika                         | 239.000                           | -                                         |
| <b>Jumlah</b>                                 | <b>239.000</b>                    | <b>-</b>                                  |
| Persentase terhadap jumlah aset konsolidasian | 0,00%                             | 0,00%                                     |

**c. Utang usaha (Catatan 18)**

|                                                     | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |
|-----------------------------------------------------|-----------------------------------|-------------------------------------------|
| PT Intisumber Hasil Sempurna                        | 2.633.238.176                     | 3.058.373.727                             |
| PT Jayatex Nonwoven Industri                        | 1.477.452.574                     | 578.823.208                               |
| PT Karya Indah Medika                               | 1.264.684.494                     | 827.582.250                               |
| PT Gehael Nusantara                                 | 82.306.893                        | -                                         |
| PT Jayamas Tata Karunia                             | -                                 | 576.014.897                               |
| <b>Jumlah</b>                                       | <b>5.457.682.137</b>              | <b>5.040.794.082</b>                      |
| Persentase terhadap jumlah liabilitas konsolidasian | 1,89%                             | 1,53%                                     |

**38. RELATED PARTY BALANCE AND TRANSACTIONS**

The Company and its Subsidiaries, in its regular conduct of business, have engaged in transactions with related parties, principally consisting of sales, purchases and loans. Such related parties represent directors and companies having the same member of commissioners and/or directors as those of the Company and its Subsidiaries.

- (i) The related party balances as of June 30, 2025 and December 31, 2024 were as follows:

**a. Trade receivables (Note 7)**

PT Gehael Nusantara  
PT Eka Husada Lestari  
PT Karya Indah Medika

**Total**

Percentage to total consolidated assets

**b. Non-trade receivables (Note 8)**

PT Karya Indah Medika

**Total**

Percentage to total consolidated assets

**c. Trade payable (Note 18)**

PT Intisumber Hasil Sempurna  
PT Jayatex Nonwoven Industri  
PT Karya Indah Medika  
PT Gehael Nusantara  
PT Jayamas Tata Karunia

**Total**

Percentage to total consolidated liabilities

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**d. Utang non-usaha (Catatan 19)**

|                                                        | <b>30 Juni/<br/>June<br/>2025</b> | <b>31 Desember/<br/>December<br/>2024</b> |
|--------------------------------------------------------|-----------------------------------|-------------------------------------------|
| PT Jayamas Tata Karunia                                | 1.316.862.508                     | 16.153.800                                |
| PT Karya Indah Medika                                  | 31.240.250                        | -                                         |
| <b>Jumlah</b>                                          | <b>1.348.102.758</b>              | <b>16.153.800</b>                         |
| Persentase terhadap jumlah<br>liabilitas konsolidasian | 0,47%                             | 0,00%                                     |

**d. Non-trade payables (Note 19)**

PT Jayamas Tata Karunia  
PT Karya Indah Medika

**T o t a l**

Percentage to total  
consolidated liabilities

(ii) Transaksi dengan pihak berelasi untuk tahun yang berakhir pada tanggal 30 Juni 2025 dan 2024 adalah sebagai berikut:

(ii) Transactions with related parties for the years ended June 30, 2025 and 2024 were as follows:

**a. Penjualan (Catatan 30)**

|                                                       | <b>30 Juni/<br/>June 2025</b> | <b>30 Juni/<br/>June 2024</b> |
|-------------------------------------------------------|-------------------------------|-------------------------------|
| PT Karya Indah Medika                                 | 2.432.246.011                 | 1.027.388.265                 |
| PT Inti Medicom Jaya                                  | 1.728.893.849                 | 1.841.510.928                 |
| PT Gehael Nusantara                                   | 1.270.140.140                 | 1.343.076.789                 |
| PT Eka Husada Lestari                                 | 599.738.396                   | 722.803.268                   |
| PT Inti Presisi Medica                                | -                             | 12.750.000                    |
| <b>Jumlah</b>                                         | <b>6.031.018.396</b>          | <b>4.947.529.250</b>          |
| Persentase terhadap jumlah<br>penjualan konsolidasian | 0,65%                         | 0,56%                         |

**a. Sales (Note 30)**

PT Karya Indah Medika  
PT Inti Medicom Jaya  
PT Gehael Nusantara  
PT Eka Husada Lestari  
PT Inti Presisi Medica

**T o t a l**

Percentage to total  
consolidated sales

**b. Pembelian (Catatan 31)**

|                                                       | <b>30 Juni/<br/>June 2025</b> | <b>30 Juni/<br/>June 2024</b> |
|-------------------------------------------------------|-------------------------------|-------------------------------|
| PT Jayatex Nonwoven Industri                          | 14.261.774.854                | 16.969.887.419                |
| PT Karya Indah Medika                                 | 10.901.382.047                | 14.002.993.345                |
| PT Gehael Nusantara                                   | 609.845.082                   | 579.795.622                   |
| PT Intisumber Hasil Sempurna                          | -                             | 18.568.188.628                |
| PT Karmen Medika                                      | -                             | 91.215.000                    |
| <b>Jumlah</b>                                         | <b>25.773.001.983</b>         | <b>50.212.080.014</b>         |
| Persentase terhadap jumlah<br>pembelian konsolidasian | 5,13%                         | 10,7%                         |

**b. Purchase (Note 31)**

PT Jayatex Nonwoven Industri  
PT Karya Indah Medika  
PT Gehael Nusantara  
PT Intisumber Hasil Sempurna  
PT Karmen Medika

**T o t a l**

Percentage to total  
consolidated purchases

**c. Biaya jasa dan lainnya (Catatan 31,32,33)**

|                                                        | <b>30 Juni/<br/>June 2025</b> | <b>30 Juni/<br/>June 2024</b> |
|--------------------------------------------------------|-------------------------------|-------------------------------|
| PT Jayamas Tata Karunia                                | 20.265.928.480                | 16.226.356.340                |
| PT Intisumber Hasil Sempurna                           | 8.833.750.000                 | 10.028.500.000                |
| PT Karya Indah Medika                                  | 163.884.000                   | 413.705.500                   |
| PT Inti Presisi Medica                                 | 43.717.680                    | 103.622.691                   |
| <b>Jumlah</b>                                          | <b>29.307.280.160</b>         | <b>26.772.184.531</b>         |
| Persentase terhadap jumlah<br>biaya jasa konsolidasian | 57,31%                        | 59,90%                        |

**c. Service expense and others (Note 31,32,33)**

PT Jayamas Tata Karunia  
PT Intisumber Hasil Sempurna  
PT Karya Indah Medika  
PT Inti Presisi Medica

**T o t a l**

Percentage to total  
consolidated service expenses

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**d. Kompensasi manajemen utama**

Gaji dan tunjangan yang dibayarkan kepada dewan komisaris dan direksi adalah sebagai berikut:

|                           | <b>30 Juni/<br/>June 2025</b> | <b>30 Juni/<br/>June 2024</b> |
|---------------------------|-------------------------------|-------------------------------|
| <b>Gaji dan tunjangan</b> | <b>7.765.226.908</b>          | <b>5.290.447.748</b>          |

Ringkasan hubungan dan sifat transaksi dengan pihak berelasi adalah sebagai berikut:

**d. Key management compensation:**

Salaries and allowances paid to the Boards of Commissioners and Directors are as follows:

**Salaries and allowance**

The summary of the relationship and nature of transactions with the related parties are as follows:

| <b>Pihak-Pihak yang berelasi/<br/>Related parties</b> | <b>Sifat dari hubungan/<br/>Nature of relationships</b>        | <b>Transaksi dan saldo ke/atau pihak berelasi<br/>Transaction and balance to/from related parties</b>         |
|-------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| PT Intisumber Hasil Sempurna                          | Pemegang saham/Shareholders                                    | Utang usaha, pembelian, biaya jasa dan lainnya /Trade payables, purchases, service expense and others         |
| PT Karya Indah Medika                                 | Memiliki pemegang saham yang sama /IHave the same shareholders | Utang usaha, piutang usaha, penjualan, dan pembelian /Trade payables, trade receivables, sales, and purchases |
| PT Gehael Nusantara                                   | Memiliki pemegang saham yang sama /IHave the same shareholders | Piutang usaha, utang usaha penjualan, dan pembelian/ Trade receivables, trade payables, sales, and purchases  |
| PT Karmen Medika                                      | Memiliki pemegang saham yang sama /IHave the same shareholders | Pembelian /Purchases                                                                                          |
| PT Eka Husada Lestari                                 | Memiliki pemegang saham yang sama /IHave the same shareholders | Piutang usaha dan penjualan /Trade Receivables and sales                                                      |
| PT Jayatex Nonwoven Industri                          | Memiliki pemegang saham yang sama /IHave the same shareholders | Utang usaha dan pembelian/Trade payables and Purchases                                                        |
| PT Jayamas Tata Karunia                               | Memiliki pemegang saham yang sama /IHave the same shareholders | Utang non-usaha, biaya jasa dan lainnya/Non Trade Payables, service expense and others                        |
| PT Inti Presisi Medica                                | Memiliki pemegang saham yang sama /IHave the same shareholders | Biaya jasa dan lainnya /service expense and others                                                            |
| PT Inti Medicom Jaya                                  | Memiliki pemegang saham yang sama /IHave the same shareholders | Penjualan / Sales                                                                                             |

**39. ASET DAN LIABILITAS MONETER DALAM MATA UANG ASING**

Informasi mengenai aset dan liabilitas moneter dalam matauang asing pada 30 Juni 2025 dan 31 Desember 2024 dan nilai setara dalam Rupiah yang dijabarkan dengan menggunakan rata-rata kurs jual dan beli yang diterbitkan oleh Bank Indonesia sebagai berikut:

**39. MONETARY ASSETS AND LIABILITIES DOMINATED IN FOREIGN CURRENCIES**

Information concerning monetary assets and liabilities denominated in foreign currencies as of June 30, 2025 and December 31, 2024 and their Rupiah equivalents converted using the middle exchange rates that were published by Bank Indonesia as follows:

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

| <b>30 Juni/June 2025</b>         |                                              |            |                                                      |                                    |
|----------------------------------|----------------------------------------------|------------|------------------------------------------------------|------------------------------------|
|                                  | <b>Mata uang asing/<br/>Foreign currency</b> |            | <b>Nilai setara<br/>Rupiah/Rupiah<br/>equivalent</b> |                                    |
| <b><u>Aset moneter</u></b>       |                                              |            |                                                      | <b><u>Monetary assets</u></b>      |
| Kas dan setara kas               | USD                                          | 13.480.284 | 218.825.442.055                                      | Cash and cash equivalents          |
|                                  | CNY                                          | 32.917.199 | 74.553.177.564                                       |                                    |
| Piutang usaha                    | USD                                          | 62.452     | 1.013.778.122                                        | Trade receivables                  |
| Piutang non-usaha                | USD                                          | 152.273    | 2.471.849.021                                        | Non-trade receivables              |
| Investasi Jangka Panjang         | USD                                          | 6.273.204  | 101.832.915.428                                      | Long-term Investment               |
| Sub-jumlah                       |                                              |            | 398.697.162.190                                      | Sub-total                          |
| <b><u>Liabilitas moneter</u></b> |                                              |            |                                                      | <b><u>Monetary liabilities</u></b> |
| Utang usaha                      | USD                                          | 1.629.681  | 26.454.603.718                                       | Trade payables                     |
|                                  | CNY                                          | 11.751.980 | 26.616.705.850                                       |                                    |
|                                  | EUR                                          | 11.719     | 222.762.482                                          |                                    |
| Utang non-usaha                  | USD                                          | 59.525     | 966.284.466                                          | Non-trade payables                 |
|                                  | EUR                                          | 761        | 14.459.584                                           |                                    |
|                                  | CNY                                          | 1.329.795  | 3.011.811.993                                        |                                    |
| Sub-jumlah                       |                                              |            | 57.286.628.093                                       | Sub-total                          |
| Aset neto                        |                                              |            | 341.410.534.097                                      | Net Assets                         |
| <b>31 Desember/December 2024</b> |                                              |            |                                                      |                                    |
|                                  | <b>Mata uang asing/<br/>Foreign currency</b> |            | <b>Nilai setara<br/>Rupiah/Rupiah<br/>equivalent</b> |                                    |
| <b><u>Aset moneter</u></b>       |                                              |            |                                                      | <b><u>Monetary assets</u></b>      |
| Kas dan setara kas               | USD                                          | 14.390.853 | 232.584.968.932                                      | Cash and cash equivalent           |
|                                  | CNY                                          | 34.985.678 | 77.464.238.657                                       |                                    |
| Piutang usaha                    | USD                                          | 35.817     | 578.877.371                                          | Trade receivables                  |
| Piutang non-usaha                | USD                                          | 23.517     | 380.076.281                                          | Non-trade receivables              |
| Investasi jangka pendek          | USD                                          | 1.751.145  | 28.302.010.733                                       | Short-term Investment              |
| Investasi jangka panjang         | USD                                          | 2.628.713  | 42.485.255.281                                       | Long-term Investment               |
| Sub-jumlah                       |                                              |            | 381.795.427.255                                      | Sub-total                          |
| <b><u>Liabilitas moneter</u></b> |                                              |            |                                                      | <b><u>Monetary liabilities</u></b> |
| Utang usaha                      | USD                                          | 796.570    | 12.874.156.653                                       | Trade payables                     |
|                                  | CNY                                          | 10.753.640 | 23.810.386.368                                       |                                    |
|                                  | JPY                                          | 20.467.059 | 2.095.058.265                                        |                                    |
| Utang non-usaha                  | USD                                          | 4.277      | 69.117.037                                           | Non- trade payables                |
|                                  | CNY                                          | 49.118     | 108.756.139                                          |                                    |
| Sub-jumlah                       |                                              |            | 38.957.474.462                                       | Sub-total                          |
| Aset neto                        |                                              |            | 342.837.952.793                                      | Net Assets                         |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**40. TRANSAKSI DENGAN KEPENTINGAN NON PENGENDALI**

Proporsi kepemilikan saham yang dimiliki oleh kepentingan nonpengendali dengan jumlah material adalah sebagai berikut:

**40. TRANSACTIONS WITH NON-CONTROLLING INTEREST**

The proportion of ownership of shares held by non-controlling interests in the amount of material is as follows::

| Entitas Anak/Subsidiary             | Persentase kepemilikan (%)/<br>Percentage of ownership (%) |                              |
|-------------------------------------|------------------------------------------------------------|------------------------------|
|                                     | 30 Juni/June<br>2025                                       | 31 Desember/December<br>2024 |
| PT Intisumber Hasil Sempurna Global | 1%                                                         | 1%                           |
| PT Jayamas Wellong Medical          | 49%                                                        | 49%                          |

Rincian kepentingan nonpengendali atas ekuitas dan bagian atas hasil bersih Entitas Anak yang dikonsolidasi adalah sebagai berikut:

Details of non-controlling interests in the equity and shares of results of consolidated subsidiaries are as follows:

| 30 Juni/June 2025                   |                                              |                                            |                          |                                  |                                            |                                     |
|-------------------------------------|----------------------------------------------|--------------------------------------------|--------------------------|----------------------------------|--------------------------------------------|-------------------------------------|
| Entitas Anak                        | Pada awal tahun/<br>At beginning of the year | Laba Komprehensif/<br>Comprehensive income | Dividen/<br>Dividend     | Penambahan Modal/Paid up Capital | Pada akhir tahun/<br>At ending of the year | Subsidiary                          |
| PT Intisumber Hasil Sempurna Global | 29.669.749.793                               | 1.077.186.620                              | ( 4.000.000.000 )        | -                                | 26.746.936.413                             | PT Intisumber Hasil Sempurna Global |
| PT Jayamas Wellong Medical          | 4.682.609.246                                | ( 128.484.392 )                            | -                        | -                                | 4.554.124.854                              | PT Jayamas Wellong Medical          |
| <b>Jumlah</b>                       | <b>34.352.359.039</b>                        | <b>948.702.228</b>                         | <b>( 4.000.000.000 )</b> | <b>-</b>                         | <b>31.301.061.267</b>                      | <b>T o t a l</b>                    |
| 31 Desember/December 2024           |                                              |                                            |                          |                                  |                                            |                                     |
| Entitas Anak                        | Pada awal tahun/<br>At beginning of the year | Laba Komprehensif/<br>Comprehensive income | Dividen/<br>Dividend     | Penambahan Modal/Paid up Capital | Pada akhir tahun/<br>At ending of the year | Subsidiary                          |
| PT Intisumber Hasil Sempurna Global | 27.188.847.889                               | 2.480.901.904                              | -                        | -                                | 29.669.749.793                             | PT Intisumber Hasil Sempurna Global |
| PT Jayamas Wellong Medical          | -                                            | ( 217.390.754 )                            | -                        | 4.900.000.000                    | 4.682.609.246                              | PT Jayamas Wellong Medical          |
| <b>Jumlah</b>                       | <b>27.188.847.889</b>                        | <b>2.263.511.150</b>                       | <b>-</b>                 | <b>4.900.000.000</b>             | <b>34.352.359.039</b>                      | <b>T o t a l</b>                    |

**41. NILAI WAJAR DARI INSTRUMEN KEUANGAN**

Tabel berikut menyajikan aset dan liabilitas keuangan Perusahaan dan Entitas Anak pada 30 Juni 2025 dan 31 Desember 2024:

**41. FAIR VALUE OF FINANCIAL INSTRUMENTS**

The following table sets out the Company and its Subsidiaries financial assets and liabilities as of June 30, 2025 and December 31, 2024:

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

|                                   | <b>30 Juni/June 2025</b>                  |                                    |                                    |
|-----------------------------------|-------------------------------------------|------------------------------------|------------------------------------|
|                                   | <b>Nilai tercatat/<br/>Carrying value</b> | <b>Nilai wajar/<br/>Fair value</b> |                                    |
| <b>Aset Keuangan</b>              |                                           |                                    | <b>Financial Asset</b>             |
| <b>Aset Lancar</b>                |                                           |                                    | <b>Current Assets</b>              |
| Kas dan setara kas                | 1.130.358.960.131                         | 1.130.358.960.131                  | Cash and cash equivalents          |
| Investasi jangka pendek           | 35.270.449.858                            | 35.270.449.858                     | Short-term investment              |
| Piutang usaha - neto              | 302.301.211.667                           | 302.301.211.667                    | Trade receivables - net            |
| Piutang non-usaha - neto          | 5.537.850.068                             | 5.537.850.068                      | Non-trade receivables - net        |
| Aset lancar lainnya               | 66.763.900                                | 66.763.900                         | Other current assets               |
| <b>Aset Tidak Lancar</b>          |                                           |                                    | <b>Non-Current Assets</b>          |
| Investasi jangka panjang          | 190.006.366.110                           | 190.006.366.110                    | Long term-investment               |
| Deposito Berjangka                | 5.000.000.000                             | 5.000.000.000                      | Time Deposit                       |
| <b>Jumlah Aset Keuangan</b>       | <b>1.668.541.601.734</b>                  | <b>1.668.541.601.734</b>           | <b>Total Financial Asset</b>       |
| <b>Liabilitas Keuangan</b>        |                                           |                                    | <b>Financial liabilities</b>       |
| <b>Liabilitas Jangka Pendek</b>   |                                           |                                    | <b>Current Liabilities</b>         |
| Utang usaha                       | 99.459.423.099                            | 99.459.423.099                     | Trade payables                     |
| Utang non-usaha                   | 8.545.105.223                             | 8.545.105.223                      | Non-trade payables                 |
| Beban masih harus dibayar         | 5.449.333.055                             | 5.449.333.055                      | Accrued expenses                   |
| Liabilitas sewa                   | 11.989.936.291                            | 11.989.936.291                     | Lease liabilities                  |
| Pinjaman bank                     | 1.790.258.963                             | 1.790.258.963                      | Bank loan                          |
| <b>Liabilitas Jangka Panjang</b>  |                                           |                                    | <b>Non-Current Liabilities</b>     |
| Liabilitas sewa                   | 14.303.725.318                            | 14.303.725.318                     | Lease liabilities                  |
| Pinjaman bank                     | 2.916.666.663                             | 2.916.666.663                      | Bank loan                          |
| <b>Jumlah Liabilitas Keuangan</b> | <b>144.454.448.612</b>                    | <b>144.454.448.612</b>             | <b>Total Financial Liabilities</b> |
|                                   |                                           |                                    |                                    |
|                                   | <b>31 Desember/Desember 2024</b>          |                                    |                                    |
|                                   | <b>Nilai tercatat/<br/>Carrying value</b> | <b>Nilai wajar/<br/>Fair value</b> |                                    |
| <b>Aset Keuangan</b>              |                                           |                                    | <b>Financial Asset</b>             |
| <b>Aset Lancar</b>                |                                           |                                    | <b>Current Assets</b>              |
| Kas dan setara kas                | 1.224.705.775.933                         | 1.224.705.775.933                  | Cash and cash equivalents          |
| Investasi jangka pendek           | 89.496.731.646                            | 89.496.731.646                     | Short-term investment              |
| Piutang usaha - neto              | 265.191.997.451                           | 265.191.997.451                    | Trade receivables - net            |
| Piutang non-usaha - neto          | 3.372.465.399                             | 3.372.465.399                      | Non-trade receivables - net        |
| Aset lancar lainnya               | 66.763.900                                | 66.763.900                         | Other current assets               |
| <b>Aset Tidak Lancar</b>          |                                           |                                    | <b>Non-Current Assets</b>          |
| Investasi jangka panjang          | 76.364.882.225                            | 76.364.882.225                     | Long term-investment               |
| Aset tidak lancar lainnya         | 84.000.000                                | 84.000.000                         | Other non-current assets           |
| <b>Jumlah Aset Keuangan</b>       | <b>1.659.282.616.554</b>                  | <b>1.659.282.616.554</b>           | <b>Total Financial Asset</b>       |
| <b>Liabilitas Keuangan</b>        |                                           |                                    | <b>Financial liabilities</b>       |
| <b>Liabilitas Jangka Pendek</b>   |                                           |                                    | <b>Current Liabilities</b>         |
| Utang usaha                       | 90.594.104.054                            | 90.594.104.054                     | Trade payables                     |
| Utang non-usaha                   | 3.892.849.948                             | 3.892.849.948                      | Non-trade payables                 |
| Beban masih harus dibayar         | 8.889.867.743                             | 8.889.867.743                      | Accrued expenses                   |
| Liabilitas sewa                   | 11.926.541.615                            | 11.926.541.615                     | Lease liabilities                  |
| <b>Liabilitas Jangka Panjang</b>  |                                           |                                    | <b>Non-Current Liabilities</b>     |
| Liabilitas sewa                   | 13.683.411.015                            | 13.683.411.015                     | Lease liabilities                  |
| Surat utang jangka menengah       | 159.916.759.651                           | 159.916.759.651                    | Medium-term notes                  |
| <b>Jumlah Liabilitas Keuangan</b> | <b>288.903.534.026</b>                    | <b>288.903.534.026</b>             | <b>Total Financial Liabilities</b> |

Nilai wajar adalah harga yang akan diterima untuk menjual suatu aset atau harga yang akan dibayarkan untuk mengalihkan suatu liabilitas dalam transaksi teratur antara pelaku pasar pada tanggal pengukuran. Nilai wajar didapatkan dari kuotasi harga pasar, model arus kas diskonto dan model penentuan harga opsi yang sewajarnya.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair values are obtained from quoted market prices, discounted cash flow models and option pricing models as appropriate.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Instrumen keuangan yang disajikan di dalam laporan posisi keuangan konsolidasian dicatat sebesar nilai wajar, atau sebaliknya, disajikan dalam jumlah tercatat apabila jumlah tersebut mendekati nilai wajarnya atau nilai wajarnya tidak dapat diukur secara andal. Metode-metode dan asumsi-asumsi di bawah ini digunakan untuk mengestimasi nilai wajar untuk masing-masing kelas instrumen keuangan:

- Instrumen keuangan dengan jumlah tercatat yang mendekati nilai wajarnya

Nilai wajar untuk kas dan setara kas, investasi jangka pendek, piutang usaha, piutang lain-lain, aset lancar lainnya, utang usaha, utang lain-lain, beban masih harus dibayar, liabilitas lancar lainnya dan liabilitas imbalan kerja, mendekati nilai tercatatnya karena bersifat jangka pendek. Jumlah tercatat dari investasi jangka panjang, liabilitas sewa, surat utang jangka menengah dan obligasi dengan suku bunga mengambang mendekati nilai wajarnya karena selalu dinilai ulang secara berkala.

- Instrumen keuangan dicatat pada nilai selain nilai wajar.

Liabilitas sewa dan surat utang jangka menengah dilaporkan sebesar nilai kininya, yang mendekati jumlah kas yang akan sepenuhnya memenuhi kewajiban pada tanggal pelaporan.

- dan liabilitas keuangan tidak lancar yang tidak memiliki kuotasi pasar yang dipublikasikan pada pasar aktif dan nilai wajar tidak dapat diukur secara andal (penyertaan saham) dicatat pada biaya perolehan.

Financial instruments presented in the consolidated statement of financial position are carried at their fair values, otherwise, they are presented at carrying values as either these are reasonable approximation of fair values or their fair values cannot be reliably measured. The following methods and assumptions are used to estimate the fair value of each class of financial instruments:

- Financial instruments with carrying amounts that approximate their fair values

The fair value of cash and cash equivalents, short-term investment, trade receivables, other receivables, other current assets, trade payables, other payables, accrued expenses and other current liabilities approximate their carrying values due to their short-term nature. The carrying values of long-term investments, lease liabilities, Medium-Term Notes and floating rate bonds approximate their fair value as effect of discounting is considered immaterial.

- Financial instruments recorded at amounts other than fair value.

Lease liabilities and Medium-Term Notes are reported at their present values, which approximate the cash amounts that would fully satisfy the obligations as at reporting date.

- Non-current financial assets and liabilities which do not have quoted prices in active market and whose fair value cannot be measured reliably (such as investment in equity securities) are recorded at cost.

| 30 Juni/June 2025         |                     |                     |                                                           |
|---------------------------|---------------------|---------------------|-----------------------------------------------------------|
|                           | Tingkat/<br>Level 1 | Tingkat/<br>Level 2 | Tingkat/<br>Level 3                                       |
| Aset Keuangan             |                     |                     |                                                           |
| Aset Lancar               |                     |                     |                                                           |
| Aset lancar lainnya       | -                   | -                   | 66.763.900                                                |
|                           |                     |                     | Financial Asset<br>Current Assets<br>Other current assets |
| 31 Desember/December 2024 |                     |                     |                                                           |
|                           | Tingkat/<br>Level 1 | Tingkat/<br>Level 2 | Tingkat/<br>Level 3                                       |
| Aset Keuangan             |                     |                     |                                                           |
| Aset Lancar               |                     |                     |                                                           |
| Aset lancar lainnya       | -                   | -                   | 66.763.900                                                |
|                           |                     |                     | Financial Asset<br>Current Assets<br>Other current assets |

Aset lancar lainnya merupakan logam mulia sebesar Rp 66.763.900.

Other current assets represents precious metals amounting to Rp 66,763,900.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**42. TUJUAN DAN KEBIJAKAN MANAJEMEN RISIKO KEUANGAN**

Dalam transaksi normal Perusahaan, secara umum terekspos risiko keuangan sebagai berikut:

- Risiko tingkat suku bunga
- Risiko kredit
- Risiko likuiditas
- Risiko nilai tukar mata uang asing

Catatan ini menjelaskan mengenai eksposur Perusahaan dan Entitas Anak terhadap masing-masing risiko di atas dan pengungkapan secara kuantitatif termasuk seluruh eksposur risiko serta merangkum kebijakan dan proses-proses yang dilakukan untuk mengukur dan mengelola risiko yang timbul, termasuk yang terkait dengan pengelolaan modal.

Direksi Perusahaan dan Entitas Anak bertanggung jawab dalam melaksanakan kebijakan manajemen risiko keuangan Perusahaan dan Entitas Anak dan secara keseluruhan program manajemen risiko keuangan Perusahaan dan Entitas Anak difokuskan pada ketidakpastian pasar keuangan dan meminimalisasi potensi kerugian yang berdampak pada kinerja keuangan Perusahaan dan Entitas Anak.

Risiko Tingkat Suku Bunga

Kebijakan manajemen risiko Perusahaan dan Entitas Anak adalah untuk meminimalkan eksposur risiko arus kas suku bunga terhadap perubahan suku bunga. Perusahaan dan Entitas Anak memiliki liabilitas sewa dan surat utang jangka menengah dengan tingkat bunga tetap. Oleh karena itu, Perusahaan dan Entitas Anak tidak terpengaruh oleh perubahan tingkat suku bunga.

Risiko kredit

Risiko kredit merupakan risiko atas kerugian keuangan Perusahaan dan Entitas Anak jika pelanggan atau pihak lain dari instrumen keuangan gagal memenuhi liabilitas kontraktualnya. Manajemen berpendapat bahwa tidak terdapat risiko kredit yang terkonsentrasi secara signifikan. Perusahaan dan Entitas Anak selalu melakukan pemantauan kolektibilitas dan penelaahan atas masing-masing piutang pelanggan secara berkala untuk mengantisipasi kemungkinan tidak tertagihnya piutang dan melakukan pembentukan cadangan dari hasil penelaahan tersebut.

Untuk mengurangi risiko gagal bayar atas penempatan deposito berjangka pada bank, Perusahaan dan Entitas Anak memiliki kebijakan hanya akan menempatkan deposito berjangka pada bank yang memiliki reputasi yang baik.

**42. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES**

*In the normal transactions of the Company, generally exposed to financial risk as follows:*

- Interest rate risk*
- Credit risk*
- Liquidity risk*
- Foreign currency risk*

*This note describes the Company and its Subsidiaries' exposure to each of the above risks and quantitative disclosures including all risk exposures and summarizes the policies and processes undertaken to measure and manage the risks that arise, including those related to capital management.*

*The Company and its Subsidiaries' Directors are responsible for implementing the Company and its Subsidiaries' financial risk management policies and the Company and its Subsidiaries' overall financial risk management program is focused on financial market uncertainty and minimizing potential losses that may impact the Company and its Subsidiaries' financial performance.*

Interest Rate Risk

*The Company and its Subsidiaries' risk management policy is to minimize interest rate cash flow risk exposures to changes in interest rates. The Company and its Subsidiaries have lease liabilities and Medium-Term Notes with fixed interest rates. Therefore, the Company and its Subsidiaries are not subject to the effect of changes in interest rates.*

Interest Rate Risk

*Credit risk is the risk of financial loss to the Company and its Subsidiaries' if the customer or other party to the financial instrument fails to fulfill its contractual obligations. Management believes that there is no significant concentration of credit risk. The Company and its Subsidiaries' always monitor the collectibility and reviews of each customer's receivables on a regular basis to anticipate the possibility of uncollectible receivables and makes allowances for the results of the review.*

*To mitigate the default risk of banks on the Company and its Subsidiaries' time deposits, the Company and its Subsidiaries have policies to place its time deposits only in banks with good reputation.*

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

Tabel di bawah ini menunjukkan risiko kredit maksimum untuk komponen-komponen dari laporan posisi keuangan konsolidasian pada 30 Juni 2025 dan 31 Desember 2024:

The table below shows the maximum exposure to credit risk on the components of the consolidated statement of financial position as of June 30, 2025 and December 31, 2024:

|                          | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                           |
|--------------------------|--------------------------|----------------------------------|---------------------------|
| Kas dan setara kas       | 1.130.358.960.131        | 1.224.705.775.933                | Cash and cash equivalents |
| Investasi jangka pendek  | 34.458.799.858           | 89.496.731.646                   | Short-term investments    |
| Piutang usaha            | 302.301.211.667          | 265.191.997.451                  | Trade receivables         |
| Piutang non-usaha        | 5.537.850.068            | 3.372.465.398                    | Non-trade receivables     |
| Aset lancar lainnya      | 66.763.900               | 66.763.900                       | Other current assets      |
| Investasi jangka panjang | 190.006.366.110          | 76.364.882.225                   | Long-term Investment      |
| Deposito Berjangka       | 5.000.000.000            | -                                | Time Deposit              |
| Aset tidak lancar lain   | -                        | 84.000.000                       | Other non-current assets  |
| <b>Jumlah</b>            | <b>1.667.729.951.734</b> | <b>1.659.282.616.553</b>         | <b>Total</b>              |

Pada 30 Juni 2025 dan 31 Desember 2024, piutang usaha sebesar Rp 234.625.660.734 dan Rp 209.101.784.113 belum jatuh tempo dan tidak mengalami penurunan nilai. Piutang tersebut akan jatuh tempo dalam 30 hari ke depan.

As of June 30, 2025 and December 31, 2024, trade receivables of Rp 234,625,660,734 and Rp 209,101,784,113 were not yet past due not impaired. Those receivables will be due within 30 days.

Pada 30 Juni 2025 dan 31 Desember 2024, piutang usaha sebesar Rp 73.099.444.485 dan Rp 56.090.213.338 telah lewat jatuh tempo namun tidak mengalami penurunan nilai. Pada 30 Juni 2025 dan 31 Desember 2024, piutang usaha sebesar Rp 5.423.893.552 dan Rp. 5.448.970.460 mengalami penurunan nilai dan telah diprovisikan secara penuh.

As of June 30, 2025 and December 31, 2024, trade receivables of Rp 73,099,444,485 and Rp 56,090,213,338 were past due but not impaired. As of June 30, 2025 and December 31, 2024, trade receivables of Rp 5,423,893,552 and Rp. 5,448,970,460 were impaired and provision has been fully made.

Tabel di bawah ini menyajikan eksposur Perusahaan dan Entitas Anak terhadap risiko kredit dan menunjukkan kualitas kredit aset dengan menunjukkan apakah aset tersebut dikenakan ECL 12 bulan atau ECL seumur hidup. Aset yang mengalami penurunan nilai kredit disajikan secara terpisah.

The table below presents the Company and its Subsidiaries's exposure to credit risk and show the credit quality of the assets by indicating whether the assets are subjected to 12-month ECL or lifetime ECL. Assets that are credit-impaired are separately presented.

|                         | 30 Juni/June 2025                                                                       |                                                                                                 |                                                                                        |                          |                           |
|-------------------------|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|--------------------------|---------------------------|
|                         | Aset keuangan pada biaya perolehan diamortisasi/<br>Financial assets at amortized costs |                                                                                                 |                                                                                        |                          |                           |
|                         |                                                                                         | ECL<br>selamanya-<br>tidak ada<br>penurunan<br>nilai/<br>Lifetime ECL-<br>no credit<br>impaired | ECL<br>selamanya-<br>ada<br>penurunan<br>nilai/<br>Lifetime ECL-<br>credit<br>impaired | Jumlah/<br>Total         |                           |
|                         | ECL 12 bulan/<br>12-month ECL                                                           |                                                                                                 |                                                                                        |                          |                           |
| Kas dan setara kas      | 1.130.358.960.131                                                                       | -                                                                                               | -                                                                                      | 1.130.358.960.131        | Cash and cash equivalents |
| Investasi jangka pendek | 34.458.799.858                                                                          | -                                                                                               | -                                                                                      | 34.458.799.858           | Short-term investments    |
| Piutang usaha           | -                                                                                       | 302.301.211.667                                                                                 | 5.423.893.552                                                                          | 307.725.105.219          | Trade receivables         |
| Piutang non-usaha       | -                                                                                       | 5.537.850.068                                                                                   | -                                                                                      | 5.537.850.068            | Non-trade receivables     |
| Aset lancar lain        | 66.763.900                                                                              | -                                                                                               | -                                                                                      | 66.763.900               | Other current assets      |
| Aset tidak lancar lain  | -                                                                                       | -                                                                                               | -                                                                                      | -                        | Other-noncurrent assets   |
| <b>Jumlah</b>           | <b>1.164.884.523.889</b>                                                                | <b>307.839.061.735</b>                                                                          | <b>5.423.893.552</b>                                                                   | <b>1.478.147.479.176</b> | <b>Total</b>              |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

| <b>31 Desember/December 2024</b>                       |                                       |                                                                                                               |                                                                                                      |                          |                           |
|--------------------------------------------------------|---------------------------------------|---------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|--------------------------|---------------------------|
| <b>Aset keuangan pada biaya perolehan diamortisasi</b> |                                       |                                                                                                               |                                                                                                      |                          |                           |
| <b>Financial assets at amortized costs</b>             |                                       |                                                                                                               |                                                                                                      |                          |                           |
|                                                        |                                       | <b>ECL<br/>selamanya-<br/>tidak ada<br/>penurunan<br/>nilai/<br/>Lifetime ECL-<br/>no credit<br/>impaired</b> | <b>ECL<br/>selamanya-<br/>ada<br/>penurunan<br/>nilai/<br/>Lifetime ECL-<br/>credit<br/>impaired</b> | <b>Jumlah/<br/>Total</b> |                           |
|                                                        | <b>ECL 12 bulan/<br/>12-month ECL</b> |                                                                                                               |                                                                                                      |                          |                           |
| Kas dan setara kas                                     | 1.224.705.775.933                     | -                                                                                                             | -                                                                                                    | 1.224.705.775.933        | Cash and cash equivalents |
| Investasi jangka pendek                                | 89.496.731.646                        | -                                                                                                             | -                                                                                                    | 89.496.731.646           | Short-term investments    |
| Piutang usaha                                          | -                                     | 265.191.997.451                                                                                               | 5.448.970.460                                                                                        | 270.640.967.911          | Trade receivables         |
| Piutang non-usaha                                      | -                                     | 3.372.465.398                                                                                                 | -                                                                                                    | 3.372.465.398            | Non-trade receivables     |
| Aset lancar lain                                       | 66.763.900                            | -                                                                                                             | -                                                                                                    | 66.763.900               | Other current assets      |
| Aset tidak lancar lain                                 | 84.000.000                            | -                                                                                                             | -                                                                                                    | 84.000.000               | Other-noncurrent assets   |
| <b>Jumlah</b>                                          | <b>1.314.353.271.479</b>              | <b>268.564.462.849</b>                                                                                        | <b>5.448.970.460</b>                                                                                 | <b>1.588.366.704.788</b> | <b>Total</b>              |

Berikut kualitas kredit aset keuangan Perusahaan dan Entitas Anak:

The following is the credit quality of the Company and its Subsidiaries financial assets:

| <b>30 Juni/June 2025</b> |                                                 |                                   |                          |                           |
|--------------------------|-------------------------------------------------|-----------------------------------|--------------------------|---------------------------|
|                          | <b>Level<br/>menengah/<br/>Medium<br/>grade</b> | <b>Level bawah/<br/>Low grade</b> | <b>Jumlah/<br/>Total</b> |                           |
|                          | <b>Level tinggi/<br/>High grade</b>             |                                   |                          |                           |
| Kas dan setara kas       | 1.130.358.960.131                               | -                                 | 1.130.358.960.131        | Cash and cash equivalents |
| Investasi jangka pendek  | 34.458.799.858                                  | -                                 | 34.458.799.858           | Short-term investments    |
| Piutang usaha            | 234.625.660.734                                 | 61.479.166.057                    | 307.725.105.219          | Trade receivables         |
| Piutang non-usaha        | 5.537.850.068                                   | -                                 | 5.537.850.068            | Non-trade receivables     |
| Investasi jangka panjang | 190.006.366.110                                 | -                                 | 190.006.366.110          | Long-term investment      |
| Deposito Berjangka       | 5.000.000.000                                   | -                                 | 5.000.000.000            | Time Deposit              |
| Aset tidak lancar lain   | -                                               | -                                 | -                        | Other-noncurrent assets   |
| <b>Jumlah</b>            | <b>1.599.987.636.901</b>                        | <b>61.479.166.057</b>             | <b>1.673.087.081.386</b> | <b>Total</b>              |

| <b>31 Desember/December 2024</b> |                                                 |                                   |                          |                           |
|----------------------------------|-------------------------------------------------|-----------------------------------|--------------------------|---------------------------|
|                                  | <b>Level<br/>menengah/<br/>Medium<br/>grade</b> | <b>Level bawah/<br/>Low grade</b> | <b>Jumlah/<br/>Total</b> |                           |
|                                  | <b>Level tinggi/<br/>High grade</b>             |                                   |                          |                           |
| Kas dan setara kas               | 1.224.705.775.933                               | -                                 | 1.224.705.775.933        | Cash and cash equivalents |
| Investasi jangka pendek          | 89.496.731.646                                  | -                                 | 89.496.731.646           | Short-term investments    |
| Piutang usaha                    | 209.101.784.113                                 | 55.084.048.109                    | 270.640.967.911          | Trade receivables         |
| Piutang non-usaha                | 3.372.465.398                                   | -                                 | 3.372.465.398            | Non-trade receivables     |
| Investasi jangka panjang         | 76.364.882.225                                  | -                                 | 76.364.882.225           | Long-term investment      |
| Aset tidak lancar lain           | 84.000.000                                      | -                                 | 84.000.000               | Other-noncurrent assets   |
| <b>Jumlah</b>                    | <b>1.603.125.639.315</b>                        | <b>55.084.048.109</b>             | <b>1.664.664.823.113</b> | <b>Total</b>              |

Piutang usaha dan non-usaha yang dinilai *high grade* berkaitan dengan piutang dari pembeli yang tidak mengalami gagal bayar; *medium grade* adalah piutang dari pembeli yang memiliki riwayat jatuh tempo 1 sampai 90 hari; dan *low grade* berkaitan dengan piutang dari pembeli yang memiliki riwayat jatuh tempo lebih dari 90 hari. Saldo piutang dipantau secara teratur untuk memastikan pelaksanaan upaya intervensi yang diperlukan tepat waktu. Perusahaan dan Entitas Anak melakukan investigasi dan evaluasi kredit untuk setiap

Trade and non-trade receivables assessed as *high grade* pertains to receivable from buyer that had no default in payment; *medium grade* pertains to receivable from buyer who has history of being 1 to 90 days past due; and *low grade* pertains to receivable from buyer who has history of being over 90 days past due. Receivable balances are being monitored on a regular basis to ensure timely execution of necessary intervention efforts. The Company and its Subsidiaries perform credit investigation and evaluation of each

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

pembeli untuk menetapkan kapasitas pembayaran dan kelayakan kredit. Perusahaan dan Entitas Anak akan menilai kolektibilitas piutang dan memberikan penyisihan penyisihan setelah akun tersebut dianggap mengalami penurunan nilai. Perusahaan dan Entitas Anak menilai kualitas kredit dari kas yang tidak dibatasi penggunaannya dan aset lancar lain sebagai kualitas tinggi karena disimpan dan diinvestasikan pada bank terkemuka dengan kemungkinan kebangkrutan yang rendah.

**Risiko likuiditas**

Risiko kredit untuk aset lancar lainnya dan aset tidak lancar lainnya - jaminan yang dapat dikembalikan dianggap dapat diabaikan dikarenakan entitas yang secara umum memiliki financial yang stabil.

Perusahaan dan Entitas Anak mengelola profil likuiditasnya untuk dapat mendanai pengeluaran modalnya dan mengelola utang yang jatuh tempo dengan mengatur kas dan ketersediaan pendanaan melalui jumlah komitmen fasilitas kredit yang cukup.

Perusahaan dan Entitas Anak secara reguler mengevaluasi proyeksi arus kas dan terus-menerus menilai kondisi pasar keuangan untuk mengidentifikasi kesempatan dalam penggalangan dana.

Tabel di bawah ini merupakan jadwal jatuh tempo liabilitas keuangan Perusahaan dan Entitas Anak berdasarkan pembayaran kontraktual semula yang tidak didiskontokan:

buyer to establish paying capacity and creditworthiness. The Company and its Subsidiaries will assess the collectibility of its receivables and provide a corresponding allowance provision once the account is considered impaired. The Company and its Subsidiaries assessed the credit quality of unrestricted cash and other current assets as high grade since this is deposited and invested with reputable banks with low probability of insolvency.

**Liquidity risk**

The credit risk for other current assets and other non-current assets - refundable deposits is considered negligible because this was due from entities that are generally financially stable.

The Company and its Subsidiaries manage its liquidity profile to be able to finance its capital expenditures and service its maturity debts by maintaining sufficient cash and the availability of funding through an adequate amount of committed credit facilities.

The Company and its Subsidiaries regularly evaluate its projected cash flow information and continuously assesses conditions in the financial markets for opportunities to pursue fundraising initiatives.

The table below summarizes the maturity periods of the Company and its Subsidiaries' financial liabilities based on original contractual undiscounted amounts to be paid:

| <b>30 Juni/June 2025</b>         |                          |                                                   |                                                    |
|----------------------------------|--------------------------|---------------------------------------------------|----------------------------------------------------|
|                                  | <b>Jumlah/<br/>Total</b> | <b>Dalam waktu<br/>1 tahun/<br/>Within 1 year</b> | <b>Lebih dari<br/>1 tahun/More<br/>than 1 year</b> |
| Utang usaha                      | 99.459.423.099           | 99.459.423.099                                    | -                                                  |
| Utang non-usaha                  | 8.545.105.223            | 8.545.105.223                                     | -                                                  |
| Beban masih harus dibayar        | 5.449.333.055            | 5.449.333.055                                     | -                                                  |
| Liabilitas sewa                  | 26.293.661.609           | 11.989.936.291                                    | 14.303.725.318                                     |
| Pinjaman Bank                    | 4.706.925.626            | 1.790.258.963                                     | 2.916.666.663                                      |
| Surat utang jangka menengah      | -                        | -                                                 | -                                                  |
| <b>Jumlah</b>                    | <b>144.454.448.612</b>   | <b>127.234.056.631</b>                            | <b>17.220.391.981</b>                              |
| <b>31 Desember/December 2024</b> |                          |                                                   |                                                    |
|                                  | <b>Jumlah/<br/>Total</b> | <b>Dalam waktu<br/>1 tahun/<br/>Within 1 year</b> | <b>Lebih dari<br/>1 tahun/More<br/>than 1 year</b> |
| Utang usaha                      | 90.594.104.054           | 90.594.104.054                                    | -                                                  |
| Utang non-usaha                  | 3.892.849.948            | 3.892.849.948                                     | -                                                  |
| Beban masih harus dibayar        | 8.889.867.741            | 8.889.867.741                                     | -                                                  |
| Liabilitas sewa                  | 25.609.952.630           | 11.926.541.615                                    | 13.683.411.015                                     |
| Surat utang jangka menengah      | 171.200.000.000          | 171.200.000.000                                   | -                                                  |
| <b>Jumlah</b>                    | <b>300.186.774.373</b>   | <b>286.503.363.358</b>                            | <b>13.683.411.015</b>                              |
|                                  |                          |                                                   | <b>T o t a l</b>                                   |

**Risiko mata uang asing**

Mata uang pelaporan Perusahaan dan Entitas Anak adalah Rupiah. Perusahaan dan Entitas Anak

**Foreign currency risk**

The Company and Subsidiaries' reporting currency is the Indonesian Rupiah. The Company and Subsidiaries

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

menghadapi risiko nilai tukar mata uang asing karena sebagian dari penjualannya dan biaya pembelian dan pengeluaran tertentu dalam mata uang asing (terutama USD) atau yang harganya dipengaruhi secara signifikan oleh patokan pergerakan harga dalam mata uang asing seperti dikutip dalam pasar internasional.

Perusahaan dan Entitas Anak tidak memiliki kebijakan formal lindung nilai untuk eksposur valuta asing. Namun, karena Perusahaan dan Entitas Anak melakukan penjualan dalam mata uang asing dan menimbulkan biaya/beban dalam mata uang asing yang sama, hal ini sesuai dengan hal-hal yang dibahas dalam paragraf sebelumnya, fluktuasi nilai tukar antara Rupiah Indonesia dan mata uang asing lainnya (terutama USD) memberikan beberapa tingkat lindung nilai alami untuk eksposur mata uang asing Perusahaan dan Entitas Anak.

Pada tanggal 30 Juni 2025 dan 31 Desember 2024, jika Rupiah melemah/menguat sebesar 10% terhadap mata uang asing, dengan semua variabel lain dianggap konstan, laba sebelum pajak penghasilan untuk tahun yang berakhir pada tanggal 30 Juni 2025 dan 31 Desember 2024 akan menjadi Rp 34.164.789.344 dan Rp 30.754.570.387 lebih tinggi/rendah, terutama sebagai akibat dari keuntungan/(kerugian) selisih kurs atas penjabaran aset dan kewajiban moneter bersih dalam mata uang asing.

face foreign exchange risk as a portion of its sales and the costs of certain purchases and expenses are either denominated in foreign currencies (mainly USD) or whose price is significantly influenced by their benchmark price movements in foreign currencies as quoted in the international markets.

The Company and Subsidiaries do not have any formal hedging policy for foreign exchange exposure. However, since Company and Subsidiaries generate sales in foreign currencies and incur costs/expenses in those same foreign currencies, this in accordance with matters discussed in the preceding paragraph, the fluctuations in the exchange rates between the Indonesian Rupiah and other foreign currencies (mainly USD) provides some degree of natural hedge for the Company and Subsidiaries' foreign currency exposure.

As of June 30 2025 and December 31, 2024, if the Indonesian Rupiah had weakened/strengthened by 10% against the foreign currencies, with all other variables held constant, profit before income tax for the years ended June 30, 2025 and December 31, 2024 would have been Rp 34,164,789,344 and Rp 30,754,570,387 higher/lower, mainly as a result of foreign exchange gains/(losses) on the translation of the net monetary assets and liabilities denominated in foreign currencies.

**43. MANAJEMEN PERMODALAN**

Tujuan utama dari pengelolaan modal Perusahaan dan Entitas Anak adalah untuk memastikan bahwa dipertahankannya peringkat kredit yang kuat dan rasio modal yang sehat agar dapat mendukung kelancaran usahanya dan memaksimalkan nilai dari pemegang saham.

Perusahaan dan Entitas Anak tidak memiliki kebijakan formal lindung nilai untuk eksposur valuta asing. Namun, karena Perusahaan dan Entitas Anak melakukan penjualan dalam mata uang asing dan menimbulkan biaya/beban dalam mata uang asing yang sama, hal ini sesuai dengan hal-hal yang dibahas dalam paragraf sebelumnya, fluktuasi nilai tukar antara Rupiah Indonesia dan mata uang asing lainnya (terutama USD) memberikan beberapa tingkat lindung nilai alami untuk eksposur mata uang asing Perusahaan dan Entitas Anak.

**43. CAPITAL MANAGEMENT**

The main objective of the Company and its Subsidiaries' capital management is to ensure that it maintains a strong credit rating and healthy capital ratios in order to support its business and maximize shareholder value.

The Company and Subsidiaries do not have any formal hedging policy for foreign exchange exposure. However, since Company and Subsidiaries generate sales in foreign currencies and incur costs/expenses in those same foreign currencies, this in accordance with matters discussed in the preceding paragraph, the fluctuations in the exchange rates between the Indonesian Rupiah and other foreign currencies (mainly USD) provides some degree of natural hedge for the Company and Subsidiaries' foreign currency exposure.

|                                            | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |                                 |
|--------------------------------------------|--------------------------|----------------------------------|---------------------------------|
| Utang dan pinjaman                         | 146.293.973.265          | 290.246.496.692                  | Payables and loan               |
| Dikurangi: kas dan setara kas              | ( 1.130.358.960.131)     | ( 1.224.705.775.933)             | Less: Cash and cash equivalents |
| Pinjaman neto                              | ( 984.064.986.866)       | ( 934.459.279.241)               | Net debt                        |
| Jumlah ekuitas                             | 2.547.925.997.279        | 2.495.688.705.886                | Total equity                    |
| <b>Rasio utang terhadap permodalan (%)</b> | <b>-</b>                 | <b>-</b>                         | <b>Debt to Equity (%)</b>       |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**44. PERJANJIAN-PERJANJIAN PENTING, KOMITMEN  
DAN KONTINJENSI**

**Perusahaan**

**Perjanjian Kerjasama Manufaktur dengan PT Ultra Sakti**

Berdasarkan perjanjian No. 004/JMI-LEGAL/VI/2025 tanggal 15 Mei 2025 antara Perusahaan dengan PT Ultra Sakti mengenai kerjasama pembuatan produk aerosol dengan merek datang "Hotin Cool Spray". Perjanjian ini berlaku sejak tanggal 15 Mei 2025 sampai dengan 15 Mei 2030

**Perjanjian Pabrik dengan PT MEDCAPTAIN MEDICAL INDONESIA**

Pada tanggal 15 Mei 2024, Perusahaan mengadakan perjanjian kerja sama dengan PT Medcaptain Medical Indonesia untuk merakit komponen dan memproduksi pompa infus dan pompa jarum suntik merek Medcaptain sejak tanggal 1 Mei 2024 sampai dengan 30 Desember 2029.

**Perjanjian Pasokan Gas PT Jayamas Medica Industri Tbk dengan Perusahaan Gas Negara Tbk**

Berdasarkan perjanjian, PGN akan menyerahkan Gas kepada pelanggan di titik penyerahan yaitu Kawasan KITB, Kavling II-1, Kecamatan Gringsing, Kabupaten Batang, Jawa Tengah. PGN dan JMI menyepakati tanggal dimulainya pasokan Gas di Desember 2024. JMI dan PGN sepakat untuk memulai perjanjian ini di Desember 2024 dan berakhir di 31 Maret 2029.

**Perjanjian Distribusi dengan Tianjin Huahong Technology Co., Ltd. China**

Pada tanggal 3 Agustus 2020, Perusahaan mengadakan perjanjian distribusi dengan Tianjin Huahong Technology Co., Ltd. China ("Tianjin"). Berdasarkan perjanjian ini, Tianjin menunjuk Perusahaan untuk menjual alat kesehatan di wilayah Republik Indonesia, antara lain Safety Lancet, Blood Lancet dan Autoclick Lancing Device, dengan merek Perusahaan, 'OneMed'. Perjanjian ini berfungsi sebagai otorisasi bagi perusahaan untuk mendistribusikan produk Tianjin di Indonesia. Para pihak akan meninjau harga produk setiap tahun. Perjanjian ini berlaku sejak tanggal 3 Agustus 2020 sampai dengan tanggal 31 Desember 2025.

**Perjanjian Kerjasama Ekspedisi dengan PT Jayamas Tata Karunia**

Berdasarkan perjanjian No. 44/JMI/III/2022 tanggal 21 Maret 2022 antara Perusahaan dengan PT Jayamas Tata Karunia mengenai pengiriman barang yang meliputi alat-alat kesehatan rumah tangga hasil produksi untuk periode 1 Januari 2022 sampai 31 Desember 2026.

**44. SIGNIFICANT AGREEMENTS, COMMITMENTS AND CONTINGENCIES**

**Company**

**Manufacture Cooperation Agreement with PT Ultra Sakti**

Based on agreement No 004/JMI-LEGAL/VI/2025 dated May 15, 2025 between the Company and PT Ultra Sakti regarding the manufacture of aerosol product of brand "Hotin Cool Spray". This agreement is valid starting from May 15, 2025 until May 15, 2030

**Manufacture Agreement with PT MEDCAPTAIN MEDICAL INDONESIA**

On May 15, 2024, the Company entered into a distribution agreement with PT Medcaptain Medical Indonesia agrees to cooperate with Medcaptain in assembling components and manufacture product for Medcaptain-brand infusion pumps and syringe pumps valid from May 1, 2024 until December 30, 2029.

**Agreement Gas Supply of PT Jayamas Medica Industri Tbk with Perusahaan Gas Negara Tbk**

Based on agreement, PGN will hand over gas to customers at the point of delivery, namely the KITB Area, Plot II-1, Gringsing District, Batang Regency, Central Java. PGN and JMI agreed on the start date of gas supply in December 2024. JMI and PGN agreed to start this agreement in December 2024 and end on March 31, 2029.

**Distribution Agreement with Tianjin Huahong Technology Co., Ltd. China**

On August 3, 2020, the Company entered into a distribution agreement with Tianjin Huahong Technology Co., Ltd. China ("Tianjin"). Based on this agreement, Tianjin appoints the Company to sell medical devices in territory of the Republic of Indonesia, including Safety Lancet, Blood Lancet and Autoclick Lancing Device, under the Company's brand, 'OneMed'. This agreement serves as an authorization for the company to distribute Tianjin's products in Indonesia. The parties will review the price of the products annually. This agreement is valid from August 3, 2020 until December 31, 2025.

**Expedition Cooperation Agreement with PT Jayamas Tata Karunia**

Based on agreement No. 44/JMI/III/2022 dated March 21, 2022 between the Company and PT Jayamas Tata Karunia regarding the delivery of goods which include household medical equipment production result for period January 1, 2022 until December 31, 2026.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**Entitas Anak**

**Perjanjian Distribusi dengan Bionet Co., Ltd.**

Pada tanggal 1 Februari 2024, Perusahaan mengadakan perjanjian distribusi dengan Bionet Co., Ltd. Berdasarkan perjanjian ini, Bionet menunjuk Perusahaan untuk menjual alat kesehatan di wilayah Republik Indonesia, antara lain ECG devices, fetal monitor, dan pulse oximeter dengan merek perusahaan, 'OneMed'. Perjanjian ini berlaku selama dua tahun terhitung sejak 1 Februari 2024 sampai dengan 31 Januari 2026.

**Perjanjian IHSG dengan PT Fresenius Kabi Indonesia**

Berdasarkan perjanjian No. 015/FKI-IHS/MU-ADD/AGR-00/01- 2020 tanggal 1 Januari 2020, addendum No. 094/FKI-IHS/MU-DD/AMD-01/11-2020 tanggal 10 November 2020 dan perjanjian terakhir No. 116/FKI-IHS/MU-QTY/AMD-01/12-2020 tanggal 17 Desember 2020, PT Fresenius Kabi Indonesia menunjuk PT Intisumber Hasil Sempurna sebagai distributornya, dengan periode 3 tahun sejak tanggal perjanjian. Dengan perjanjian No. 005/FKI-IHS-IHSG/MU-AD/AGR-00/02-2021 tanggal 1 Februari 2021, perikatan dari PT Intisumber Hasil Sempurna dialihkan ke PT Intisumber Hasil Sempurna Global. Berdasarkan perjanjian No. 005/FKI-IHSG/MU-ADD/AMD-02/01-2023 tanggal 1 Januari 2023, PT Intisumber Hasil Sempurna Global dan PT Fresenius Kabi Indonesia menandatangani amandemen kedua atas perjanjian distribusi yang mengubah dan menyatakan kembali mengenai jangka waktu perjanjian yang awalnya dimulai sejak tanggal 1 Januari 2020 dan akan otomatis sampai pada tanggal 31 Desember 2026.

Pada tanggal 12 Juni 2023 berdasarkan perjanjian No. 005/FKI-IHSG/MU-ADD/AMD-03/06-2023, PT Intisumber Hasil Sempurna Global dan PT Fresenius Kabi Indonesia menandatangani kembali perjanjian distribusi untuk amandemen yang ketiga mengenai ketentuan standar tinggi, komitmen untuk bertindak dengan cara yang etis dan sesuai hukum serta menjaga kualitas dan kerahasiaan yang berlaku bagi distributor dan semua pihak yang bekerja sama dengan PT Fresenius Kabi Indonesia.

Pada tanggal 17 Desember 2023 berdasarkan perjanjian No. 015/FKI-IHS/MU-QTY/QTA-01/12-2023, PT Intisumber Hasil Sempurna Global dan PT Fresenius Kabi Indonesia menandatangani kembali perjanjian distribusi untuk amandemen yang keempat yang mengubah dan menyatakan kembali mengenai jangka waktu perjanjian yang awalnya dimulai sejak tanggal 17 Desember 2023 dan akan otomatis sampai pada tanggal 17 Desember 2026.

**Subsidiaries**

**Distribution Agreement with Bionet Co., Ltd.**

On February 1, 2024, the Company entered into a distribution agreement with Bionet Co., Ltd. Under this agreement, Bionet appointed the Company to sell medical devices in the territory of the Republic of Indonesia, including ECG devices, fetal monitors, and pulse oximeters under the company brand, 'OneMed'. This agreement is valid for two years starting from February 1, 2024 until January 31, 2026.

**Agreement of IHSG with PT Fresenius Kabi Indonesia**

Based on agreement No. 015/FKI-IHS/MU-ADD/AGR-00/01-2020 dated January 1, 2020, No. 094/FKI-IHS/MU-DD/AMD-01/11-2020 dated 10 November 2020, the latest agreement No. 116/FKI-IHS/MU-QTY/AMD-01/12-2020 dated December 17, 2020, PT Fresenius Kabi Indonesia assign PT Intisumber Hasil Sempurna as distributor, period 3 years since date in the agreement. With agreement No. 05/FKI-IHS-IHSG/MU-AD/AGR-00/02-2021 dated February 1, 2021, the engagement from PT Intisumber Hasil Sempurna was transferred to PT Intisumber Hasil Sempurna Global. Based on agreement No. 005/FKI-IHSG/MU-ADD/AMD-02/01-2023 dated January 1, 2023, PT Intisumber Hasil Sempurna Global and PT Fresenius Kabi Indonesia entered into the second amendment to the distribution agreement which amended and restated the term of the agreement which initially commenced on January 1, 2020 and will automatically run until December 31, 2026.

Based on agreement No. 005/FKI-IHSG/MU-ADD/AMD-03/06-2023 dated June 12, 2023, PT Intisumber Hasil Sempurna Global and PT Fresenius Kabi Indonesia re signed a distribution agreement for the third amendment regarding high standard provisions, commitment to act ethically and legally, and to maintain the quality and confidentiality applicable to the distributor and all parties cooperating with PT Fresenius Kabi Indonesia.

Based on agreement No. 015/FKI-IHS/MU-QTY/QTA-01/12-2023 dated December 17, 2023, PT Intisumber Hasil Sempurna Global and PT Fresenius Kabi Indonesia re-signed a distribution agreement for the fourth amendment which amended and restated the term of the agreement which initially commenced on December 17, 2023 and will automatically run until December 17, 2026.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**Perjanjian IHSG dengan PT Prodia Widyahusada Tbk**

Berdasarkan perjanjian No. 006/SPK/PRODIA-IHSG/PENGADAAN/XI/2021 dan No. 002/IHSG-PST/XI/2021 tanggal 1 November 2021 antara PT Intisumber Hasil Sempurna Global dengan PT Prodia Widyahusada Tbk mengenai pengadaan barang untuk laboratorium selama 1 tahun dan otomatis diperpanjang.

**Kontrak Katalog Nasional IHSG**

Berdasarkan Kontrak Katalog Nasional No. 975 Tahun 2021 tanggal 8 Juni 2021 antara PT Intisumber Hasil Sempurna Global dan Lembaga Kebijakan Pengadaan Barang/Jasa Pemerintah. Melalui kontrak ini, PT Intisumber Hasil Sempurna Global mencantumkan dan menyediakan produk alat kesehatan dan penunjang pelayanan kesehatan (non alat kesehatan) melalui Katalog Elektronik Nasional sesuai dengan produk dan harga sebagaimana tercantum dalam Aplikasi Katalog Elektronik selama 1 tahun dan otomatis diperpanjang.

**Kontrak ekspedisi IHSG dengan PT Jayamas Tata Karunia**

Berdasarkan perjanjian No. 003/IHSG-PST/II/2024 tanggal 2 Januari 2024 antara PT Intisumber Hasil Sempurna Global dengan PT Jayamas Tata Karunia mengenai pengiriman barang (sebagai contoh: alat-alat kesehatan dan dokumen) untuk periode 1 Januari 2024 sampai 31 Desember 2025.

**Perjanjian dengan Eka Hospital Group**

Berdasarkan perjanjian No. 009/PKS UMUM/EHG/CORP/II/2023 tanggal 7 Februari 2023, PT Intisumber Hasil Sempurna Global menjalin hubungan kerjasama dengan berbagai pihak, yakni PT Pelita Reliance International Hospital "PRIH", PT Ekamas International Hospital "EIH", PT Pluit Mas Bahagia Sejahtera "PMBS" dan PT Family Bahagia Sejahtera "FBS" perihal komitmen atas harga dan pengadaan alat Kesehatan yang berlaku secara efektif sampai pada tanggal 31 Desember 2024.

**Perjanjian dengan PT Medcaptain Medical Indonesia**

Berdasarkan perjanjian No. 009/IHSG-PST/IV/2023 tanggal 20 April 2023, PT Intisumber Hasil Sempurna Global dan PT Medcaptain Medical Indonesia menandatangani perjanjian distribusi yang menyatakan bahwa Perusahaan telah ditunjuk sebagai distributor atas penjualan produk dari PT Medcaptain Medical Indonesia yang berlaku efektif sampai dengan 31 Desember 2024.

**Agreement of IHSG with PT Prodia Widyahusada Tbk**

Based on agreement No. 006/SPK/PRODIA-IHSG/PENGADAAN/XI/2021 and No. 002/IHSG-PST/XI/2021 dated November 1, 2021 with PT Intisumber Hasil Sempurna Global and PT Prodia Widyahusada Tbk regarding provide goods for laboratorium during 1 year and automatic extend.

**National Catalog Contract of IHSG**

Based on the National Catalog Contract No. 975 of 2021 dated June 8, 2021 between PT Intisumber Hasil Sempurna Global and the Government Goods/Services Procurement Policy Agency. Through this contract, the Company lists and provides medical device products and supporting health services (non-medical devices) through the National Electronic Catalog in accordance with the products and prices as stated in the Electronic Catalog Application during 1 year and automatic extend.

**Expedition contract of IHSG with PT Jayamas Tata Karunia**

Based on agreement No. 003/IHSG-PST/II/2024 dated January 2, 2024 with PT Intisumber Hasil Sempurna Global and PT Jayamas Tata Karunia regarding the delivery of goods (for example: medical equipment and documents) for period January 1, 2024 until December 31, 2025.

**Agreement with Eka Hospital Group**

Based on agreement No. 009/PKS UMUM/EHG/CORP/II/2023 dated February 7, 2023, PT Intisumber Hasil Sempurna Global has established cooperation relationships with various parties, namely PT Pelita Reliance International Hospital "PRIH", PT Ekamas International Hospital "EIH", PT Pluit Mas Bahagia Sejahtera "PMBS" and PT Family Bahagia Sejahtera "FBS" regarding the commitment to prices and procurement of health equipment effective until December 31, 2024.

**Agreement with PT Medcaptain Medical Indonesia**

Based on agreement No. 009/IHSG-PST/IV/2023 dated April 20, 2023, PT Intisumber Hasil Sempurna Global and PT Medcaptain Medical Indonesia have signed a distribution agreement stating that the Company has been appointed as the distributor for the sale of products from PT Medcaptain Medical Indonesia, effective until December 31, 2024.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

**Perjanjian Distributor Antara PT Intisumber Hasil Sempurna Global dan PT Oricare Medical Indonesia.**

Berdasarkan nomor perjanjian OMI/23/MD/DA/007 dijelaskan bahwa JCI merupakan Distributor Eksekutif PT Oricare Medical Indonesia untuk produk tertentu yaitu Anestesi dan Ventilator untuk wilayah tertentu yaitu wilayah DKI Jakarta. Perjanjian ini berlaku sejak tanggal 12 Desember 2023 dan berakhir pada tanggal 31 Desember 2024..

**Perjanjian Implementasi Program Jadi Sistem Informasi Akuntansi (Inspira SIA) IMR**

Berdasarkan Perjanjian No. IPN-IT-SP-1908-001 tanggal 3 Agustus 2019, PT Inti Medicom Retailindo mengadakan kerjasama mengenai implementasi program jadi Sistem Informasi Akuntansi (Inspira SIA) dengan PT Inaugurasi Pelangi Nusantara. Berdasarkan perjanjian ini, PT Inaugurasi Pelangi Nusantara setuju untuk layanan/system untuk membantu operasional IMR. Perjanjian ini berlaku sampai dengan tanggal yang tidak ditentukan.

**Perjanjian Kerjasama IMR Tentang Layanan dan Penggunaan Sistem Jubelio.com**

Berdasarkan Perjanjian Kerjasama No. 1483/JUBE/03/2021 tanggal 8 Maret 2021, PT Inti Medicom Retailindo mengadakan perjanjian kerjasama mengenai sistem Jubelio.com dengan PT Guardia Teknologi Indonesia sebagai penyedia layanan. Berdasarkan perjanjian kerjasama ini, PT Guardia Teknologi Indonesia setuju untuk menyediakan layanan/sistem untuk membantu operasional penjualan omnichannel IMR. Perjanjian kerjasama ini berlaku sampai dengan tanggal 8 Maret 2023 dan otomatis diperpanjang jika membayar iuran tahunan.

**Agreement Between PT Intisumber Hasil Sempurna Global and PT Oricare Medical Indonesia.**

Based on the agreement number OMI/23/MD/DA/007, it is explained that JCI is the Executive distributor of PT Oricare Medical Indonesia for certain products, namely Anesthesia and Ventilators for certain areas, namely the DKI Jakarta area. This agreement starts from December 12, 2023 and ends on December 31, 2024.

**Agreement on the Implementation of the Accounting Information System Program (Inspira SIA) of IMR**

Based on Agreement No. IPN-IT-SP-1908-001 dated August 3, 2019, PT Inti Medicom Retailindo entered into a partnership agreement regarding the implementation of the Accounting Information System (Inspira SIA) program with PT Inaugurasi Pelangi Nusantara. Based on this partnership agreement, PT Inaugurasi Pelangi Nusantara agrees to provide services/system to assist IMR's operational. This agreement is valid until an undetermined date.

**Cooperation Agreement of IMR About Services and Use of Jubelio.com System**

Based on Cooperation Agreement No. 1483/JUBE/03/2021 dated 8 March 2021, PT Inti Medicom Retailindo entered into a partnership agreement regarding Jubelio.com system with PT Guardia Teknologi Indonesia as the service provider. Based on this partnership agreement, PT Guardia Teknologi Indonesia agrees to provide services/system to assist IMR's omnichannel sales operations. This partnership agreement is valid until 8 March 2023 and automatically extended once annual subscription paid.

**45. SEGMENT OPERASI**

Penjelasan jenis-jenis produk dan jasa yang menghasilkan pendapatan dari setiap pelaporan segmen.

Perusahaan dan anak perusahaan memiliki tiga divisi utama:

- Manufaktur – Divisi ini terlibat dalam pembuatan perlengkapan dan peralatan medis.
- Distribusi – Divisi ini terlibat dalam pendistribusian persediaan dan alat kesehatan dalam skala besar di lokasi yang strategis.
- Ritel – Divisi ini terlibat dengan ritel perlengkapan dan peralatan medis melalui toko Medicom dan platform online.

Perusahaan dan Entitas Anak mengklasifikasikan laba rugi dan penghasilan komprehensif berdasarkan produk, yaitu medis sekali pakai dan bahan habis pakai, antiseptik dan dialisis, diagnostik dan peralatan, bioteknologi dan

**45. OPERATING SEGMENT**

Description of the types of products and services from which each reportable segment derives its revenues.

The Company and its Subsidiaries has three main divisions:

- Manufacturing – This division is involved in the manufacture of medical supplies and equipment.
- Distribution – This division is involved with the large scale distribution of medical supplies and equipment at strategic location.
- Retail – This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms.

The Company and its Subsidiaries classify revenue based on product, namely medical disposable and consumables, antiseptic and dialysis, diagnostic and equipment, biotechnology and laboratory, hospital

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

laboratorium, perabotan rumah sakit, alat bantu jalan dan rehabilitasi dan lain-lain.

Faktor-faktor yang digunakan manajemen untuk mengidentifikasi segmen dilaporkan Perusahaan dan Entitas Anak

Segmen pelaporan Perusahaan dan Entitas Anak adalah unit bisnis strategis yang menawarkan produk dan jasa yang berbeda. Unit bisnis strategis dikelola secara terpisah karena masing-masing bisnis memerlukan strategi teknologi dan pemasaran yang berbeda.

Segmen operasi dilaporkan dengan cara yang konsisten dengan pelaporan internal yang diberikan kepada pengambil keputusan operasional utama. Pengambil keputusan operasional utama telah diidentifikasi sebagai tim manajemen termasuk Komisaris Utama, Direktur Utama, dan Direktur Operasi.

Pengukuran segmen operasi laba atau rugi, aset dan liabilitas

Perusahaan dan Entitas Anak mengevaluasi kinerja segmental dengan dasar laba atau rugi dari operasi yang dihitung sesuai dengan PSAK tetapi tidak termasuk kerugian yang tidak berulang.

Harga penjualan antar segmen memiliki ketentuan yang sama seperti penjualan kepada pelanggan eksternal, dengan diskon yang sesuai diterapkan untuk mendorong penggunaan sumber daya Perusahaan dan Entitas Anak pada tingkat yang dapat diterima oleh otoritas pajak setempat. Kebijakan ini diterapkan secara konsisten selama periode kini dan sebelumnya.

furniture, walking aids and rehabilitation care and others.

Factors that management used to identify the Company and its Subsidiaries' reportable segment

The Company and its Subsidiaries' reportable segments are strategic business units that offer different products and services. They are managed separately because each business requires different technology and marketing strategies.

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision maker has been identified as the management team including the President Commissioner, President Director and Director - Operation.

Factors that management used to identify the Company and its Subsidiaries' reportable segment

The Company and its Subsidiaries evaluate segmental performance on the basis of profit or loss from operations calculated in accordance with PSAK but excluding non-recurring losses.

Inter-segment sales are priced along the same lines as sales to external customers, with an appropriate discount being applied to encourage use of the Company and its Subsidiaries' resources at a rate acceptable to local tax authorities. This policy was applied consistently throughout the current and prior period.

| 30 Juni/June 2025                                |                            |                             |                        |                            |                          |                                              |
|--------------------------------------------------|----------------------------|-----------------------------|------------------------|----------------------------|--------------------------|----------------------------------------------|
|                                                  | Manufaktur/<br>Manufacture | Distribusi/<br>Distribution | Eceran/<br>Retail      | Eliminasi/<br>Elimination  | Jumlah/<br>Total         |                                              |
| <b>Pendapatan</b>                                |                            |                             |                        |                            |                          |                                              |
| Jumlah pendapatan                                | 504.003.514.650            | 892.751.988.529             | 99.830.869.141         | -                          | 1.496.586.372.320        | Total revenue                                |
| Antar segmen                                     | ( 482.448.908.634 )        | ( 88.291.330.233 )          | ( - )                  | -                          | ( 570.740.238.867 )      | Inter-segment                                |
| <b>Total pendapatan dari pelanggan eksternal</b> | <b>21.554.606.016</b>      | <b>804.460.658.296</b>      | <b>99.830.869.141</b>  |                            | <b>925.846.133.453</b>   | <b>Total revenue from external customers</b> |
| <b>Laba segmen</b>                               | <b>481.752.677.427</b>     | <b>84.213.709.642</b>       | <b>( 633.001.001 )</b> | <b>( 396.000.000.000 )</b> | <b>169.333.386.068</b>   | <b>Segment profit</b>                        |
| Pendapatan keuangan                              | 19.750.615.873             | 9.343.398.509               | 2.291.983.154          | -                          | 31.385.997.536           | Finance income                               |
| Beban keuangan                                   | ( 748.959.577 )            | ( 6.658.798.457 )           | ( 83.583.407 )         | -                          | ( 7.491.341.441 )        | Finance charges                              |
| <b>Laba sebelum pajak</b>                        | <b>500.754.333.723</b>     | <b>86.898.309.694</b>       | <b>1.575.398.746</b>   | <b>( 396.000.000.000 )</b> | <b>193.228.042.163</b>   | <b>Profit before tax</b>                     |
| Segment aset                                     | 2.408.373.167.669          | 1.162.364.623.005           | 104.365.183.462        | ( 838.242.153.027 )        | 2.836.860.821.079        | Segment assets                               |
| <b>Jumlah aset</b>                               |                            |                             |                        |                            | <b>2.836.860.821.079</b> | <b>Total assets</b>                          |
| Segment liabilitas                               | 205.945.061.073            | 788.718.767.336             | 10.669.464.146         | ( 716.398.468.755 )        | 288.934.823.800          | Segment liabilities                          |
| <b>Jumlah liabilitas</b>                         |                            |                             |                        |                            | <b>288.934.823.800</b>   | <b>Total liabilities</b>                     |
| <b>Informasi lainnya</b>                         |                            |                             |                        |                            |                          | <b>Other information</b>                     |
| Capital expenditure                              | 24.458.729.271             | 1.250.468.059               | 911.292.003            |                            | 26.620.489.333           | Capital expenditure                          |
| Penyusutan dan amortisasi                        | 22.112.867.091             | 7.771.750.334               | 2.568.676.438          |                            | 32.453.293.863           | Depreciation and amortization                |

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

|                                                  | 30 Juni/June 2024          |                             |                       |                           |                          |                                              |
|--------------------------------------------------|----------------------------|-----------------------------|-----------------------|---------------------------|--------------------------|----------------------------------------------|
|                                                  | Manufaktur/<br>Manufacture | Distribusi/<br>Distribution | Eceran/<br>Retail     | Eliminasi/<br>Elimination | Jumlah/<br>Total         | Revenue                                      |
| Pendapatan                                       |                            |                             |                       |                           |                          | Total revenue                                |
| Jumlah pendapatan                                | 532.379.295.241            | 848.215.362.087             | 74.774.965.697        | -                         | 1.455.369.623.025        | Inter-segment                                |
| Antar segmen                                     | ( 507.006.124.399)         | ( 68.699.850.514)           | ( 15.587.296)         | -                         | ( 575.721.562.209)       |                                              |
| <b>Total pendapatan dari pelanggan eksternal</b> | <b>25.373.170.842</b>      | <b>779.515.511.573</b>      | <b>74.759.378.401</b> |                           | <b>879.648.060.816</b>   | <b>Total revenue from external customers</b> |
| <b>Laba segmen</b>                               | <b>93.633.430.913</b>      | <b>69.972.157.500</b>       | <b>1.396.665.068</b>  | -                         | <b>165.002.253.481</b>   | <b>Segment profit</b>                        |
| Pendapatan keuangan                              | 20.129.229.799             | 4.566.352.935               | 2.152.814.830         | -                         | 26.848.397.564           | Finance income                               |
| Beban keuangan                                   | ( 848.792.590)             | ( 8.657.987.559)            | ( 68.079.471)         | -                         | ( 9.574.859.620)         | Finance charges                              |
| <b>Laba sebelum pajak</b>                        | <b>112.913.868.122</b>     | <b>65.880.522.876</b>       | <b>3.481.400.427</b>  |                           | <b>182.275.791.425</b>   | <b>Profit before tax</b>                     |
| Segment aset                                     | 1.890.167.088.215          | 1.094.449.422.255           | 95.751.040.426        | ( 353.787.003.131)        | 2.726.580.553.692        | Segment assets                               |
| <b>Jumlah aset</b>                               |                            |                             |                       |                           | <b>2.729.580.553.692</b> | <b>Total assets</b>                          |
| Segment liabilitas                               | 180.371.099.359            | 465.283.962.664             | 5.252.450.860         | ( 241.944.318.830)        | 408.963.194.053          | Segment liabilities                          |
| <b>Jumlah liabilitas</b>                         |                            |                             |                       |                           | <b>408.963.194.053</b>   | <b>Total liabilities</b>                     |
| Informasi lainnya                                |                            |                             |                       |                           |                          | Other information                            |
| Capital expenditure                              | 62.655.542.730             | 816.789.217                 | 525.987.269           |                           | 63.998.319.216           | Capital expenditure                          |
| Penyusutan dan amortisasi                        | 19.237.982.456             | 8.016.731.265               | 277.556.901           |                           | 27.532.270.622           | Depreciation and amortization                |

Manajemen memantau hasil operasi dari setiap departemen di atas secara terpisah untuk keperluan pengambilan keputusan mengenai alokasi sumber daya dan penilaian kinerja. Oleh karena itu, penentuan segmen operasi Perusahaan dan Entitas Anak konsisten dengan klasifikasi di atas.

Management monitors the operating results of each of the above divisions separately for the purpose of making decisions about resource allocation and performance assessment. Therefore, the determination of the Company and Subsidiaries' operating segments is consistent with the above classification.

Kinerja segmen dievaluasi berdasarkan laba atau rugi operasi dan diukur secara konsisten dengan laba atau rugi operasi pada laporan keuangan konsolidasian.

Segment performance is evaluated on the basis of operating profit or loss and is measured consistently with operating profit or loss in the consolidated financial statements.

#### 46. TAMBAHAN INFORMASI ARUS KAS

Aktivitas investasi signifikan yang tidak mempengaruhi arus kas:

|                                               | 30 Juni/<br>June<br>2025 | 31 Desember/<br>December<br>2024 |
|-----------------------------------------------|--------------------------|----------------------------------|
| Penambahan aset tetap melalui Utang non-usaha | 6.845.381.681            | 990.823.600                      |
| Penambahan aset tetap melalui uang muka       | 8.494.503.085            | 39.372.828.526                   |
| Penjualan aset tetap melalui piutang dagang   | -                        | 6.500.000                        |
| <b>Jumlah</b>                                 | <b>15.339.885.766</b>    | <b>40.370.152.126</b>            |

Berikut ini transaksi kas dan non-kas dari aktivitas pendanaan yang ditunjukkan dalam rekonsiliasi liabilitas dari transaksi pendanaan.

#### 46. SUPPLEMENTARY CASH FLOW INFORMATION

Significant investing activities not affecting cash flows:

|                                                           |
|-----------------------------------------------------------|
| Acquisition of fixed assets through Non-trade payables    |
| Acquisition of fixed assets through advance for purchases |
| Sale of fixed assets through accounts receivable          |
| <b>Total</b>                                              |

Following is the cash and non-cash transactions from financial activities which are showed in the reconciliation of liabilities. from financing activities.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

|                                             | <b>30 Juni/June 2025</b>                                              |                                                   |                                          |
|---------------------------------------------|-----------------------------------------------------------------------|---------------------------------------------------|------------------------------------------|
|                                             | <b>Surat utang<br/>jangka<br/>Menengah/<br/>Medium-term<br/>notes</b> | <b>Liabilitas<br/>Sewa/<br/>Lease liabilities</b> |                                          |
| Saldo awal                                  | <u>159.916.759.651</u>                                                | <u>25.609.952.630</u>                             | <i>Beginning balance</i>                 |
| Perubahan transaksi non-kas                 |                                                                       |                                                   | <i>Non-cash changes</i>                  |
| Tambahan                                    | -                                                                     | 16.309.277.779                                    | <i>Addition</i>                          |
| Bunga                                       | -                                                                     | 683.708.979                                       | <i>Interest</i>                          |
| Amortisasi biaya ditangguhkan               | <u>83.240.349</u>                                                     | <u>-</u>                                          | <i>Amortization of deferred expenses</i> |
|                                             | <u>160.000.000.000</u>                                                | <u>16.992.986.758</u>                             |                                          |
| Perubahan arus kas dari aktivitas pendanaan |                                                                       |                                                   | <i>Changes from financing</i>            |
| Pembayaran                                  | <u>( 160.000.000.000 )</u>                                            | <u>( 16.309.277.779 )</u>                         | <i>Cash flows Payments</i>               |
| Saldo 30 Juni 2025                          | <u>-</u>                                                              | <u>26.293.661.609</u>                             | <i>Balance as of June 30, 2025</i>       |

|                                             | <b>31 Desember/December 2024</b>                                      |                                                   |                                          |
|---------------------------------------------|-----------------------------------------------------------------------|---------------------------------------------------|------------------------------------------|
|                                             | <b>Surat utang<br/>jangka<br/>Menengah/<br/>Medium-term<br/>notes</b> | <b>Liabilitas<br/>Sewa/<br/>Lease liabilities</b> |                                          |
| Saldo awal                                  | <u>159.730.215.562</u>                                                | <u>29.497.751.943</u>                             | <i>Beginning balance</i>                 |
| Perubahan transaksi non-kas                 |                                                                       |                                                   | <i>Non-cash changes</i>                  |
| Tambahan                                    | -                                                                     | 10.574.806.431                                    | <i>Addition</i>                          |
| Bunga                                       | -                                                                     | 2.802.428.825                                     | <i>Interest</i>                          |
| Amortisasi biaya ditangguhkan               | <u>186.544.089</u>                                                    | <u>-</u>                                          | <i>Amortization of deferred expenses</i> |
|                                             | <u>186.544.089</u>                                                    | <u>13.377.235.256</u>                             |                                          |
| Perubahan arus kas dari aktivitas pendanaan |                                                                       |                                                   | <i>Changes from financing</i>            |
| Pembayaran                                  | <u>-</u>                                                              | <u>( 17.265.039.569 )</u>                         | <i>Cash flows Payments</i>               |
| Saldo 31 Desember 2024                      | <u>159.916.759.651</u>                                                | <u>25.609.947.630</u>                             | <i>Balance as of December 31, 2024</i>   |

**47. PERISTIWA SETELAH PERIODE PELAPORAN**

Berdasarkan akta Notaris No. 13 tanggal 14 Juli 2025 dari Notaris Vita Cahyojati, S.H., M.Hum, PT Intisumber Hasil Sempurna Global, Entitas Anak, menerbitkan Surat Utang Jangka Menengah/Medium-Term Notes (MTN) dengan nilai pokok sebesar Rp 180.000.000.000. Surat utang jangka menengah tersebut berlaku selama 5 tahun dan jatuh tempo pada tanggal 25 Juli 2030, dengan tingkat suku bunga 10,35% per tahun..

**48. SURAT UTANG JANGKA MENENGAH/ MEDIUM TERM NOTES AFTER REFINANCING**

Based on Notarial deed No. 13 dated on July 14, 2025 of Notary Vita Cahyojati, S.H., M.Hum., PT Intisumber Hasil Sempurna Global, a Subsidiary issued a Medium-Term Notes (MTN) with a principal amount of Rp 180,000,000,000. Medium Term Note has term for 5 years and will mature on July 25, 2030, bearing interest rates at 10.35% per annum.

**PT JAYAMAS MEDICA INDUSTRI TBK  
DAN ENTITAS ANAKNYA  
CATATAN ATAS LAPORAN KEUANGAN  
KONSOLIDASIAN  
Tanggal 30 Juni 2025  
(Disajikan dalam Rupiah,  
kecuali dinyatakan lain)**

**PT JAYAMAS MEDICA INDUSTRI TBK  
AND ITS SUBSIDIARIES  
NOTES TO THE CONSOLIDATED  
FINANCIAL STATEMENTS  
As at June 30, 2025  
(Expressed in Rupiah,  
unless otherwise stated)**

47.

**48. REKLASIFIKASI**

Akun berikut dalam laporan laba rugi dan penghasilan komprehensif lain konsolidasian tanggal 30 Juni 2024 telah diklasifikasikan kembali agar sesuai dengan penyajian akun dalam laba rugi dan penghasilan komprehensif lain konsolidasian pada tanggal 30 Juni 2025:

**48. RECLASSIFICATION**

The following accounts in the consolidated statement of profit or loss and other comprehensive income as of 30 June 2024 have been reclassified to conform with the presentation of accounts in the consolidated statement of profit or loss and other comprehensive income as of 30 June 2025:

| <u>30 Juni 2024</u>                                                                  | <u>Sebelum<br/>reklasifikasi/<br/>Before<br/>reclassification</u> | <u>Reklasifikasi/<br/>Reclassification</u> | <u>Sesudah<br/>reklasifikasi/<br/>After<br/>reclassification</u> | <u>June 30, 2024</u>                                                                    |
|--------------------------------------------------------------------------------------|-------------------------------------------------------------------|--------------------------------------------|------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| <b>LAPORAN LABA RUGI DAN<br/>PENGHASILAN<br/>KOMPREHENSIF<br/>LAIN KONSOLIDASIAN</b> |                                                                   |                                            |                                                                  | <b>CONSOLIDATED STATEMENTS OF<br/>PROFIT OR LOSS AND OTHER<br/>COMPREHENSIVE INCOME</b> |
| Beban penjualan dan pemasaran                                                        | ( 70.961.638.247 )                                                | ( 723.041.301 )                            | ( 71.684.679.548 )                                               | Selling and marketing expenses                                                          |
| Beban umum dan administrasi                                                          | ( 61.169.609.219 )                                                | 723.041.301                                | ( 60.446.567.918 )                                               | General and administrative expenses                                                     |

**49. PENERBITAN LAPORAN KEUANGAN  
KONSOLIDASIAN**

Penyusunan dan penyajian wajar laporan keuangan konsolidasian dari halaman 1 sampai 106 merupakan tanggung jawab manajemen, dan telah disetujui oleh Direksi untuk diterbitkan pada tanggal 29 Juli 2025.

**49. ISSUANCE OF CONSOLIDATED FINANCIAL  
STATEMENTS**

The preparation and fair presentation of the consolidated financial statements on pages 1 to 106 were the responsibilities of the management, and were approved by the Company's Directors and authorized for issue on July 29, 2025.